SCORE Placeholder Sheet for IFW Content

Application Number: 17738354 Document Date: 05/06/2022

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

- Drawing

At the time of document entry (noted above):

- USPTO employees may access SCORE content via DAV or via the SCORE web page.
- External customers may access SCORE content via PAIR using the Supplemental Content tab.

Form Revision Date: March 1, 2019

Electronic Acknowledgement Receipt	
EFS ID:	45652259
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua Babiarz
Customer Number:	110711
Filer:	Anton John Bokal/Jeremy Johnston
Filer Authorized By:	Anton John Bokal
Attorney Docket Number:	N.012.US.44
Receipt Date:	06-MAY-2022
Filing Date:	
Time Stamp:	13:49:34
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$7840
RAM confirmation Number	E202256D50054268
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Track One Request	N012US44_Track_1_Request-SIGNED.pdf	877357 480aa3d2d100ff8b26bad15e1e34187d5f5751f0	no	2
Warnings:					
Information:					
2		N012US44_Specification.pdf	1677682 0888bce09e3ca09e0c4359831a9adf7709512df6	yes	241

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Specification	1	238
	Claims	239	240
	Abstract	241	241

Warnings:					
Information:					
3	Application Data Sheet	N012US44_ADS-SIGNED.pdf	1257133 c21366f31993e3c7cbcc3d290e9bfee904d02023	no	12
Warnings:					
Information:					
4	Oath or Declaration filed	N012US44_Declaration.pdf	3333943 f45349796b9227e0fe21a6dfe271de6b4cfaa473	no	20
Warnings:					
Information:					
5	Drawings-other than black and white line drawings	N012US44_Drawings.pdf	2307032 62f6c6ef50dbf467a3ed0bf0db3d319b73aeb1a0	no	105

Warnings:					
Information:					
6	Fee Worksheet (SB06)	fee-info.pdf	53371 459d99906c21c76b6495e0a7b84e6e025bc3239c	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	9506518		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Patent Application Fee Transmittal	
Application Number:	
Filing Date:	
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua Babiarz
Filer:	Anton John Bokal/Jeremy Johnston
Attorney Docket Number:	N.012.US.44
Filed as Large Entity	
Filing Fees for Track I Prioritized Examination - Nonprovisional Application under 35 USC 111(a)	

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
UTILITY APPLICATION FILING	1011	1	320	320
UTILITY SEARCH FEE	1111	1	700	700
UTILITY EXAMINATION FEE	1311	1	800	800
REQUEST FOR PRIORITIZED EXAMINATION	1817	1	4200	4200
Pages:				
UTILITY APPL SIZE FEE PER 50 SHEETS >100	1081	4	420	1680
Claims:				
Miscellaneous-Filing:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
PUBL. FEE- EARLY, VOLUNTARY, OR NORMAL	1504	1	0	0
PROCESSING FEE, EXCEPT PROV. APPLS.	1830	1	140	140
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
		Total in USD ($)		**7840**



Tumor Fraction: 1%, Number of SNPs: 100
Total Seq Reads: 5e+04
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 56%
Hom 1 del
μ: 0.562-FNR: 25%
Hom 2 del
μ: 0.438-FNR: 20%
Hom 1 dup
μ: 0.438-FNR: 20%
Hom 2 dup
μ: 0.562-FNR: 25%

FIG. 1A



Tumor Fraction: 1%, Number of SNPs: 333
Total Seq Reads: 2e+05
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 30%
Hom 1 del
μ: 0.562-FNR: 19%
Hom 2 del
μ: 0.438-FNR: 6.4%
Hom 1 dup
μ: 0.438-FNR: 6.6%
Hom 2 dup
μ: 0.562-FNR: 20%

FIG. 1B



Tumor Fraction: 1%, Number of SNPs: 667
Total Seq Reads: 3e+05
Probability
Test Statistic S/T
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 14%
Hom 1 del
μ: 0.562-FNR: 13%
Hom 2 del
μ: 0.438-FNR: 1.9%
Hom 1 dup
μ: 0.438-FNR: 2%
Hom 2 dup
μ: 0.562-FNR: 13%

FIG. 1C



Tumor Fraction: 1%, Number of SNPs: 1000
Total Seq Reads: 5e+05
Probability
Test Statistic S/T
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 9%
Hom 1 del
μ: 0.562-FNR: 7.2%
Hom 2 del
μ: 0.438-FNR: 0.56%
Hom 1 dup
μ: 0.438-FNR: 0.6%
Hom 2 dup
μ: 0.562-FNR: 7.6%

FIG. 1D



Tumor Fraction: 2%, Number of SNPs: 100
Total Seq Reads: 5e+04
Probability
Test Statistic S/T
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 28%
Hom 1 del
μ: 0.607-FNR: 20%
Hom 2 del
μ: 0.393-FNR: 10%
Hom 1 dup
μ: 0.395-FNR: 11%
Hom 2 dup
μ: 0.605-FNR: 20%

FIG. 2A



Tumor Fraction: 2%, Number of SNPs: 333
Total Seq Reads: 2e+05
Probability
Test Statistic S/T
0.045
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 6%
Hom 1 del
μ: 0.607-FNR: 5.2%
Hom 2 del
μ: 0.393-FNR: 1.1%
Hom 1 dup
μ: 0.395-FNR: 1.3%
Hom 2 dup
μ: 0.605-FNR: 5.9%

FIG. 2B



Tumor Fraction: 2%, Number of SNPs: 667
Total Seq Reads: 3e+05
Probability
Test Statistic S/T
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 1.3%
Hom 1 del
μ: 0.607-FNR: 0.87%
Hom 2 del
μ: 0.393-FNR: 0.045%
Hom 1 dup
μ: 0.395-FNR: 0.063%
Hom 2 dup
μ: 0.605-FNR: 1.1%

FIG. 2C



Tumor Fraction: 2%, Number of SNPs: 1000
Total Seq Reads: 5e+05
Probability
Test Statistic S/T
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 0.29%
Hom 1 del
μ: 0.607-FNR: 0.18%
Hom 2 del
μ: 0.393-FNR: 0.0032%
Hom 1 dup
μ: 0.395-FNR: 0.0051%
Hom 2 dup
μ: 0.605-FNR: 0.26%

FIG. 2D



Tumor Fraction: 3%, Number of SNPs: 100
Total Seq Reads: 5e+04
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 14%
Hom 1 del
μ: 0.65-FNR: 8.8%
Hom 2 del
μ: 0.35-FNR: 3.9%
Hom 1 dup
μ: 0.354-FNR: 4.6%
Hom 2 dup
μ: 0.646-FNR: 10%

FIG. 3A



Tumor Fraction: 3%, Number of SNPs: 333
Total Seq Reads: 2e+05
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.87%
Hom 1 del
μ: 0.65-FNR: 0.63%
Hom 2 del
μ: 0.35-FNR: 0.077%
Hom 1 dup
μ: 0.354-FNR: 0.13%
Hom 2 dup
μ: 0.646-FNR: 0.93%

FIG. 3B



Tumor Fraction: 3%, Number of SNPs: 667
Total Seq Reads: 3e+05
Probability
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.041%
Hom 1 del
μ: 0.65-FNR: 0.015%
Hom 2 del
μ: 0.35-FNR: 0.00036%
Hom 1 dup
μ: 0.354-FNR: 0.00093%
Hom 2 dup
μ: 0.646-FNR: 0.032%

FIG. 3C



Tumor Fraction: 3%, Number of SNPs: 1000
Total Seq Reads: 5e+05
Probability
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.0015%
Hom 1 del
μ: 0.65-FNR: 0.00065%
Hom 2 del
μ: 0.35-FNR: 1.7e-06%
Hom 1 dup
μ: 0.354-FNR: 6.8e-06%
Hom 2 dup
μ: 0.646-FNR: 0.002%

FIG. 3D



Tumor Fraction: 4%, Number of SNPs: 100
Total Seq Reads: 5e+04
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 6%
Hom 1 del
μ: 0.692-FNR: 3.2%
Hom 2 del
μ: 0.308-FNR: 1.2%
Hom 1 dup
μ: 0.314-FNR: 1.7%
Hom 2 dup
μ: 0.686-FNR: 4.3%

FIG. 4A



Tumor Fraction: 4%, Number of SNPs: 333
Total Seq Reads: 2e+05
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.075%
Hom 1 del
μ: 0.692-FNR: 0.039%
Hom 2 del
μ: 0.308-FNR: 0.0026%
Hom 1 dup
μ: 0.314-FNR: 0.0076%
Hom 2 dup
μ: 0.686-FNR: 0.094%

FIG. 4B



Tumor Fraction: 4%, Number of SNPs: 667
Total Seq Reads: 3e+05
Probability
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.00044%
Hom 1 del
μ: 0.692-FNR: 6.4e-05%
Hom 2 del
μ: 0.308-FNR: 5.1e-07%
Hom 1 dup
μ: 0.314-FNR: 4.1e-06%
Hom 2 dup
μ: 0.686-FNR: 0.00037%

FIG. 4C



Tumor Fraction: 4%, Number of SNPs: 1000
Total Seq Reads: 5e+05
Probability
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.518-FPR: 2.6e-06%
Hom 1 del
μ: 0.692-FNR: 1.6e-07%
Hom 2 del
μ: 0.308-FNR: 9.7e-11%
Hom 1 dup
μ: 0.314-FNR: 2.1e-09%
Hom 2 dup
μ: 0.686-FNR: 2.1e-06%

FIG. 4D



Tumor Fraction: 5%, Number of SNPs: 100
Total Seq Reads: 5e+04
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 2.2%
Hom 1 del
μ: 0.732-FNR: 0.95%
Hom 2 del
μ: 0.268-FNR: 0.28%
Hom 1 dup
μ: 0.277-FNR: 0.54%
Hom 2 dup
μ: 0.723-FNR: 1.7%

FIG. 5A



Tumor Fraction: 5%, Number of SNPs: 333
Total Seq Reads: 2e+05
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.0057%
Hom 1 del
μ: 0.732-FNR: 0.00074%
Hom 2 del
μ: 0.268-FNR: 4.6e-05%
Hom 1 dup
μ: 0.277-FNR: 0.00032%
Hom 2 dup
μ: 0.723-FNR: 0.0041%

FIG. 5B



Tumor Fraction: 5%, Number of SNPs: 667
Total Seq Reads: 3e+05
Probability
Test Statistic S/T
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 1.5e-06%
Hom 1 del
μ: 0.732-FNR: 7.1e-08%
Hom 2 del
μ: 0.268-FNR: 1e-10%
Hom 1 dup
μ: 0.277-FNR: 4.8e-09%
Hom 2 dup
μ: 0.723-FNR: 2e-06%

FIG. 5C



Tumor Fraction: 5%, Number of SNPs: 1000
Total Seq Reads: 5e+05
Probability
Test Statistic S/T
0.03
0.025
0.02
0.015
0.01
0.005
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 8.5e-10%
Hom 1 del
μ: 0.732-FNR: 4e-12%
Hom 2 del
μ: 0.268-FNR: 3.8e-16%
Hom 1 dup
μ: 0.277-FNR: 1.2e-13%
Hom 2 dup
μ: 0.723-FNR: 5.7e-10%

FIG. 5D



Tumor Fraction: 6%, Number of SNPs: 100
Total Seq Reads: 5e+04
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.72%
Hom 1 del
μ: 0.769-FNR: 0.24%
Hom 2 del
μ: 0.231-FNR: 0.057%
Hom 1 dup
μ: 0.243-FNR: 0.16%
Hom 2 dup
μ: 0.757-FNR: 0.59%

FIG. 6A



Tumor Fraction: 6%, Number of SNPs: 333
Total Seq Reads: 2e+05
Probability
Test Statistic S/T
Disomy
μ: 0.518-FPR: 0.00017%
Hom 1 del
μ: 0.769-FNR: 1.2e-05%
Hom 2 del
μ: 0.231-FNR: 2.1e-07%
Hom 1 dup
μ: 0.243-FNR: 5.5e-06%
Hom 2 dup
μ: 0.757-FNR: 0.00021%

FIG. 6B



Tumor Fraction: 6%, Number of SNPs: 667
Total Seq Reads: 3e+05
Probability
Test Statistic S/T
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 2.5e-09%
Hom 1 del
μ: 0.769-FNR: 1.3e-11%
Hom 2 del
μ: 0.231-FNR: 4.5e-15%
Hom 1 dup
μ: 0.243-FNR: 2.8e-12%
Hom 2 dup
μ: 0.757-FNR: 3.4e-09%

FIG. 6C



Tumor Fraction: 6%, Number of SNPs: 1000
Total Seq Reads: 5e+05
Probability
Test Statistic S/T
0.03
0.025
0.02
0.015
0.01
0.005
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.518-FPR: 5.3e-14%
Hom 1 del
μ: 0.769-FNR: 1.3e-17%
Hom 2 del
μ: 0.231-FNR: 1.8e-22%
Hom 1 dup
μ: 0.243-FNR: 2.5e-18%
Hom 2 dup
μ: 0.757-FNR: 5.6e-14%

FIG. 6D



Tumor Fraction: 0.5%, Number of SNPs: 100
Total Seq Reads: 1e+05
Probability
Test Statistic S/T
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.513-FPR: 69%
Hom 1 del
μ: 0.544-FNR: 23%
Hom 2 del
μ: 0.456-FNR: 20%
Hom 1 dup
μ: 0.456-FNR: 20%
Hom 2 dup
μ: 0.544-FNR: 23%

FIG. 7A



Tumor Fraction: 0.5%, Number of SNPs: 333
Total Seq Reads: 3e+05
Probability
Test Statistic S/T
0.045
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.513-FPR: 46%
Hom 1 del
μ: 0.544-FNR: 25%
Hom 2 del
μ: 0.456-FNR: 14%
Hom 1 dup
μ: 0.456-FNR: 14%
Hom 2 dup
μ: 0.544-FNR: 25%

FIG. 7B



Tumor Fraction: 0.5%, Number of SNPs: 667
Total Seq Reads: 7e+05
Probability
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.513-FPR: 28%
Hom 1 del
μ: 0.544-FNR: 21%
Hom 2 del
μ: 0.456-FNR: 6.5%
Hom 1 dup
μ: 0.456-FNR: 6.6%
Hom 2 dup
μ: 0.544-FNR: 21%

FIG. 7C



Tumor Fraction: 0.5%, Number of SNPs: 1000
Total Seq Reads: 1e+05
Probability
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.513-FPR: 20%
Hom 1 del
μ: 0.544-FNR: 16%
Hom 2 del
μ: 0.456-FNR: 3.5%
Hom 1 dup
μ: 0.456-FNR: 3.5%
Hom 2 dup
μ: 0.544-FNR: 16%

FIG. 7D



Tumor Fraction: 1%, Number of SNPs: 100
Total Seq Reads: 1e+05
Probability
Test Statistic S/T
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.513-FPR: 43%
Hom 1 del
μ: 0.576-FNR: 25%
Hom 2 del
μ: 0.424-FNR: 20%
Hom 1 dup
μ: 0.425-FNR: 20%
Hom 2 dup
μ: 0.575-FNR: 26%

FIG. 8A



Tumor Fraction: 1%, Number of SNPs: 333
Total Seq Reads: 3e+05
Probability
Test Statistic S/T
0.045
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.513-FPR: 18%
Hom 1 del
μ: 0.576-FNR: 13%
Hom 2 del
μ: 0.424-FNR: 4.7%
Hom 1 dup
μ: 0.425-FNR: 4.9%
Hom 2 dup
μ: 0.575-FNR: 13%

FIG. 8B



Tumor Fraction: 1%, Number of SNPs: 667
Total Seq Reads: 7e+05
Probability
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.513-FPR: 6.7%
Hom 1 del
μ: 0.576-FNR: 4.7%
Hom 2 del
μ: 0.424-FNR: 1.1%
Hom 1 dup
μ: 0.425-FNR: 1.2%
Hom 2 dup
μ: 0.575-FNR: 5%

FIG. 8C



Tumor Fraction: 1%, Number of SNPs: 1000
Total Seq Reads: 1e+06
Probability
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Test Statistic S/T
Disomy
μ: 0.513-FPR: 2.8%
Hom 1 del
μ: 0.576-FNR: 2%
Hom 2 del
μ: 0.424-FNR: 0.25%
Hom 1 dup
μ: 0.425-FNR: 0.28%
Hom 2 dup
μ: 0.575-FNR: 2.2%

FIG. 8D



Tumor Fraction: 2%, Number of SNPs: 100
Total Seq Reads: 1e+05
Probability
Test Statistic S/T
Disomy
μ: 0.513-FPR: 17%
Hom 1 del
μ: 0.637-FNR: 9.9%
Hom 2 del
μ: 0.363-FNR: 6.8%
Hom 1 dup
μ: 0.365-FNR: 7.5%
Hom 2 dup
μ: 0.635-FNR: 11%

FIG. 9A



Tumor Fraction: 2%, Number of SNPs: 333
Total Seq Reads: 3e+05
Probability
Test Statistic S/T
Disomy
μ: 0.513-FPR: 1.4%
Hom 1 del
μ: 0.637-FNR: 0.97%
Hom 2 del
μ: 0.363-FNR: 0.27%
Hom 1 dup
μ: 0.365-FNR: 0.35%
Hom 2 dup
μ: 0.635-FNR: 1.2%

FIG. 9B



Tumor Fraction: 2%, Number of SNPs: 667
Total Seq Reads: 7e+05
Probability
Test Statistic S/T
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.513-FPR: 0.069%
Hom 1 del
μ: 0.637-FNR: 0.046%
Hom 2 del
μ: 0.363-FNR: 0.0029%
Hom 1 dup
μ: 0.365-FNR: 0.0049%
Hom 2 dup
μ: 0.635-FNR: 0.072%

FIG. 9C



Tumor Fraction: 2%, Number of SNPs: 1000
Total Seq Reads: 1e+06
Probability
Test Statistic S/T
0.03
0.025
0.02
0.015
0.01
0.005
0
0
0.2
0.4
0.6
0.8
1
Disomy
μ: 0.513-FPR: 0.0045%
Hom 1 del
μ: 0.637-FNR: 0.0022%
Hom 2 del
μ: 0.363-FNR: 5.9e-05%
Hom 1 dup
μ: 0.365-FNR: 0.00013%
Hom 2 dup
μ: 0.635-FNR: 0.0043%

FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D

Syndrome	Sensitivity	Specificity
22q11.2 Deletion/ DiGeorge	97.8% (45/46) [CI: 88.5 – 99.95%]	99.2% (392/395) [CI: 97.8 - 99.8%]
Angelman	100% (21/21) [CI: 83.9 – 100%]	100% (418/418) [CI: 99.1 – 100%]
Cri du chat	100% (24/24) [CI: 85.7 – 100%]	99.8% (415/416) [CI: 98.7 – 99.99%]
Monosomy 1p36	100% (1/1) [CI: 2.5 – 100%]	100% (438/438) [CI: 99.2 – 100%]
Prader-Willi	100% (15/15) [CI: 78.2 – 100%]	100% (424/424) [CI: 99.1 – 100%]
Wolf-Hirschhorn	100% (2/2) [CI: 15.8 – 100%]	99.8% (437/438) [CI: 98.7 – 100%]

FIG. 14



Allele Frequency Plots: Visualizing Data
Fetal Genotype
Maternal Genotype
AA
AB
AA
AB
BB
AB
BB
0% FF
12% FF
26% FF
Chromosome Position
Fraction of A Allele Reads
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.13
0.06

FIG. 15




FIG. 16A




FIG. 16B

Maternally Inherited Cri-du-Chat Syndrome
33% Fetal Fraction
Fraction of A Allele Reads
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1p36
Wolf-Hirschhorn
Cri-du-chat
Prader-Willi/Angelman
Miller-Dieker
DiGeorge
Phelan-McDermid

FIG. 17



Paternally Inherited Wolf-Hirschhorn Syndrome
17% Fetal Fraction
Fraction of A Allele Reads
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1p36
Wolf-Hirschhorn
Cri-du-chat
Prader-Willi/Angelman
Miller-Dieker
DiGeorge
Phelan-McDermid

FIG. 18

16% Father in Daughter
unmatched
selectedSample (M, MM, MMM)
selectedSample (RM, RRM, RMM)
selectedSample (R, RR, RRR)
Hide all
Ref Allele Ratio
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0M
10M
20M
30M
40M
50M
60M
70M
80M
90M
100M
110M
120M
130M
140M
150M
chrX Location

FIG. 19A

10% Father in Daughter
unmatched
selectedSample (M, MM, MMM)
selectedSample (RM, RRM, RMM)
selectedSample (R, RR, RRR)
Hide all
Ref Allele Ratio
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0M
10M
20M
30M
40M
50M
60M
70M
80M
90M
100M
110M
120M
130M
140M
150M
chrX Location

FIG. 19B

1% Father in Daughter
unmatched
selectedSample (M, MM, MMM)
selectedSample (RM, RRM, RMM)
selectedSample (R, RR, RRR)
Hide all
Ref Allele Ratio
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0M
10M
20M
30M
40M
50M
60M
70M
80M
90M
100M
110M
120M
130M
140M
150M
chrX Location

FIG. 19C

0.1% Father in Daughter
unmatched
selectedSample (M, MM, MMM)
selectedSample (RM, RRM, RMM)
selectedSample (R, RR, RRR)
Hide all
Ref Allele Ratio
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0M
10M
20M
30M
40M
50M
60M
70M
80M
90M
100M
110M
120M
130M
140M
150M
chrX Location

FIG. 19D




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22B




FIG. 23A




FIG. 23B




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B

	S=1000,D=1000	S=500,D=1000	S=1000,D=500	S=500,D=500
With Phase	1.50%	8.80%	10.20%	22.30%
Without Phase	10.60%	10.80%	17.90%	20.80%

FIG. 26

	S=1000,D=1000	S=500,D=1000	S=1000,D=500	S=500,D=500
p =1%,WithPhase	0.00%	0.10%	3.00%	9.70%
p =1%,WithoutPhase	74.20%	73.70%	74.60%	76.00%
p =2%,WithPhase	0.00%	0.00%	0.00%	0.00%
p =2%,WithoutPhase	13.90%	14.80%	41.00%	42.70%
p =3%,WithPhase	0.00%	0.00%	0.00%	0.00%
p =3%,WithoutPhase	0.00%	0.00%	5.70%	5.00%
p =4%,WithPhase	0.00%	0.00%	0.00%	0.00%
p =4%,WithoutPhase	0.00%	0.00%	0.00%	0.00%
p =5%,WithPhase	0.00%	0.00%	0.00%	0.00%
p =5%,WithoutPhase	0.00%	0.00%	0.00%	0.00%

FIG. 27

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 48



Mixture: Normal + Cancer
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
95%
5%
Normal Cell Line
Cancer Cell Line

FIG. 28



• Large tumor fraction (4.33%)
CNV present, separation visible
No CNV present in this segment
Reference counts / total counts
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
500
1000
1500
2000

FIG. 29



No CNV present in this segment, open diamonds
• Small tumor fraction (0.58%)
Reference counts / total counts
CNV present, no separation visible
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0
200
400
600
800
1000

FIG. 30




FIG. 31A




FIG. 31B




FIG. 32A




FIG. 32B



Odds Ratio Plot
Odds Ratio
0.5
0
-0.5
-1
-1.5
-2
-2.5
-3
0.004
0.006
0.008
0.01
0.012
0.014
0.016
Tumor Fraction

FIG. 33



SQ515 noEDTA
LOD-mr5
LOD-z5.0
LOD-zs5.0-mr5
10
1
0.1
0.01
1
101
201
301
401
501
601
701
801
901
1001
1101
1201
1301
1401
1501
1601

FIG. 34



SQ589 noEDTA
LOD-mr5
LOD-z5.0
LOD-zs5.0-mr5
10
1
0.1
0.01
0.001
1
101
201
301
401
501
601
701
801
901
1001
1101
1201
1301
1401
1501
1601

FIG. 35



1.000
0.950
0.900
0.850
0.800
0.750
0.700
0.650
0.600
0.550
0.500
0.450
0.400
0.350
0.300
0.250
0.200
0.150
0.100
0.050
0.000
chr1
chr2
chr13
chr18
chr21
chrX
chr26
Genomics

FIG. 36A



1.000
0.950
0.900
0.850
0.800
0.750
0.700
0.650
0.600
0.550
0.500
0.450
0.400
0.350
0.300
0.250
0.200
0.150
0.100
0.050
0.000
chr1
chr2
chr13
chr18
chr21
chrX
chr26
Single Cell

FIG. 36B



1.000
0.950
0.900
0.850
0.800
0.750
0.700
0.650
0.600
0.550
0.500
0.450
0.400
0.350
0.300
0.250
0.200
0.150
0.100
0.050
0.000
chr1
chr2
di_george
Genomics

FIG. 37A



1.000
0.950
0.900
0.850
0.800
0.750
0.700
0.650
0.600
0.550
0.500
0.450
0.400
0.350
0.300
0.250
0.200
0.150
0.100
0.050
0.000
chr1
chr2
di_george
Single Cell

FIG. 37B



ALL CHR1 CHR2 DiGeorge
ALL CHR1 CHR2 DiGeorge
ALL CHR1 CHR2 DiGeorge
ALL CHR1 CHR2 DiGeorge
ALL CHR1 CHR2 DiGeorge
ALL CHR1 CHR2 DiGeorge
MEDIAN(346.0)
4
2
1
0.04
0.02
0.01
0.04
0.02
0.01
0.004
0.002
LOG (DOR/MEDIAN)
DiGeorge
Chr 1 & 2
All
0
250
500
750
1000
1250
1500
1750
2000
2250
2500
2750
3000
SNP INDEX

FIG. 38

	gDNA	Single Cell
Count	75	510
Mean	0.15 %	0.51 %
Median	0.09 %	0.33 %
Max	1.03 %	10 %
Standard Deviation	0.16%	0.79 %
95th percentile	0.43 %	1.22 %
90th percentile	0.37 %	0.92 %

FIG. 39




FIG. 40




FIG. 41A




FIG. 41B




FIG. 41C




FIG. 41D




FIG. 42A




FIG. 42B




FIG. 43A




FIG. 43B

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 66




FIG. 43C




FIG. 43D

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 67



Breast CNVs in ctDNA
CNV
1p
1q
2p
2q
22q
% ctDNA
100
10
1
0.1
700k (I)
TB100400901 (I)
1071/14 K (IIA)
5995/12 (IIA)
343 (IIA)
393 (IIA)
601k (IIA)
405 (IIB)
430 (IIB)
445 (IIB)
462 (IIB)
1129/14K (III B)
1156A Vh (IIB)
1451/14 K (IIB)
5987/12 (IIB)
TB100401921 (II)
TB100401531 (II)
TB100402771 (II)
396 (IIIA)
601312 (IIIA)
TB100401971 (III)
Sample Name (stage)

FIG. 44



Ovarian CNVs in ctDNA
Chromosome Segment
1p
1q
2p
2q
22q
% ctDNA
100
10
1
0.1
TB100040218
TB100040220
TB100040346
TB100040385
TB100040421
Samples

FIG. 45

		SNVs Only		Combined SNVs & CNVs		
Cancer Type	Total # of Positives	Detected	%	Detected w/ low Depth of Read	%	Expected Diagnostic Load Based on TCGA and COMSIC Datasets
Breast	41	29	71%	34	83%	>97%
Lung	24	17	71%	22	92%	>98%

FIG. 46A




FIG. 46B




FIG. 46C




FIG. 46D




FIG. 47A

Stage	Positive Samples, N	Detected, N	% Detected
I	10	6	60%
II	25	22	88%
III	6	6	100%

LOQ for SNVs= 0.2% ctDNA
LOQ for CNVs= 0.45% ctDNA

FIG. 47B




FIG. 48A

Stage	Positive Samples, N	Detected, N	% Detected
I	10	6	60%
II	5	5	100%
IIA	10	9	90%
IIB	10	8	80%
III	3	3	100%
IIIA	2	2	100%
IIIB	1	1	100%

LOQ for SNVs= 0.2% ctDNA
LOQ for CNVs= 0.45% ctDNA

FIG. 48B




FIG. 49A

Stage	Positive Samples, N	Detected, N	% Detected
I	17	15	88%
II	5	5	100%
III	2	2	100%

LOQ for SNVs= 0.2% ctDNA
LOQ for CNVs= 0.45% ctDNA

FIG. 49B




FIG. 50A

Stage	Positive Samples, N	Detected, N	% Detected
IA	6	6	100%
IB	11	9	82%
IIB	5	5	100%
IIIA	2	2	100%

LOQ for SNVs= 0.2% ctDNA
LOQ for CNVs= 0.45% ctDNA

FIG. 50B

	Histology	Stage	Age	Dia (mm)	Smoker (Pack Years)	
L12	SSC	IB	69	40	Yes (?)	
L13	SSC	IA	68	30	Yes (100)	
L15	SSC	IB	68	50	Yes (50)	
L17	Adeno	IIB	61	20	Yes (48)	

FIG. 51A

Sample	Gene	Chr	ChrStart	VAF R1	VAF R2	VAF R3
L12	BRIP1	chr17	59924572	14	6	8
L12	CARS	chr11	3062181	22	11	16
L12	CIC	chr19	42797381	0	0	7
L12	CYFIP1	chr15	22940733	0	6	0
L12	FAT1	chr4	187519147	8	4	0
L12	KDM6A	chrX	44921898	10	5	0
L12	MLLT4	chr6	168347475	9	3	0
L12	NFE2L2	chr2	178098801	69	31	50
L12	RASA1	chr5	86642517	7	0	0
L12	TP53	chr17	7578406	23	9	17
L12	TP53	chr17	7578190	22	8	16
L13	EGFR	chr7	55241708	21	25	55
L13	EGFR	chr7	55242511	20	17	48
L13	HERC4	chr10	69793756	0	3	6
L13	JAK2	chr9	5022084	0	11	7
L13	KMT2C	chr7	151947008	0	0	4
L13	MSH2	chr2	47693816	5	0	11
L13	MTOR	chr1	11292495	2	0	3
L13	PLCG2	chr16	81942036	5	0	6
L13	TP53	chr17	7579509	7	4	16
L15	ALK	chr2	29940530	6	2	
L15	GABRG1	chr4	46060315	13	0	
L15	KDM6A	chrX	44922755	18	6	
L15	MLL2	chr12	49443815	5	0	
L15	ROS1	chr6	117687379	10	3	
L15	SLC39A4	chr8	145638322	14	0	
L15	TP53	chr17	7578254	19	3	
L15	ZFHX4	chr8	77776735	13	5	
L15	ZMYM4	chr1	35827319	14	2	
L17	BRCA2	chr13	32914959	16	28	0
L17	KRAS	chr12	25398284	13	22	0
L17	NF1	chr17	29653134	20	25	0
L17	NF1	chr17	29528088	0	0	20
L17	PAX8	chr2	113984793	9	0	0
L17	TP53	chr17	7577610	0	0	16
L17	TP53	chr17	7577079	20	35	0
L17	TRIM67	chr1	231299607	0	50	0
L17	TRIP11	chr14	92471631	7	0	0

FIG. 51B




FIG. 52

Sample	Gene	Chrom	ChromStart	Swanton		
				VAF R1	VAF R2	VAF R3
L12	BRIP1	chr17	59924572	14	6	8
L12	CARS	chr11	3062181	22	11	16
L12	CIC	chr19	42797381	0	0	7
L12	CYFIP1	chr15	22940733	0	6	0
L12	FAT1	chr4	187519147	8	4	0
L12	KDM6A	chrX	44921898	10	5	0
L12	MLLT4	chr6	168347475	9	3	0
L12	NFE2L2	chr2	178098801	69	31	50
L12	RASA1	chr5	86642517	7	0	0
L12	TP53	chr17	7578406	23	9	17
L12	TP53	chr17	7578190	22	8	16
L13	EGFR	chr7	55241708	21	25	55
L13	EGFR	chr7	55242511	20	17	48
L13	HERC4	chr10	69793756	0	3	6
L13	JAK2	chr9	5022084	0	11	7
L13	KMT2C	chr7	151947008	0	0	4
L13	MSH2	chr2	47693816	5	0	11
L13	MTOR	chr1	11292495	2	0	3
L13	PLCG2	chr16	81942036	5	0	6
L13	TP53	chr17	7579509	7	4	16
L15	ALK	chr2	29940530	6	2	
L15	GABRG1	chr4	46060315	13	0	
L15	KDM6A	chrX	44922755	18	6	
L15	MLL2	chr12	49443815	5	0	
L15	ROS1	chr6	117687379	10	3	
L15	SLC39A4	chr8	145638322	14	0	
L15	TP53	chr17	7578254	19	3	
L15	ZFHX4	chr8	77776735	13	5	
L15	ZMYM4	chr1	35827319	14	2	
L17	BRCA2	chr13	32914959	16	28	
L17	KRAS	chr12	25398284	13	22	
L17	NF1	chr17	29653134	20	25	
L17	NF1	chr17	29528088	0	0	20
L17	PAX8	chr2	113984793	9	0	0
L17	TP53	chr17	7577610	0	0	16
L17	TP53	chr17	7577079	20	35	0
L17	TRIM67	chr1	231299607	0	50	0
L17	TRIP11	chr14	92471631	7	0	0

= Ampliseq

FIG. 53A

Sample	Gene	Chrom	ChromStart	Natera			
				VAF R1	VAF R2	VAF R3	VAF Plasma
L12	BRIP1	chr17	59924572	22.6	7.74	10.07	3.71
L12	CARS	chr11	3062181	22.39	10.47	18.21	5.02
L12	CIC	chr19	42797381	0	0	8.17	1.71
L12	CYFIP1	chr15	22940733	0	0	0	0
L12	FAT1	chr4	187519147	9.81	4.26	0.77	0.57
L12	KDM6A	chrX	44921898	6.33	3.54	0	0.28
L12	MLLT4	chr6	168347475	9.04	4.26	0.73	0.95
L12	NFE2L2	chr2	178098801	73.12	39.92	53.94	23.25
L12	RASA1	chr5	86642517	7.37	0	0.35	0
L12	TP53	chr17	7578406	22.93	9.17	16.97	4.89
L12	TP53	chr17	7578190	21.48	8.67	22.09	5.77
L13	EGFR	chr7	55241708	27.06	23.14	60.79	1.16
L13	EGFR	chr7	55242511	23.93	18.01	56.31	1.09
L13	HERC4	chr10	69793756	0.16	1.92	5.72	0
L13	JAK2	chr9	5022084	0.27	2.79	6.09	0
L13	KMT2C	chr7	151947008	0	0	6.69	0
L13	MSH2	chr2	47693816	5.04	3.33	12.67	0
L13	MTOR	chr1	11292495	2.4	1.38	6.01	0
L13	PLCG2	chr16	81942036	2.8	1.7	6.89	0
L13	TP53	chr17	7579509	6.11	3.76	15.4	0.4
L15	ALK	chr2	29940530	7.2	1.39		0
L15	GABRG1	chr4	46060315	11.84	2.04		0
L15	KDM6A	chrX	44922755	6.54	0.91		0.17
L15	MLL2	chr12	49443815	12.41	0		
L15	ROS1	chr6	117687379	10.82	2.94		0.15
L15	SLC39A4	chr8	145638322	18.59	0		0
L15	TP53	chr17	7578254	12.6	2.5		0
L15	ZFHX4	chr8	77776735	10.26	2.3		0
L15	ZMYM4	chr1	35827319	12.84	3.46		0
L17	BRCA2	chr13	32914959	15.03	27		0
L17	KRAS	chr12	25398284	14.22	23.79		0
L17	NF1	chr17	29653134	18.6	23.1		0
L17	NF1	chr17	29528088	0	0	17.79	0.37
L17	PAX8	chr2	113984793	6.6	0		0
L17	TP53	chr17	7577610	0	0	18.97	0
L17	TP53	chr17	7577079	15.36	33.7		0
L17	TRIM67	chr1	231299607	18.38	30.95		0.57
L17	RIP11	chr14	92471631	6.44	0		0

= mmPCR-NGS

FIG. 53B




FIG. 54A




FIG. 54B



84-plex pool 1
Depth of Read
Thousands
500
400
300
200
100
0
15cycles
20cycles
15cycles
25cycles
20cycles
25cycles

FIG. 55



84-plex pool 2
Depth of Reed
Thousands
500
400
300
200
100
0
15cycles
20cycles
15cycles
20cycles
25cycles
25cycles

FIG. 56



84-plex pool 3
Depth of Read
Thousands
500
400
300
200
100
0
15cycles
20cycles
15cycles
25cycles
20cycles
25cycles

FIG. 57



84-plex pool 4
Depth of Read
Thousands
500
400
300
200
100
0
15cycles
20cycles
15cycles
25cycles
20cycles
25cycles

FIG. 58



15 cycles
Limit of Detection
1
0.1
0.01
0.001
0
100
200
300
400
500
600
700
Thousands
Deph of Reed
Transition
Transversion

FIG. 59



20 cycles
Thousands
0
50
100
150
200
250
300
350
400
1
0.1
0.01
0.001
Limit of Detection
Transition
Transversion
Power (Transition)
Power (Transversionn)

FIG. 60



25 cycles
Thousands
0
50
100
150
200
250
300
350
400
1
0.1
0.01
0.001
Limit of Detection
Transition
Transversion
Power (Transversionn)

FIG. 61

FIG. 62A

- 28K-plex PCR
- > 85% mapped reads
- 4.7M reads (~167 reads per target)
- Mosaicism observed among cells

FIG. 62B

FIG. 62C

FIG. 62D



Tumor tissue
Blood Sample
FFPE
Fresh frozen
Single cells
Germline control
ctDNA
DNA isolation and preparation
Massively multiplexed PCR (mmPCR) targeting SNPs
Next-generation sequencing
Detection of CNVs

FIG. 63A




FIG. 63B




FIG. 63C




FIG. 63D




FIG. 63E




FIG. 63F




FIG. 64A




FIG. 64B




FIG. 64C




FIG. 64D




FIG. 64E




FIG. 64F




FIG. 64G




FIG. 64H




FIG. 65A




FIG. 65B




FIG. 65C




FIG. 65D




FIG. 66B




FIG. 66A

	1p	1q	2p	2q	22q11.2
OV1					
OV2					
OV3					
OV4					
OV5					




FIG. 66C

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
9:163985-163985_T>C	9:5050714-5050714_T>C	17:7577587-7577587_A>T
1:17275337-17275337_C>T	9:21971111-21971111_C>T	17:7577590-7577590_A>T
1:23689289-23689289_T>G	9:32632175-32632175_C>T	17:7577592-7577592_C>A
1:26774085-26774085_G>A	9:108097968-108097968_G>A	17:7577598-7577598_A>G
1:36226206-36226206_A>G	9:130931780-130931780_C>T	17:7577599-7577599_G>C
1:43032078-43032078_C>T	9:141071078-141071078_A>G	17:7577604-7577604_G>T
1:43912067-43912067_G>A	10:37486216-37486216_C>G	17:7578177-7578177_G>C
1:64515405-64515405_C>T	10:46254776-46254776_A>C	17:7578183-7578183_G>T
1:99771528-99771528_G>A	10:47207813-47207813_A>G	17:7578188-7578188_G>T
1:110173662-110173662_G>A	10:50678650-50678650_A>T	17:7578190-7578190_A>G
1:115256528-115256528_A>C	10:51853633-51853633_C>T	17:7578191-7578191_T>C
1:115256529-115256529_A>G	10:72358324-72358324_C>T	17:7578196-7578196_T>A
1:120458147-120458147_C>T	10:81058322-81058322_C>G	17:7578202-7578202_T>A
1:145323656-145323656_A>T	10:89624275-89624275_C>T	17:7578203-7578203_G>T
1:148343792-148343792_G>T	10:89624305-89624305_T>G	17:7578204-7578204_T>G
1:151149263-151149263_A>G	10:89692790-89692790_G>A	17:7578206-7578206_A>G
1:152186837-152186837_G>A	10:89692794-89692794_A>T	17:7578207-7578207_T>C
1:152189016-152189016_C>T	10:89692835-89692835_G>A	17:7578208-7578208_A>G
1:152328936-152328936_C>G	10:89692839-89692839_T>G	17:7578212-7578212_C>T
1:157805906-157805906_G>A	10:89692883-89692883_C>G	17:7578215-7578215_T>A
1:158609792-158609792_A>T	10:89692893-89692893_C>A	17:7578216-7578216_T>C
1:186276240-186276240_T>C	10:89692900-89692900_G>C	17:7578224-7578224_A>T
1:198675866-198675866_A>C	10:89692905-89692905_G>A	17:7578225-7578225_C>A
1:202699028-202699028_A>G	10:89692923-89692923_G>A	17:7578235-7578235_A>G
1:225306960-225306960_T>G	10:89692980-89692980_A>G	17:7578236-7578236_T>G
1:227288919-227288919_C>T	10:89692998-89692998_G>T	17:7578239-7578239_G>T

FIG. 67A

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
1:228560700-228560700_T>C	10:123258034-123258034_T>A	17:7578244-7578244_G>C
1:235884036-235884036_A>G	10:127548395-127548395_C>G	17:7578245-7578245_C>A
1:247614573-247614573_C>T	11:534288-534288_G>A	17:7578253-7578253_G>T
1:248402566-248402566_T>A	11:1093430-1093430_C>A	17:7578254-7578254_G>A
2:32820108-32820108_A>C	11:1643049-1643049_T>G	17:7578257-7578257_G>T
2:61719472-61719472_G>A	11:1651157-1651157_A>G	17:7578259-7578259_T>G
2:107049425-107049425_T>G	11:48171648-48171648_A>T	17:7578260-7578260_G>T
2:107460402-107460402_G>A	11:49854989-49854989_G>A	17:7578262-7578262_G>C
2:118715997-118715997_C>G	11:55541605-55541605_G>A	17:7578263-7578263_C>T
2:119752091-119752091_G>A	11:55861593-55861593_G>A	17:7578265-7578265_T>C
2:129075877-129075877_C>A	11:60666746-60666746_A>C	17:7578266-7578266_A>T
2:165986535-165986535_A>G	11:64544046-64544046_A>G	17:7578268-7578268_T>C
2:178098803-178098803_G>A	11:66335548-66335548_T>C	17:7578269-7578269_C>T
2:179434772-179434772_C>T	11:71932638-71932638_C>T	17:7578271-7578271_A>G
2:179635206-179635206_C>G	11:94204875-94204875_T>G	17:7578272-7578272_C>T
2:197641324-197641324_C>G	11:103182692-103182692_G>A	17:7578275-7578275_C>T
2:198266834-198266834_A>G	11:108117798-108117798_C>T	17:7578280-7578280_C>T
2:198363501-198363501_G>A	11:108175462-108175462_G>A	17:7578281-7578281_C>T
2:209113113-209113113_C>T	11:108200961-108200961_G>A	17:7578284-7578284_G>T
2:238672328-238672328_C>T	12:4627253-4627253_G>A	17:7578371-7578371_G>A
3:1269641-1269641_A>G	12:9453702-9453702_C>T	17:7578374-7578374_G>C
3:19924193-19924193_G>A	12:9574020-9574020_A>G	17:7578375-7578375_C>G
3:25832827-25832827_T>A	12:9583286-9583286_T>C	17:7578380-7578380_G>A
3:38104250-38104250_C>G	12:12630318-12630318_C>T	17:7578382-7578382_C>T
3:41266100-41266100_T>A	12:21953991-21953991_G>A	17:7578388-7578388_G>C
3:41266101-41266101_C>G	12:22677465-22677465_G>A	17:7578389-7578389_C>T

FIG. 67B

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
3:41266104-41266104_G>T	12:25380275-25380275_A>T	17:7578392-7578392_G>C
3:41266113-41266113_C>A	12:25380276-25380276_A>T	17:7578393-7578393_T>A
3:41266124-41266124_A>G	12:25380277-25380277_C>A	17:7578394-7578394_A>G
3:44612650-44612650_G>T	12:25398281-25398281_G>A	17:7578395-7578395_C>A
3:58191274-58191274_G>C	12:25398282-25398282_G>T	17:7578400-7578400_C>G
3:108788596-108788596_C>T	12:25398284-25398284_G>A	17:7578402-7578402_C>A
3:138022433-138022433_C>T	12:25398285-25398285_G>C	17:7578403-7578403_G>A
3:149245633-149245633_T>G	12:30888067-30888067_G>A	17:7578404-7578404_T>A
3:172533490-172533490_A>C	12:31231425-31231425_T>G	17:7578406-7578406_G>A
3:178916854-178916854_G>A	12:31242869-31242869_G>A	17:7578407-7578407_C>A
3:178916876-178916876_G>A	12:50745677-50745677_A>T	17:7578409-7578409_G>A
3:178916936-178916936_G>A	12:50746243-50746243_A>C	17:7578410-7578410_A>T
3:178916941-178916941_G>A	12:52385715-52385715_C>T	17:7578413-7578413_G>T
3:178916944-178916944_A>G	12:56482341-56482341_G>T	17:7578415-7578415_T>A
3:178916946-178916946_G>C	12:91502039-91502039_G>A	17:7578416-7578416_G>A
3:178917478-178917478_G>A	12:101745882-101745882_A>T	17:7578419-7578419_G>A
3:178921548-178921548_G>A	13:28919595-28919595_G>A	17:7578420-7578420_G>A
3:178921552-178921552_A>T	13:32968854-32968854_C>A	17:7578423-7578423_G>A
3:178921553-178921553_T>A	13:36700097-36700097_C>T	17:7578428-7578428_C>T
3:178927974-178927974_G>A	13:48953760-48953760_C>T	17:7578431-7578431_C>T
3:178927980-178927980_T>C	13:49033955-49033955_A>T	17:7578433-7578433_C>G
3:178928079-178928079_G>A	14:20215706-20215706_G>T	17:7578437-7578437_C>T
3:178936050-178936050_T>C	14:21873400-21873400_G>A	17:7578440-7578440_A>G
3:178936074- 178936074_C>G	14:44973867-44973867_C>T	17:7578442-7578442_A>C
3:178936082-178936082_G>A	14:63784405-63784405_C>T	17:7578443-7578443_T>A
3:178936083-178936083_A>T	14:102323093-102323093_T>C	17:7578448-7578448_C>A

FIG. 67C

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
3:178936091-178936091_G>A	14:105246551-105246551_G>A	17:7578449-7578449_G>A
3:178936092-178936092_A>C	15:22743235-22743235_A>G	17:7578452-7578452_A>G
3:178936093-178936093_G>C	15:33954810-33954810_G>A	17:7578454-7578454_C>T
3:178936094-178936094_C>A	15:66774131-66774131_G>A	17:7578455-7578455_G>C
3:178936095-178936095_A>G	15:75047325-75047325_G>A	17:7578457-7578457_G>A
3:178936097-178936097_G>A	15:83014132-83014132_G>C	17:7578460-7578460_T>G
3:178937019-178937019_A>G	15:84909434-84909434_G>A	17:7578461-7578461_G>T
3:178938860-178938860_A>C	15:102516424-102516424_G>T	17:7578463-7578463_G>C
3:178938934-178938934_G>A	16:1004605-1004605_T>C	17:7578464-7578464_C>G
3:178947827-178947827_G>T	16:2049640-2049640_T>C	17:7578466-7578466_C>T
3:178951957-178951957_G>A	16:3820773-3820773_C>T	17:7578467-7578467_A>C
3:178951964-178951964_G>C	16:4432029-4432029_A>C	17:7578469-7578469_G>A
3:178952004-178952004_C>T	16:28507445-28507445_G>C	17:7578471-7578471_C>T
3:178952013-178952013_G>T	16:29110458-29110458_T>C	17:7578472-7578472_C>T
3:178952018-178952018_A>K	16:56782199-56782199_G>A	17:7578475-7578475_C>T
3:178952019-178952019_C>T	16:68772218-68772218_C>T	17:7578476-7578476_C>T
3:178952020-178952020_C>T	16:68844139-68844139_G>A	17:7578478-7578478_C>A
3:178952030-178952030_G>C	17:7573982-7573982_G>T	17:7578479-7578479_C>T
3:178952072-178952072_A>G	17:7574002-7574002_G>C	17:7578490-7578490_T>A
3:178952074-178952074_G>C	17:7574003-7574003_C>T	17:7578492-7578492_G>A
3:178952075-178952075_A>T	17:7574012-7574012_G>T	17:7578493-7578493_G>A
3:178952077-178952077_T>A	17:7574017-7574017_G>T	17:7578496-7578496_T>A
3:178952081-178952081_G>A	17:7574018-7574018_C>T	17:7578498-7578498_G>T
3:178952082-178952082_C>T	17:7576855-7576855_C>T	17:7578499-7578499_A>C
3:178952084-178952084_C>T	17:7576857-7576857_T>G	17:7578500-7578500_C>T
3:178952085-178952085_A>G	17:7576883-7576883_A>G	17:7578502-7578502_T>C

FIG. 67D

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
3:178952088-178952088_A>G	17:7576897-7576897_C>T	17:7578506-7578506_C>A
3:178952090-178952090_G>C	17:7577022-7577022_C>T	17:7578507-7578507_C>A
3:178952091-178952091_G>C	17:7577036-7577036_C>A	17:7578508-7578508_G>A
3:178952100-178952100_C>A	17:7577046-7577046_G>T	17:7578509-7578509_T>C
3:192516720-192516720_C>G	17:7577052-7577052_C>A	17:7578513-7578513_G>A
3:195452649-195452649_C>T	17:7577058-7577058_G>T	17:7578514-7578514_A>G
3:195505836-195505836_C>G	17:7577069-7577069_G>A	17:7578517-7578517_C>T
3:195506597-195506597_C>T	17:7577079-7577079_G>T	17:7578518-7578518_G>A
3:195506940-195506940_C>G	17:7577081-7577081_A>C	17:7578524-7578524_C>T
3:195511945-195511945_C>T	17:7577082-7577082_G>C	17:7578525-7578525_C>G
4:11400898-11400898_G>A	17:7577085-7577085_G>A	17:7578526-7578526_G>A
4:15443812-15443812_C>A	17:7577088-7577088_A>C	17:7578527-7578527_T>G
4:40356408-40356408_C>A	17:7577090-7577090_G>C	17:7578528-7578528_T>G
4:46930361-46930361_A>C	17:7577091-7577091_C>T	17:7578529-7578529_T>G
4:48597671-48597671_G>A	17:7577093-7577093_G>A	17:7578530-7578530_T>C
4:55593613-55593613_T>A	17:7577094-7577094_C>T	17:7578532-7578532_T>A
4:55593661-55593661_T>C	17:7577095-7577095_C>A	17:7578534-7578534_G>T
4:55594212-55594212_T>C	17:7577096-7577096_A>G	17:7578535-7578535_A>G
4:55594221-55594221_A>G	17:7577097-7577097_G>A	17:7578536-7578536_A>G
4:55599320-55599320_G>C	17:7577099-7577099_G>A	17:7578541-7578541_T>G
4:71469002-71469002_C>G	17:7577100-7577100_A>T	17:7578542-7578542_C>T
4:83778206-83778206_C>T	17:7577102-7577102_G>A	17:7578548-7578548_C>T
4:88537243-88537243_C>A	17:7577105-7577105_C>G	17:7578550-7578550_C>G
4:88537249-88537249_T>C	17:7577106-7577106_C>A	17:7578551-7578551_T>A
4:107845202-107845202_G>A	17:7577107-7577107_T>G	17:7578553-7578553_A>G
4:144336805-144336805_A>G	17:7577108-7577108_G>T	17:7578554-7578554_T>G

FIG. 67E

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
4:153245446-153245446_C>T	17:7577111-7577111_C>T	17:7579312-7579312_G>C
4:153247168-153247168_A>G	17:7577112-7577112_G>C	17:7579313-7579313_C>G
4:153247288-153247288_G>H	17:7577113-7577113_T>G	17:7579329-7579329_A>G
4:153247366-153247366_G>T	17:7577114-7577114_G>T	17:7579349-7579349_T>G
4:153249456-153249456_G>T	17:7577115-7577115_T>G	17:7579355-7579355_T>C
4:164507069-164507069_C>T	17:7577117-7577117_T>C	17:7579358-7579358_G>C
4:170321765-170321765_C>T	17:7577118-7577118_G>T	17:7579366-7579366_C>G
4:175896768-175896768_C>T	17:7577120-7577120_G>A	17:7579377-7579377_C>T
5:13762932-13762932_G>A	17:7577121-7577121_C>T	17:7579378-7579378_C>A
5:26906161-26906161_G>A	17:7577123-7577123_T>C	17:7579414-7579414_G>A
5:67591128-67591128_G>C	17:7577124-7577124_G>T	17:7579503-7579503_G>T
5:112173917-112173917_C>T	17:7577127-7577127_G>T	17:7579521-7579521_G>A
5:112175118-112175118_C>T	17:7577129-7577129_T>G	17:7579547-7579547_C>T
5:112175219-112175219_A>T	17:7577130-7577130_T>C	17:7579882-7579882_G>C
5:112175681-112175681_G>T	17:7577138-7577138_G>A	17:11554600-11554600_G>T
5:112175786-112175786_G>T	17:7577141-7577141_G>A	17:11998898-11998898_C>T
5:112176020-112176020_G>T	17:7577142-7577142_G>T	17:12011144-12011144_C>T
5:126791225-126791225_C>T	17:7577144-7577144_T>C	17:37868208-37868208_C>T
5:129030517-129030517_C>T	17:7577148-7577148_C>G	17:37880220-37880220_T>C
5:131931452-131931452_A>T	17:7577501-7577501_C>T	17:37880261-37880261_G>T
5:135394826-135394826_G>A	17:7577505-7577505_A>T	17:37881000-37881000_G>C
5:140683389-140683389_C>T	17:7577506-7577506_G>T	17:37881332-37881332_G>A
5:170239186-170239186_A>G	17:7577508-7577508_A>G	17:39240627-39240627_T>C
5:180335598-180335598_T>G	17:7577509-7577509_G>A	17:39274087-39274087_C>G
6:10756728-10756728_C>T	17:7577511-7577511_T>A	17:39274157-39274157_C>T
6:26032069-26032069_G>A	17:7577517-7577517_T>C	17:39305800-39305800_A>T

FIG. 67F

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
6:28497279-28497279_G>A	17:7577518-7577518_A>T	17:39595484-39595484_C>T
6:29910622-29910622_C>T	17:7577520-7577520_T>C	17:39673185-39673185_G>A
6:93956553-93956553_C>G	17:7577521-7577521_A>G	17:41245274-41245274_G>C
6:112452259-112452259_G>A	17:7577524-7577524_A>C	17:45219311-45219311_A>G
6:130497111-130497111_C>T	17:7577526-7577526_T>C	17:48777241-48777241_T>A
6:150001395-150001395_C>T	17:7577529-7577529_T>A	17:58288421-58288421_G>A
6:170871013-170871013_A>G	17:7577532-7577532_C>A	17:61958402-61958402_C>T
7:2577781-2577781_A>G	17:7577533-7577533_C>G	18:29470816-29470816_G>A
7:6426892-6426892_C>T	17:7577534-7577534_G>A	18:45368211-45368211_C>G
7:27832791-27832791_A>G	17:7577535-7577535_G>C	18:48575671-48575671_C>G
7:43591930-43591930_G>A	17:7577536-7577536_A>T	18:48604754-48604754_G>T
7:55259482-55259482_C>A	17:7577538-7577538_G>A	19:1223125-1223125_C>G
7:55259515-55259515_T>G	17:7577539-7577539_C>T	19:22836805-22836805_G>A
7:77379331-77379331_T>G	17:7577541-7577541_A>T	19:40383905-40383905_C>T
7:100643088-100643088_A>G	17:7577543-7577543_G>A	19:49926533-49926533_C>G
7:100677279-100677279_G>C	17:7577544-7577544_T>G	19:51274851-51274851_A>C
7:138268672-138268672_C>T	17:7577545-7577545_A>G	19:56369444-56369444_G>A
7:140453136-140453136_T>A	17:7577547-7577547_G>T	20:3209652-3209652_T>G
7:140453137-140453137_G>A	17:7577548-7577548_G>A	20:6751034-6751034_A>G
7:140481411-140481411_G>T	17:7577549-7577549_C>G	20:29623210-29623210_C>T
7:140481412-140481412_G>C	17:7577550-7577550_G>T	20:29623224-29623224_C>A
7:140481417-140481417_G>T	17:7577551-7577551_G>C	20:29628236-29628236_G>C
7:140500165-140500165_T>C	17:7577552-7577552_G>C	20:29628263-29628263_A>G
7:151970859-151970859_G>A	17:7577554-7577554_A>T	20:29632643-29632643_T>C
7:151970951-151970951_G>A	17:7577555-7577555_C>A	20:31671497-31671497_C>T
8:2796250-2796250_C>T	17:7577556-7577556_G>A	20:34242060-34242060_G>A

FIG. 67G

Chr No.:Position_Mutation	Chr No.:Position_Mutation	Chr No.:Position_Mutation
8:2855562-2855562_A>G	17:7577557-7577557_T>A	20:57484420-57484420_C>T
8:3009020-3009020_C>G	17:7577559-7577559_C>A	20:57484421-57484421_G>A
8:3205603-3205603_G>A	17:7577565-7577565_A>C	21:10951281-10951281_G>A
8:3245034-3245034_G>T	17:7577566-7577566_A>G	21:32127654-32127654_G>A
8:10467948-10467948_C>T	17:7577568-7577568_G>A	22:16449539-16449539_T>C
8:77768353-77768353_C>T	17:7577569-7577569_T>A	22:22899234-22899234_T>C
8:89086854-89086854_G>A	17:7577570-7577570_G>A	22:29092948-29092948_C>T
8:101083610-101083610_T>C	17:7577571-7577571_T>A	22:30398972-30398972_G>C
8:109796543-109796543_G>A	17:7577574-7577574_A>G	23:15821891-15821891_C>G
8:116426722-116426722_G>T	17:7577575-7577575_T>A	23:66765161-66765161_A>T
8:121344960-121344960_G>A	17:7577577-7577577_A>G	23:78011285-78011285_G>A
8:144940290-144940290_G>C	17:7577580-7577580_A>G	23:105153675-105153675_C>A
8:144940331-144940331_G>A	17:7577581-7577581_T>A	17:7577586-7577586_T>G

FIG. 67H




FIG. 68A




FIG. 68B

System Architecture
X00
GENETIC DATA SOURCE
X10
LIS
X04
NETWORK
X02
X08
INPUT PROCESSOR
X12
HYPOTHESIS MANAGER
X14
MODELER
X16
ERROR CORRECTION UNIT
X18
MACHINE LEARNING UNIT
X20
OUTPUT PROCESSOR
X22
LIS
X06
GENETIC DATA SOURCE
X10

FIG. 69



Computer System
Y00
PROCESSOR
Y10
MEMORY CONTROLLER
Y75
MAIN MEMORY
Y30
SECONDARY MEMORY
Y40
HARD DISK DRIVE
Y50
REMOVABLE STORAGE DRIVE
Y60
REMOVABLE STORAGE UNIT
Y70
BUS
Y20
COMMUNICATION PATH
Y85
COMMUNICATION & NETWORK INTERFACE
Y80
INPUT/OUTPUT DEVICES
Y90

FIG. 70

PTO/AIA/01 (08-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Joshua Babiarz Date (Optional): _____

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (08-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Tudor Pompiliu Constantin Date (Optional): 08/05/15

Signature: Tudor Constantin

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Lane A. Eubank Date (Optional) 16Dec2015

Signature: Lane A. Eubank

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/692,703

filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: George Gemelos Date (Optional): 09/23/2015

Signature: George H Gemelos

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (09-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Matthew Micah Hill Date (Optional): 8/4/2015

Signature: Matthew Hill

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/692,703

filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Huseyin Eser Kirkizlar Date (Optional): 8/3/2015

Signature: [signature]

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Matthew Rabinowitz Date (Optional): 08/03/15

Signature: Matthew Rabinowitz

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Onur Sakarya Date (Optional): 08/03/2015

Signature: Onur Sakarya

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Styrmir Sigurjonsson Date (Optional): 8/3/15

Signature: Styrmir Sigurjonsson

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 14/692,703 filed on April 21, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Bernhard Zimmermann Date (Optional): _____

Signature: Bernhard Zimmermann

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Joshua		BABIARZ	

Residence Information (Select One) ● US Residency Non US Residency Active US Military Service

City	Castro Valley	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	201 Industrial Road
Address 2	Suite 410

City	San Carlos	State/Province	CA
Postal Code	94070	Country	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Tudor	Pompiliu	CONSTANTIN	

Residence Information (Select One) ◉ US Residency Non US Residency Active US Military Service

City	Berkeley	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	201 Industrial Road
Address 2	Suite 410

City	San Carlos	State/Province	CA
Postal Code	94070	Country	US

Inventor 3 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Lane	A.	EUBANK	

Residence Information (Select One) ◉ US Residency Non US Residency Active US Military Service

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

City	San Carlos	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	201 Industrial Road		
Address 2	Suite 410		
City	San Carlos	State/Province	CA
Postal Code	94070	Country	US

Inventor 4 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	George		GEMELOS	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Portland	State/Province	OR	Country of Residence	US

Mailing Address of Inventor:

Address 1	201 Industrial Road		
Address 2	Suite 410		
City	San Carlos	State/Province	CA
Postal Code	94070	Country	US

Inventor 5 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Matthew	Micah	HILL	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Belmont	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	201 Industrial Road		
Address 2	Suite 410		
City	San Carlos	State/Province	CA
Postal Code	94070	Country	US

Inventor 6 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Huseyin	Eser	KIRKIZLAR	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Los Angeles	State/Province	CA	Country of Residence	US

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Mailing Address of Inventor:

Address 1	201 Industrial Road
Address 2	Suite 410
City	San Carlos
State/Province	CA
Postal Code	94070
Country	US

Inventor 7 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Matthew		RABINOWITZ	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	State/Province	Country of Residence
San Francisco	CA	US

Mailing Address of Inventor:

Address 1	201 Industrial Road
Address 2	Suite 410
City	San Carlos
State/Province	CA
Postal Code	94070
Country	US

Inventor 8 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Onur		SAKARYA	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	State/Province	Country of Residence
Redwood City	CA	US

Mailing Address of Inventor:

Address 1	201 Industrial Road
Address 2	Suite 410
City	San Carlos
State/Province	CA
Postal Code	94070
Country	US

Inventor 9 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Styrmir		SIGURJONSSON	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	State/Province	Country of Residence
San Jose	CA	US

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Mailing Address of Inventor:

Address 1	201 Industrial Road		
Address 2	Suite 410		
City	San Carlos	**State/Province**	CA
Postal Code	94070	**Country** i	US

Inventor 10 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Bernhard		ZIMMERMANN	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Manteca	**State/Province**	CA	**Country of Residence** i	US

Mailing Address of Inventor:

Address 1	201 Industrial Road		
Address 2	Suite 410		
City	San Carlos	**State/Province**	CA
Postal Code	94070	**Country** i	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ **An Address is being provided for the correspondence Information of this application.**

Customer Number	110711		
Email Address	IP@Natera.com	Add Email	Remove Email

Application Information:

Title of the Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS		
Attorney Docket Number	N.012.US.44	**Small Entity Status Claimed**	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	105	**Suggested Figure for Publication (if any)**	

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	● Customer Number	US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	110711		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation of	17692469	2022-03-11

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Prior Application Status	Patented				Remove
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
17692469	Continuation of	15898145	2018-02-15	11319595	2022-05-03
Prior Application Status	Patented				Remove
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
15898145	Continuation of	14692703	2015-04-21	10179937	2019-01-15
Prior Application Status	Expired				Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14692703	Claims benefit of provisional	61982245	2014-04-21		
Prior Application Status	Expired				Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14692703	Claims benefit of provisional	61987407	2014-05-01		
Prior Application Status	Expired				Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14692703	Claims benefit of provisional	61994791	2014-05-16		
Prior Application Status	Expired				Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14692703	Claims benefit of provisional	62066514	2014-10-21		
Prior Application Status	Expired				Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14692703	Claims benefit of provisional	62146188	2015-04-10		
Prior Application Status	Expired				Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14692703	Claims benefit of provisional	62147377	2015-04-14		
Prior Application Status	Expired				Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14692703	Claims benefit of provisional	62148173	2015-04-15		
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.					Add

EFS Web 2.2.13

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)[i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Remove

Application Number	Country[i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button. Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1 Remove

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

● Assignee	Legal Representative under 35 U.S.C. 117	Joint Inventor
Person to whom the inventor is obligated to assign.	Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. ☒

Organization Name	Natera, Inc.		
Mailing Address Information For Applicant:			
Address 1	201 Industrial Road		
Address 2	Suite 410		
City	San Carlos	**State/Province**	CA
Country	US	Postal Code	94070
Phone Number	650-249-9091	Fax Number	
Email Address	IP@Natera.com		

Additional Applicant Data may be generated within this form by selecting the Add button. Add

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

Remove

If the Assignee or Non-Applicant Assignee is an Organization check here. ☒

Organization Name	Natera, Inc.

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1	201 Industrial Road		
Address 2	Suite 410		
City	San Carlos	**State/Province**	CA
Country i	US	Postal Code	94070
Phone Number	650-249-9091	Fax Number	
Email Address	IP@Natera.com		

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button. Add

Signature:

Remove

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Tianran Yan/			Date (YYYY-MM-DD)	2022-05-06
First Name	Tianran	Last Name	Yan	Registration Number	67162

Additional Signature may be generated within this form by selecting the Add button. Add

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	N.012.US.44
	Application Number	
Title of Invention	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1 The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3 A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent CooperationTreaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ABSTRACT

The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 144

CLAIMS

What is claimed is:

1. A method for detecting one or more single nucleotide variant (SNV) mutations in a plasma sample of a subject having cancer or suspected of having cancer, the method comprising:

identifying a plurality of tumor-specific SNV mutations in a tumor sample of the subject by whole exome sequencing or whole genome sequencing;

performing targeted multiplex amplification to amplify at least 20 target loci each encompassing a different tumor-specific SNV mutation from the cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom to obtain amplicons, wherein the target loci are amplified together in the same reaction volume; and

performing high-throughput sequencing to sequence the amplicons to obtain sequence reads, and detecting one or more of the tumor-specific SNV mutations present in the cell-free DNA from the sequence reads.

2. The method of claim 1, wherein the high-throughput sequencing has a depth of read of at least 50,000 per target locus.

3. The method of claim 1, wherein the cell-free DNA comprises circulating tumor DNA.

4. The method of claim 1, wherein the SNV mutations comprise one or more clonal SNV mutations.

5. The method of claim 1, wherein the SNV mutations comprise one or more subclonal SNV mutations.

6. The method of claim 1, wherein the SNV mutations comprise one or more clonal SNV mutations and one or more subclonal SNV mutations.

7. The method of claim 1, wherein the tumor sample of the subject is a tumor tissue sample.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 145

8. The method of claim 1, wherein the method further comprises determining clonal heterogeneity of the tumor sample.

9. The method of claim 1, wherein the targeted multiplex amplification amplifies 20 to 50 target loci each encompassing a different tumor-specific SNV mutation.

10. The method of claim 1, wherein the targeted multiplex amplification amplifies 50 to 100 target loci each encompassing a different tumor-specific SNV mutation.

11. The method of claim 1, wherein the method further comprises designing patient-specific PCR primers or hybrid capture probes targeting the plurality of SNV mutations identified in the tumor sample.

12. The method of claim 1, wherein the method further comprises performing barcoding PCR prior to the high-throughput sequencing.

13. The method of claim 1, wherein the method further comprises detecting recurrence and/or metastases of the cancer from the SNV mutations detected in the cell-free DNA.

14. The method of claim 1, wherein the cancer is colorectal cancer, lung cancer, bladder cancer, or breast cancer.

15. The method of claim 1, wherein an SNV mutation that is present in less than or equal to 0.015% of the cell-free DNA comprising the SNV locus is detected from the sequence reads.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 146

DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of US Utility Application Ser. No. 17/692,469, filed March 11, 2022. US Utility Application Ser. No. 17/692,469 is a continuation of US Utility Application Ser. No. 15/898,145, filed February 15, 2018 (now Patent No. 11,319,595). US Utility Application Ser. No. 15/898,145 is a continuation of U.S. Utility Application Ser. No. 14/692,703, filed April 21, 2015 (now Patent No. 10,179,937), which claims the benefit of and priority to U.S. Provisional Application Ser. No. 61/982,245, filed April 21, 2014; U.S. Provisional Application Ser. No. 61/987,407, filed May 1, 2014; U.S. Provisional Application Ser. No. 62/066,514, filed October 21, 2014; U.S. Provisional Application Ser. No. 62/146,188, filed April 10, 2015; U.S. Provisional Application Ser. No. 62/147,377, filed April 14, 2015; U.S. Provisional Application Ser. No. 62/148,173, filed April 15, 2015, the entirety of these applications are hereby incorporated herein by reference for the teachings therein.

FIELD OF THE INVENTION

[0002] The present invention generally relates to methods and systems for detecting ploidy of a chromosome segment, and methods and systems for detecting a single nucleotide variant.

BACKGROUND OF THE INVENTION

[0003] Copy number variation (CNV) has been identified as a major cause of structural variation in the genome, involving both duplications and deletions of sequences that typically range in length from 1,000 base pairs (1 kb) to 20 megabases (mb). Deletions and duplications of chromosome segments or entire chromosomes are associated with a variety of conditions, such as susceptibility or resistance to disease.

[0004] CNVs are often assigned to one of two main categories, based on the length of the affected sequence. The first category includes copy number polymorphisms (CNPs), which are common in the general population, occurring with an overall frequency of greater than 1%. CNPs are typically small (most are less than 10 kilobases in length), and they are often enriched for genes that encode proteins important in drug detoxification and immunity. A subset of these CNPs is highly variable

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 147

with respect to copy number. As a result, different human chromosomes can have a wide range of copy numbers (*e.g.*, 2, 3, 4, 5, *etc.*) for a particular set of genes. CNPs associated with immune response genes have recently been associated with susceptibility to complex genetic diseases, including psoriasis, Crohn's disease, and glomerulonephritis.

[0005] The second class of CNVs includes relatively rare variants that are much longer than CNPs, ranging in size from hundreds of thousands of base pairs to over 1 million base pairs in length. In some cases, these CNVs may have arisen during production of the sperm or egg that gave rise to a particular individual, or they may have been passed down for only a few generations within a family. These large and rare structural variants have been observed disproportionately in subjects with mental retardation, developmental delay, schizophrenia, and autism. Their appearance in such subjects has led to speculation that large and rare CNVs may be more important in neurocognitive diseases than other forms of inherited mutations, including single nucleotide substitutions.

[0006] Gene copy number can be altered in cancer cells. For instance, duplication of Chr1p is common in breast cancer, and the EGFR copy number can be higher than normal in non-small cell lung cancer. Cancer is one of the leading causes of death; thus, early diagnosis and treatment of cancer is important, since it can improve the patient's outcome (such as by increasing the probability of remission and the duration of remission). Early diagnosis can also allow the patient to undergo fewer or less drastic treatment alternatives. Many of the current treatments that destroy cancerous cells also affect normal cells, resulting in a variety of possible side-effects, such as nausea, vomiting, low blood cell counts, increased risk of infection, hair loss, and ulcers in mucous membranes. Thus, early detection of cancer is desirable since it can reduce the amount and/or number of treatments (such as chemotherapeutic agents or radiation) needed to eliminate the cancer.

[0007] Copy number variation has also been associated with severe mental and physical handicaps, and idiopathic learning disability. Non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) can be used to detect abnormalities, such as fetal trisomies 13, 18, and 21, triploidy, and sex chromosome aneuploidies. Subchromosomal microdeletions, which can also result in severe mental and physical handicaps, are more challenging to detect due to their smaller size. Eight of the microdeletion syndromes have an aggregate incidence of more than 1 in 1000, making them nearly as common as fetal autosomal trisomies.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 148

[0008] In addition, a higher copy number of CCL3L1 has been associated with lower susceptibility to HIV infection, and a low copy number of FCGR3B (the CD16 cell surface immunoglobulin receptor) can increase susceptibility to systemic lupus erythematosus and similar inflammatory autoimmune disorders.

[0009] Thus, improved methods are needed to detect deletions and duplications of chromosome segments or entire chromosomes. Preferably, these methods can be used to more accurately diagnose disease or an increased risk of disease, such as cancer or CNVs in a gestating fetus.

SUMMARY OF THE INVENTION

[0010] In illustrative embodiments, provided herein is a method for determining ploidy of a chromosomal segment in a sample of an individual. The method includes the following steps:

a. receiving allele frequency data comprising the amount of each allele present in the sample at each loci in a set of polymorphic loci on the chromosomal segment;
b. generating phased allelic information for the set of polymorphic loci by estimating the phase of the allele frequency data;
c. generating individual probabilities of allele frequencies for the polymorphic loci for different ploidy states using the allele frequency data;
d. generating joint probabilities for the set of polymorphic loci using the individual probabilities and the phased allelic information; and
e. selecting, based on the joint probabilities, a best fit model indicative of chromosomal ploidy, thereby determining ploidy of the chromosomal segment.

[0011] In one illustrative embodiment of the method for determining ploidy, the data is generated using nucleic acid sequence data, especially high throughput nucleic acid sequence data. In certain illustrative examples of the method for determining ploidy, the allele frequency data is corrected for errors before it is used to generate individual probabilities. In specific illustrative embodiments, the errors that are corrected include allele amplification efficiency bias. In other embodiments, the errors that are corrected include ambient contamination and genotype contamination. In some embodiments, errors that are corrected include allele amplification bias, ambient contamination and genotype contamination.

[0012] In certain embodiments of the method for determining ploidy, the individual probabilities are generated using a set of models of both different ploidy states and allelic imbalance fractions

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 149

for the set of polymorphic loci. In these embodiments, and other embodiments, the joint probabilities are generated by considering the linkage between polymorphic loci on the chromosome segment.

[0013] Accordingly, in one illustrative embodiment that combines some of these embodiments, provided herein is a method for detecting chromosomal ploidy in a sample of an individual, that includes the following steps:

a. receiving nucleic acid sequence data for alleles at a set of polymorphic loci on a chromosome segment in the individual;
b. detecting allele frequencies at the set of loci using the nucleic acid sequence data;
c. correcting for allele amplification efficiency bias in the detected allele frequencies to generate corrected allele frequencies for the set of polymorphic loci;
d. generating phased allelic information for the set of polymorphic loci by estimating the phase of the nucleic acid sequence data;
e. generating individual probabilities of allele frequencies for the polymorphic loci for different ploidy states by comparing the corrected allele frequencies to a set of models of different ploidy states and allelic imbalance fractions of the set of polymorphic loci;
f. generating joint probabilities for the set of polymorphic loci by combining the individual probabilities considering the linkage between polymorphic loci on the chromosome segment; and
g. selecting, based on the joint probabilities, the best fit model indicative of chromosomal aneuploidy.

[0014] In another aspect, provided herein is a system for detecting chromosomal ploidy in a sample of an individual, the system comprising:

a. an input processor configured to receive allelic frequency data comprising the amount of each allele present in the sample at each loci in a set of polymorphic loci on the chromosomal segment;
b. a modeler configured to:
    i. generate phased allelic information for the set of polymorphic loci by estimating the phase of the allele frequency data; and

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 150

ii. generate individual probabilities of allele frequencies for the polymorphic loci for different ploidy states using the allele frequency data; and

iii. generate joint probabilities for the set of polymorphic loci using the individual probabilities and the phased allelic information; and

c. a hypothesis manager configured to select, based on the joint probabilities, a best fit model indicative of chromosomal ploidy, thereby determining ploidy of the chromosomal segment.

[0015] In certain embodiments of this system embodiment, the allele frequency data is data generated by a nucleic acid sequencing system. In certain embodiments, the system further comprises an error correction unit configured to correct for errors in the allele frequency data, wherein the corrected allele frequency data is used by the modeler for to generate individual probabilities. In certain embodiments the error correction unit corrects for allele amplification efficiency bias. In certain embodiments, the modeler generates the individual probabilities using a set of models of both different ploidy states and allelic imbalance fractions for the set of polymorphic loci. The modeler, in certain exemplary embodiments generates the joint probabilities by considering the linkage between polymorphic loci on the chromosome segment.

[0016] In one illustrative embodiment, provided herein is a system for detecting chromosomal ploidy in a sample of an individual, that includes the following:

a. an input processor configured to receive nucleic acid sequence data for alleles at a set of polymorphic loci on a chromosome segment in the individual and detect allele frequencies at the set of loci using the nucleic acid sequence data;

b. an error correction unit configured to correct for errors in the detected allele frequencies and generate corrected allele frequencies for the set of polymorphic loci;

c. a modeler configured to:

i. generate phased allelic information for the set of polymorphic loci by estimating the phase of the nucleic acid sequence data;

ii. generate individual probabilities of allele frequencies for the polymorphic loci for different ploidy states by comparing the phased allelic information to a set of models of different ploidy states and allelic imbalance fractions of the set of polymorphic loci; and

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 151

iii. generate joint probabilities for the set of polymorphic loci by combining the individual probabilities considering the relative distance between polymorphic loci on the chromosome segment; and

d. a hypothesis manager configured to select, based on the joint probabilities, a best fit model indicative of chromosomal aneuploidy.

[0017] In certain aspects, the present invention provides a method for determining whether circulating tumor nucleic acids are present in a sample in an individual, comprising

a. analyzing the sample to determine a ploidy at a set of polymorphic loci on a chromosome segment in the individual; and

b. determining the level of allelic imbalance present at the polymorphic loci based on the ploidy determination, wherein an allelic imbalance equal to or greater than 0.4%, 0.45%, or 0.5% is indicative of the presence of circulating tumor nucleic acids in the sample.

[0018] In certain embodiments the method for determining whether circulating tumor nucleic acids are present, further comprises detecting a single nucleotide variant at a single nucleotide variance site in a set of single nucleotide variance locations, wherein detecting either an allelic imbalance equal to or greater than 45% or detecting the single nucleotide variant, or both, is indicative of the presence of circulating tumor nucleic acids in the sample.

[0019] In certain embodiments analyzing step in the method for determining whether circulating tumor nucleic acids are present, includes analyzing a set of chromosome segments known to exhibit aneuploidy in cancer. In certain embodiments analyzing step in the method for determining whether circulating tumor nucleic acids are present, includes analyzing between 1,000 and 50,000 or between 100 and 1000, polymorphic loci for ploidy.

[0020] In certain aspects, provided herein are methods for detecting single nucleotide variants in a sample. Accordingly, provided herein is a method for determining whether a single nucleotide variant is present at a set of genomic positions in a sample from an individual, the method comprising:

a. for each genomic position, generating an estimate of efficiency and a per cycle error rate for an amplicon spanning that genomic position, using a training data set;

b. receiving observed nucleotide identity information for each genomic position in the sample;

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 152

c. determining a set of probabilities of single nucleotide variant percentage resulting from one or more real mutations at each genomic position, by comparing the observed nucleotide identity information at each genomic position to a model of different variant percentages using the estimated amplification efficiency and the per cycle error rate for each genomic position independently; and

d. determining the most-likely real variant percentage and confidence from the set of probabilities for each genomic position.

[0021] In illustrative embodiments of the method for determining whether a single nucleotide variant is present, the estimate of efficiency and the per cycle error rate is generated for a set of amplicons that span the genomic position. For example, 2, 3, 4, 5, 10, 15, 20, 25, 50, 100 or more amplicons can be included that span the genomic position. In certain embodiments of this method for detecting one or more SNVs the limit of detection is 0.015%, 0.017%, or 0.02%.

[0022] In illustrative embodiments of the method for determining whether a single nucleotide variant is present, the observed nucleotide identity information comprises an observed number of total reads for each genomic position and an observed number of variant allele reads for each genomic position.

[0023] In illustrative embodiments of the method for determining whether a single nucleotide variant is present, the sample is a plasma sample and the single nucleotide variant is present in circulating tumor DNA of the sample.

[0024] In another embodiment, provided herein is a method for detecting one or more single nucleotide variants in a test sample from an individual. The method according to this embodiment, includes the following steps:

a. determining a median variant allele frequency for a plurality of control samples from each of a plurality of normal individuals, for each single nucleotide variant position in a set of single nucleotide variance positions based on results generated in a sequencing run, to identify selected single nucleotide variant positions having variant median allele frequencies in normal samples below a threshold value and to determine background error for each of the single nucleotide variant positions after removing outlier samples for each of the single nucleotide variant positions;

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 153

b. determining an observed depth of read weighted mean and variance for the selected single nucleotide variant positions for the test sample based on data generated in the sequencing run for the test sample; and

c. identifying using a computer, one or more single nucleotide variant positions with a statistically significant depth of read weighted mean compared to the background error for that position, thereby detecting the one or more single nucleotide variants.

[0025] In certain embodiments of this method for detecting one or more SNVs the sample is a plasma sample, the control samples are plasma samples, and the detected one or more single nucleotide variants detected is present in circulating tumor DNA of the sample. In certain embodiments of this method for detecting one or more SNVs the plurality of control samples comprises at least 25 samples. In certain embodiments of this method for detecting one or more SNVs, outliers are removed from the data generated in the high throughput sequencing run to calculate the observed depth of read weighted mean and observed variance are determined. In certain embodiments of this method for detecting one or more SNVs the depth of read for each single nucleotide variant position for the test sample is at least 100 reads.

[0026] In certain embodiments of this method for detecting one or more SNVs the sequencing run comprises a multiplex amplification reaction performed under limited primer reaction conditions. In certain embodiments of this method for detecting one or more SNVs the limit of detection is 0.015%, 0.017%, or 0.02%.

[0027] In one aspect, the invention features a method of determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of one or more cells from an individual. In some embodiments, the method includes obtaining phased genetic data for the first homologous chromosome segment comprising, the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, obtaining phased genetic data for the second homologous chromosome segment comprising the identity of the allele present at that locus on the second homologous chromosome segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and obtaining measured genetic allelic data comprising the amount of each allele present in a sample of DNA or RNA from one or more cells from the individual , for each of the alleles at each of the loci in the set of polymorphic loci. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 154

embodiments, the method includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment in the genome of one or more cells from the individual, calculating (such as calculating on a computer) a likelihood of one or more of the hypotheses based on the obtained genetic data of the sample and the obtained phased genetic data, and selecting the hypothesis with the greatest likelihood, thereby determining the degree of overrepresentation of the number of copies of the first homologous chromosome segment in the genome of one or more cells from the individual. In some embodiments, the phased data includes inferred phased data using population based haplotype frequencies and/or measured phased data (*e.g.*, phased data obtained by measuring a sample containing DNA or RNA from the individual or a relative of the individual).

[0028] In one aspect, the invention provides a method for determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of one or more cells from an individual. In some embodiments, the method includes obtaining phased genetic data for the first homologous chromosome segment comprising the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, obtaining phased genetic data for the second homologous chromosome segment comprising the identity of the allele present at that locus on the second homologous chromosome segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and obtaining measured genetic allelic data comprising the amount of each allele present in a sample of DNA or RNA from one or more cells from the individual for each of the alleles at each of the loci in the set of polymorphic loci. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment; calculating, for each of the hypotheses, expected genetic data for the plurality of loci in the sample from the obtained phased genetic data; calculating (such as calculating on a computer) the data fit between the obtained genetic data of the sample and the expected genetic data for the sample; ranking one or more of the hypotheses according to the data fit; and selecting the hypothesis that is ranked the highest, thereby determining the degree of overrepresentation of the number of copies of the first homologous chromosome segment in the genome of one or more cells from the individual.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 155

[0029] In one aspect, the invention features a method for determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of one or more cells from an individual. In some embodiments, the method includes obtaining phased genetic data for the first homologous chromosome segment comprising the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, obtaining phased genetic data for the second homologous chromosome segment comprising the identity of the allele present at that locus on the second homologous chromosome segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and obtaining measured genetic allelic data comprising, for each of the alleles at each of the loci in the set of polymorphic loci, the amount of each allele present in a sample of DNA or RNA from one or more target cells and one or more non-target cells from the individual. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment; calculating (such as calculating on a computer), for each of the hypotheses, expected genetic data for the plurality of loci in the sample from the obtained phased genetic data for one or more possible ratios of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample; calculating (such as calculating on a computer) for each possible ratio of DNA or RNA and for each hypothesis, the data fit between the obtained genetic data of the sample and the expected genetic data for the sample for that possible ratio of DNA or RNA and for that hypothesis; ranking one or more of the hypotheses according to the data fit; and s e l e c t i n g the hypothesis that is ranked the highest, thereby determining the degree of overrepresentation of the number of copies of the first homologous chromosome segment in the genome of one or more cells from the individual.

[0030] In one aspect, the invention features a method for determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of one or more cells from an individual. In some embodiments, the method includes obtaining phased genetic data for the first homologous chromosome segment comprising the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, obtaining phased genetic data for the second homologous

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 156

chromosome segment comprising the identity of the allele present at that locus on the second homologous chromosome segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and obtaining measured genetic allelic data comprising the amount of each allele present in a sample of DNA or RNA from one or more target cells and one or more non-target cells from the individual for each of the alleles at each of the loci in the set of polymorphic loci. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment; calculating (such as calculating on a computer), for each of the hypotheses, expected genetic data for the plurality of loci in the sample from the obtained phased genetic data for one or more possible ratios of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample; calculating (such as calculating on a computer) for each locus in the plurality of loci, each possible ratio of DNA or RNA, and each hypothesis, the likelihood that the hypothesis is correct by comparing the obtained genetic data of the sample for that locus and the expected genetic data for that locus for that possible ratio of DNA or RNA and for that hypothesis; determining the combined probability for each hypothesis by combining the probabilities of that hypothesis for each locus and each possible ratio; and selecting the hypothesis with the greatest combined probability, thereby determining the degree of overrepresentation of the number of copies of the first homologous chromosome segment. In some embodiments, all of the loci are considered at once to calculate the probability of a particular hypothesis, and the hypothesis with the greatest probability is selected.

[0031] In one aspect, the invention features a method for determining a number of copies of a chromosome segment of interest in the genome of a fetus. In some embodiments, the method includes obtaining phased genetic data for at least one biological parent of the fetus, wherein the phased genetic data comprises the identity of the allele present for each locus in a set of polymorphic loci on a first homologous chromosome segment and a second homologous chromosome segment in a pair of homologous chromosome segments that comprises the chromosome segment of interest. In some embodiments, the method includes obtaining genetic data at the set of polymorphic loci on the chromosome segment of interest in a mixed sample of DNA or RNA comprising fetal DNA or RNA and maternal DNA or RNA from the mother of the fetus by measuring the quantity of each allele at each locus. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 157

number of copies of the chromosome segment of interest present in the genome of the fetus. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying, for one or both parents, the number of copies of the first homologous chromosome segment or portion thereof from the parent in the genome of the fetus, the number of copies of the second homologous chromosome segment or portion thereof from the parent in the genome of the fetus, and the total number of copies of the chromosome segment of interest present in the genome of the fetus. In some embodiments, the method includes calculating (such as calculating on a computer), for each of the hypotheses, expected genetic data for the plurality of loci in the mixed sample from the obtained phased genetic data from the parent(s); calculating (such as calculating on a computer) the data fit between the obtained genetic data of the mixed sample and the expected genetic data for the mixed sample; ranking one or more of the hypotheses according to the data fit; and selecting the hypothesis that is ranked the highest, thereby determining the number of copies of the chromosome segment of interest in the genome of the fetus.

[0032] In one aspect, the invention features a method for determining a number of copies of a chromosome or chromosome segment of interest in the genome of a fetus. In some embodiments, the method includes obtaining phased genetic data for at least one biological parent of the fetus, wherein the phased genetic data comprises the identity of the allele present for each locus in a set of polymorphic loci on a first homologous chromosome segment and a second homologous chromosome segment in the parent. In some embodiments, the method includes obtaining genetic data at the set of polymorphic loci on the chromosome or chromosome segment in a mixed sample of DNA or RNA comprising fetal DNA or RNA and maternal DNA or RNA from the mother of the fetus by measuring the quantity of each allele at each locus. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the number of copies of the chromosome or chromosome segment of interest present in the genome of the fetus. In some embodiments, the method includes creating (such as creating on a computer) for each of the hypotheses, a probability distribution of the expected quantity of each allele at each of the plurality of loci in mixed sample from the (i) the obtained phased genetic data from the parent(s) and (ii) optionally the probability of one or more crossovers that may have occurred during the formation of a gamete that contributed a copy of the chromosome or chromosome segment of interest to the fetus; calculating (such as calculating on a computer) a fit, for each of the hypotheses, between (1) the obtained genetic data of the mixed

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 158

sample and (2) the probability distribution of the expected quantity of each allele at each of the plurality of loci in mixed sample for that hypothesis; ranking one or more of the hypotheses according to the data fit; and selecting the hypothesis that is ranked the highest, thereby determining the number of copies of the chromosome segment of interest in the genome of the fetus.

[0033] In some embodiments, the method includes obtaining phased genetic data for the mother of the fetus. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the number of copies of the first homologous chromosome segment or portion thereof from the mother in the genome of the fetus, the number of copies of the second homologous chromosome segment or portion thereof from the mother in the genome of the fetus, and the total number of copies of the chromosome segment of interest present in the genome of the fetus. In some embodiments, the method includes calculating, for each of the hypotheses, expected genetic data for the plurality of loci in the mixed sample from the obtained phased genetic data from the mother.

[0034] In some embodiments, the expected genetic data for each of the hypotheses comprises the identity and an amount of one or more alleles at each locus in the plurality of loci from the maternal DNA or RNA and fetal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating (such as calculating on a computer) expected genetic data by determining a fraction of fetal DNA or RNA and a fraction of maternal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating, for each locus in the plurality of loci, the expected amount of one or more of the alleles for that locus in the maternal DNA or RNA in the mixed sample using the identity of the allele(s) present at that locus in the obtained phased genetic data of the mother and the fraction of maternal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating (such as calculating on a computer), for each locus in the plurality of loci for each hypothesis, the expected amount of one or more of the alleles for that locus in the fetal DNA or RNA inherited from the mother in the mixed sample using the identity of the allele present at that locus in the first or second homologous chromosome segment from the mother that is specified by the hypothesis to have been inherited by the fetus, the number of copies of the first or second homologous chromosome segment from the mother that is specified by the hypothesis to have been inherited by the fetus, and the fraction of fetal DNA or RNA in the mixed sample.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 159

[0035] In some embodiments, the expected genetic data for each of the hypotheses comprises the identity and an amount of one or more alleles at each locus in the plurality of loci from the maternal DNA or RNA and fetal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating expected genetic data by determining a fraction of fetal DNA or RNA and a fraction of maternal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating (such as calculating on a computer), for each locus in the plurality of loci, the expected amount of one or more of the alleles for that locus in the maternal DNA or RNA in the mixed sample using the identity of the allele(s) present at that locus in the obtained phased genetic data of the mother and the fraction of maternal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating (such as calculating on a computer), for each locus in the plurality of loci for each hypothesis, the expected amount of one or more of the alleles for that locus in the fetal DNA or RNA inherited from the mother in the mixed sample using the identity of the allele present at that locus in the first or second homologous chromosome segment from the mother that is specified by the hypothesis to have been inherited by the fetus, the number of copies of the first or second homologous chromosome segment from the mother that is specified by the hypothesis to have been inherited by the fetus, the identity of one or more possible alleles at that locus in the first or second homologous chromosome segment from the father that is specified by the hypothesis to have been inherited by the fetus, the number of copies of the first or second homologous chromosome segment from the father that is specified by the hypothesis to have been inherited by the fetus, and the fraction of fetal DNA or RNA in the mixed sample. In some embodiments, population frequencies are used to predict the identity of the alleles in the first or second homologous chromosome segment from the father. In some embodiments, the probability for each of the possible alleles at each locus in the first or second homologous chromosome segment from the father are considered to be the same.

[0036] In some embodiments, the method includes obtaining phased genetic data for both the mother and father of the fetus. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the number of copies of the first homologous chromosome segment or portion thereof from the mother in the genome of the fetus, the number of copies of the second homologous chromosome segment or portion thereof from the mother in the genome of the fetus, the number of copies of the first homologous chromosome segment or portion thereof from the father in the genome of the fetus, the number of copies of the second homologous

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 160

chromosome segment or portion thereof from the father in the genome of the fetus, and the total number of copies of the chromosome segment of interest present in the genome of the fetus. In some embodiments, the method includes calculating (such as calculating on a computer), for each of the hypotheses, expected genetic data for the plurality of loci in the mixed sample from the obtained phased genetic data from the mother and obtained phased genetic data from the father.

[0037] In some embodiments, the expected genetic data for each of the hypotheses comprises the identity and an amount of one or more alleles at each locus in the plurality of loci from the maternal DNA or RNA and fetal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating expected genetic data by determining a fraction of fetal DNA or RNA and a fraction of maternal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating (such as calculating on a computer), for each locus in the plurality of loci, the expected amount of one or more of the alleles for that locus in the maternal DNA or RNA in the mixed sample using the identity of the allele(s) present at that locus in the obtained phased genetic data of the mother and the fraction of maternal DNA or RNA in the mixed sample. In some embodiments, the method includes calculating (such as calculating on a computer), for each locus in the plurality of loci for each hypothesis, the expected amount of one or more of the alleles for that locus in the fetal DNA or RNA in the mixed sample using the identity of the allele present at that locus in the first or second homologous chromosome segment from the mother that is specified by the hypothesis to have been inherited by the fetus, the number of copies of the first or second homologous chromosome segment from the mother that is specified by the hypothesis to have been inherited by the fetus, the identity of the allele present at that locus in the first or second homologous chromosome segment from the father that is specified by the hypothesis to have been inherited by the fetus, the number of copies of the first or second homologous chromosome segment from the father that is specified by the hypothesis to have been inherited by the fetus, and the fraction of fetal DNA or RNA in the mixed sample.

[0038] In some embodiments, the method includes calculating (such as calculating on a computer), for each of the hypotheses, a probability distribution of expected genetic data for the plurality of loci in the mixed sample from the obtained phased genetic data from the parent(s). In some embodiments, the method includes increasing the probability in the probability distribution of an a particular allele being present at a first locus in the mixed sample if that particular allele is present in the first homologous segment in the parent and an allele at a nearby locus in the first homologous

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 161

segment in the parent is observed in the obtained genetic data of the mixed sample; or decreasing the probability in the probability distribution of an a particular allele being present at a first locus in the mixed sample if that particular allele is present in the first homologous segment in the parent and an allele at a nearby locus in the first homologous segment in the parent is not observed in the obtained genetic data of the mixed sample. In some embodiments, the method includes increasing the probability in the probability distribution of an a particular allele being present at a second locus in the mixed sample if that particular allele is present in the second homologous segment in the parent and an allele at a nearby locus in the second homologous segment in the parent is observed in the obtained genetic data of the mixed sample; or decreasing the probability in the probability distribution of an a particular allele being present at a second locus in the mixed sample if that particular allele is present in the second homologous segment in the parent and an allele at a nearby locus in the second homologous segment in the parent is not observed in the obtained genetic data of the mixed sample.

[0039] In some embodiments, the method includes obtaining phased genetic data for both the mother and father of the fetus. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the number of copies of the first homologous chromosome segment or portion thereof from the mother in the genome of the fetus, the number of copies of the second homologous chromosome segment or portion thereof from the mother in the genome of the fetus, the number of copies of the first homologous chromosome segment or portion thereof from the father in the genome of the fetus, the number of copies of the second homologous chromosome segment or portion thereof from the father in the genome of the fetus, and the total number of copies of the chromosome segment of interest present in the genome of the fetus. In some embodiments, the method includes calculating (such as calculating on a computer), for each of the hypotheses, a probability distribution of expected genetic data for the plurality of loci in the mixed sample from the obtained phased genetic data from the mother and father. In some embodiments, the method includes increasing the probability in the probability distribution of an a particular allele being present at a first locus in the mixed sample if that particular allele is present in the first homologous segment in the mother or father and an allele at a nearby locus in the first homologous segment in that parent is observed in the obtained genetic data of the mixed sample; or decreasing the probability in the probability distribution of an a particular allele being present at a first locus in the mixed sample if that particular allele is present in the first homologous

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 162

segment in the mother or father and an allele at a nearby locus in the first homologous segment in that parent is not observed in the obtained genetic data of the mixed sample. In some embodiments, the method includes increasing the probability in the probability distribution of an a particular allele being present at a second locus in the mixed sample if that particular allele is present in the second homologous segment in the mother or father and an allele at a nearby locus in the second homologous segment in that parent is observed in the obtained genetic data of the mixed sample; or decreasing the probability in the probability distribution of an a particular allele being present at a second locus in the mixed sample if that particular allele is present in the second homologous segment in the mother or father and an allele at a nearby locus in the second homologous segment in that parent is not observed in the obtained genetic data of the mixed sample.

[0040] In some embodiments, the first locus and the locus that is nearby to the first locus co-segregate. In some embodiments, the second locus and the locus that is nearby to the second locus co-segregate. In some embodiments, no crossovers are expected to occur between the first locus and the locus that is nearby to the first locus. In some embodiments, no crossovers are expected to occur between the second locus and the locus that is nearby to the second locus. In some embodiments, the distance between the first locus and the locus that is nearby to the first locus is less than 5 mb, 1 mb, 100 kb, 10 kb, 1 kb, 0.1 kb, or 0.01 kb. In some embodiments, the distance between the second locus and the locus that is nearby to the second locus is less than 5 mb, 1 mb, 100 kb, 10 kb, 1 kb, 0.1 kb, or 0.01 kb.

[0041] In some embodiments, one or more crossovers occurs during the formation of a gamete that contributed a copy of the chromosome segment of interest to the fetus; and the crossover produces a chromosome segment of interest in the genome of the fetus that comprises a portion of the first homologous segment and a portion of the second homologous segment from the parent. In some embodiments, the set of hypothesis comprises one or more hypotheses specifying the number of copies of the chromosome segment of interest in the genome of the fetus that comprises a portion of the first homologous segment and a portion of the second homologous segment from the parent.

[0042] In some embodiments, the expected genetic data of the mixed sample comprises the expected amount of one or more of the alleles at each locus in the plurality of loci in the mixed sample for each of the hypotheses.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 163

[0043] In one aspect, the invention features a method of determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of an individual (such as in the genome of one or more cells, cfDNA, cfRNA, an individual suspected of having cancer, a fetus, or an embryo) using phased genetic data. In some embodiments, the method involves simultaneously or sequentially in any order (i) obtaining phased genetic data for the first homologous chromosome segment comprising the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, (ii) obtaining phased genetic data for the second homologous chromosome segment comprising the identity of the allele present at that locus on the second homologous chromosome segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and (iii) obtaining measured genetic allelic data comprising the amount of each allele at each of the loci in the set of polymorphic loci in a sample of DNA or RNA from one or more cells from the individual or in a mixed sample of cell-free DNA or RNA from two or more genetically different cells from the individual. In some embodiments, the method involves calculating allele ratios for one or more loci in the set of polymorphic loci that are heterozygous in at least one cell from which the sample was derived. In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles divided by the total measured quantity of all the alleles for the locus. In some embodiments, the method involves determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment by comparing one or more calculated allele ratios for a locus to an expected allele ratio, such as a ratio that is expected for that locus if the first and second homologous chromosome segments are present in equal proportions. In some embodiments, the expected ratio is 0.5 for biallelic loci.

[0044] In some embodiments for prenatal testing, the method involves simultaneously or sequentially in any order (i) obtaining phased genetic data for the first homologous chromosome segment in the genome of a fetus (such as a fetus gestating in a pregnant mother) comprising the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, (ii) obtaining phased genetic data for the second homologous chromosome segment in the genome of the fetus comprising the identity of the allele present at that locus on the second homologous chromosome

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 164

segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and (iii) obtaining measured genetic allelic data comprising the amount of each allele at each of the loci in the set of polymorphic loci in a mixed sample of DNA or RNA from the mother of the fetus that includes fetal DNA or RNA and maternal DNA or RNA (such as a mixed sample of cell-free DNA or RNA originating from a blood sample from the mother that includes fetal cell-free DNA or RNA and maternal cell-free DNA or RNA). In some embodiments, the method involves calculating allele ratios for one or more loci in the set of polymorphic loci that are heterozygous in the fetus and/or heterozygous in the mother. In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles divided by the total measured quantity of all the alleles for the locus. In some embodiments, the method involves determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment by comparing one or more calculated allele ratios for a locus to an expected allele ratio, such as a ratio that is expected for that locus if the first and second homologous chromosome segments are present in equal proportions.

[0045] In some embodiments, a calculated allele ratio is indicative of an overrepresentation of the number of copies of the first homologous chromosome segment if either (i) the allele ratio for the measured quantity of the allele present at that locus on the first homologous chromosome divided by the total measured quantity of all the alleles for the locus is greater than the expected allele ratio for that locus, or (ii) the allele ratio for the measured quantity of the allele present at that locus on the second homologous chromosome divided by the total measured quantity of all the alleles for the locus is less than the expected allele ratio for that locus. In some embodiments, a calculated allele ratio is indicative of no overrepresentation of the number of copies of the first homologous chromosome segment if either (i) the allele ratio for the measured quantity of the allele present at that locus on the first homologous chromosome divided by the total measured quantity of all the alleles for the locus is less than or equal to the expected allele ratio for that locus, or (ii) the allele ratio for the measured quantity of the allele present at that locus on the second homologous chromosome divided by the total measured quantity of all the alleles for the locus is greater than or equal to the expected allele ratio for that locus.

[0046] In some embodiments, determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 165

segment. In some embodiments, predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) are estimated for each hypothesis given the degree of overrepresentation specified by that hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing the calculated allele ratios to the predicted allele ratios, and the hypothesis with the greatest likelihood is selected. In some embodiments, an expected distribution of a test statistic is calculated using the predicted allele ratios for each hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing a test statistic that is calculated using the calculated allele ratios to the expected distribution of the test statistic that is calculated using the predicted allele ratios, and the hypothesis with the greatest likelihood is selected. In some embodiments, predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) are estimated given the phased genetic data for the first homologous chromosome segment, the phased genetic data for the second homologous chromosome segment, and the degree of overrepresentation specified by that hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing the calculated allele ratios to the predicted allele ratios; and the hypothesis with the greatest likelihood is selected.

[0047] In some embodiments, the ratio of DNA (or RNA) from one or more target cells to the total DNA (or RNA) in the sample is calculated. An exemplary ratio is the ratio of fetal DNA (or RNA) to the total DNA (or RNA) in the sample. In some embodiments, the ratio of fetal DNA to total DNA in the sample is determined by measuring the amount of an allele at one or more loci in which the fetus has the allele and the mother does not have the allele. In some embodiments, the ratio of fetal DNA to total DNA in the sample is determined by measuring the difference in methylation between one or more maternal and fetal alleles. In some embodiments, a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment are enumerated. In some embodiments, predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) are estimated given the calculated ratio of DNA or RNA and the degree of overrepresentation specified by that hypothesis are estimated for each hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing the calculated allele ratios to the predicted allele ratios, and the hypothesis with the greatest likelihood

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 166

is selected. In some embodiments, an expected distribution of a test statistic calculated using the predicted allele ratios and the calculated ratio of DNA or RNA is estimated for each hypothesis. In some embodiments, the likelihood that the hypothesis is correct is determined by comparing a test statistic calculated using the calculated allele ratios and the calculated ratio of DNA or RNA to the expected distribution of the test statistic calculated using the predicted allele ratios and the calculated ratio of DNA or RNA, and the hypothesis with the greatest likelihood is selected.

[0048] In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment. In some embodiments, the method includes estimating, for each hypothesis, either (i) predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) given the degree of overrepresentation specified by that hypothesis or (ii) for one or more possible ratios of DNA or RNA (such as ratios of fetal DNA or RNA to the total DNA or RNA in the sample), an expected distribution of a test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA from the one or more target cells (such as fetal cells) to the total DNA or RNA in the sample. In some embodiments, a data fit is calculated by comparing either (i) the calculated allele ratios to the predicted allele ratios, or (ii) a test statistic calculated using the calculated allele ratios and the possible ratio of DNA or RNA to the expected distribution of the test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA. In some embodiments, one or more of the hypotheses are ranked according to the data fit, and the hypothesis that is ranked the highest is selected. In some embodiments, a technique or algorithm, such as a search algorithm, is used for one or more of the following steps: calculating the data fit, ranking the hypotheses, or selecting the hypothesis that is ranked the highest. In some embodiments, the data fit is a fit to a beta-binomial distribution or a fit to a binomial distribution. In some embodiments, the technique or algorithm is selected from the group consisting of maximum likelihood estimation, maximum a-posteriori estimation, Bayesian estimation, dynamic estimation (such as dynamic Bayesian estimation), and expectation-maximization estimation. In some embodiments, the method includes applying the technique or algorithm to the obtained genetic data and the expected genetic data.

[0049] In some embodiments, the method includes creating a partition of possible ratios (such as ratios of fetal DNA or RNA to the total DNA or RNA in the sample) that range from a lower limit

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 167

to an upper limit for the ratio of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample. In some embodiments, a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment are enumerated. In some embodiments, the method includes estimating, for each of the possible ratios of DNA or RNA in the partition and for each hypothesis, either (i) predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) given the possible ratio of DNA or RNA and the degree of overrepresentation specified by that hypothesis or (ii) an expected distribution of a test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA. In some embodiments, the method includes calculating, for each of the possible ratios of DNA or RNA in the partition and for each hypothesis, the likelihood that the hypothesis is correct by comparing either (i) the calculated allele ratios to the predicted allele ratios, or (ii) a test statistic calculated using the calculated allele ratios and the possible ratio of DNA or RNA to the expected distribution of the test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA. In some embodiments, the combined probability for each hypothesis is determined by combining the probabilities of that hypothesis for each of the possible ratios in the partition; and the hypothesis with the greatest combined probability is selected. In some embodiments, the combined probability for each hypothesis is determining by weighting the probability of a hypothesis for a particular possible ratio based on the likelihood that the possible ratio is the correct ratio.

[0050] In one aspect, the invention features a method for determining a number of copies of a chromosome or chromosome segment in the genome of one or more cells from an individual using phased or unphased genetic data. In some embodiments, the method involves obtaining genetic data at a set of polymorphic loci on the chromosome or chromosome segment in a sample by measuring the quantity of each allele at each locus. In some embodiments, the sample is a sample of DNA or RNA from one or more cells from the individual or a mixed sample of cell-free DNA from the individual that includes cell-free DNA from two or more genetically different cells. In some embodiments, allele ratios are calculated for the loci that are heterozygous in at least one cell from which the sample was derived. In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles divided by the total measured quantity of all the alleles for the locus. In some embodiments, the calculated allele ratio for a particular

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 168

locus is the measured quantity of one of the alleles (such as the allele on the first homologous chromosome segment) divided by the measured quantity of one or more other alleles (such as the allele on the second homologous chromosome segment) for the locus. In some embodiments, a set of one or more hypotheses specifying the number of copies of the chromosome or chromosome segment in the genome of one or more of the cells are enumerated. In some embodiments, the hypothesis that is most likely based on the test statistic is selected, thereby determining the number of copies of the chromosome or chromosome segment in the genome of one or more of the cells.

[0051] In one aspect, the invention features a method for determining a number of copies of a chromosome or chromosome segment in the genome of a fetus (such as a fetus that is gestating in a pregnant mother) using phased or unphased genetic data. In some embodiments, the method involves obtaining genetic data at a set of polymorphic loci on the chromosome or chromosome segment in a sample by measuring the quantity of each allele at each locus. In some embodiments, the sample is a mixed sample of DNA comprising fetal DNA or RNA and maternal DNA or RNA from the mother of the fetus (such as a mixed sample of cell-free DNA or RNA originating from a blood sample from the mother that includes fetal cell-free DNA or RNA and maternal cell-free DNA or RNA). In some embodiments, allele ratios are calculated for the loci that are heterozygous in the fetus and/or heterozygous in the mother. In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles divided by the total measured quantity of all the alleles for the locus. In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles (such as the allele on the first homologous chromosome segment) divided by the measured quantity of one or more other alleles (such as the allele on the second homologous chromosome segment) for the locus. In some embodiments, a set of one or more hypotheses specifying the number of copies of the chromosome or chromosome segment in the genome of fetus are enumerated. In some embodiments, the hypothesis that is most likely based on the test statistic is selected, thereby determining the number of copies of the chromosome or chromosome segment in the genome of the fetus.

[0052] In some embodiments, a hypotheses is selected if the probability that the test statistic belongs to a distribution of the test statistic for that hypothesis is above an upper threshold; one or more of the hypotheses is rejected if the probability that the test statistic belongs to the distribution of the test statistic for that hypothesis is below an lower threshold; or a hypothesis is neither selected

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 169

nor rejected if the probability that the test statistic belongs to the distribution of the test statistic for that hypothesis is between the lower threshold and the upper threshold, or if the probability is not determined with sufficiently high confidence. In some embodiments, the overrepresentation of the number of copies of the first homologous chromosome segment is due to a duplication of the first homologous chromosome segment or a deletion of the second homologous chromosome segment. In some embodiments, the total measured quantity of all the alleles for one or more of the loci is compared to a reference amount to determine whether the overrepresentation of the number of copies of the first homologous chromosome segment is due to a duplication of the first homologous chromosome segment or a deletion of the second homologous chromosome segment. In some embodiments, the magnitude of the difference between the calculated allele ratio and the expected allele ratio for one or more loci is used to determine whether the overrepresentation of the number of copies of the first homologous chromosome segment is due to a duplication of the first homologous chromosome segment or a deletion of the second homologous chromosome segment. In some embodiments, the first and second homologous chromosome segments are determined to be present in equal proportions if there is not an overrepresentation of the number of copies of the first homologous chromosome segment, and there is not an overrepresentation of the second homologous chromosome segment (such as in the genome of the cells, cfDNA, cfRNA, individual, fetus, or embryo).

[0053] In some embodiments, the ratio of DNA from the one or more target cells to the total DNA in the sample is determined based on the total or relative amount of one or more alleles at one or more loci for which the genotype of the target cells differs from the genotype of the non-target cells and for which the target cells and non-target cells are expected to be disomic. In some embodiments, this ratio is used to determine whether the overrepresentation of the number of copies of the first homologous chromosome segment is due to a duplication of the first homologous chromosome segment or a deletion of the second homologous chromosome segment. In some embodiments, the ratio is used to determine the number of extra copies of a chromosome segment or chromosome that is duplicated. In some embodiments, the phased genetic data includes probabilistic data. In some embodiments, obtaining the phased genetic data for the first homologous chromosome segment and/or the second homologous chromosome segment in the genome of the fetus includes obtaining phased genetic data for the first homologous chromosome segment and/or the second homologous chromosome segment in the genome of one or both

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 170

biological parents of the fetus, and inferring which homologous chromosome segment the fetus inherited from one or both biological parents. In some embodiments, the probability of one or more crossovers (such as 1, 2, 3, or 4 crossovers) that may have occurred during the formation of a gamete that contributed a copy of the first homologous chromosome segment or the second homologous chromosome segment to the fetus individual is used to infer which homologous chromosome segment(s) the fetus inherited from one or both biological parents. In some embodiments, phased genetic data for the mother and/or father of the fetus is obtained using a technique selected from the group consisting of digital PCR, inferring a haplotype using population based haplotype frequencies, haplotyping using a haploid cell such as a sperm or egg, haplotyping using genetic data from one or more first degree relatives, and combinations thereof. In some embodiments, the phased genetic data for the individual is obtained by phasing a portion or all of region corresponding to a deletion or duplication in a sample from the individual. In some embodiments, the phased genetic data for a fetus is obtained by phasing a portion or all of region corresponding to a deletion or duplication in a sample from the fetus or the mother of the fetus. In some embodiments, obtaining phased genetic data for the first and second homologous chromosome segments includes determining the identity of alleles present in one of the chromosome segments and determining the identity of alleles present in the other chromosome segment by inference. In some embodiments, alleles from unphased genetic data that are not present in the first homologous chromosome segment are assigned to the second homologous chromosome segment. For example, if the genotype of the individual is (AB, AB) and the phased data for the individual indicates that the first haplotype is (A,A); then, the other haplotype can be inferred to be (B,B). In some embodiments, if only one allele is measured at a locus then that allele is determined to be part of both the first and second homologous chromosome segments (e.g., if the genotype is AA at a locus than both haplotypes have the A allele). In some embodiments, the phased genetic data for the individual comprises determining whether or not one or more possible chromosome crossovers occurred, such as by determining the sequence of a recombination hotspot and optionally of a region flanking a recombination hotspot. In some embodiments, any of the primer libraries of the invention are used to detect a recombination event to determine what haplotype blocks are present in the genome of an individual.

[0054] In some embodiments, the method includes using a joint distribution model (such as a joint distribution model that takes into account the linkage between loci), performing a linkage analysis,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 171

using a binomial distribution model, using a beta-binomial distribution model, and/or using the likelihood of crossovers having occurred during the meiosis that gave rise to the gametes that formed the embryo that grew into the fetus (such as using the probability of chromosomes crossing over at different locations in a chromosome to model dependence between polymorphic alleles on the chromosome or chromosome segment of interest).

[0055] In some embodiments, one or more of the calculated allele ratios for the cfDNA or cfRNA are indicative of the corresponding allele ratios for DNA or RNA in the cells from which the cfDNA or cfRNA was derived. In some embodiments, one or more of the calculated allele ratios for the cfDNA or cfRNA are indicative of the corresponding allele ratios in the genome of the individual. In some embodiments, an allele ratio is only calculated or is only compared to an expected allele ratio if the measured genetic data indicate that more than one different allele is present for that locus in the sample (such as in a cfDNA or cfRNA sample). In some embodiments, an allele ratio is only calculated or is only compared to an expected allele ratio if the locus is heterozygous in at least one of the cells from which the sample was derived (such as a locus that is heterozygous in the fetus and/or heterozygous in the mother). In some embodiments, an allele ratio is only calculated or is only compared to an expected allele ratio if the locus is heterozygous in the fetus. In some embodiments, an allele ratio is calculated and compared to an expected allele ratio for a homozygous locus. For example, allele ratios for loci that are predicted to be homozygous for a particular individual being tested (or for both a fetus and pregnant mother) may be analyzed to determine the level of noise or error in the system.

[0056] In some embodiments, at least 10; 50; 100; 200; 300; 500; 750; 1,000; 2,000; 3,000; 4,000, or more loci (such as SNPs) are analyzed for a chromosome or chromosome segment of interest. In some embodiments, the average number of loci (such as SNPs) per mb in a chromosome or chromosome segment of interest is at least 1; 10; 25; 50; 100; 150; 200; 300; 500; 750; 1,000; or more loci per mb. In some embodiments, the average number of loci (such as SNPs) per mb in a chromosome or chromosome segment of interest is between 1 and 500 loci per mb, such as between 1 and 50, 50 and 100, 100 and 200, 200 and 400, 200 and 300, or 300 and 400 loci per mb, inclusive. In some embodiments, loci in multiple portions of a potential deletion or duplication are analyzed to increase the sensitivity and/or specificity of the CNV determination compared to

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 172

only analyzing 1 loci or only analyzing a few loci that are near each other. In some embodiments, only the two most common alleles at each locus are measured or are used to determine the calculated allele ratio. In some embodiments, the amplification of loci is performed using a polymerase (*e.g.*, a DNA polymerase, RNA polymerase, or reverse transcriptase) with low 5′→ 3′ exonuclease and/or low strand displacement activity. In some embodiments, the measured genetic allelic data is obtained by (i) sequencing the DNA or RNA in the sample,(ii) amplifying DNA or RNA in the sample and then sequencing the amplified DNA, or (ii) amplifying the DNA or RNA in the sample, ligating PCR products, and then sequencing the ligated products. In some embodiments, measured genetic allelic data is obtained by dividing the DNA or RNA from the sample into a plurality of fractions, adding a different barcode to the DNA or RNA in each fraction (*e.g.*, such that all the DNA or RNA in a particular fraction has the same barcode), optionally amplifying the barcoded DNA or RNA, combining the fractions, and then sequencing the barcoded DNA or RNA in the combined fractions. In some embodiments, alleles of the polymorphic loci (such as SNPs) are identified using one or more of the following methods: sequencing (such as nanopore sequencing or Halcyon Molecular sequencing), SNP array, real time PCR, TaqMan, Nanostring nCounter® Analysis System, Illumina GoldenGate Genotyping Assay that uses a discriminatory DNA polymerase and ligase, ligation-mediated PCR, or Linked Inverted Probes (LIPs; which can also be called pre-circularized probes, pre-circularizing probes, circularizing probes, Padlock Probes, or Molecular Inversion Probes (MIPs)). In some embodiments, two or more (such as 3 or 4) target amplicons are ligated together and then the ligated products are sequenced. In some embodiments, measurements for different alleles for the same locus are adjusted for differences in metabolism, apoptosis, histones, inactivation, and/or amplification between the alleles (such as differences in amplification efficiency between different alleles of the same locus). In some embodiments, this adjustment is performed prior to calculating allele ratios for the obtained genetic data or prior to comparing the measured genetic data to the expected genetic data.

[0057] In some embodiments, the method also includes determining the presence or absence of one or more risk factors for a disease or disorder. In some embodiments, the method also includes determining the presence or absence of one or more polymorphisms or mutations associated with the disease or disorder or an increased risk for a disease or disorder. In some embodiments, the method also includes determining the total level of cfDNA cf mDNA, cf nDNA, cfRNA, miRNA,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 173

or any combination thereof. In some embodiments, the method includes determining the level of one or more cfDNA cf mDNA, cf nDNA, cfRNA, and/or miRNA molecules of interest, such as molecules with a polymorphism or mutation associated with a disease or disorder or an increased risk for a disease or disorder. In some embodiments, the fraction of tumor DNA out of total DNA (such as the fraction of tumor cfDNA out of total cfDNA or the fraction of tumor cfDNA with a particular mutation out of total cfDNA) is determined. In some embodiments, this tumor fraction is used to determine the stage of a cancer (since higher tumor fractions can be associated with more advanced stages of cancer). In some embodiments, the method also includes determining the total level of DNA or RNA level. In some embodiments, the method includes determining the methylation level of one or more DNA or RNA molecules of interest, such as molecules with a polymorphism or mutation associated with a disease or disorder or an increased risk for a disease or disorder. In some embodiments, the method includes determining the presence or absence of a change in DNA integrity. In some embodiments, the method also includes determining the total level of mRNA splicing. In some embodiments, the method includes determining the level of mRNA splicing or detecting alternative mRNA splicing for one or RNA molecules of interest, such as molecules with a polymorphism or mutation associated with a disease or disorder or an increased risk for a disease or disorder.

[0058] In some embodiments, the invention features a method for detecting a cancer phenotype in an individual, wherein the cancer phenotype is defined by the presence of at least one of a set of mutations. In some embodiments, the method includes obtaining DNA or RNA measurements for a sample of DNA or RNA from one or more cells from the individual, wherein one or more of the cells is suspected of having the cancer phenotype; and analyzing the DNA or RNA measurements to determine, for each of the mutations in the set of mutations, the likelihood that at least one of the cells has that mutation. In some embodiments, the method includes determining that the individual has the cancer phenotype if either (i) for at least one of the mutations, the likelihood that at least one of the cells contains that mutations is greater than a threshold, or (ii) for at least one of the mutations, the likelihood that at least one of the cells has that mutations is less than the threshold, and for a plurality of the mutations, the combined likelihood that at least one of the cells has at least one of the mutations is greater than the threshold. In some embodiments, one or more cells have a subset or all of the mutations in the set of mutations. In some embodiments, the subset of mutations is associated with cancer or an increased risk for

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 174

cancer. In some embodiments, the sample includes cell-free DNA or RNA. In some embodiments, the DNA or RNA measurements include measurements (such as the quantity of each allele at each locus) at a set of polymorphic loci on one or more chromosomes or chromosome segments of interest.

[0059] In one aspect, the invention features methods for selecting a therapy for the treatment, stabilization, or prevention of a disease or disorder in a mammal. In some embodiments, the method includes determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment using any of the methods described herein. In some embodiments, a therapy is selected for the mammal (such as a therapy for a disease or disorder associated with the overrepresentation of the first homologous chromosome segment).

[0060] In one aspect, the invention features methods for preventing, delaying, stabilizing, or treating a disease or disorder in a mammal. In some embodiments, the method includes determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment using any of the methods described herein. In some embodiments, a therapy is selected for the mammal (such as a therapy for a disease or disorder associated with the overrepresentation of the first homologous chromosome segment) and then the therapy is administered to the mammal.

[0061] In some embodiments, treating, stabilizing, or preventing a disease or disorder includes preventing or delaying an initial or subsequent occurrence of a disease or disorder, increasing the disease-free survival time between the disappearance of a condition and its reoccurrence, stabilizing or reducing an adverse symptom associated with a condition, or inhibiting or stabilizing the progression of a condition. In some embodiments, at least 20, 40, 60, 80, 90, or 95% of the treated subjects have a complete remission in which all evidence of the condition disappears. In some embodiments, the length of time a subject survives after being diagnosed with a condition and treated is at least 20, 40, 60, 80, 100, 200, or even 500% greater than (i) the average amount of time an untreated subject survives or (ii) the average amount of time a subject treated with another therapy survives.

[0062] In some embodiments, treating, stabilizing, or preventing cancer includes reducing or stabilizing the size of a tumor (*e.g.*, a benign or malignant tumor), slowing or preventing an increase in the size of a tumor, reducing or stabilizing the number of tumor cells, increasing the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 175

disease-free survival time between the disappearance of a tumor and its reappearance, preventing an initial or subsequent occurrence of a tumor, or reducing or stabilizing an adverse symptom associated with a tumor. In one embodiment, the number of cancerous cells surviving the treatment is at least 10, 20, 40, 60, 80, or 100% lower than the initial number of cancerous cells, as measured using any standard assay. In some embodiments, the decrease in the number of cancerous cells induced by administration of a therapy of the invention is at least 2, 5, 10, 20, or 50-fold greater than the decrease in the number of non-cancerous cells. In some embodiments, the number of cancerous cells present after administration of a therapy is at least 2, 5, 10, 20, or 50-fold lower than the number of cancerous cells present after administration of a control (such as administration of saline or a buffer). In some embodiments, the methods of the present invention result in a decrease of 10, 20, 40, 60, 80, or 100% in the size of a tumor as determined using standard methods. In some embodiments, at least 10, 20, 40, 60, 80, 90, or 95% of the treated subjects have a complete remission in which there are no detectable cancerous cells. In some embodiments, the cancer does not reappear, or reappears after at least 2, 5, 10, 15, or 20 years. In some embodiments, the length of time a subject survives after being diagnosed with cancer and treated with a therapy of the invention is at least 10, 20, 40, 60, 80, 100, 200, or even 500% greater than (i) the average amount of time an untreated subject survives or (ii) the average amount of time a subject treated with another therapy survives.

[0063] In one aspect, the invention features methods for stratification of subjects involved in a clinical trial for the treatment, stabilization, or prevention of a disease or disorder in a mammal. In some embodiments, the method includes determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment using any of the methods described herein before, during, or after the clinical trial. In some embodiments, the presence or absence of the overrepresentation of the first homologous chromosome segment in the genome of the subject places the subject into a subgroup for the clinical trial.

[0064] In some embodiments, the disease or disorder is selected from the group consisting of cancer, mental handicap, learning disability (*e.g.*, idiopathic learning disability), mental retardation, developmental delay, autism, neurodegenerative disease or disorder, schizophrenia, physical handicap, autoimmune disease or disorder, systemic lupus erythematosus, psoriasis, Crohn's disease, glomerulonephritis, HIV infection, AIDS, and combinations thereof. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 176

embodiments, the disease or disorder is selected from the group consisting of DiGeorge syndrome, DiGeorge 2 syndrome, DiGeorge/VCFS syndrome, Prader-Willi syndrome, Angelman syndrome, Beckwith-Wiedemann syndrome, 1p36 deletion syndrome, 2q37 deletion syndrome, 3q29 deletion syndrome, 9q34 deletion syndrome, 17q21.31 deletion syndrome, Cri-du-chat syndrome, Jacobsen syndrome, Miller Dieker syndrome, Phelan-McDermid syndrome, Smith-Magenis syndrome, WAGR syndrome, Wolf-Hirschhorn syndrome, Williams syndrome, Williams-Beuren syndrome, Miller-Dieker syndrome, Phelan-McDermid syndrome, Smith-Magenis syndrome, Down syndrome, Edward syndrome, Patau syndrome, Klinefelter syndrome, Turner syndrome, 47,XXX syndrome, 47,XYY syndrome, Sotos syndrome, and combinations thereof. In some embodiments, the method determines the presence or absence of one or more of the following chromosomal abnormalities: nullsomy, monosomy, uniparental disomy, trisomy, matched trisomy, unmatched trisomy, maternal trisomy, paternal trisomy, triploidy, mosaicism tetrasomy, matched tetrasomy, unmatched tetrasomy, other aneuploidies, unbalanced translocations, balanced translocations, insertions, deletions, recombinations, and combinations thereof. In some embodiments, the chromosomal abnormality is any deviation in the copy number of a specific chromosome or chromosome segment from the most common number of copies of that segment or chromosome, for example in a human somatic cell, any deviation from 2 copies can be regarded as a chromosomal abnormality. In some embodiments, the method determines the presence or absence of a euploidy. In some embodiments, the copy number hypotheses include one or more copy number hypotheses for a singleton pregnancy. In some embodiments, the copy number hypotheses include one or more copy number hypotheses for a multiple pregnancy, such as a twin pregnancy (*e.g.*, identical or fraternal twins or a vanishing twin). In some embodiments, the copy number hypotheses include all fetuses in a multiple pregnancy being euploid, all fetuses in a multiple pregnancy being aneuploid (such as any of the aneuploidies disclosed herein), and/or one or more fetuses in a multiple pregnancy being euploid and one or more fetuses in a multiple pregnancy being aneuploidy. In some embodiments, the copy number hypotheses include identical twins (also referred to as monozygotic twins) or fraternal twins (also referred to as dizygotic twins). In some embodiments, the copy number hypotheses include a molar pregnancy, such as a complete or partial molar pregnancy. In some embodiments, the chromosome segment of interest is an entire chromosome. In some embodiments, the chromosome or chromosome segment is selected from the group consisting of chromosome 13, chromosome 18, chromosome 21, the X chromosome,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 177

the Y chromosome, segments thereof, and combinations thereof. In some embodiments, the first homologous chromosome segment and second homologous chromosome segment are a pair of homologous chromosome segments that comprises the chromosome segment of interest. In some embodiments, the first homologous chromosome segment and second homologous chromosome segment are a pair of homologous chromosomes of interest. In some embodiments, a confidence is computed for the CNV determination or the diagnosis of the disease or disorder.

[0065] In some embodiments, the deletion is a deletion of at least 0.01 kb, 0.1 kb, 1 kb, 10 kb, 100 kb, 1 mb, 2 mb, 3 mb, 5 mb, 10 mb, 15 mb, 20 mb, 30 mb, or 40 mb. In some embodiments, the deletion is a deletion of between 1 kb to 40 mb, such as between 1 kb to 100 kb, 100 kb to 1 mb, 1 to 5 mb, 5 to 10 mb, 10 to 15 mb, 15 to 20 mb, 20 to 25 mb, 25 to 30 mb, or 30 to 40 mb, inclusive. In some embodiments, one copy of the chromosome segment is deleted and one copy is present. In some embodiments, two copies of the chromosome segment are deleted. In some embodiments, an entire chromosome is deleted.

[0066] In some embodiments, the duplication is a duplication of at least 0.01 kb, 0.1 kb, 1 kb, 10 kb, 100 kb, 1 mb, 2 mb, 3 mb, 5 mb, 10 mb, 15 mb, 20 mb, 30 mb, or 40 mb. In some embodiments, the duplication is a duplication of between 1 kb to 40 mb, such as between 1 kb to 100 kb, 100 kb to 1 mb, 1 to 5 mb, 5 to 10 mb, 10 to 15 mb, 15 to 20 mb, 20 to 25 mb, 25 to 30 mb, or 30 to 40 mb, inclusive. In some embodiments, the chromosome segment is duplicated one time. In some embodiments, the chromosome segment is duplicated more than one time, such as 2, 3, 4, or 5 times. In some embodiments, an entire chromosome is duplicated. In some embodiments, a region in a first homologous segment is deleted, and the same region or another region in the second homologous segment is duplicated. In some embodiments, at least 50, 60, 70, 80, 90, 95, 96, 98, 99, or 100% of the SNVs tested for are transversion mutations rather than transition mutations.

[0067] In some embodiments, the sample comprises DNA and/or RNA from (i) one or more target cells or (ii) one or more non-target cells. In some embodiments, the sample is a mixed sample with DNA and/or RNA from one or more target cells and one or more non-target cells. In some embodiments, the target cells are cells that have a CNV, such as a deletion or duplication of interest, and the non-target cells are cells that do not have the copy number variation of interest. In some embodiments in which the one or more target cells are cancer cell(s) and the one or more non-target cells are non-cancerous cell(s), the method includes determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment in the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 178

genome of one or more of the cancer cells. In some embodiments in which the one or more target cells are genetically identical cancer cell(s) and the one or more non-target cells are non-cancerous cell(s), the method includes determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment in the genome of the cancer cell(s). In some embodiments in which the one or more target cells are genetically non-identical cancer cell(s) and the one or more non-target cells are non-cancerous cell(s), the method includes determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment in the genome of one or more of the genetically non-identical cancer cells. In some embodiments in which the sample comprises cell-free DNA from a mixture of one or more cancer cells and one or more non-cancerous cells, the method includes determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment in the genome of one or more of the cancer cells. In some embodiments in which the one or more target cells are genetically identical fetal cell(s) and the one or more non-target cells are maternal cell(s), the method includes determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment in the genome of the fetal cell(s). In some embodiments in which the one or more target cells are genetically non-identical fetal cell(s) and the one or more non-target cells are maternal cell(s), the method includes determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment in the genome of one or more of the genetically non-identical fetal cells. As the cells of most individuals contain a nearly identical set of nuclear DNA, the term "target cell" may be used interchangeably with the term "individual" in some embodiments. Cancerous cells have genotypes that are distinct from the host individual. In this case, the cancer itself may be considered an individual. Moreover, many cancers are heterogeneous meaning that different cells in a tumor are genetically distinct from other cells in the same tumor. In this case, the different genetically identical regions can be considered different individuals. Alternately, the cancer may be considered a single individual with a mixture of cells with distinct genomes. Typically, non-target cells are euploid, though this is not necessarily the case.

[0068] In some embodiments, the sample is obtained from a maternal whole blood sample or fraction thereof, cells isolated from a maternal blood sample, an amniocentesis sample, a products of conception sample, a placental tissue sample, a chorionic villus sample, a placental membrane sample, a cervical mucus sample, or a sample from a fetus. In some embodiments, the sample

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 179

comprises cell-free DNA obtained from a blood sample or fraction thereof from the mother. In some embodiments, the sample comprises nuclear DNA obtained from a mixture of fetal cells and maternal cells. In some embodiments, the sample is obtained from a fraction of maternal blood containing nucleated cells that has been enriched for fetal cells. In some embodiments, a sample is divided into multiple fractions (such as 2, 3, 4 5, or more fractions) that are each analyzed using a method of the invention. If each fraction produces the same results (such as the presence or absence of one or more CNVs of interest), the confidence in the results increases. In different fractions produce different results, the sample could be re-analyzed or another sample could be collected from the same subject and analyzed.

[0069] Exemplary subjects include mammals, such as humans and mammals of veterinary interest. In some embodiments, the mammal is a primate *(e.g.,* a human, a monkey, a gorilla, an ape, a lemur, *etc.*), a bovine, an equine, a porcine, a canine, or a feline.

[0070] In some embodiments, any of the methods include generating a report (such as a written or electronic report) disclosing a result of the method of the invention (such as the presence or absence of a deletion or duplication).

[0071] In some embodiments, any of the methods include taking a clinical action based on a result of a method of the invention (such as the presence or absence of a deletion or duplication). In some embodiments in which an embryo or fetus has one or more polymorphisms or mutations of interest (such as a CNV) based on a result of a method of the invention, the clinical action includes performing additional testing (such as testing to confirm the presence of the polymorphism or mutation), not implanting the embryo for IVF, implanting a different embryo for IVF, terminating a pregnancy, preparing for a special needs child, or undergoing an intervention designed to decrease the severity of the phenotypic presentation of a genetic disorder. In some embodiments, the clinical action is selected from the group consisting of performing an ultrasound, amniocentesis on the fetus, amniocentesis on a subsequent fetus that inherits genetic material from the mother and/or father, chorion villus biopsy on the fetus, chorion villus biopsy on a subsequent fetus that inherits genetic material from the mother and/or father, *in vitro* fertilization, preimplantation genetic diagnosis on one or more embryos that inherited genetic material from the mother and/or father, karyotyping on the mother, karyotyping on the father, fetal echocardiogram (such as an echocardiogram of a fetus with trisomy 21, 18, or 13, monosomy X, or a microdeletion) and combinations thereof. In some embodiments, the clinical action is selected from the group

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 180

consisting of administering growth hormone to a born child with monosomy X (such as administration starting at ~9 months), administering calcium to a born child with a 22q deletion (such as DiGeorge syndrome), administering an androgen such as testosterone to a born child with 47,XXY (such as one injection per month for 3 months of 25 mg testosterone enanthate to an infant or toddler), performing a test for cancer on a woman with a complete or partial molar pregnancy (such as a triploid fetus), administering a therapy for cancer such as a chemotherapeutic agent to a woman with a complete or partial molar pregnancy (such as a triploid fetus), screening a fetus determined to be male (such as a fetus determined to be male using a method of the invention) for one or more X-linked genetic disorders such as Duchenne muscular dystrophy (DMD), adrenoleukodystrophy, or hemophilia, performing amniocentesis on a male fetus at risk for an X-linked disorder, administering dexamethasone to a women with a female fetus (such as a fetus determined to be female using a method of the invention) at risk for congenital adrenal hyperplasia, performing amniocentesis on a female fetus at risk for congenital adrenal hyperplasia, administering killed vaccines (instead of live vaccines) or not administering certain vaccines to a born child that is (or is suspected of being) immune deficient from a 22q11.2 deletion, performing occupational and/or physical therapy, performing early intervention in education, delivering the baby at a tertiary care center with a NICU and/or having pediatric specialists available at delivery, behavioral intervention for born child (such as a child with XXX, XXY, or XYY), and combinations thereof.

[0072] In some embodiments, ultrasound or another screening test is performed on a women determined to have multiple pregnancies (such as twins) to determine whether or not two or more of the fetus are monochorionic. Monozygotic twins result from ovulation and fertilization of a single oocyte, with subsequent division of the zygote; placentation may be dichorionic or monochorionic. Dizygotic twins occur from ovulation and fertilization of two oocytes, which usually results in dichorionic placentation. Monochorionic twins have a risk of twin-to-twin transfusion syndrome, which may cause unequal distribution of blood between fetuses that results in differences in their growth and development, sometimes resulting in stillbirth. Thus, twins determined to be monozygotic twins using a method of the invention are desirably tested (such as by ultrasound) to determine if they are monochorionic twins, and if so, these twins can be monitored (such as bi-weekly ultrasounds from 16 weeks) for signs of win-to-twin transfusion syndrome.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 181

[0073] In some embodiments in which an embryo or fetus does not have one or more one or more polymorphisms or mutations of interest (such as a CNV) based on a result of a method of the invention, the clinical action includes implanting the embryo for IVF or continuing a pregnancy. In some embodiments, the clinical action is additional testing to confirm the absence of the polymorphism or mutation selected from the group consisting of performing an ultrasound, amniocentesis, chorion villus biopsy, and combinations thereof.

[0074] In some embodiments in which an individual has one or more one or more polymorphisms or mutations (such as a polymorphism or mutation associated with a disease or disorder such as cancer or an increased risk for a disease or disorder such as cancer) based on a result of a method of the invention, the clinical action includes performing additional testing or administering one or more therapies for a disease or disorder (such as a therapy for cancer, a therapy for the specific type of cancer or type of mutation the individual is diagnosed with, or any of the therapies disclosed herein). In some embodiments, the clinical action is additional testing to confirm the presence or absence of a polymorphism or mutation selected from the group consisting of biopsy, surgery, medical imaging (such as a mammogram or an ultrasound), and combinations thereof.

[0075] In some embodiments, the additional testing includes performing the same or a different method (such as any of the methods described herein) to confirm the presence or absence of the polymorphism or mutation (such as a CNV), such as testing either a second fraction of the same sample that was tested or a different sample from the same individual (such as the same pregnant mother, fetus, embryo, or individual at increased risk for cancer). In some embodiments, the additional testing is performed for an individual for whom the probability of a polymorphism or mutation (such as a CNV) is above a threshold value (such as additional testing to confirm the presence of a likely polymorphism or mutation). In some embodiments, the additional testing is performed for an individual for whom the confidence or z-score for the determination of a polymorphism or mutation (such as a CNV) is above a threshold value (such as additional testing to confirm the presence of a likely polymorphism or mutation). In some embodiments, the additional testing is performed for an individual for whom the confidence or z-score for the determination of a polymorphism or mutation (such as a CNV) is between minimum and maximum threshold values (such as additional testing to increase the confidence that the initial result is correct). In some embodiments, the additional testing is performed for an individual for whom the confidence for the determination of the presence or absence of a polymorphism or mutation (such

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 182

as a CNV) is below a threshold value (such as a "no call" result due to not being able to determine the presence or absence of the CNV with sufficient confidence). An exemplary Z core is calculated in Chiu et al. BMJ 2011;342:c7401 (which is hereby incorporated by reference in its entirety) in which chromosome 21 is used as an example and can be replaced with any other chromosome or chromosome segment in the test sample.

> Z score for percentage chromosome 21 in test case = ((percentage chromosome 21 in test case) − (mean percentage chromosome 21 in reference controls)) / (standard deviation of percentage chromosome 21 in reference controls).

In some embodiments, the additional testing is performed for an individual for whom the initial sample did not meet quality control guidelines or had a fetal fraction or a tumor fraction below a threshold value. In some embodiments, the method includes selecting an individual for additional testing based on the result of a method of the invention, the probability of the result, the confidence of the result, or the z-score; and performing the additional testing on the individual (such as on the same or a different sample). In some embodiments, a subject diagnosed with a disease or disorder (such as cancer) undergoes repeat testing using a method of the invention or known testing for the disease or disorder at multiple time points to monitor the progression of the disease or disorder or the remission or reoccurrence of the disease or disorder.

[0076] In one aspect, the invention features a report (such as a written or electronic report) with a result from a method of the invention (such as the presence or absence of a deletion or duplication).

[0077] In various embodiments, the primer extension reaction or the polymerase chain reaction includes the addition of one or more nucleotides by a polymerase. In some embodiments, the primers are in solution. In some embodiments, the primers are in solution and are not immobilized on a solid support. In some embodiments, the primers are not part of a microarray. In various embodiments, the primer extension reaction or the polymerase chain reaction does not include ligation-mediated PCR. In various embodiments, the primer extension reaction or the polymerase chain reaction does not include the joining of two primers by a ligase. In various embodiments, the primers do not include Linked Inverted Probes (LIPs), which can also be called pre-circularized

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 183

probes, pre-circularizing probes, circularizing probes, Padlock Probes, or Molecular Inversion Probes (MIPs).

[0078] It is understood that aspects and embodiments of the invention described herein include combinations of any two or more of the aspects or embodiments of the invention.

Definitions

[0079] *Single Nucleotide Polymorphism (SNP)* refers to a single nucleotide that may differ between the genomes of two members of the same species. The usage of the term should not imply any limit on the frequency with which each variant occurs.

[0080] *Sequence* refers to a DNA sequence or a genetic sequence. It may refer to the primary, physical structure of the DNA molecule or strand in an individual. It may refer to the sequence of nucleotides found in that DNA molecule, or the complementary strand to the DNA molecule. It may refer to the information contained in the DNA molecule as its representation *in silico*.

[0081] *Locus* refers to a particular region of interest on the DNA of an individual, which may refer to a SNP, the site of a possible insertion or deletion, or the site of some other relevant genetic variation. Disease-linked SNPs may also refer to disease-linked loci.

[0082] *Polymorphic Allele,* also "*Polymorphic Locus*," refers to an allele or locus where the genotype varies between individuals within a given species. Some examples of polymorphic alleles include single nucleotide polymorphisms, short tandem repeats, deletions, duplications, and inversions.

[0083] *Polymorphic Site* refers to the specific nucleotides found in a polymorphic region that vary between individuals.

[0084] *Mutation* refers to an alteration in a naturally-occurring or reference nucleic acid sequence, such as an insertion, deletion, duplication, translocation, substitution, frameshift mutation, silent mutation, nonsense mutation, missense mutation, point mutation, transition mutation, transversion mutation, reverse mutation, or microsatellite alteration. In some embodiments, the amino acid sequence encoded by the nucleic acid sequence has at least one amino acid alteration from a naturally-occurring sequence.

[0085] *Allele* refers to the genes that occupy a particular locus.

[0086] *Genetic Data* also "*Genotypic Data"* refers to the data describing aspects of the genome of one or more individuals. It may refer to one or a set of loci, partial or entire sequences, partial

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 184

or entire chromosomes, or the entire genome. It may refer to the identity of one or a plurality of nucleotides; it may refer to a set of sequential nucleotides, or nucleotides from different locations in the genome, or a combination thereof. Genotypic data is typically *in silico*, however, it is also possible to consider physical nucleotides in a sequence as chemically encoded genetic data. Genotypic Data may be said to be "on," "of," "at," "from" or "on" the individual(s). Genotypic Data may refer to output measurements from a genotyping platform where those measurements are made on genetic material.

[0087] *Genetic Material* also "*Genetic Sample"* refers to physical matter, such as tissue or blood, from one or more individuals comprising DNA or RNA.

[0088] *Confidence* refers to the statistical likelihood that the called SNP, allele, set of alleles, determined number of copies of a chromosome or chromosome segment, or diagnosis of the presence or absence of a disease correctly represents the real genetic state of the individual.

[0089] *Ploidy Calling*, also "Chromosome Copy Number Calling," or "Copy Number Calling" (CNC), may refer to the act of determining the quantity and/or chromosomal identity of one or more chromosomes or chromosome segments present in a cell.

[0090] *Aneuploidy* refers to the state where the wrong number of chromosomes (*e.g.,* the wrong number of full chromosomes or the wrong number of chromosome segments, such as the presence of deletions or duplications of a chromosome segment) is present in a cell. In the case of a somatic human cell it may refer to the case where a cell does not contain 22 pairs of autosomal chromosomes and one pair of sex chromosomes. In the case of a human gamete, it may refer to the case where a cell does not contain one of each of the 23 chromosomes. In the case of a single chromosome type, it may refer to the case where more or less than two homologous but non-identical chromosome copies are present, or where there are two chromosome copies present that originate from the same parent. In some embodiments, the deletion of a chromosome segment is a microdeletion.

[0091] *Ploidy State* refers to the quantity and/or chromosomal identity of one or more chromosomes or chromosome segments in a cell.

[0092] *Chromosome* may refer to a single chromosome copy, meaning a single molecule of DNA of which there are 46 in a normal somatic cell; an example is 'the maternally derived chromosome 18'. Chromosome may also refer to a chromosome type, of which there are 23 in a normal human somatic cell; an example is 'chromosome 18'.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 185

[0093] *Chromosomal Identity* may refer to the referent chromosome number, *i.e.* the chromosome type. Normal humans have 22 types of numbered autosomal chromosome types, and two types of sex chromosomes. It may also refer to the parental origin of the chromosome. It may also refer to a specific chromosome inherited from the parent. It may also refer to other identifying features of a chromosome.

[0094] *Allelic Data* refers to a set of genotypic data concerning a set of one or more alleles. It may refer to the phased, haplotypic data. It may refer to SNP identities, and it may refer to the sequence data of the DNA, including insertions, deletions, repeats and mutations. It may include the parental origin of each allele.

[0095] *Allelic State* refers to the actual state of the genes in a set of one or more alleles. It may refer to the actual state of the genes described by the allelic data.

[0096] *Allele Count* refers to the number of sequences that map to a particular locus, and if that locus is polymorphic, it refers to the number of sequences that map to each of the alleles. If each allele is counted in a binary fashion, then the allele count will be whole number. If the alleles are counted probabilistically, then the allele count can be a fractional number.

[0097] *Allele Count Probability* refers to the number of sequences that are likely to map to a particular locus or a set of alleles at a polymorphic locus, combined with the probability of the mapping. Note that allele counts are equivalent to allele count probabilities where the probability of the mapping for each counted sequence is binary (zero or one). In some embodiments, the allele count probabilities may be binary. In some embodiments, the allele count probabilities may be set to be equal to the DNA measurements.

[0098] *Allelic Distribution,* or "*allele count distribution*" refers to the relative amount of each allele that is present for each locus in a set of loci. An allelic distribution can refer to an individual, to a sample, or to a set of measurements made on a sample. In the context of digital allele measurements such as sequencing, the allelic distribution refers to the number or probable number of reads that map to a particular allele for each allele in a set of polymorphic loci. In the context of analog allele measurements such as SNP arrays, the allelic distribution refers to allele intensities and/or allele ratios. The allele measurements may be treated probabilistically, that is, the likelihood that a given allele is present for a give sequence read is a fraction between 0 and 1, or they may be treated in a binary fashion, that is, any given read is considered to be exactly zero or one copies of a particular allele.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 186

[0099] *Allelic Distribution Pattern* refers to a set of different allele distributions for different contexts, such as different parental contexts. Certain allelic distribution patterns may be indicative of certain ploidy states.

[0100] *Allelic Bias* refers to the degree to which the measured ratio of alleles at a heterozygous locus is different to the ratio that was present in the original sample of DNA or RNA. The degree of allelic bias at a particular locus is equal to the observed allelic ratio at that locus, as measured, divided by the ratio of alleles in the original DNA or RNA sample at that locus. Allelic bias maybe due to amplification bias, purification bias, or some other phenomenon that affects different alleles differently.

[0101] *Allelic imbalance* refers for SNVs, to the proportion of abnormal DNA is typically measured using mutant allele frequency (number of mutant alleles at a locus / total number of alleles at that locus). Since the difference between the amounts of two homologs in tumours is analogous, we measure the proportion of abnormal DNA for a CNV by the average allelic imbalance (AAI), defined as $|(H1 - H2)|/(H1 + H2)$, where Hi is the average number of copies of homolog i in the sample and $Hi/(H1 + H2)$ is the fractional abundance, or homolog ratio, of homolog i. The maximum homolog ratio is the homolog ratio of the more abundant homolog.

[0102] *Assay drop-out rate* is the percentage of SNPs with no reads, estimated using all SNPs.

[0103] *Single allele drop-out (ADO) rate* is the percentage of SNPs with only one allele present, estimated using only heterozygous SNPs.

[0104] *Primer,* also "*PCR probe*" refers to a single nucleic acid molecule (such as a DNA molecule or a DNA oligomer) or a collection of nucleic acid molecules (such as DNA molecules or DNA oligomers) where the molecules are identical, or nearly so, and wherein the primer contains a region that is designed to hybridize to a targeted locus (*e.g.*, a targeted polymorphic locus or a non-polymorphic locus) or to a universal priming sequence, and may contain a priming sequence designed to allow PCR amplification. A primer may also contain a molecular barcode. A primer may contain a random region that differs for each individual molecule.

[0105] *Library of primers* refers to a population of two or more primers. In various embodiments, the library includes at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different primers. In various embodiments, the library includes at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different primer pairs, wherein each pair of primers includes a

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 187

forward test primer and a reverse test primer where each pair of test primers hybridize to a target locus. In some embodiments, the library of primers includes at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different individual primers that each hybridize to a different target locus, wherein the individual primers are not part of primer pairs. In some embodiments, the library has both (i) primer pairs and (ii) individual primers (such as universal primers) that are not part of primer pairs.

[0106] *Different primers* refers to non-identical primers.

[0107] *Different pools* refers to non-identical pools.

[0108] *Different target loci* refers to non-identical target loci.

[0109] *Different amplicons* refers to non-identical amplicons.

[0110] *Hybrid Capture Probe* refers to any nucleic acid sequence, possibly modified, that is generated by various methods such as PCR or direct synthesis and intended to be complementary to one strand of a specific target DNA sequence in a sample. The exogenous hybrid capture probes may be added to a prepared sample and hybridized through a denature-reannealing process to form duplexes of exogenous-endogenous fragments. These duplexes may then be physically separated from the sample by various means.

[0111] *Sequence Read* refers to data representing a sequence of nucleotide bases that were measured, *e.g.*, using a clonal sequencing method. Clonal sequencing may produce sequence data representing single, or clones, or clusters of one original DNA molecule. A sequence read may also have associated quality score at each base position of the sequence indicating the probability that nucleotide has been called correctly.

[0112] *Mapping a sequence read* is the process of determining a sequence read's location of origin in the genome sequence of a particular organism. The location of origin of sequence reads is based on similarity of nucleotide sequence of the read and the genome sequence.

[0113] *Matched Copy Error*, also "*Matching Chromosome Aneuploidy*" (MCA), refers to a state of aneuploidy where one cell contains two identical or nearly identical chromosomes. This type of aneuploidy may arise during the formation of the gametes in meiosis, and may be referred to as a meiotic non-disjunction error. This type of error may arise in mitosis. Matching trisomy may refer to the case where three copies of a given chromosome are present in an individual and two of the copies are identical.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 188

[0114] *Unmatched Copy Error*, also "*Unique Chromosome Aneuploidy*" (UCA), refers to a state of aneuploidy where one cell contains two chromosomes that are from the same parent, and that may be homologous but not identical. This type of aneuploidy may arise during meiosis, and may be referred to as a meiotic error. Unmatching trisomy may refer to the case where three copies of a given chromosome are present in an individual and two of the copies are from the same parent, and are homologous, but are not identical. Note that unmatching trisomy may refer to the case where two homologous chromosomes from one parent are present, and where some segments of the chromosomes are identical while other segments are merely homologous.

[0115] *Homologous Chromosomes* refers to chromosome copies that contain the same set of genes that normally pair up during meiosis.

[0116] *Identical Chromosomes* refers to chromosome copies that contain the same set of genes, and for each gene they have the same set of alleles that are identical, or nearly identical.

[0117] *Allele Drop Out (ADO)* refers to the situation where at least one of the base pairs in a set of base pairs from homologous chromosomes at a given allele is not detected.

[0118] *Locus Drop Out (LDO)* refers to the situation where both base pairs in a set of base pairs from homologous chromosomes at a given allele are not detected.

[0119] *Homozygous* refers to having similar alleles as corresponding chromosomal loci.

[0120] *Heterozygous* refers to having dissimilar alleles as corresponding chromosomal loci.

[0121] *Heterozygosity Rate* refers to the rate of individuals in the population having heterozygous alleles at a given locus. The heterozygosity rate may also refer to the expected or measured ratio of alleles, at a given locus in an individual, or a sample of DNA or RNA.

[0122] *Chromosomal Region* refers to a segment of a chromosome, or a full chromosome.

[0123] *Segment of a Chromosome* refers to a section of a chromosome that can range in size from one base pair to the entire chromosome.

[0124] *Chromosome* refers to either a full chromosome, or a segment or section of a chromosome.

[0125] *Copies* refers to the number of copies of a chromosome segment. It may refer to identical copies, or to non-identical, homologous copies of a chromosome segment wherein the different copies of the chromosome segment contain a substantially similar set of loci, and where one or more of the alleles are different. Note that in some cases of aneuploidy, such as the M2 copy error, it is possible to have some copies of the given chromosome segment that are identical as well as some copies of the same chromosome segment that are not identical.

[0126] *Haplotype* refers to a combination of alleles at multiple loci that are typically inherited together on the same chromosome. Haplotype may refer to as few as two loci or to an entire chromosome depending on the number of recombination events that have occurred between a given set of loci. Haplotype can also refer to a set of SNPs on a single chromatid that are statistically associated.

[0127] *Haplotypic Data*, also "*Phased Data*" or "*Ordered Genetic Data*," refers to data from a single chromosome or chromosome segment in a diploid or polyploid genome, *e.g.*, either the segregated maternal or paternal copy of a chromosome in a diploid genome.

[0128] *Phasing* refers to the act of determining the haplotypic genetic data of an individual given unordered, diploid (or polyploidy) genetic data. It may refer to the act of determining which of two genes at an allele, for a set of alleles found on one chromosome, are associated with each of the two homologous chromosomes in an individual.

[0129] *Phased Data* refers to genetic data where one or more haplotypes have been determined.

[0130] *Hypothesis* refers to a possible state, such as a possible degree of overrepresentation of the number of copies of a first homologous chromosome or chromosome segment as compared to a second homologous chromosome or chromosome segment, a possible deletion, a possible duplication, a possible ploidy state at a given set of one or more chromosomes or chromosome segments, a possible allelic state at a given set of one or more loci, a possible paternity relationship, or a possible DNA, RNA, fetal fraction at a given set of one or more chromosomes or chromosome segment, or a set of quantities of genetic material from a set of loci. The genetic states can optionally be linked with probabilities indicating the relative likelihood of each of the elements in the hypothesis being true in relation to other elements in the hypothesis, or the relative likelihood of the hypothesis as a whole being true. The set of possibilities may comprise one or more elements.

[0131] *Copy Number Hypothesis*, also "*Ploidy State Hypothesis*," refers to a hypothesis concerning the number of copies of a chromosome or chromosome segment in an individual. It may also refer to a hypothesis concerning the identity of each of the chromosomes, including the parent of origin of each chromosome, and which of the parent's two chromosomes are present in the individual. It may also refer to a hypothesis concerning which chromosomes, or chromosome segments, if any, from a related individual correspond genetically to a given chromosome from an individual.

[0132] *Related Individual* refers to any individual who is genetically related to, and thus shares haplotype blocks with, the target individual. In one context, the related individual may be a genetic parent of the target individual, or any genetic material derived from a parent, such as a sperm, a polar body, an embryo, a fetus, or a child. It may also refer to a sibling, parent, or grandparent.

[0133] *Sibling* refers to any individual whose genetic parents are the same as the individual in question. In some embodiments, it may refer to a born child, an embryo, or a fetus, or one or more cells originating from a born child, an embryo, or a fetus. A sibling may also refer to a haploid individual that originates from one of the parents, such as a sperm, a polar body, or any other set of haplotypic genetic matter. An individual may be considered to be a sibling of itself.

[0134] *Child* may refer to an embryo, a blastomere, or a fetus. Note that in the presently disclosed embodiments, the concepts described apply equally well to individuals who are a born child, a fetus, an embryo, or a set of cells therefrom. The use of the term child may simply be meant to connote that the individual referred to as the child is the genetic offspring of the parents.

[0135] *Fetal* refers to "of the fetus," or "of the region of the placenta that is genetically similar to the fetus". In a pregnant woman, some portion of the placenta is genetically similar to the fetus, and the free floating fetal DNA found in maternal blood may have originated from the portion of the placenta with a genotype that matches the fetus. Note that the genetic information in half of the chromosomes in a fetus is inherited from the mother of the fetus. In some embodiments, the DNA from these maternally inherited chromosomes that came from a fetal cell is considered to be "of fetal origin," not "of maternal origin."

[0136] *DNA of Fetal Origin* refers to DNA that was originally part of a cell whose genotype was essentially equivalent to that of the fetus.

[0137] *DNA of Maternal Origin* refers to DNA that was originally part of a cell whose genotype was essentially equivalent to that of the mother.

[0138] *Parent* refers to the genetic mother or father of an individual. An individual typically has two parents, a mother and a father, though this may not necessarily be the case such as in genetic or chromosomal chimerism. A parent may be considered to be an individual.

[0139] *Parental Context* refers to the genetic state of a given SNP, on each of the two relevant chromosomes for one or both of the two parents of the target.

[0140] *Maternal Plasma* refers to the plasma portion of the blood from a female who is pregnant.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 191

[0141] *Clinical Decision* refers to any decision to take or not take an action that has an outcome that affects the health or survival of an individual. A clinical decision may also refer to a decision to conduct further testing, to abort or maintain a pregnancy, to take actions to mitigate an undesirable phenotype, or to take actions to prepare for a phenotype.

[0142] *Diagnostic Box* refers to one or a combination of machines designed to perform one or a plurality of aspects of the methods disclosed herein. In an embodiment, the diagnostic box may be placed at a point of patient care. In an embodiment, the diagnostic box may perform targeted amplification followed by sequencing. In an embodiment the diagnostic box may function alone or with the help of a technician.

[0143] *Informatics Based Method* refers to a method that relies heavily on statistics to make sense of a large amount of data. In the context of prenatal diagnosis, it refers to a method designed to determine the ploidy state at one or more chromosomes or chromosome segments, the allelic state at one or more alleles, or paternity by statistically inferring the most likely state, rather than by directly physically measuring the state, given a large amount of genetic data, for example from a molecular array or sequencing. In an embodiment of the present disclosure, the informatics based technique may be one disclosed in this patent application. In an embodiment of the present disclosure it may be PARENTAL SUPPORT.

[0144] *Primary Genetic Data* refers to the analog intensity signals that are output by a genotyping platform. In the context of SNP arrays, primary genetic data refers to the intensity signals before any genotype calling has been done. In the context of sequencing, primary genetic data refers to the analog measurements, analogous to the chromatogram, that comes off the sequencer before the identity of any base pairs have been determined, and before the sequence has been mapped to the genome.

[0145] *Secondary Genetic Data* refers to processed genetic data that are output by a genotyping platform. In the context of a SNP array, the secondary genetic data refers to the allele calls made by software associated with the SNP array reader, wherein the software has made a call whether a given allele is present or not present in the sample. In the context of sequencing, the secondary genetic data refers to the base pair identities of the sequences have been determined, and possibly also where the sequences have been mapped to the genome.

[0146] *Preferential Enrichment* of DNA that corresponds to a locus, or preferential enrichment of DNA at a locus, refers to any method that results in the percentage of molecules of DNA in a

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 192

post-enrichment DNA mixture that correspond to the locus being higher than the percentage of molecules of DNA in the pre-enrichment DNA mixture that correspond to the locus. The method may involve selective amplification of DNA molecules that correspond to a locus. The method may involve removing DNA molecules that do not correspond to the locus. The method may involve a combination of methods. The degree of enrichment is defined as the percentage of molecules of DNA in the post-enrichment mixture that correspond to the locus divided by the percentage of molecules of DNA in the pre-enrichment mixture that correspond to the locus. Preferential enrichment may be carried out at a plurality of loci. In some embodiments of the present disclosure, the degree of enrichment is greater than 20, 200, or 2,000. When preferential enrichment is carried out at a plurality of loci, the degree of enrichment may refer to the average degree of enrichment of all of the loci in the set of loci.

[0147] *Amplification* refers to a method that increases the number of copies of a molecule of DNA or RNA.

[0148] *Selective Amplification* may refer to a method that increases the number of copies of a particular molecule of DNA (or RNA), or molecules of DNA (or RNA) that correspond to a particular region of DNA (or RNA). It may also refer to a method that increases the number of copies of a particular targeted molecule of DNA (or RNA), or targeted region of DNA (or RNA) more than it increases non-targeted molecules or regions of DNA (or RNA). Selective amplification may be a method of preferential enrichment.

[0149] *Universal Priming Sequence* refers to a DNA (or RNA) sequence that may be appended to a population of target DNA (or RNA) molecules, for example by ligation, PCR, or ligation mediated PCR. Once added to the population of target molecules, primers specific to the universal priming sequences can be used to amplify the target population using a single pair of amplification primers. Universal priming sequences are typically not related to the target sequences.

[0150] *Universal Adapters,* or "*ligation adaptors*" or "*library tags*" are nucleic acid molecules containing a universal priming sequence that can be covalently linked to the 5-prime and 3-prime end of a population of target double stranded nucleic acid molecules. The addition of the adapters provides universal priming sequences to the 5-prime and 3-prime end of the target population from which PCR amplification can take place, amplifying all molecules from the target population, using a single pair of amplification primers.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 193

[0151] *Targeting* refers to a method used to selectively amplify or otherwise preferentially enrich those molecules of DNA (or RNA) that correspond to a set of loci in a mixture of DNA (or RNA).

[0152] *Joint Distribution Model* refers to a model that defines the probability of events defined in terms of multiple random variables, given a plurality of random variables defined on the same probability space, where the probabilities of the variable are linked. In some embodiments, the degenerate case where the probabilities of the variables are not linked may be used.

[0153] *Cancer-related gene* refers to a gene associated with an altered risk for a cancer or an altered prognosis for a cancer. Exemplary cancer-related genes that promote cancer include oncogenes; genes that enhance cell proliferation, invasion, or metastasis; genes that inhibit apoptosis; and pro-angiogenesis genes. Cancer-related genes that inhibit cancer include, but are not limited to, tumor suppressor genes; genes that inhibit cell proliferation, invasion, or metastasis; genes that promote apoptosis; and anti-angiogenesis genes.

[0154] *Estrogen-related cancer* refers to a cancer that is modulated by estrogen. Examples of estrogen-related cancers include, without limitation, breast cancer and ovarian cancer. Her2 is overexpressed in many estrogen-related cancers (U.S. Pat. No. 6,165,464, which is hereby incorporated by reference in its entirety).

[0155] *Androgen-related cancer* refers to a cancer that is modulated by androgen. An example of androgen-related cancers is prostate cancer.

[0156] *Higher than normal expression level* refers to expression of an mRNA or protein at a level that is higher than the average expression level of the corresponding molecule in control subjects (such as subjects without a disease or disorder such as cancer). In various embodiments, the expression level is at least 20, 40, 50, 75, 90, 100, 200, 500, or even 1000% higher than the level in control subjects.

[0157] *Lower than normal expression level refers to* expression of an mRNA or protein at a level that is lower than the average expression level of the corresponding molecule in control subjects (such as subjects without a disease or disorder such as cancer). In various embodiments, the expression level is at least 20, 40, 50, 75, 90, 95, or 100% lower than the level in control subjects. In some embodiments, the expression of the mRNA or protein is not detectable.

[0158] *Modulate expression or activity* refers to either increasing or decreasing expression or activity, for example, of a protein or nucleic acid sequence, relative to control conditions. In some embodiments, the modulation in expression or activity is an increase or decrease of at least 10, 20,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 194

40, 50, 75, 90, 100, 200, 500, or even 1000%. In various embodiments, transcription, translation, mRNA or protein stability, or the binding of the mRNA or protein to other molecules *in vivo* is modulated by the therapy. In some embodiments, the level of mRNA is determined by standard Northern blot analysis, and the level of protein is determined by standard Western blot analysis, such as the analyses described herein or those described by, for example, Ausubel *et al.* (Current Protocols in Molecular Biology, John Wiley & Sons, New York, July 11, 2013, which is hereby incorporated by reference in its entirety). In one embodiment, the level of a protein is determined by measuring the level of enzymatic activity, using standard methods. In another preferred embodiment, the level of mRNA, protein, or enzymatic activity is equal to or less than 20, 10, 5, or 2-fold above the corresponding level in control cells that do not express a functional form of the protein, such as cells homozygous for a nonsense mutation. In yet another embodiment, the level of mRNA, protein, or enzymatic activity is equal to or less than 20, 10, 5, or 2-fold above the corresponding basal level in control cells, such as non-cancerous cells, cells that have not been exposed to conditions that induce abnormal cell proliferation or that inhibit apoptosis, or cells from a subject without the disease or disorder of interest.

[0159] *Dosage sufficient to modulate mRNA or protein expression or activity* refers to an amount of a therapy that increases or decreases mRNA or protein expression or activity when administered to a subject. In some embodiments, for a compound that decreases expression or activity, the modulation is a decrease in expression or activity that is at least 10%, 30%, 40%, 50%, 75%, or 90% lower in a treated subject than in the same subject prior to the administration of the inhibitor or than in an untreated, control subject. In addition, In some embodiments, for a compound that increases expression or activity, the amount of expression or activity of the mRNA or protein is at least 1.5-, 2-, 3-, 5-, 10-, or 20-fold greater in a treated subject than in the same subject prior to the administration of the modulator or than in an untreated, control subject.

[0160] In some embodiments, compounds may directly or indirectly modulate the expression or activity of the mRNA or protein. For example, a compound may indirectly modulate the expression or activity of an mRNA or protein of interest by modulating the expression or activity of a molecule (*e.g.*, a nucleic acid, protein, signaling molecule, growth factor, cytokine, or chemokine) that directly or indirectly affects the expression or activity of the mRNA or protein of interest. In some embodiments, the compounds inhibit cell division or induce apoptosis. These compounds in the therapy may include, for example, unpurified or purified proteins, antibodies, synthetic organic

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 195

molecules, naturally-occurring organic molecules, nucleic acid molecules, and components thereof. The compounds in a combination therapy may be administered simultaneously or sequentially. Exemplary compounds include signal transduction inhibitors.

[0161] *Purified* refers to being separated from other components that naturally accompany it. Typically, a factor is substantially pure when it is at least 50%, by weight, free from proteins, antibodies, and naturally-occurring organic molecules with which it is naturally associated. In some embodiments, the factor is at least 75%, 90%, or 99%, by weight, pure. A substantially pure factor may be obtained by chemical synthesis, separation of the factor from natural sources, or production of the factor in a recombinant host cell that does not naturally produce the factor. Proteins and small molecules may be purified by one skilled in the art using standard techniques such as those described by Ausubel *et al.* (Current Protocols in Molecular Biology, John Wiley & Sons, New York, July 11, 2013, which is hereby incorporated by reference in its entirety). In some embodiments the factor is at least 2, 5, or 10 times as pure as the starting material, as measured using polyacrylamide gel electrophoresis, column chromatography, optical density, HPLC analysis, or western analysis (Ausubel *et al., supra*). Exemplary methods of purification include immunoprecipitation, column chromatography such as immunoaffinity chromatography, magnetic bead immunoaffinity purification, and panning with a plate-bound antibody.

[0162] Other features and advantages of the invention will be apparent from the following detailed description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0163] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0164] The presently disclosed embodiments will be further explained with reference to the attached drawings, wherein like structures are referred to by like numerals throughout the several views. The drawings shown are not necessarily to scale, with emphasis instead generally being placed upon illustrating the principles of the presently disclosed embodiments.

[0165] FIGs. 1A-1D are graphs showing the distribution of the test statistic S divided by T (the number of SNPs) ("S/T") for various copy number hypotheses for a depth of read (DOR) of 500

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 196

and a tumor fraction of 1% for an increasing number of SNPs. FIG. 1A: 100 SNPs, FIG. 1B: 333 SNPs, FIG. 1C: 667 SNPs, FIG. 1D: 1000 SNPs.

[0166] FIGs. 2A-2D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 500 and tumor fraction of 2% for an increasing number of SNPs. FIG. 2A: 100 SNPs, FIG. 2B: 333 SNPs, FIG. 2C: 667 SNPs, FIG. 2D: 1000 SNPs.

[0167] FIGs. 3A-3D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 500 and tumor fraction of 3% for an increasing number of SNPs. FIG. 3A: 100 SNPs, FIG. 3B: 333 SNPs, FIG. 3C: 667 SNPs, FIG. 3D: 1000 SNPs.

[0168] FIGs. 4A-4D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 500 and tumor fraction of 4% for an increasing number of SNPs. FIG. 4A: 100 SNPs, FIG. 4B: 333 SNPs, FIG. 4C: 667 SNPs, FIG. 4D: 1000 SNPs.

[0169] FIGs. 5A-5D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 500 and tumor fraction of 5% for an increasing number of SNPs. FIG. 5A: 100 SNPs, FIG. 5B: 333 SNPs, FIG. 5C: 667 SNPs, FIG. 5D: 1000 SNPs.

[0170] FIGs. 6A-6D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 500 and tumor fraction of 6% for an increasing number of SNPs. FIG. 6A: 100 SNPs, FIG. 6B: 333 SNPs, FIG. 6C: 667 SNPs, FIG. 6D: 1000 SNPs.

[0171] FIGs. 7A-7D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 1000 and tumor fraction of 0.5% for an increasing number of SNPs. FIG. 7A: 100 SNPs, FIG. 7B: 333 SNPs, FIG. 7C: 667 SNPs, FIG. 7D: 1000 SNPs.

[0172] FIGs. 8A-8D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 1000 and tumor fraction of 1% for an increasing number of SNPs. FIG. 8A: 100 SNPs, FIG. 8B: 333 SNPs, FIG. 8C: 667 SNPs, FIG. 8D: 1000 SNPs.

[0173] FIGs. 9A-9D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 1000 and tumor fraction of 2% for an increasing number of SNPs. FIG. 9A: 100 SNPs, FIG. 9B: 333 SNPs, FIG. 9C: 667 SNPs, FIG. 9D: 1000 SNPs.

[0174] FIGs. 10A-10D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 1000 and tumor fraction of 3% for an increasing number of SNPs. FIG. 10A: 100 SNPs, FIG. 10B: 333 SNPs, FIG. 10C: 667 SNPs, FIG. 10D: 1000 SNPs.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 197

[0175] FIGs. 11A-11D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 1000 and tumor fraction of 4% for an increasing number of SNPs. FIG. 11A: 100 SNPs, FIG. 11B: 333 SNPs, FIG. 11C: 667 SNPs, FIG. 11D: 1000 SNPs.

[0176] FIGs. 12A-12D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 3000 and tumor fraction of 0.5% for an increasing number of SNPs. FIG. 12A: 100 SNPs, FIG. 12B: 333 SNPs, FIG. 12C: 667 SNPs, FIG. 12D: 1000 SNPs.

[0177] FIGs. 13A-13D are graphs showing the distribution of S/T for various copy number hypotheses for a DOR of 3000 and tumor fraction of 1% for an increasing number of SNPs. FIG. 13A: 100 SNPs, FIG. 13B: 333 SNPs, FIG. 13C: 667 SNPs, FIG. 13D: 1000 SNPs.

[0178] FIG. 14 is a table indicating the sensitivity and specificity for detecting six microdeletion syndromes.

[0179] FIG. 15 is a graphical representation of euploidy. The x-axis represents the linear position of the individual polymorphic loci along the chromosome, and the y-axis represents the number of A allele reads as a fraction of the total (A+B) allele reads. Maternal and fetal genotypes are indicated to the right of the plots. The plots are symbol-coded according to maternal genotype, such that solid circles indicate a maternal genotype of AA, solid squares indicate a maternal genotype of BB, and open triangles indicate a maternal genotype of AB. The left plot is a plot of when two chromosomes are present, and the fetal cfDNA fraction is 0%. This plot is from a non-pregnant woman, and thus represents the pattern when the genotype is entirely maternal. Allele clusters are thus centered around 1 (AA alleles), 0.5 (AB alleles), and 0 (BB alleles). The center plot is a plot of when two chromosomes are present, and the fetal fraction is 12%. The contribution of fetal alleles to the fraction of A allele reads shifts the position of some allele spots up or down along the y-axis. The right plot is a plot of when two chromosomes are present, and the fetal fraction is 26%. The pattern, including two solid circle and two solid square peripheral bands and a trio of central open triangles, is readily apparent.

[0180] FIGs. 16A and 16B are graphical representations of 22q11.2 deletion syndrome. FIG. 16A is for maternal 22q11.2 deletion carrier (as indicated by the absence of the open triangles indicating AB SNPs). FIG 16B is for a paternally inherited 22q11 deletion in a fetus (as indicated by the presence of solid circle and solid square peripheral bands). The x-axis represents the linear position of the SNPs, and the y-axis indicates the fraction of A allele reads out of the total reads. Each individual circle, triangle or square represents a single SNP locus.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 198

[0181] FIG. 17 is a graphical representation of maternally inherited Cri-du-Chat deletion syndrome (as indicated by the presence of two central open triangle shape bands instead of three open triangle shape bands). The x-axis represents the linear position of the SNPs, and the y-axis indicates the fraction of A allele reads out of the total reads. Each individual circle, triangle or square represents a single SNP locus.

[0182] FIG. 18 is a graphical representation of paternally inherited Wolf-Hirschhorn deletion syndrome (as indicated by the presence of solid circle and solid square peripheral bands). The x-axis represents the linear position of the SNPs, and the y-axis indicates the fraction of A allele reads out of the total reads. Each individual circle, triangle or square represents a single SNP locus.

[0183] FIGs. 19A-19D are graphical representations of X chromosome spike-in experiments to represent an extra copy of a chromosome or chromosome segment. The plots show different amounts of DNA from a father mixed with DNA from the daughter: 16% father DNA (FIG. 19A), 10% father DNA (FIG. 19B), 1% father DNA (FIG. 19C), and 0.1% father DNA (FIG. 19D). The x-axis represents the linear position of the SNPs on the X chromosome, and the y-axis indicates the fraction of M allele reads out of the total reads (M + R). Each individual criss-cross, circle, triangle or square represents a single SNP locus with allele M or R.

[0184] FIGs. 20A and 20B are graphs of the false negative rate using haplotype data (FIG. 20A) and without haplotype data (FIG. 20B).

[0185] FIGs. 21A and 21B are graphs of the false positive rate for p =1% using haplotype data (FIG. 21A) and without haplotype data (FIG. 21B).

[0186] FIGs. 22A and 22B are graphs of the false positive rate for p =1.5% using haplotype data (FIG. 22A) and without haplotype data (FIG. 22B).

[0187] FIGs. 23A and 23B are graphs of the false positive rate for p =2% using haplotype data (FIG. 23A) and without haplotype data (FIG. 23B).

[0188] FIGs. 24A and 24B are graphs of the false positive rate for p =2.5% using haplotype data (FIG. 24A) and without haplotype data (FIG. 24B).

[0189] FIGs. 25A and 25B are graphs of the false positive rate for p =3% using haplotype data (FIG. 25A) and without haplotype data (FIG. 25B).

[0190] FIG. 26 is a table of false positive rates for the first simulation.

[0191] FIG. 27 is a table of false negative rates for the first simulation.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 199

[0192] FIG. 28 contains a graph of reference counts (counts of one allele, such as the "A" allele) divided by total counts for that locus for a normal (noncancerous) cell line, a graph of reference counts divided by total counts for a cancer cell line with a deletion and a graph of reference counts divided by total counts for a mixture of DNA from the normal cell line (95%) and the cancer cell line (5%).

[0193] FIG. 29 is a graph of reference counts divided by total counts for a plasma sample from a patient with stage IIa breast cancer with a tumor fraction estimated to be 4.33% (in which 4.33% of the DNA is from tumor cells). The diamond portion of the graph represents a region in which no CNV is present. The portion of the graph with solid circles and squares represents a region in which a CNV is present and there is a visible separation of the measured allele ratios from the expected allele ratio of 0.5. The solid square indicates one haplotype, and the solid circle indicates the other haplotype. Approximately 636 heterozygous SNPs were analyzed in the region of the CNV.

[0194] FIG. 30 is a graph of reference counts divided by total counts for a plasma sample from a patient with stage IIb breast cancer with a tumor fraction estimated to be 0.58%. The open diamonds of the graph represents a region in which no CNV is present. The portion of the graph with solid circles and squares represents a region in which a CNV is present but there is no clearly visible separation of the measured allele ratios from the expected allele ratio of 0.5. For this analysis, 86 heterozygous SNPs were analyzed in the region of the CNV.

[0195] FIGs. 31A and 31B are graphs showing the maximum likelihood estimation of the tumor fraction. The maximum likelihood estimate is indicated by the peak of the graph and is 4.33% for FIG. 31A and 0.58% for FIG. 31B.

[0196] FIG. 32A is a comparison of the graphs of the log of the odds ratio for various possible tumor fractions for the high tumor fraction sample (4.33%) and the low tumor fraction sample (0.58%). If the log odds ratio is less than 0, the euploid hypothesis is more likely. If the log odds ratio is greater than 0, the presence of a CNV is more likely.

[0197] FIG. 32B is a graph of small tumor results plotted in probability space. The graph depicts the probability of a deletion divided by the probability of no deletion for various possible tumor fractions for the low tumor fraction sample (0.58%).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 200

[0198] FIG. 33 is a graph of the log of the odds ratio for various possible tumor fractions for the low tumor fraction sample (0.58%). FIG. 33 is an enlarged version of the graph in FIG. 32A for the low tumor fraction sample.

[0199] FIG. 34 is a graph showing the limit of detection for single nucleotide variants in a tumor biopsy using three different methods described in Example 6.

[0200] FIG. 35 is a graph showing the limit of detection for single nucleotide variants in a plasma sample using three different methods described in Example 6.

[0201] FIGs. 36A and 36B are graphs of the analysis of genomic DNA (FIG. 36A) or DNA from a single cell (FIG. 36B) using a library of approximately 28,000 primers designed to detect CNVs. The presence of two central bands instead of one central band indicates the presence of a CNV. The x-axis represents the linear position of the SNPs, and the y-axis indicates the fraction of A allele reads out of the total reads.

[0202] FIGs. 37A and 37B are graphs of the analysis of genomic DNA (FIG. 37A) or DNA from a single cell (FIG. 37B) using a library of approximately 3,000 primers designed to detect CNVs. The presence of two central bands instead of one central band indicates the presence of a CNV. The x-axis represents the linear position of the SNPs, and the y-axis indicates the fraction of A allele reads out of the total reads.

[0203] FIG. 38 is a graph illustrating the uniformity in DOR for these ~3,000 loci.

[0204] FIG. 39 is a table comparing error call metrics for genomic DNA and DNA from a single cell.

[0205] FIG. 40 is a graph of error rates for transition mutations and transversion mutations.

[0206] FIGs. 41A-D are graphs of Sensitivity of CoNVERGe determined with PlasmArts. FIG. 41A: Correlation between CoNVERGe-calculated AAI and actual input fraction in PlasmArt samples with DNA from a 22q11.2 deletion and matched normal cell lines. FIG. 41B: Correlation between calculated AAI and actual tumour DNA input in PlasmArt samples with DNA from HCC2218 breast cancer cells with chromosome 2p and 2q CNVs and matched normal HCC2218BL cells, containing 0–9.09% tumour DNA fractions. FIG. 41C: Correlation between calculated AAI and actual tumour DNA input in PlasmArt samples with DNA from HCC1954 breast cancer cells with chromosome 1p and 1q CNVs and matched normal HCC1954BL cells, containing 0–5.66% tumour DNA fractions. FIG. 41D: Allele frequency plot for HCC1954 cells used in FIG. C. In FIGs. 41A-C, data points and error bars indicate the mean and standard deviation

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 201

(SD), respectively, of 3–8 replicates.

[0207] FIGs. 42A-B provide a model system for validation. Plasmart samples were made from cell lines with similar size profiles to plasma. FIG. 42A illustrates a son's plasma with a 22q11 deletion spiked into the father's plasma. Focal CNV: 3 MB. FIG. 42B illustrates Chromosomes 1 and 2: cancer cell lines into normal cell line of same individual. CNVs on chromosome arms 1p, 1q, 2p, 2q. FIGs. 42A and 42B are graphs showing fragment size distributions of an exemplary Plasmart standard.

[0208] FIG. 43A, FIG. 43B, FIG. 43C, and FIG. 43D provide results from a dilution curve of Plasmart synthetic ctDNA standards for validation of microdeletion and cancer panels. FIG. 43A is a graph showing the maximum likelihood of tumor. FIG. 43B is an estimate of DNA fraction results as an odds ratio plot. FIG. 43C is a plot for the detection of transversion events. FIG. 43D is a plot for the detection of Transition events.

[0209] FIG. 44 is a plot showing CNVs for various chromosomal regions as indicated for various samples at different % ctDNAs. The plot depicts plasma from 21 breast cancer patients (stage 1-IIIB) and demonstrated that CNVs could be detected in ctDNA with an AAI $\geq$0.45% and required as few as 62 heterozygous SNPs.

[0210] FIG. 45 is a plot showing CNVs for various chromosomal regions for various ovarian cancer samples with different % ctDNA levels. The plot indicates 100% detection rate at a 9.45% cutoff.

[0211] FIG. 46A is a table showing the percent of breast or lung cancer patients with an SNV or a combined SNV and/or CNV in ctDNA. The analysis was on ctDNA (plasma) from Stage I-III cancer patients and indicates that the ability to detect CNV in plasma dramatically improves detection rate vs. testing SNVs alone. FIG. 46B plots cumulative proportion TCGA breast cancer patients covered vs. genes with breast SNVs. FIG. 46C plots cumulative COSMIC patient capture vs. cumulative patient coverage (TCGA) for breast deletions. FIG. 46D plots cumulative COSMIC patient capture vs. cumulative patient coverage (TCGA) for breast amplifications.

[0212] FIG. 47A is a graph of % samples at different breast cancer stages with tumor-specific SNVs and/or CNVs in plasma. FIG. 47B is a table of percent detection of breast CNVs and SNVs by stage.

[0213] FIG. 48A is a graph of % samples at different breast cancer substages with tumor-specific SNVs and/or CNVs in plasma. Fig. 48B is a table of percent detection of breast CNVs

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 202

and SNVs by tumor substage.

[0214] FIG. 49A is a graph of % samples at different lung cancer stages with tumor-specific SNVs and/or CNVs in plasma. FIG. 49B is a table of lung plasma detection rate of lung SNVs and/or CNVs.

[0215] FIG. 50A is a graph of % samples at different lung cancer substages with tumor-specific SNVs and/or CNVs in plasma. FIG. 50B is a table of lung plasma detection rate of lung SNVs and/or CNVs by tumor substage.

[0216] FIG. 51A represents the histological finding/history for primary lung tumors analyzed for clonal and subclonal tumor heterogeneity. FIG. 51B is a table of the VAF identities of the biopsied lung tumors by whole genome sequencing and assaying by AmpliSEQ.

[0217] FIG. 52 illustrates the use of ctDNA from plasma to identify both clonal and subclonal SNV mutations to overcome tumor heterogeneity.

[0218] FIG. 53A is a table comparing VAF calls by AmpliSeq. FIG. 53B is a table comparing VAF calls by mmPCR-NGS. A comparison of the two tables for detection of SNVs in primary tumor indicate that SNVs were missed by AmpliSeq and SNV mutations were identified in ctDNA from plasma with mmPCR-NGS.

[0219] FIG. 54A is a plot of % VAF in Primary Lung Tumor. FIG. 54B is a linear regression plot of AmpliSeq VAF vs. Natera VAF.

[0220] FIG. 55 is a graph of Pool 1/4 of an 84-plex SNV PCR primer reaction when primer concentration is limited.

[0221] FIG. 56 is a graph of Pool 2/4 of an 84-plex SNV PCR primer reaction when primer concentration is limited.

[0222] FIG. 57 is a graph of Pool 3/4 of an 84-plex SNV PCR primer reaction when primer concentration is limited.

[0223] FIG. 58 is a graph of Pool 4/4 of an 84-plex SNV PCR primer reaction when primer concentration is limited.

[0224] FIG. 59 illustrates a plot of Limit of Detection (LOD) vs. Depth of Read (DOR) for detection of SNV Transition and Transversion mutations in a 84-plex PCR reaction at 15 PCR cycles.

[0225] FIG. 60 illustrates a plot of Limit of Detection (LOD) vs. Depth of Read (DOR) for detection of SNV Transition and Transversion mutations in a 84-plex PCR reaction at 20 PCR

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 203

cycles.

[0226] FIG. 61 illustrates a plot of Limit of Detection (LOD) vs. Depth of Read (DOR) for detection of SNV Transition and Transversion mutations in a 84-plex PCR reaction at 25 PCR cycles.

[0227] FIG. 62A is a plot illustrating sensitivity of detection of SNVs in tumor cell genomic DNA. FIG. 62B illustrates sensitivity of detection of SNVs in 1/3 single cells. FIG. 62C illustrates sensitivity of detection of SNVs in 2/3 single cells. FIG 62D illustrates sensitivity of detection of SNVs in 3/3 single cells. Comparable sensitivities are seen between tumor and single cell genomic DNA.

[0228] FIG. 63A illustrates the workflow for analysis of CNVs in a variety of cancer sample types in a massively multiplexed PCR (mmPCR) assay targeting SNPs. FIG. 63B illustrates detection of somatic CNVs in human breast cancer cell lines and matched normal cell lines (FIG. 63C) on the CoNVERGe platform. FIG. 63D illustrates detection of somatic CNVs in human breast cancer cell lines and matched normal cell lines (FIG. 63E) on the CytoSNP-12 microarray platform. FIG. 63F is a plot of the maximum homolog ratios for CNVs identified by CoNVERG3e or CytoSNP-12 showing a strong linear correlation of identified CNVs by either method.

[0229] FIGs. 64A-H provide a comparison of Fresh Frozen (FF) and FFPE (formalin-fixed paraffin embedded) breast cancer samples to matched buffy coat gDNA control samples. FIG. 64A is a FF breast tissue control sample analyzed by CoNVERGe. FIG. 64B is a FFPE breast tissue control sample analyzed by CoNVERGe. FIG. 64C is a FF breast tumour tissue sample analyzed by CoNVERGe. FIG. 64D is a FFPE breast tumour tissue sample analyzed by CoNVERGe. FIG. 64E is a FF breast tumour tissue sample analyzed by CytoSNP-12. FIG. 64F is a FFPE breast tumour tissue sample analyzed by CytoSNP-12. FIG. 64G compares the CoNVERGe assay to a microarray assay on breast cancer cell lines and FIG. 64H compares the CoNVERGe assay to the OneScan assay on breast cancer cell lines.

[0230] FIGs. 65A-D illustrate Allele frequency plots to reflect chromosome copy number using the CoNVERGe assay to detect CNVs in single cells. FIG. 65A is the analysis of 1/3 breast cancer single cell replicates. FIG. 65B is the analysis of 2/3 breast cancer single cell replicates. FIG. 65C is the analysis of 3/3 breast cancer single cell replicates. FIG. 65D is the analysis of a B-lymphocyte cell line lacking CNVs in the target regions.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 204

[0231] FIGs. 66A-C illustrate Allele frequency plots to reflect chromosome copy number using the CoNVERGe assay to detect CNVs in real plasma samples. FIG. 66A is a stage II breast cancer plasma cfDNA sample and its matched tumor biopsy gDNA. FIG. 66B is a late stage ovarian cancer plasma cfDNA sample and its matched tumor biopsy gDNA. FIG. 66C is a chart illustrating tumor heterogeneity as determined by CNV detection in five late stage ovarian cancer plasma and matched tissue samples.

[0232] FIGs. 67A-H lists the chromosome positions, SNVs and mutation change in breast cancer.

[0233] FIGs. 68A-B illustrate the major (FIG. 68A) and minor allele (FIG. 68B) frequencies of SNPs used in a 3168 mmPCR reaction.

[0234] FIG. 69 shows an example system architecture X00 useful for performing embodiments of the present invention. System architecture X00 includes an analysis platform X08 and a laboratory information systems ("LISs") X04. X04 can be connected to Genetic Data Source X10. X08 may be connected to LIS X04 over a network X02. Analysis platform X08 may alternatively or additionally be connected directly to LIS X06. LIS X06 can be connected to Genetic Data Source X10. Analysis platform X08 includes one or more of an input processor X12, a hypothesis manager X14, a modeler X16, an error correction unit X18, a machine learning unit X20, and an output processor X22.

[0235] FIG. 70 illustrates an example computer system Y00 for performing embodiments of the present invention. System architecture Y00 includes one or more processors Y10, a BUS Y20, a main memory Y30, a memory controller Y75, a communications and network interface Y80, a communication path Y85, an input/output/display devices Y90, and may also include a secondary memory Y40. Y40 may include a hard disk drive Y50 and a removable storage drive Y60. Y60 can write to a removable storage unit Y70.

[0236] While the above-identified drawings set forth presently disclosed embodiments, other embodiments are also contemplated, as noted in the discussion. This disclosure presents illustrative embodiments by way of representation and not limitation. Numerous other modifications and embodiments can be devised by those skilled in the art which fall within the scope and spirit of the principles of the presently disclosed embodiments.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 205

DETAILED DESCRIPTION OF THE INVENTION

[0237] In one aspect, the present invention generally relates, at least in part, to improved methods of determining the presence or absence of copy number variations, such as deletions or duplications of chromosome segments or entire chromosomes. The methods are particularly useful for detecting small deletions or duplications, which can be difficult to detect with high specificity and sensitivity using prior methods due to the small amount of data available from the relevant chromosome segment. The methods include improved analytical methods, improved bioassay methods, and combinations of improved analytical and bioassay methods. Methods of the invention can also be used to detect deletions or duplications that are only present in a small percentage of the cells or nucleic acid molecules that are tested. This allows deletions or duplications to be detected prior to the occurrence of disease (such as at a precancerous stage) or in the early stages of disease, such as before a large number of diseased cells (such as cancer cells) with the deletion or duplication accumulate. The more accurate detection of deletions or duplications associated with a disease or disorder enable improved methods for diagnosing, prognosticating, preventing, delaying, stabilizing, or treating the disease or disorder. Several deletions or duplications are known to be associated with cancer or with severe mental or physical handicaps.

[0238] In another aspect, the present invention generally relates, at least in part, to improved methods of detecting single nucleotide variations (SNVs). These improved methods include improved analytical methods, improved bioassay methods, and improved methods that use a combination of improved analytical and bioassay methods. The methods in certain illustrative embodiments are used to detect, diagnose, monitor, or stage cancer, for example in samples where the SNV is present at very low concentrations, for example less than 10%, 5%, 4%, 3%, 2.5%, 2%, 1%, 0.5%, 0.25%, or 0.1% relative to the total number of normal copies of the SNV locus, such as circulating free DNA samples. That is, these methods in certain illustrative embodiments are particularly well suited for samples where there is a relatively low percentage of a mutation or variant relative to the normal polymorphic alleles present for that genetic loci. Finally, provided herein are methods that combine the improved methods for detecting copy number variations with the improved methods for detecting single nucleotide variations.

[0239] Successful treatment of a disease such as cancer often relies on early diagnosis, correct staging of the disease, selection of an effective therapeutic regimen, and close monitoring to

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 206

prevent or detect relapse. For cancer diagnosis, histological evaluation of tumor material obtained from tissue biopsy is often considered the most reliable method. However, the invasive nature of biopsy-based sampling has rendered it impractical for mass screening and regular follow up. Therefore, the present methods have the advantage of being able to be performed non-invasively if desired for relatively low cost with fast turnaround time. The targeted sequencing that may be used by the methods of the invention requires less reads than shotgun sequencing, such as a few million reads instead of 40 million reads, thereby decreasing cost. The multiplex PCR and next generation sequencing that may be used increase throughput and reduces costs.

[0240] In some embodiments, the methods are used to detect a deletion, duplication, or single nucleotide variant in an individual. A sample from the individual that contains cells or nucleic acids suspected of having a deletion, duplication, or single nucleotide variant may be analyzed. In some embodiments, the sample is from a tissue or organ suspected of having a deletion, duplication, or single nucleotide variant, such as cells or a mass suspected of being cancerous. The methods of the invention can be used to detect deletion, duplication, or single nucleotide variant that are only present in one cell or a small number of cells in a mixture containing cells with the deletion, duplication, or single nucleotide variant and cells without the deletion, duplication, or single nucleotide variant. In some embodiments, cfDNA or cfRNA from a blood sample from the individual is analyzed. In some embodiments, cfDNA or cfRNA is secreted by cells, such as cancer cells. In some embodiments, cfDNA or cfRNA is released by cells undergoing necrosis or apoptosis, such as cancer cells. The methods of the invention can be used to detect deletion, duplication, or single nucleotide variant that are only present in a small percentage of the cfDNA or cfRNA. In some embodiments, one or more cells from an embryo are tested.

[0241] In some embodiments, the methods are used for non-invasive or invasive prenatal testing of a fetus. These methods can be used to determine the presence or absence of deletions or duplications of a chromosome segment or an entire chromosome, such as deletions or duplications known to be associated severe mental or physical handicaps, learning disabilities, or cancer. In some embodiments for non-invasive prenatal testing (NIPT), cells, cfDNA or cfRNA from a blood sample from the pregnant mother is tested. The methods allow the detection of a deletion or duplication in the cells, cfDNA, or cfRNA from the fetus despite the large amount of cells, cfDNA, or cfRNA from the mother that is also present. In some embodiments for invasive prenatal testing, DNA or RNA from a sample from the fetus is tested (such as a CVS or amniocentesis sample).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 207

Even if the sample is contaminated with DNA or RNA from the pregnant mother, the methods can be used to detect a deletion or duplication in the fetal DNA or RNA.

[0242] In addition to determining the presence or absence of copy number variation, one or more other factors can be analyzed if desired. These factors can be used to increase the accuracy of the diagnosis (such as determining the presence or absence of cancer or an increased risk for cancer, classifying the cancer, or staging the cancer) or prognosis. These factors can also be used to select a particular therapy or treatment regimen that is likely to be effective in the subject. Exemplary factors include the presence or absence of polymorphisms or mutation; altered (increased or decreased) levels of total or particular cfDNA, cfRNA, microRNA (miRNA); altered (increased or decreased) tumor fraction; altered (increased or decreased) methylation levels, altered (increased or decreased) DNA integrity, altered (increased or decreased) or alternative mRNA splicing.

[0243] The following sections describe methods for detecting deletions or duplications using phased data (such as inferred or measured phased data) or unphased data; samples that can be tested; methods for sample preparation, amplification, and quantification; methods for phasing genetic data; polymorphisms, mutations, nucleic acid alterations, mRNA splicing alterations, and changes in nucleic acid levels that can be detected; databases with results from the methods, other risk factors and screening methods; cancers that can be diagnosed or treated; cancer treatments; cancer models for testing treatments; and methods for formulating and administering treatments.

Exemplary Methods for Determining Ploidy Using Phased Data

[0244] Some of the methods of the invention are based in part on the discovery that using phased data for detecting CNVs decreases the false negative and false positive rates compared to using unphased data (Figures 20A-27). This improvement is greatest for samples with CNVs present in low levels. Thus, phase data increases the accuracy of CNV detection compared to using unphased data (such as methods that calculate allele ratios at one or more loci or aggregate allele ratios to give an aggregated value (such as an average value) over a chromosome or chromosome segment without considering whether the allele ratios at different loci indicate that the same or different haplotypes appear to be present in an abnormal amount). Using phased data allows a more accurate determination to be made of whether differences between measured and expected allele ratios are due to noise or due to the presence of a CNV. For example, if the differences between measured

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 208

and expected allele ratios at most or all of the loci in a region indicate that the same haplotype is overrepresented, then a CNV is more likely to be present. Using linkage between alleles in a haplotype allows one to determine whether the measured genetic data is consistent with the same haplotype being overrepresented (rather than random noise). In contrast, if the differences between measured and expected allele ratios are only due to noise (such as experimental error), then in some embodiments, about half the time the first haplotype appears to be overrepresented and about the other half of the time, the second haplotype appears to be overrepresented.

[0245] Accuracy can be increased by taking into account the linkage between SNPs, and the likelihood of crossovers having occurred during the meiosis that gave rise to the gametes that formed the embryo that grew into the fetus. Using linkage when creating the expected distribution of allele measurements for one or more hypotheses allows the creation of expected allele measurements distributions that correspond to reality considerably better than when linkage is not used. For example, imagine that there are two SNPs, 1 and 2 located nearby one another, and the mother is A at SNP 1 and A at SNP 2 on one homolog, and B at SNP 1 and B at SNP 2 on homolog two. If the father is A for both SNPs on both homologs, and a B is measured for the fetus SNP 1, this indicates that homolog two has been inherited by the fetus, and therefore that there is a much higher likelihood of a B being present in the fetus at SNP 2. A model that takes into account linkage can predict this, while a model that does not take linkage into account cannot. Alternately, if a mother is AB at SNP 1 and AB at nearby SNP 2, then two hypotheses corresponding to maternal trisomy at that location can be used – one involving a matching copy error (nondisjunction in meiosis II or mitosis in early fetal development), and one involving an unmatching copy error (nondisjunction in meiosis I). In the case of a matching copy error trisomy, if the fetus inherited an AA from the mother at SNP 1, then the fetus is much more likely to inherit either an AA or BB from the mother at SNP 2, but not AB. In the case of an unmatching copy error, the fetus inherits an AB from the mother at both SNPs. The allele distribution hypotheses made by a CNV calling method that takes into account linkage can make these predictions, and therefore correspond to the actual allele measurements to a considerably greater extent than a CNV calling method that does not take into account linkage.

[0246] In some embodiments, phased genetic data is used to determine if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of an individual (such

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 209

as in the genome of one or more cells or in cfDNA or cfRNA). Exemplary overrepresentations include the duplication of the first homologous chromosome segment or the deletion of the second homologous chromosome segment. In some embodiments, there is not an overrepresentation since the first and homologous chromosome segments are present in equal proportions (such as one copy of each segment in a diploid sample). In some embodiments, calculated allele ratios in a nucleic acid sample are compared to expected allele ratios to determine if there is an overrepresentation as described further below. In this specification the phrase "a first homologous chromosome segment as compared to a second homologous chromosome segment" means a first homolog of a chromosome segment and a second homolog of the chromosome segment.

[0247] In some embodiments, the method includes obtaining phased genetic data for the first homologous chromosome segment comprising the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, obtaining phased genetic data for the second homologous chromosome segment comprising the identity of the allele present at that locus on the second homologous chromosome segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and obtaining measured genetic allelic data comprising, for each of the alleles at each of the loci in the set of polymorphic loci, the amount of each allele present in a sample of DNA or RNA from one or more target cells and one or more non-target cells from the individual. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment; calculating, for each of the hypotheses, expected genetic data for the plurality of loci in the sample from the obtained phased genetic data for one or more possible ratios of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample; calculating (such as calculating on a computer) for each possible ratio of DNA or RNA and for each hypothesis, the data fit between the obtained genetic data of the sample and the expected genetic data for the sample for that possible ratio of DNA or RNA and for that hypothesis; ranking one or more of the hypotheses according to the data fit; and selecting the hypothesis that is ranked the highest, thereby determining the degree of overrepresentation of the number of copies of the first homologous chromosome segment in the genome of one or more cells from the individual.

[0248] In one aspect, the invention features a method for determining a number of copies of a chromosome or chromosome segment of interest in the genome of a fetus.

In some embodiments, the method includes obtaining phased genetic data for at least one biological parent of the fetus, wherein the phased genetic data comprises the identity of the allele present for each locus in a set of polymorphic loci on a first homologous chromosome segment and a second homologous chromosome segment in the parent. In some embodiments, the method includes obtaining genetic data at the set of polymorphic loci on the chromosome or chromosome segment in a mixed sample of DNA or RNA comprising fetal DNA or RNA and maternal DNA or RNA from the mother of the fetus by measuring the quantity of each allele at each locus. In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the number of copies of the chromosome or chromosome segment of interest present in the genome of the fetus. In some embodiments, the method includes creating (such as creating on a computer) for each of the hypotheses, a probability distribution of the expected quantity of each allele at each of the plurality of loci in mixed sample from the (i) the obtained phased genetic data from the parent(s) and optionally (ii) the probability of one or more crossovers that may have occurred during the formation of a gamete that contributed a copy of the chromosome or chromosome segment of interest to the fetus; calculating (such as calculating on a computer) a fit, for each of the hypotheses, between (1) the obtained genetic data of the mixed sample and (2) the probability distribution of the expected quantity of each allele at each of the plurality of loci in mixed sample for that hypothesis; ranking one or more of the hypotheses according to the data fit; and selecting the hypothesis that is ranked the highest, thereby determining the number of copies of the chromosome segment of interest in the genome of the fetus.

[0249] In some embodiments, the method involves obtaining phased genetic data using any of the methods described herein or any known method. In some embodiments, the method involves simultaneously or sequentially in any order (i) obtaining phased genetic data for the first homologous chromosome segment comprising the identity of the allele present at that locus on the first homologous chromosome segment for each locus in a set of polymorphic loci on the first homologous chromosome segment, (ii) obtaining phased genetic data for the second homologous chromosome segment comprising the identity of the allele present at that locus on the second homologous chromosome segment for each locus in the set of polymorphic loci on the second homologous chromosome segment, and (iii) obtaining measured genetic allelic data comprising

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 211

the amount of each allele at each of the loci in the set of polymorphic loci in a sample of DNA from one or more cells from the individual.

[0250] In some embodiments, the method involves calculating allele ratios for one or more loci in the set of polymorphic loci that are heterozygous in at least one cell from which the sample was derived (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother). In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles divided by the total measured quantity of all the alleles for the locus. In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles (such as the allele on the first homologous chromosome segment) divided by the measured quantity of one or more other alleles (such as the allele on the second homologous chromosome segment) for the locus. The calculated allele ratios may be calculated using any of the methods described herein or any standard method (such as any mathematical transformation of the calculated allele ratios described herein).

[0251] In some embodiments, the method involves determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment by comparing one or more calculated allele ratios for a locus to an allele ratio that is expected for that locus if the first and second homologous chromosome segments are present in equal proportions. In some embodiments, the expected allele ratio assumes the possible alleles for a locus have an equal likelihood of being present. In some embodiments in which the calculated allele ratio for a particular locus is the measured quantity of one of the alleles divided by the total measured quantity of all the alleles for the locus, the corresponding expected allele ratio is 0.5 for a biallelic locus, or 1/3 for a triallelic locus. In some embodiments, the expected allele ratio is the same for all the loci, such as 0.5 for all loci. In some embodiments, the expected allele ratio assumes that the possible alleles for a locus can have a different likelihood of being present, such as the likelihood based on the frequency of each of the alleles in a particular population that the subject belongs in, such as a population based on the ancestry of the subject. Such allele frequencies are publicly available (*see, e.g.,* HapMap Project; Perlegen Human Haplotype Project; web at ncbi.nlm.nih.gov/projects/SNP/; Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001 Jan 1;29(1):308-11, which are each incorporated by reference in its entirety). In some embodiments, the expected allele ratio is the allele ratio that is expected for the particular individual being tested for a particular hypothesis

specifying the degree of overrepresentation of the first homologous chromosome segment. For example, the expected allele ratio for a particular individual may be determined based on phased or unphased genetic data from the individual (such as from a sample from the individual that is unlikely to have a deletion or duplication such as a noncancerous sample) or data from one or more relatives from the individual. In some embodiments for prenatal testing, the expected allele ratio is the allele ratio that is expected for a mixed sample that includes DNA or RNA from the pregnant mother and the fetus (such as a maternal plasma or serum sample that includes cfDNA from the mother and cfDNA from the fetus) for a particular hypothesis specifying the degree of overrepresentation of the first homologous chromosome segment. For example, the expected allele ratio for the mixed sample may be determined based on genetic data from the mother and predicted genetic data for the fetus (such as predictions for alleles that the fetus may have inherited from the mother and/or father). In some embodiments, phased or unphased genetic data from a sample of DNA or RNA from only the mother (such as the buffy coat from a maternal blood sample) is to determine the alleles from the maternal DNA or RNA in the mixed sample as well as alleles that the fetus may have been inherited from the mother (and thus may be present in the fetal DNA or RNA in the mixed sample). In some embodiments, phased or unphased genetic data from a sample of DNA or RNA from only the father is used to determine the alleles that the fetus may have been inherited from the father (and thus may be present in the fetal DNA or RNA in the mixed sample). The expected allele ratios may be calculated using any of the methods described herein or any standard method (such as any mathematical transformation of the expected allele ratios described herein) (U.S. Publication No 2012/0270212, filed Nov. 18, 2011, which is hereby incorporated by reference in its entirety).

[0252] In some embodiments, a calculated allele ratio is indicative of an overrepresentation of the number of copies of the first homologous chromosome segment if either (i) the allele ratio for the measured quantity of the allele present at that locus on the first homologous chromosome divided by the total measured quantity of all the alleles for the locus is greater than the expected allele ratio for that locus, or (ii) the allele ratio for the measured quantity of the allele present at that locus on the second homologous chromosome divided by the total measured quantity of all the alleles for the locus is less than the expected allele ratio for that locus. In some embodiments, a calculated allele ratio is only considered indicative of overrepresentation if it is significantly greater or lower than the expected ratio for that locus. In some embodiments, a calculated allele ratio is indicative

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 213

of no overrepresentation of the number of copies of the first homologous chromosome segment if either (i) the allele ratio for the measured quantity of the allele present at that locus on the first homologous chromosome divided by the total measured quantity of all the alleles for the locus is less than or equal to the expected allele ratio for that locus, or (ii) the allele ratio for the measured quantity of the allele present at that locus on the second homologous chromosome divided by the total measured quantity of all the alleles for the locus is greater than or equal to the expected allele ratio for that locus. In some embodiments, calculated ratios equal to the corresponding expected ratio are ignored (since they are indicative of no overrepresentation).

[0253] In various embodiments, one or more of the following methods is used to compare one or more of the calculated allele ratios to the corresponding expected allele ratio(s). In some embodiments, one determines whether the calculated allele ratio is above or below the expected allele ratio for a particular locus irrespective of the magnitude of the difference. In some embodiments, one determines the magnitude of the difference between the calculated allele ratio and the expected allele ratio for a particular locus irrespective of whether the calculated allele ratio is above or below the expected allele ratio. In some embodiments, one determines whether the calculated allele ratio is above or below the expected allele ratio and the magnitude of the difference for a particular locus. In some embodiments, one determines whether the average or weighted average value of the calculated allele ratios is above or below the average or weighted average value of the expected allele ratios irrespective of the magnitude of the difference. In some embodiments, one determines the magnitude of the difference between the average or weighted average value of the calculated allele ratios and the average or weighted average value of the expected allele ratios irrespective of whether the average or weighted average of the calculated allele ratio is above or below the average or weighted average value of the expected allele ratio. In some embodiments, one determines whether the average or weighted average value of the calculated allele ratios is above or below the average or weighted average value of the expected allele ratios and the magnitude of the difference. In some embodiments, one determines an average or weighted average value of the magnitude of the difference between the calculated allele ratios and the expected allele ratios.

[0254] In some embodiments, the magnitude of the difference between the calculated allele ratio and the expected allele ratio for one or more loci is used to determine whether the overrepresentation of the number of copies of the first homologous chromosome segment is due

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 214

to a duplication of the first homologous chromosome segment or a deletion of the second homologous chromosome segment in the genome of one or more of the cells.

[0255] In some embodiments, an overrepresentation of the number of copies of the first homologous chromosome segment is determined to be present if one or more of following conditions is met. In some embodiments, the number of calculated allele ratios that are indicative of an overrepresentation of the number of copies of the first homologous chromosome segment is above a threshold value. In some embodiments, the number of calculated allele ratios that are indicative of no overrepresentation of the number of copies of the first homologous chromosome segment is below a threshold value. In some embodiments, the magnitude of the difference between the calculated allele ratios that are indicative of an overrepresentation of the number of copies of the first homologous chromosome segment and the corresponding expected allele ratios is above a threshold value. In some embodiments, for all calculated allele ratios that are indicative of overrepresentation, the sum of the magnitude of the difference between a calculated allele ratio and the corresponding expected allele ratio is above a threshold value. In some embodiments, the magnitude of the difference between the calculated allele ratios that are indicative of no overrepresentation of the number of copies of the first homologous chromosome segment and the corresponding expected allele ratios is below a threshold value. In some embodiments, the average or weighted average value of the calculated allele ratios for the measured quantity of the allele present on the first homologous chromosome divided by the total measured quantity of all the alleles for the locus is greater than the average or weighted average value of the expected allele ratios by at least a threshold value. In some embodiments, the average or weighted average value of the calculated allele ratios for the measured quantity of the allele present on the second homologous chromosome divided by the total measured quantity of all the alleles for the locus is less than the average or weighted average value of the expected allele ratios by at least a threshold value. In some embodiments, the data fit between the calculated allele ratios and allele ratios that are predicted for an overrepresentation of the number of copies of the first homologous chromosome segment is below a threshold value (indicative of a good data fit). In some embodiments, the data fit between the calculated allele ratios and allele ratios that are predicted for no overrepresentation of the number of copies of the first homologous chromosome segment is above a threshold value (indicative of a poor data fit).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 215

[0256] In some embodiments, an overrepresentation of the number of copies of the first homologous chromosome segment is determined to be absent if one or more of following conditions is met. In some embodiments, the number of calculated allele ratios that are indicative of an overrepresentation of the number of copies of the first homologous chromosome segment is below a threshold value. In some embodiments, the number of calculated allele ratios that are indicative of no overrepresentation of the number of copies of the first homologous chromosome segment is above a threshold value. In some embodiments, the magnitude of the difference between the calculated allele ratios that are indicative of an overrepresentation of the number of copies of the first homologous chromosome segment and the corresponding expected allele ratios is below a threshold value. In some embodiments, the magnitude of the difference between the calculated allele ratios that are indicative of no overrepresentation of the number of copies of the first homologous chromosome segment and the corresponding expected allele ratios is above a threshold value. In some embodiments, the average or weighted average value of the calculated allele ratios for the measured quantity of the allele present on the first homologous chromosome divided by the total measured quantity of all the alleles for the locus minus the average or weighted average value of the expected allele ratios is less than a threshold value. In some embodiments, the average or weighted average value of the expected allele ratios minus the average or weighted average value of the calculated allele ratios for the measured quantity of the allele present on the second homologous chromosome divided by the total measured quantity of all the alleles for the locus is less than a threshold value. In some embodiments, the data fit between the calculated allele ratios and allele ratios that are predicted for an overrepresentation of the number of copies of the first homologous chromosome segment is above a threshold value. In some embodiments, the data fit between the calculated allele ratios and allele ratios that are predicted for no overrepresentation of the number of copies of the first homologous chromosome segment is below a threshold value. In some embodiments, the threshold is determined from empirical testing of samples known to have a CNV of interest and/or samples known to lack the CNV.

[0257] In some embodiments, determining if there is an overrepresentation of the number of copies of the first homologous chromosome segment includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment. On exemplary hypothesis is the absence of an overrepresentation since the first and homologous chromosome segments are present in equal proportions (such as one copy of each

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 216

segment in a diploid sample). Other exemplary hypotheses include the first homologous chromosome segment being duplicated one or more times (such as 1, 2, 3, 4, 5, or more extra copies of the first homologous chromosome compared to the number of copies of the second homologous chromosome segment). Another exemplary hypothesis includes the deletion of the second homologous chromosome segment. Yet another exemplary hypothesis is the deletion of both the first and the second homologous chromosome segments. In some embodiments, predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) are estimated for each hypothesis given the degree of overrepresentation specified by that hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing the calculated allele ratios to the predicted allele ratios, and the hypothesis with the greatest likelihood is selected.

[0258] In some embodiments, an expected distribution of a test statistic is calculated using the predicted allele ratios for each hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing a test statistic that is calculated using the calculated allele ratios to the expected distribution of the test statistic that is calculated using the predicted allele ratios, and the hypothesis with the greatest likelihood is selected.

[0259] In some embodiments, predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) are estimated given the phased genetic data for the first homologous chromosome segment, the phased genetic data for the second homologous chromosome segment, and the degree of overrepresentation specified by that hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing the calculated allele ratios to the predicted allele ratios; and the hypothesis with the greatest likelihood is selected.

Use of Mixed Samples

[0260] It will be understood that for many embodiments, the sample is a mixed sample with DNA or RNA from one or more target cells and one or more non-target cells. In some embodiments, the target cells are cells that have a CNV, such as a deletion or duplication of interest, and the non-target cells are cells that do not have the copy number variation of interest (such as a mixture of cells with the deletion or duplication of interest and cells without any of the deletions or duplications being tested). In some embodiments, the target cells are cells that are associated with

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 217

a disease or disorder or an increased risk for disease or disorder (such as cancer cells), and the non-target cells are cells that are not associated with a disease or disorder or an increased risk for disease or disorder (such as noncancerous cells). In some embodiments, the target cells all have the same CNV. In some embodiments, two or more target cells have different CNVs. In some embodiments, one or more of the target cells has a CNV, polymorphism, or mutation associated with the disease or disorder or an increased risk for disease or disorder that is not found it at least one other target cell. In some such embodiments, the fraction of the cells that are associated with the disease or disorder or an increased risk for disease or disorder out of the total cells from a sample is assumed to be greater than or equal to the fraction of the most frequent of these CNVs, polymorphisms, or mutations in the sample. For example if 6% of the cells have a K-ras mutation, and 8% of the cells have a BRAF mutation, at least 8% of the cells are assumed to be cancerous.

[0261] In some embodiments, the ratio of DNA (or RNA) from the one or more target cells to the total DNA (or RNA) in the sample is calculated. In some embodiments, a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment are enumerated. In some embodiments, predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) are estimated given the calculated ratio of DNA or RNA and the degree of overrepresentation specified by that hypothesis are estimated for each hypothesis. In some embodiments, the likelihood that the hypothesis is correct is calculated by comparing the calculated allele ratios to the predicted allele ratios, and the hypothesis with the greatest likelihood is selected.

[0262] In some embodiments, an expected distribution of a test statistic calculated using the predicted allele ratios and the calculated ratio of DNA or RNA is estimated for each hypothesis. In some embodiments, the likelihood that the hypothesis is correct is determined by comparing a test statistic calculated using the calculated allele ratios and the calculated ratio of DNA or RNA to the expected distribution of the test statistic calculated using the predicted allele ratios and the calculated ratio of DNA or RNA, and the hypothesis with the greatest likelihood is selected.

[0263] In some embodiments, the method includes enumerating a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment. In some embodiments, the method includes estimating, for each hypothesis, either (i) predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 218

in the fetus and/or heterozygous in the mother) given the degree of overrepresentation specified by that hypothesis or (ii) for one or more possible ratios of DNA or RNA, an expected distribution of a test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample. In some embodiments, a data fit is calculated by comparing either (i) the calculated allele ratios to the predicted allele ratios, or (ii) a test statistic calculated using the calculated allele ratios and the possible ratio of DNA or RNA to the expected distribution of the test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA. In some embodiments, one or more of the hypotheses are ranked according to the data fit, and the hypothesis that is ranked the highest is selected. In some embodiments, a technique or algorithm, such as a search algorithm, is used for one or more of the following steps: calculating the data fit, ranking the hypotheses, or selecting the hypothesis that is ranked the highest. In some embodiments, the data fit is a fit to a beta-binomial distribution or a fit to a binomial distribution. In some embodiments, the technique or algorithm is selected from the group consisting of maximum likelihood estimation, maximum a-posteriori estimation, Bayesian estimation, dynamic estimation (such as dynamic Bayesian estimation), and expectation-maximization estimation. In some embodiments, the method includes applying the technique or algorithm to the obtained genetic data and the expected genetic data.

[0264] In some embodiments, the method includes creating a partition of possible ratios that range from a lower limit to an upper limit for the ratio of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample. In some embodiments, a set of one or more hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment are enumerated. In some embodiments, the method includes estimating, for each of the possible ratios of DNA or RNA in the partition and for each hypothesis, either (i) predicted allele ratios for the loci that are heterozygous in at least one cell (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother) given the possible ratio of DNA or RNA and the degree of overrepresentation specified by that hypothesis or (ii) an expected distribution of a test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA. In some embodiments, the method includes calculating, for each of the possible ratios of DNA or RNA in the partition and for each hypothesis, the likelihood that the hypothesis is correct by comparing either (i) the calculated allele ratios to the predicted allele ratios, or (ii) a test statistic calculated using the calculated allele ratios and the possible ratio of

DNA or RNA to the expected distribution of the test statistic calculated using the predicted allele ratios and the possible ratio of DNA or RNA. In some embodiments, the combined probability for each hypothesis is determined by combining the probabilities of that hypothesis for each of the possible ratios in the partition; and the hypothesis with the greatest combined probability is selected. In some embodiments, the combined probability for each hypothesis is determining by weighting the probability of a hypothesis for a particular possible ratio based on the likelihood that the possible ratio is the correct ratio.

[0265] In some embodiments, a technique selected from the group consisting of maximum likelihood estimation, maximum a-posteriori estimation, Bayesian estimation, dynamic estimation (such as dynamic Bayesian estimation), and expectation-maximization estimation is used to estimate the ratio of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample. In some embodiments, the ratio of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample is assumed to be the same for two or more (or all) of the CNVs of interest. In some embodiments, the ratio of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample is calculated for each CNV of interest.

Exemplary Methods for Using Imperfectly Phased Data

[0266] It will be understood that for many embodiments, imperfectly phased data is used. For example, it may not be known with 100% certainty which allele is present for one or more of the loci on the first and/or second homologous chromosome segment. In some embodiments, the priors for possible haplotypes of the individual (such as haplotypes based on population based haplotype frequencies) are used in calculating the probability of each hypothesis. In some embodiments, the priors for possible haplotypes are adjusted by either using another method to phase the genetic data or by using phased data from other subjects (such as prior subjects) to refine population data used for informatics based phasing of the individual.

[0267] In some embodiments, the phased genetic data comprises probabilistic data for two or more possible sets of phased genetic data, wherein each possible set of phased data comprises a possible identity of the allele present at each locus in the set of polymorphic loci on the first homologous chromosome segment and a possible identity of the allele present at each locus in the set of polymorphic loci on the second homologous chromosome segment. In some embodiments, the probability for at least one of the hypotheses is determined for each of the possible sets of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 220

phased genetic data. In some embodiments, the combined probability for the hypothesis is determined by combining the probabilities of the hypothesis for each of the possible sets of phased genetic data; and the hypothesis with the greatest combined probability is selected.

[0268] Any of the methods disclosed herein or any known method may be used to generate imperfectly phased data (such as using population based haplotype frequencies to infer the most likely phase) for use in the claimed methods. In some embodiments, phased data is obtained by probabilistically combining haplotypes of smaller segments. For example, possible haplotypes can be determined based on possible combinations of one haplotype from a first region with another haplotype from another region from the same chromosome. The probability that particular haplotypes from different regions are part of the same, larger haplotype block on the same chromosome can be determined using, *e.g.*, population based haplotype frequencies and/or known recombination rates between the different regions.

[0269] In some embodiments, a single hypothesis rejection test is used for the null hypothesis of disomy. In some embodiments, the probability of the disomy hypothesis is calculated, and the hypothesis of disomy is rejected if the probability is below a given threshold value (such as less than 1 in 1,000). If the null hypothesis is rejected, this could be due to errors in the imperfectly phased data or due to the presence of a CNV. In some embodiments, more accurate phased data is obtained (such as phased data from any of the molecular phasing methods disclosed herein to obtain actual phased data rather than bioinformatics-based inferred phased data). In some embodiments, the probability of the disomy hypothesis is recalculated using the more accurate phased data to determine if the disomy hypothesis should still be rejected. Rejection of this hypothesis indicates that a duplication or deletion of the chromosome segment is present. If desired, the false positive rate can be altered by adjusting the threshold value.

Further Exemplary Embodiments for Determining Ploidy Using Phased Data

[0270] In illustrative embodiments, provided herein is a method for determining ploidy of a chromosomal segment in a sample of an individual. The method includes the following steps:

a. receiving allele frequency data comprising the amount of each allele present in the sample at each loci in a set of polymorphic loci on the chromosomal segment;
b. generating phased allelic information for the set of polymorphic loci by estimating the phase of the allele frequency data;

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 221

c. generating individual probabilities of allele frequencies for the polymorphic loci for different ploidy states using the allele frequency data;
d. generating joint probabilities for the set of polymorphic loci using the individual probabilities and the phased allelic information; and
e. selecting, based on the joint probabilities, a best fit model indicative of chromosomal ploidy, thereby determining ploidy of the chromosomal segment.

[0271] As disclosed herein, the allele frequency data (also referred to herein as measured genetic allelic data) can be generated by methods known in the art. For example, the data can be generated using qPCR or microarrays. In one illustrative embodiment, the data is generated using nucleic acid sequence data, especially high throughput nucleic acid sequence data.

[0272] In certain illustrative examples, the allele frequency data is corrected for errors before it is used to generate individual probabilities. In specific illustrative embodiments, the errors that are corrected include allele amplification efficiency bias. In other embodiments, the errors that are corrected include ambient contamination and genotype contamination. In some embodiments, errors that are corrected include allele amplification bias, ambient contamination and genotype contamination.

[0273] In certain embodiments, the individual probabilities are generated using a set of models of both different ploidy states and allelic imbalance fractions for the set of polymorphic loci. In these embodiments, and other embodiments, the joint probabilities are generated by considering the linkage between polymorphic loci on the chromosome segment.

[0274] Accordingly, in one illustrative embodiment that combines some of these embodiments, provided herein is a method for detecting chromosomal ploidy in a sample of an individual, that includes the following steps:

a. receiving nucleic acid sequence data for alleles at a set of polymorphic loci on a chromosome segment in the individual;
b. detecting allele frequencies at the set of loci using the nucleic acid sequence data;
c. correcting for allele amplification efficiency bias in the detected allele frequencies to generate corrected allele frequencies for the set of polymorphic loci;
d. generating phased allelic information for the set of polymorphic loci by estimating the phase of the nucleic acid sequence data;

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 222

e. generating individual probabilities of allele frequencies for the polymorphic loci for different ploidy states by comparing the corrected allele frequencies to a set of models of different ploidy states and allelic imbalance fractions of the set of polymorphic loci;
f. generating joint probabilities for the set of polymorphic loci by combining the individual probabilities considering the linkage between polymorphic loci on the chromosome segment; and
g. selecting, based on the joint probabilities, the best fit model indicative of chromosomal aneuploidy.

[0275] As disclosed herein, the individual probabilities can be generated using a set of models or hypothesis of both different ploidy states and average allelic imbalance fractions for the set of polymorphic loci. For example, in a particularly illustrative example, individual probabilities are generated by modeling ploidy states of a first homolog of the chromosome segment and a second homolog of the chromosome segment. The ploidy states that are modeled include the following:

[0276] (1) all cells have no deletion or amplification of the first homolog or the second homolog of the chromosome segment;

[0277] (2) at least some cells have a deletion of the first homolog or an amplification of the second homolog of the chromosome segment; and

[0278] (3) at least some cells have a deletion of the second homolog or an amplification of the first homolog of the chromosome segment.

[0279] It will be understood that the above models can also be referred to as hypothesis that are used to constrain a model. Therefore, demonstrated above are 3 hypothesis that can be used.

[0280] The average allelic imbalance fractions modeled can include any range of average allelic imbalance that includes the actual average allelic imbalance of the chromosomal segment. For example, in certain illustrative embodiments, the range of average allelic imbalance that is modeled can be between 0, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.75, 1, 2, 2.5, 3, 4, and 5% on the low end, and 1, 2, 2.5, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70 80 90, 95, and 99% on the high end. The intervals for the modeling with the range can be any interval depending on the computing power used and the time allowed for the analysis. For example, 0.01, 0.05, 0.02, or 0.1 intervals can be modeled.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 223

[0281] In certain illustrative embodiments, the sample has an average allelic imbalance for the chromosomal segment of between 0.4% and 5%. In certain embodiments, the average allelic imbalance is low. In these embodiments, average allelic imbalance is typically less than 10%. In certain illustrative embodiments, the allelic imbalance is between 0.25, 0.3, 0.4, 0.5, 0.6, 0.75, 1, 2, 2.5, 3, 4, and 5% on the low end, and 1, 2, 2.5, 3, 4, and 5% on the high end. In other exemplary embodiments, the average allelic imbalance is between 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0? on the low end and 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 3.0, 4.0, or 5.0? on the high end. For example, the average allelic imbalance of the sample in an illustrative example is between 0.45 and 2.5%. In another example, the average allelic imbalance is detected with a sensitivity of 0.45, 0.5, 0.6, 0.8, 0.8, 0.9, or 1.0. In An exemplary sample with low allelic imbalance in methods of the present invention include plasma samples from individuals with cancer having circulating tumor DNA or plasma samples from pregnant females having circulating fetal DNA.

[0282] It will be understood that for SNVs, the proportion of abnormal DNA is typically measured using mutant allele frequency (number of mutant alleles at a locus / total number of alleles at that locus). Since the difference between the amounts of two homologs in tumours is analogous, we measure the proportion of abnormal DNA for a CNV by the average allelic imbalance (AAI), defined as $|(H1 - H2)|/(H1 + H2)$, where Hi is the average number of copies of homolog i in the sample and $Hi/(H1 + H2)$ is the fractional abundance, or homolog ratio, of homolog i. The maximum homolog ratio is the homolog ratio of the more abundant homolog.

[0283] Assay drop-out rate is the percentage of SNPs with no reads, estimated using all SNPs. Single allele drop-out (ADO) rate is the percentage of SNPs with only one allele present, estimated using only heterozygous SNPs. Genotype confidence can be determined by fitting a binomial distribution to the number of reads at each SNP that were B-allele reads, and using the ploidy status of the focal region of the SNP to estimate the probability of each genotype.

[0284] For tumor tissue samples, chromosomal aneuploidy (exemplified in this paragraph by CNVs) can be delineated by transitions between allele frequency distributions. In plasma samples, CNVs can be identified by a maximum likelihood algorithm that searches for plasma CNVs in regions where the tumor sample from the same individual also has CNVs, using haplotype information deduced from the tumor sample. This algorithm can model expected allelic frequencies across all allelic imbalance ratios at 0.025% intervals for three sets of hypotheses: (1) all cells are normal (no allelic imbalance), (2) some/all cells have a homolog 1 deletion or homolog

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 224

2 amplification, or (3) some/all cells have a homolog 2 deletion or homolog 1 amplification. The likelihood of each hypothesis can be determined at each SNP using a Bayesian classifier based on a beta binomial model of expected and observed allele frequencies at all heterozygous SNPs, and then the joint likelihood across multiple SNPs can be calculated, in certain illustrative embodiments taking linkage of the SNP loci into consideration, as exemplified herein. The maximum likelihood hypothesis can then be selected.

[0285] Consider a chromosomal region with an average of N copies in the tumor, and let c denote the fraction of DNA in plasma derived from the mixture of normal and tumour cells in a disomic region. AAI is calculated as:

[0286] $$AAI = \frac{c\,|N-2|}{2+c(N-2)}$$

[0287] In certain illustrative examples, the allele frequency data is corrected for errors before it is used to generate individual probabilities. Different types of error and/or bias correction are disclosed herein. In specific illustrative embodiments, the errors that are corrected are allele amplification efficiency bias. In other embodiments, the errors that are corrected include ambient contamination and genotype contamination. In some embodiments, errors that are corrected include allele amplification bias, ambient contamination and genotype contamination.

[0288] It will be understood that allele amplification efficiency bias can be determined for an allele as part of an experiment or laboratory determination that includes an on test sample, or it can be determined at a different time using a set of samples that include the allele whose efficiency is being calculated. Ambient contamination and genotype contamination are typically determined on the same run as the on-test sample analysis.

[0289] In certain embodiments, ambient contamination and genotype contamination are determined for homozygous alleles in the sample. It will be understood that for any given sample from an individual some loci in the sample, will be heterozygous and others will be homozygous, even if a locus is selected for analysis because it has a relatively high heterozygosity in the population. It is advantageous in some embodiments, although ploidy of a chromosomal segment may be determined using heterozygous loci for an individual, homozygous loci can be used to calculate ambient and genotype contamination.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 225

[0290] In certain illustrative examples, the selecting is performed by analyzing a magnitude of a difference between the phased allelic information and estimated allelic frequencies generated for the models.

[0291] In illustrative examples, the individual probabilities of allele frequencies are generated based on a beta binomial model of expected and observed allele frequencies at the set of polymorphic loci. In illustrative examples, the individual probabilities are generated using a Bayesian classifier.

[0292] In certain illustrative embodiments, the nucleic acid sequence data is generated by performing high throughput DNA sequencing of a plurality of copies of a series of amplicons generated using a multiplex amplification reaction, wherein each amplicon of the series of amplicons spans at least one polymorphic loci of the set of polymorphic loci and wherein each of the polymeric loci of the set is amplified. In certain embodiments, the multiplex amplification reaction is performed under limiting primer conditions for at least ½ of the reactions. In some embodiments, limiting primer concentrations are used in 1/10, 1/5, ¼, 1/3, ½, or all of the reactions of the multiplex reaction. Provided herein are factors to consider to achieve limiting primer conditions in an amplification reaction such as PCR.

[0293] In certain embodiments, methods provided herein detect ploidy for multiple chromosomal segments across multiple chromosomes. Accordingly, the chromosomal ploidy in these embodiments is determined for a set of chromosome segments in the sample. For these embodiments, higher multiplex amplification reactions are needed. Accordingly, for these embodiments the multiplex amplification reaction can include, for example, between 2,500 and 50,000 multiplex reactions. In certain embodiments, the following ranges of multiplex reactions are performed: between 100, 200, 250, 500, 1000, 2500, 5000, 10,000, 20,000, 25000, 50000 on the low end of the range and between 200, 250, 500, 1000, 2500, 5000, 10,000, 20,000, 25000, 50000, and 100,000 on the high end of the range.

[0294] In illustrative embodiments, the set of polymorphic loci is a set of loci that are known to exhibit high heterozygosity. However, it is expected that for any given individual, some of those loci will be homozygous. In certain illustrative embodiments, methods of the invention utilize nucleic acid sequence information for both homozygous and heterozygous loci for an individual. The homozygous loci of an individual are used, for example, for error correction, whereas

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 226

heterozygous loci are used for the determination of allelic imbalance of the sample. In certain embodiments, at least 10% of the polymorphic loci are heterozygous loci for the individual.

[0295] As disclosed herein, preference is given for analyzing target SNP loci that are known to be heterozygous in the population. Accordingly, in certain embodiments, polymorphic loci are chosen wherein at least 10, 20, 25, 50, 75, 80, 90, 95, 99, or 100% of the polymorphic loci are known to be heterozygous in the population.

[0296] As disclosed herein, in certain embodiments the sample is a plasma sample from a pregnant female.

[0297] In some examples, the method further comprises performing the method on a control sample with a known average allelic imbalance ratio. The control can have an average allelic imbalance ratio for a particular allelic state indicative of aneuploidy of the chromosome segment, of between 0.4 and 10% to mimic an average allelic imbalance of an allele in a sample that is present in low concentrations, such as would be expected for a circulating free DNA from a fetus or from a tumor.

[0298] In some embodiments, PlasmArt controls, as disclosed herein, are used as the controls. Accordingly, in certain aspects the is a sample generated by a method comprising fragmenting a nucleic acid sample known to exhibit a chromosomal aneuploidy into fragments that mimic the size of fragments of DNA circulating in plasma of the individual. In certain aspects a control is used that has no aneuploidy for the chromosome segment.

[0299] In illustrative embodiments, data from one or more controls can be analyzed in the method along with a test sample. The controls for example, can include a different sample from the individual that is not suspected of containing Chromosomal aneuploidy, or a sample that is suspected of containing CNV or a chromosomal aneuploidy. For example, where a test sample is a plasma sample suspected of containing circulating free tumor DNA, the method can be also be performed for a control sample from a tumor from the subject along with the plasma sample. As disclosed herein, the control sample can be prepared by fragmenting a DNA sample known to exhibit a chromosomal aneuploidy. Such fragmenting can result in a DNA sample that mimics the DNA composition of an apoptotic cell, especially when the sample is from an individual afflicted with cancer. Data from the control sample will increase the confidence of the detection of Chromosomal aneuploidy.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 227

[0300] In certain embodiments of the methods of determining ploidy, the sample is a plasma sample from an individual suspected of having cancer. In these embodiments, the method further comprises determining based on the selecting whether copy number variation is present in cells of a tumor of the individual. For these embodiments, the sample can be a plasma sample from an individual. For these embodiments, the method can further include determining, based on the selecting, whether cancer is present in the individual.

[0301] These embodiments for determining ploidy of a chromosomal segment, can further include detecting a single nucleotide variant at a single nucleotide variance location in a set of single nucleotide variance locations, wherein detecting either a chromosomal aneuploidy or the single nucleotide variant or both, indicates the presence of circulating tumor nucleic acids in the sample.

[0302] These embodiments can further include receiving haplotype information of the chromosome segment for a tumor of the individual and using the haplotype information to generate the set of models of different ploidy states and allelic imbalance fractions of the set of polymorphic loci.

[0303] As disclosed herein, certain embodiments of the methods of determining ploidy can further include removing outliers from the initial or corrected allele frequency data before comparing the initial or the corrected allele frequencies to the set of models. For example, in certain embodiments, loci allele frequencies that are at least 2 or 3 standard deviations above or below the mean value for other loci on the chromosome segment, are removed from the data before being used for the modeling.

[0304] As mentioned herein, it will be understood that for many of the embodiments provided herein, including those for determining ploidy of a chromosomal segment, imperfectly or perfectly phased data is preferably used. It will also be understood, that provided herein are a number of features that provide improvements over prior methods for detecting ploidy, and that many different combinations of these features could be used.

[0305] In certain embodiments, as illustrated in FIGS. 69-70, provided herein are computer systems and computer readable media to perform any methods of the present invention. These include systems and computer readable media for performing methods of determining ploidy. Accordingly, and as non-limiting examples of system embodiments, to demonstrate that any of the methods provided herein can be performed using a system and a computer readable medium using

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 228

the disclosure herein, in another aspect, provided herein is a system for detecting chromosomal ploidy in a sample of an individual, the system comprising:

a. an input processor configured to receive allelic frequency data comprising the amount of each allele present in the sample at each loci in a set of polymorphic loci on the chromosomal segment;

b. a modeler configured to:

i. generate phased allelic information for the set of polymorphic loci by estimating the phase of the allele frequency data; and

ii. generate individual probabilities of allele frequencies for the polymorphic loci for different ploidy states using the allele frequency data; and

iii. generate joint probabilities for the set of polymorphic loci using the individual probabilities and the phased allelic information; and

c. a hypothesis manager configured to select, based on the joint probabilities, a best fit model indicative of chromosomal ploidy, thereby determining ploidy of the chromosomal segment.

[0306] In certain embodiments of this system embodiment, the allele frequency data is data generated by a nucleic acid sequencing system. In certain embodiments, the system further comprises an error correction unit configured to correct for errors in the allele frequency data, wherein the corrected allele frequency data is used by the modeler for to generate individual probabilities. In certain embodiments the error correction unit corrects for allele amplification efficiency bias. In certain embodiments, the modeler generates the individual probabilities using a set of models of both different ploidy states and allelic imbalance fractions for the set of polymorphic loci. The modeler, in certain exemplary embodiments generates the joint probabilities by considering the linkage between polymorphic loci on the chromosome segment.

[0307] In one illustrative embodiment, provided herein is a system for detecting chromosomal ploidy in a sample of an individual, that includes the following:

a. an input processor configured to receive nucleic acid sequence data for alleles at a set of polymorphic loci on a chromosome segment in the individual and detect allele frequencies at the set of loci using the nucleic acid sequence data;

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 229

b. an error correction unit configured to correct for errors in the detected allele frequencies and generate corrected allele frequencies for the set of polymorphic loci;

c. a modeler configured to:

i. generate phased allelic information for the set of polymorphic loci by estimating the phase of the nucleic acid sequence data;

ii. generate individual probabilities of allele frequencies for the polymorphic loci for different ploidy states by comparing the phased allelic information to a set of models of different ploidy states and allelic imbalance fractions of the set of polymorphic loci; and

iii. generate joint probabilities for the set of polymorphic loci by combining the individual probabilities considering the relative distance between polymorphic loci on the chromosome segment; and

d. a hypothesis manager configured to select, based on the joint probabilities, a best fit model indicative of chromosomal aneuploidy.

[0308] In certain exemplary system embodiments provided herein the set of polymorphic loci comprises between 1000 and 50,000 polymorphic loci. In certain exemplary system embodiments provided herein the set of polymorphic loci comprises 100 known heterozygosity hot spot loci. In certain exemplary system embodiments provided herein the set of polymorphic loci comprise 100 loci that are at or within 0.5kb of a recombination hot spot.

[0309] In certain exemplary system embodiments provided herein the best fit model analyzes the following ploidy states of a first homolog of the chromosome segment and a second homolog of the chromosome segment:

[0310] (1) all cells have no deletion or amplification of the first homolog or the second homolog of the chromosome segment;

[0311] (2) some or all cells have a deletion of the first homolog or an amplification of the second homolog of the chromosome segment; and

[0312] (3) some or all cells have a deletion of the second homolog or an amplification of the first homolog of the chromosome segment.

[0313] In certain exemplary system embodiments provided herein the errors that are corrected comprise allelic amplification efficiency bias, contamination, and/or sequencing errors. In certain

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 230

exemplary system embodiments provided herein the contamination comprises ambient contamination and genotype contamination. In certain exemplary system embodiments provided herein the ambient contamination and genotype contamination is determined for homozygous alleles.

[0314] In certain exemplary system embodiments provided herein the hypothesis manager is configured to analyze a magnitude of a difference between the phased allelic information and estimated allelic frequencies generated for the models. In certain exemplary system embodiments provided herein the modeler generates individual probabilities of allele frequencies based on a beta binomial model of expected and observed allele frequencies at the set of polymorphic loci. In certain exemplary system embodiments provided herein the modeler generates individual probabilities using a Bayesian classifier.

[0315] In certain exemplary system embodiments provided herein the nucleic acid sequence data is generated by performing high throughput DNA sequencing of a plurality of copies of a series of amplicons generated using a multiplex amplification reaction, wherein each amplicon of the series of amplicons spans at least one polymorphic loci of the set of polymorphic loci and wherein each of the polymeric loci of the set is amplified. In certain exemplary system embodiments provided herein, wherein the multiplex amplification reaction is performed under limiting primer conditions for at least ½ of the reactions. In certain exemplary system embodiments provided herein, wherein the sample has an average allelic imbalance of between 0.4% and 5%.

[0316] In certain exemplary system embodiments provided herein, the sample is a plasma sample from an individual suspected of having cancer, and the hypothesis manager is further configured to determine, based on the best fit model, whether copy number variation is present in cells of a tumor of the individual.

[0317] In certain exemplary system embodiments provided herein the sample is a plasma sample from an individual and the hypothesis manager is further configured to determine, based on the best fit model, that cancer is present in the individual. In these embodiments, the hypothesis manager can be further configured to detect a single nucleotide variant at a single nucleotide variance location in a set of single nucleotide variance locations, wherein detecting either a chromosomal aneuploidy or the single nucleotide variant or both, indicates the presence of circulating tumor nucleic acids in the sample.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 231

[0318] In certain exemplary system embodiments provided herein, the input processor is further configured to receiving haplotype information of the chromosome segment for a tumor of the individual, and the modeler is configured to use the haplotype information to generate the set of models of different ploidy states and allelic imbalance fractions of the set of polymorphic loci.

[0319] In certain exemplary system embodiments provided herein, the modeler generates the models over allelic imbalance fractions ranging from 0% to 25%.

[0320] It will be understood that any of the methods provided herein can be executed by computer readable code that is stored on nontransitory computer readable medium. Accordingly, provided herein in one embodiment, is a nontransitory computer readable medium for detecting chromosomal ploidy in a sample of an individual, comprising computer readable code that, when executed by a processing device, causes the processing device to:

a. receive allele frequency data comprising the amount of each allele present in the sample at each loci in a set of polymorphic loci on the chromosomal segment;
b. generate phased allelic information for the set of polymorphic loci by estimating the phase of the allele frequency data;
c. generate individual probabilities of allele frequencies for the polymorphic loci for different ploidy states using the allele frequency data;
d. generate joint probabilities for the set of polymorphic loci using the individual probabilities and the phased allelic information; and
e. select, based on the joint probabilities, a best fit model indicative of chromosomal ploidy, thereby determining ploidy of the chromosomal segment.

[0321] In certain computer readable medium embodiments, the allele frequency data is generated from nucleic acid sequence data. certain computer readable medium embodiments further comprise correcting for errors in the allele frequency data and using the corrected allele frequency data for the generating individual probabilities step. In certain computer readable medium embodiments the errors that are corrected are allele amplification efficiency bias. In certain computer readable medium embodiments the individual probabilities are generated using a set of models of both different ploidy states and allelic imbalance fractions for the set of polymorphic loci. In certain computer readable medium embodiments the joint probabilities are generated by considering the linkage between polymorphic loci on the chromosome segment.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 232

[0322] In one particular embodiment, provided herein is a nontransitory computer readable medium for detecting chromosomal ploidy in a sample of an individual, comprising computer readable code that, when executed by a processing device, causes the processing device to:

a. receive nucleic acid sequence data for alleles at a set of polymorphic loci on a chromosome segment in the individual;

b. detect allele frequencies at the set of loci using the nucleic acid sequence data;

c. correcting for allele amplification efficiency bias in the detected allele frequencies to generate corrected allele frequencies for the set of polymorphic loci;

d. generate phased allelic information for the set of polymorphic loci by estimating the phase of the nucleic acid sequence data;

e. generate individual probabilities of allele frequencies for the polymorphic loci for different ploidy states by comparing the corrected allele frequencies to a set of models of different ploidy states and allelic imbalance fractions of the set of polymorphic loci;

f. generate joint probabilities for the set of polymorphic loci by combining the individual probabilities considering the linkage between polymorphic loci on the chromosome segment; and

g. select, based on the joint probabilities, the best fit model indicative of chromosomal aneuploidy.

[0323] In certain illustrative computer readable medium embodiments, the selecting is performed by analyzing a magnitude of a difference between the phased allelic information and estimated allelic frequencies generated for the models.

[0324] In certain illustrative computer readable medium embodiments the individual probabilities of allele frequencies are generated based on a beta binomial model of expected and observed allele frequencies at the set of polymorphic loci.

[0325] It will be understood that any of the method embodiments provided herein can be performed by executing code stored on nontransitory computer readable medium.

Exemplary Embodiments for Detecting Cancer

[0326] In certain aspects, the present invention provides a method for detecting cancer. The sample, it will be understood can be a tumor sample or a liquid sample, such as plasma, from an individual suspected of having cancer. The methods are especially effective at detecting genetic mutations such as single nucleotide alterations such as SNVs, or copy number alterations, such as

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 233

CNVs in samples with low levels of these genetic alterations as a fraction of the total DNA in a sample. Thus the sensitivity for detecting DNA or RNA from a cancer in samples is exceptional. The methods can combine any or all of the improvements provided herein for detecting CNV and SNV to achieve this exceptional sensitivity.

[0327] Accordingly, in certain embodiments provided herein, is a method for determining whether circulating tumor nucleic acids are present in a sample in an individual, and a nontransitory computer readable medium comprising computer readable code that, when executed by a processing device, causes the processing device to carry out the method. The method includes the following steps:

c. analyzing the sample to determine a ploidy at a set of polymorphic loci on a chromosome segment in the individual; and

d. determining the level of average allelic imbalance present at the polymorphic loci based on the ploidy determination, wherein an average allelic imbalance equal to or greater than 0.4%, 0.45%, 0.5%, 0.6%, 0.7%, 0.75%, 0.8%, 0.9%, or 1% is indicative of the presence of circulating tumor nucleic acids, such as ctDNA, in the sample.

[0328] In certain illustrative examples, an average allelic imbalance greater than 0.4, 0.45, or 0.5% is indicative the presence of ctDNA. In certain embodiments the method for determining whether circulating tumor nucleic acids are present, further comprises detecting a single nucleotide variant at a single nucleotide variance site in a set of single nucleotide variance locations, wherein detecting either an allelic imbalance equal to or greater than 0.5% or detecting the single nucleotide variant, or both, is indicative of the presence of circulating tumor nucleic acids in the sample. It will be understood that any of the methods provided for detecting chromosomal ploidy or CNV can be used to determine the level of allelic imbalance, typically expressed as average allelic imbalance. It will be understood that any of the methods provided herein for detecting an SNV can be used to detect the single nucleotide for this aspect of the present invention.

[0329] In certain embodiments the method for determining whether circulating tumor nucleic acids are present, further comprises performing the method on a control sample with a known average allelic imbalance ratio. The control, for example, can be a sample from the tumor of the individual. In some embodiments, the control has an average allelic imbalance expected for the sample under analysis. For example, an AAI between 0.5% and 5% or an average allelic imbalance ratio of 0.5%.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 234

[0330] In certain embodiments analyzing step in the method for determining whether circulating tumor nucleic acids are present, includes analyzing a set of chromosome segments known to exhibit aneuploidy in cancer. In certain embodiments analyzing step in the method for determining whether circulating tumor nucleic acids are present, includes analyzing between 1,000 and 50,000 or between 100 and 1000, polymorphic loci for ploidy. In certain embodiments analyzing step in the method for determining whether circulating tumor nucleic acids are present, includes analyzing between 100 and 1000 single nucleotide variant sites. For example, in these embodiments the analyzing step can include performing a multiplex PCR to amplify amplicons across the 1000 to 50,000 polymeric loci and the 100 to 1000 single nucleotide variant sites. This multiplex reaction can be set up as a single reaction or as pools of different subset multiplex reactions. The multiplex reaction methods provided herein, such as the massive multiplex PCR disclosed herein provide an exemplary process for carrying out the amplification reaction to help attain improved multiplexing and therefore, sensitivity levels.

[0331] In certain embodiments, the multiplex PCR reaction is carried out under limiting primer conditions for at least 10%, 20%, 25%, 50%, 75%, 90%, 95%, 98%, 99%, or 100% of the reactions. Improved conditions for performing the massive multiplex reaction provided herein can be used.

[0332] In certain aspects, the above method for determining whether circulating tumor nucleic acids are present in a sample in an individual, and all embodiments thereof, can be carried out with a system. The disclosure provides teachings regarding specific functional and structural features to carry out the methods. As a non-limiting example, the system includes the following:

a. An input processor configured to analyze data from the sample to determine a ploidy at a set of polymorphic loci on a chromosome segment in the individual; and

b. A modeler configured to determine the level of allelic imbalance present at the polymorphic loci based on the ploidy determination, wherein an allelic imbalance equal to or greater than 0.5% is indicative of the presence of circulating.

Exemplary Embodiments for Detecting Single Nucleotide Variants

[0333] In certain aspects, provided herein are methods for detecting single nucleotide variants in a sample. The improved methods provided herein can achieve limits of detection of 0.015, 0.017, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4 or 0.5 percent SNV in a sample. All the embodiments for detecting SNVs can be carried out with a system. The disclosure provides teachings regarding specific

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 235

functional and structural features to carry out the methods. Furthermore, provided herein are embodiments comprising a nontransitory computer readable medium comprising computer readable code that, when executed by a processing device, causes the processing device to carry out the methods for detecting SNVs provided herein.

[0334] Accordingly, provided herein in one embodiment, is a method for determining whether a single nucleotide variant is present at a set of genomic positions in a sample from an individual, the method comprising:

a. for each genomic position, generating an estimate of efficiency and a per cycle error rate for an amplicon spanning that genomic position, using a training data set;

b. receiving observed nucleotide identity information for each genomic position in the sample;

c. determining a set of probabilities of single nucleotide variant percentage resulting from one or more real mutations at each genomic position, by comparing the observed nucleotide identity information at each genomic position to a model of different variant percentages using the estimated amplification efficiency and the per cycle error rate for each genomic position independently; and

d. determining the most-likely real variant percentage and confidence from the set of probabilities for each genomic position.

[0335] In illustrative embodiments of the method for determining whether a single nucleotide variant is present, the estimate of efficiency and the per cycle error rate is generated for a set of amplicons that span the genomic position. For example, 2, 3, 4, 5, 10, 15, 20, 25, 50, 100 or more amplicons can be included that span the genomic position.

[0336] In illustrative embodiments of the method for determining whether a single nucleotide variant is present, the observed nucleotide identity information comprises an observed number of total reads for each genomic position and an observed number of variant allele reads for each genomic position.

[0337] In illustrative embodiments of the method for determining whether a single nucleotide variant is present, the sample is a plasma sample and the single nucleotide variant is present in circulating tumor DNA of the sample.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 236

[0338] In another embodiment provided herein is a method for estimating the percent of single nucleotide variants that are present in a sample from an individual. The method includes the following steps:

a. at a set of genomic positions, generating an estimate of efficiency and a per cycle error rate for one or more amplicon spanning those genomic positions, using a training data set;

b. receiving observed nucleotide identity information for each genomic position in the sample;

c. generating an estimated mean and variance for the total number of molecules, background error molecules and real mutation molecules for a search space comprising an initial percentage of real mutation molecules using the amplification efficiency and the per cycle error rate of the amplicons; and

d. determining the percentage of single nucleotide variants present in the sample resulting from real mutations by determining a most-likely real single nucleotide variant percentage by fitting a distribution using the estimated means and variances to an observed nucleotide identity information in the sample.

[0339] In illustrative examples of this method for estimating the percent of single nucleotide variants that are present in a sample, the sample is a plasma sample and the single nucleotide variant is present in circulating tumor DNA of the sample.

[0340] The training data set for this embodiment of the invention typically includes samples from one or preferably a group of healthy individuals. In certain illustrative embodiments, the training data set is analyzed on the same day or even on the same run as one or more on-test samples. For example, samples from a group of 2, 3, 4, 5, 10, 15, 20, 25, 30, 36, 48, 96, 100, 192, 200, 250, 500, 1000 or more healthy individuals can be used to generate the training data set. Where data is available for larger number of healthy individuals, e.g. 96 or more, confidence increases for amplification efficiency estimates even if runs are performed in advance of performing the method for on-test samples. The PCR error rate can use nucleic acid sequence information generated not only for the SNV base location, but for the entire amplified region around the SNV, since the error rate is per amplicon. For example, using samples from 50 individuals and sequencing a 20 base pair amplicon around the SNV, error frequency data from 1000 base reads can be used to determine error frequency rate.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 237

[0341] Typically the amplification efficiency is estimating by estimating a mean and standard deviation for amplification efficiency for an amplified segment and then fitting that to a distribution model, such as a binomial distribution or a beta binomial distribution. Error rates are determined for a PCR reaction with a known number of cycles and then a per cycle error rate is estimated.

[0342] In certain illustrative embodiments, estimating the starting molecules of the test data set further includes updating the estimate of the efficiency for the testing data set using the starting number of molecules estimated in step (b) if the observed number of reads is significantly different than the estimated number of reads. Then the estimate can be updated for a new efficiency and/or starting molecules.

[0343] The search space used for estimating the total number of molecules, background error molecules and real mutation molecules can include a search space from 0.1%, 0.2%, 0.25%, 0.5%, 1%, 2.5%, 5%, 10%, 15%, 20%, or 25% on the low end and 1%, 2%, 2.5%, 5%, 10%, 12.5%, 15%, 20%, 25%, 50%, 75%, 90%, or 95% on the high end copies of a base at an SNV position being the SNV base. Lower ranges, 0.1%, 0.2%, 0.25%, 0.5%, or 1% on the low end and 1%, 2%, 2.5%, 5%, 10%, 12.5%, or 15% on the high end can be used in illustrative examples for plasma samples where the method is detecting circulating tumor DNA. Higher ranges are used for tumor samples.

[0344] A distribution is fit to the number of total error molecules (background error and real mutation) in the total molecules to calculate the likelihood or probability for each possible real mutation in the search space. This distribution could be a binomial distribution or a beta binomial distribution.

[0345] The most likely real mutation is determined by determining the most likely real mutation percentage and calculating the confidence using the data from fitting the distribution. As an illustrative example and not intended to limit the clinical interpretation of the methods provided herein, if the mean mutation rate is high then the percent confidence needed to make a positive determination of an SNV is lower. For example, if the mean mutation rate for an SNV in a sample using the most likely hypothesis is 5% and the percent confidence is 99%, then a positive SNV call would be made. On the other hand for this illustrative example, if the mean mutation rate for an SNV in a sample using the most likely hypothesis is 1% and the percent confidence is 50%, then in certain situations a positive SNV call would not be made. It will be understood that clinical

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 238

interpretation of the data would be a function of sensitivity, specificity, prevalence rate, and alternative product availability.

[0346] In one illustrative embodiment, the sample is a circulating DNA sample, such as a circulating tumor DNA sample.

[0347] In another embodiment, provided herein is a method for detecting one or more single nucleotide variants in a test sample from an individual. The method according to this embodiment, includes the following steps:

d. determining a median variant allele frequency for a plurality of control samples from each of a plurality of normal individuals, for each single nucleotide variant position in a set of single nucleotide variance positions based on results generated in a sequencing run, to identify selected single nucleotide variant positions having variant median allele frequencies in normal samples below a threshold value and to determine background error for each of the single nucleotide variant positions after removing outlier samples for each of the single nucleotide variant positions;

e. determining an observed depth of read weighted mean and variance for the selected single nucleotide variant positions for the test sample based on data generated in the sequencing run for the test sample; and

f. identifying using a computer, one or more single nucleotide variant positions with a statistically significant depth of read weighted mean compared to the background error for that position, thereby detecting the one or more single nucleotide variants.

[0348] In certain embodiments of this method for detecting one or more SNVs the sample is a plasma sample, the control samples are plasma samples, and the detected one or more single nucleotide variants detected is present in circulating tumor DNA of the sample. In certain embodiments of this method for detecting one or more SNVs the plurality of control samples comprises at least 25 samples. In certain illustrative embodiments, the plurality of control samples is at least 5, 10, 15, 20, 25, 50, 75, 100, 200, or 250 samples on the low end and 10, 15, 20, 25, 50, 75, 100, 200, 250, 500, and 1000 samples on the high end.

[0349] In certain embodiments of this method for detecting one or more SNVs, outliers are removed from the data generated in the high throughput sequencing run to calculate the observed depth of read weighted mean and observed variance are determined. In certain embodiments of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 239

this method for detecting one or more SNVs the depth of read for each single nucleotide variant position for the test sample is at least 100 reads.

[0350] In certain embodiments of this method for detecting one or more SNVs the sequencing run comprises a multiplex amplification reaction performed under limited primer reaction conditions. Improved methods for performing multiplex amplification reactions provided herein, are used to perform these embodiments in illustrative examples.

[0351] Not to be limited by theory, methods of the present embodiment utilize a background error model using normal plasma samples, that are sequenced on the same sequencing run as an on-test sample, to account for run-specific artifacts. Noisy positions with normal median variant allele frequencies above a threshold, for example > 0.1%, 0.2%, 0.25%, 0.5% 0.75%, and 1.0%, are removed.

[0352] Outlier samples are iteratively removed from the model to account for noise and contamination. For each base substitution of every genomic loci, the depth of read weighted mean and standard deviation of the error are calculated. In certain illustrative embodiments, samples, such as tumor or cell-free plasma samples, with single nucleotide variant positions with at least a threshold number of reads, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 250, 500, or 1000 variant reads and a1 Z-score greater than 2.5, 5, 7.5 or 10 against the background error model in certain embodiments, are counted as a candidate mutation.

[0353] In certain embodiments, a depth of read of greater than 100, 250, 500, 1,000, 2000, 2500, 5000, 10,000, 20,000, 25,000, 50,000, or 100,000 on the low end of the range and 2000, 2500, 5,000, 7,500, 10,000, 25,000, 50,000, 100,000, 250,000 or 500,000 reads on the high end, is attained in the sequencing run for each single nucleotide variant position in the set of single nucleotide variant positions. Typically, the sequencing run is a high throughput sequencing run. The mean or median values generated for the on-test samples, in illustrative embodiments are weighted by depth of reads. Therefore, the likelihood that a variant allele determination is real in a sample with 1 variant allele detected in 1000 reads is weighed higher than a sample with 1 variant allele detected in 10,000 reads. Since determinations of a variant allele (i.e. mutation) are not made with 100% confidence, the identified single nucleotide variant can be considered a candidate variant or a candidate mutations.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 240

Exemplary Test Statistic for Analysis of Phased Data

[0354] An exemplary test statistic is described below for analysis of phased data from a sample known or suspected of being a mixed sample containing DNA or RNA that originated from two or more cells that are not genetically identical. Let f denote the fraction of DNA or RNA of interest, for example the fraction of DNA or RNA with a CNV of interest, or the fraction of DNA or RNA from cells of interest, such as cancer cells. In some embodiments for prenatal testing, f denotes the fraction of fetal DNA, RNA, or cells in a mixture of fetal and maternal DNA, RNA, or cells. Note that this refers to the fraction of DNA from cells of interest assuming two copies of DNA are given by each cell of interest. This differs from the DNA fraction from cells of interest at a segment that is deleted or duplicated.

[0355] The possible allelic values of each SNP are denoted A and B. AA, AB, BA, and BB are used to denote all possible ordered allele pairs. In some embodiments, SNPs with ordered alleles AB or BA are analyzed. Let N_i denote the number of sequence reads of the ith SNP, and A_i and B_i denote the number of reads of the ith SNP that indicate allele A and B, respectively. It is assumed:

$$N_i = A_i + B_i.$$

The allele ratio R_i is defined:

$$R_i \triangleq \frac{A_i}{N_i}.$$

Let T denote the number of SNPs targeted.

[0356] Without loss of generality, some embodiments focus on a single chromosome segment. As a matter of further clarity, in this specification the phrase "a first homologous chromosome segment as compared to a second homologous chromosome segment" means a first homolog of a chromosome segment and a second homolog of the chromosome segment. In some such embodiments, all of the target SNPs are contained in the segment chromosome of interest. In other embodiments, multiple chromosome segments are analyzed for possible copy number variations.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 241

MAP Estimation

[0357] This method leverages the knowledge of phasing via ordered alleles to detect the deletion or duplication of the target segment. For each SNP i, define

$$X_i \triangleq \begin{cases} 1 & R_i < 0.5 \; and \; SNP \; i \; AB \\ 0 & R_i \geq 0.5 \; and \; SNP \; i \; AB \\ 0 & R_i < 0.5 \; and \; SNP \; i \; BA \\ 1 & R_i \geq 0.5 \; and \; SNP \; i \; BA \end{cases}$$

[0358] Then define

$$S \triangleq \sum_{All \; SNPs} X_i.$$

The distributions of the X_i and S under various copy number hypotheses (such as hypotheses for disomy, deletion of the first or second homolog, or duplication of the first or second homolog) are described below.

Disomy Hypothesis

[0359] Under the hypothesis that the target segment is not deleted or duplicated,

$$X_i = \begin{cases} 0 & wp \; 1 - p\left(\frac{1}{2}, N_i\right) \\ 1 & wp \; p\left(\frac{1}{2}, N_i\right) \end{cases}$$

where

$$p(b, n) \triangleq Pr\left\{X \sim Bino(b, n) \geq \frac{n}{2}\right\}.$$

If we assume a constant depth of read N, this gives us a Binomial distribution S with parameters

$$p\left(\frac{1}{2}, N\right) \text{ and T.}$$

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 242

Deletion Hypotheses

[0360] Under the hypothesis that the first homolog is deleted (*i.e.*, an AB SNP becomes B, and a BA SNP becomes A), then R_i has a Binomial distribution with parameters $1-\frac{1}{2-f}$ and T for AB SNPs, and $\frac{1}{2-f}$ and T for BA SNPs. Therefore,

$$X_i = \begin{cases} 0 & wp\ 1-p\left(\frac{1}{2-f}, N_i\right) \\ 1 & wp\ p\left(\frac{1}{2-f}, N_i\right) \end{cases}$$

If we assume a constant depth of read N, this gives a Binomial distribution S with parameters

$$p\left(\frac{1}{2-f}, N\right) \text{ and T.}$$

[0361] Under the hypothesis that the second homolog is deleted (*i.e.*, an AB SNP becomes A, and a BA SNP becomes B), then R_i has a Binomial distribution with parameters $\frac{1}{2-f}$ and T for AB SNPs, and $1-\frac{1}{2-f}$ and T for BA SNPs. Therefore,

$$X_i = \begin{cases} 0 & wp\ p\left(\frac{1}{2-f}, N_i\right) \\ 1 & wp\ 1-p\left(\frac{1}{2-f}, N_i\right) \end{cases}$$

If we assume a constant depth of read N, this gives a Binomial distribution S with parameters

$$1-p\left(\frac{1}{2-f}, N\right) \text{ and T.}$$

Duplication Hypotheses

[0362] Under the hypothesis that the first homolog is duplicated (*i.e.*, an AB SNP becomes AAB, and a BA SNP becomes BBA), then R_i has a Binomial distribution with parameters $\frac{1+f}{2+f}$ and T for AB SNPs, and $1-\frac{1+f}{2+f}$ and T for BA SNPs. Therefore,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 243

$$X_i = \begin{cases} 0 & wp\ p\left(\frac{1+f}{2+f}, N_i\right) \\ 1 & wp\ 1-p\left(\frac{1+f}{2+f}, N_i\right) \end{cases}$$

If we assume a constant depth of read N, this gives us a Binomial distribution S with parameters

$$1-p\left(\tfrac{1+f}{2+f}, N\right) \text{ and T.}$$

[0363] Under the hypothesis that the second homolog is duplicated (*i.e.*, an AB SNP becomes ABB, and a BA SNP becomes BAA), then R_i has a Binomial distribution with parameters $1-\frac{1+f}{2+f}$ and T for AB SNPs, and $\frac{1+f}{2+f}$ and T for BA SNPs. Therefore,

$$X_i = \begin{cases} 0 & wp\ 1-p\left(\frac{1+f}{2+f}, N_i\right) \\ 1 & wp\ p\left(\frac{1+f}{2+f}, N_i\right) \end{cases}$$

If we assume a constant depth of read N, this gives a Binomial distribution S with parameters

$$p\left(\tfrac{1+f}{2+f}, N\right) \text{ and T.}$$

Classification

[0364] As demonstrated in the sections above, X_i is a binary random variable with

$$Pr\{X_1 = 1\} = \begin{cases} p\left(\frac{1}{2}, N_i\right) & given\ disomy \\ p\left(\frac{1}{2-f}, N_i\right) & homolog\ 1\ deletion \\ 1-p\left(\frac{1}{2-f}, N_i\right) & homolog\ 2\ deletion \\ 1-p\left(\frac{1+f}{2+f}, N_i\right) & homolog\ 1\ duplication \\ p\left(\frac{1+f}{2+f}, N_i\right) & homolog\ 2\ duplication \end{cases}$$

[0365] This allows one to calculate the probability of the test statistic S under each hypothesis. The probability of each hypothesis given the measured data can be calculated. In some embodiments, the hypothesis with the greatest probability is selected. If desired, the distribution

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 244

on S can be simplified by either approximating each N_i with a constant depth of reach N or by truncating the depth of reads to a constant N. This simplification gives

$$S \sim \begin{cases} Bino\left(p\left(\frac{1}{2}, N\right), T\right) & given\ disomy \\ Bino\left(p\left(\frac{1}{2-f}, N\right), T\right) & homolog\ 1\ deletion \\ Bino\left(1-p\left(\frac{1}{2-f}, N\right), T\right) & homolog\ 2\ deletion \\ Bino\left(1-p\left(\frac{1+f}{2+f}, N\right), T\right) & homolog\ 1\ duplication \\ Bino\left(p\left(\frac{1+f}{2+f}, N\right), T\right) & homolog\ 2\ duplication \end{cases}$$

[0366] The value for f can be estimate by selecting the most likely value of f given the measured data, such as the value of f that generates the best data fit using an algorithm (*e.g.*, a search algorithm) such as maximum likelihood estimation, maximum a-posteriori estimation, or Bayesian estimation. In some embodiments, multiple chromosome segments are analyzed and a value for f is estimated based on the data for each segment. If all the target cells have these duplications or deletions, the estimated values for f based on data for these different segments are similar. In some embodiments, f is experimentally measured such as by determining the fraction of DNA or RNA from cancer cells based on methylation differences (hypomethylation or hypermethylation) between cancer and non-cancerous DNA or RNA.

[0367] In some embodiments for mixed samples of fetal and maternal nucleic acids, the value of f is the fetal fraction, that is the fraction of fetal DNA (or RNA) out of the total amount of DNA (or RNA) in the sample. In some embodiments, the fetal fraction is determined by obtaining genotypic data from a maternal blood sample (or fraction thereof) for a set of polymorphic loci on at least one chromosome that is expected to be disomic in both the mother and the fetus; creating a plurality of hypotheses each corresponding to different possible fetal fractions at the chromosome; building a model for the expected allele measurements in the blood sample at the set of polymorphic loci on the chromosome for possible fetal fractions; calculating a relative probability of each of the fetal fractions hypotheses using the model and the allele measurements from the blood sample or fraction thereof; and determining the fetal fraction in the blood sample by selecting the fetal fraction corresponding to the hypothesis with the greatest probability. In some embodiments, the fetal fraction is determined by identifying those polymorphic loci where

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 245

the mother is homozygous for a first allele at the polymorphic locus, and the father is (i) heterozygous for the first allele and a second allele or (ii) homozygous for a second allele at the polymorphic locus; and using the amount of the second allele detected in the blood sample for each of the identified polymorphic loci to determine the fetal fraction in the blood sample (see, *e.g.*, US Publ. No. 2012/0185176, filed March 29, 2012, and US Pub. No. 2014/0065621, filed March 13, 2013 which are each incorporated herein by reference in their entirety).

[0368] Another method for determining fetal fraction includes using a high throughput DNA sequencer to count alleles at a large number of polymorphic (such as SNP) genetic loci and modeling the likely fetal fraction (see, for example, US Publ. No. 2012/0264121, which is incorporated herein by reference in its entirety). Another method for calculating fetal fraction can be found in Sparks *et al.*," Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18," Am J Obstet Gynecol 2012;206:319.e1-9, which is incorporated herein by reference in its entirety. In some embodiments, fetal fraction is determined using a methylation assay (*see, e.g.*, US Patent Nos. 7,754,428; 7,901,884; and 8,166,382, which are each incorporated herein by reference in their entirety) that assumes certain loci are methylated or preferentially methylated in the fetus, and those same loci are unmethylated or preferentially unmethylated in the mother.

[0369] FIGs. 1A-13D are graphs showing the distribution of the test statistic S divided by T (the number of SNPs) ("S/T") for various copy number hypotheses for various depth of reads and tumor fractions (where f is the fraction of tumor DNA out of total DNA) for an increasing number of SNPs.

Single Hypothesis Rejection

[0370] The distribution of S for the disomy hypothesis does not depend on f. Thus, the probability of the measured data can be calculated for the disomy hypothesis without calculating f. A single hypothesis rejection test can be used for the null hypothesis of disomy. In some embodiments, the probability of S under the disomy hypothesis is calculated, and the hypothesis of disomy is rejected if the probability is below a given threshold value (such as less than 1 in 1,000). This indicates that a duplication or deletion of the chromosome segment is present. If desired, the false positive rate can be altered by adjusting the threshold value.

Exemplary Methods for Analysis of Phased Data

[0371] Exemplary methods are described below for analysis of data from a sample known or suspected of being a mixed sample containing DNA or RNA that originated from two or more cells that are not genetically identical. In some embodiments, phased data is used. In some embodiments, the method involves determining, for each calculated allele ratio, whether the calculated allele ratio is above or below the expected allele ratio and the magnitude of the difference for a particular locus. In some embodiments, a likelihood distribution is determined for the allele ratio at a locus for a particular hypothesis and the closer the calculated allele ratio is to the center of the likelihood distribution, the more likely the hypothesis is correct. In some embodiments, the method involves determining the likelihood that a hypothesis is correct for each locus. In some embodiments, the method involves determining the likelihood that a hypothesis is correct for each locus, and combining the probabilities of that hypothesis for each locus, and the hypothesis with the greatest combined probability is selected. In some embodiments, the method involves determining the likelihood that a hypothesis is correct for each locus and for each possible ratio of DNA or RNA from the one or more target cells to the total DNA or RNA in the sample. In some embodiments, a combined probability for each hypothesis is determined by combining the probabilities of that hypothesis for each locus and each possible ratio, and the hypothesis with the greatest combined probability is selected.

[0372] In one embodiment, the following hypotheses are considered: H_{11} (all cells are normal), H_{10} (presence of cells with only homolog 1, hence homolog 2 deletion), H_{01} (presence of cells with only homolog 2, hence homolog 1 deletion), H_{21} (presence of cells with homolog 1 duplication), H_{12} (presence of cells with homolog 2 duplication). For a fraction f of target cells such as cancer cells or mosaic cells (or the fraction of DNA or RNA from the target cells), the expected allele ratio for heterozygous (*AB* or *BA*) SNPs can be found as follows:

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 247

Equation (1):

$$
\begin{aligned}
r(AB,H_{11}) = r(BA,H_{11}) &= 0.5, \\
r(AB,H_{10}) = r(BA,H_{01}) &= \frac{1}{2-f}, \\
r(AB,H_{01}) = r(BA,H_{10}) &= \frac{1-f}{2-f}, \\
r(AB,H_{21}) = r(BA,H_{12}) &= \frac{1+f}{2+f}, \\
r(AB,H_{12}) = r(BA,H_{21}) &= \frac{1}{2+f}.
\end{aligned}
$$

Bias, Contamination, and Sequencing Error Correction:

[0373] The observation D_s at the SNP consists of the number of original mapped reads with each allele present, n_A^0 and n_B^0. Then, we can find the corrected reads n_A and n_B using the expected bias in the amplification of A and B alleles.

[0374] Let c_a to denote the ambient contamination (such as contamination from DNA in the air or environment) and $r(c_a)$ to denote the allele ratio for the ambient contaminant (which is taken to be 0.5 initially). Moreover, c_g denotes the genotyped contamination rate (such as the contamination from another sample), and $r(c_g)$ is the allele ratio for the contaminant. Let $s_e(A,B)$ and $s_e(B,A)$ denote the sequencing errors for calling one allele a different allele (such as by erroneously detecting an A allele when a B allele is present).

[0375] One can find the observed allele ratio $q(r, c_a, r(c_a), c_g, r(c_g), s_e(A,B), s_e(B,A))$ for a given expected allele ratio r by correcting for ambient contamination, genotyped contamination, and sequencing error.

[0376] Since the contaminant genotypes are unknown, population frequencies can be used to find $P(r(c_g))$. More specifically, let p be the population frequency for one of the alleles (which may be referred to as a reference allele). Then, we have $P(r(c_g) = 0) = (1-p)^2$, $P(r(c_g) = 0) = 2p(1-p)$, and $P(r(cg) = 0) = p^2$. The conditional expectation over $r(c_g)$ can be used to determine the $\boldsymbol{E}[q(r, c_a, r(c_a), c_g, r(c_g), s_e(A,B), s_e(B,A))]$. Note that the ambient and genotyped contamination are

determined using the homozygous SNPs, hence they are not affected by the absence or presence of deletions or duplications. Moreover, it is possible to measure the ambient and genotyped contamination using a reference chromosome if desired.

Likelihood at each SNP:

[0377] The equation below gives the probability of observing n_A and n_B given an allele ratio r:

Equation (2):

$$P(n_A, n_B|r) = p_{bino}(n_A; n_A + n_B, r) = \binom{n_A+n_B}{n_A} r^{n_A}(1-r)^{n_B}.$$

[0378] Let D_s denote the data for SNP s. For each hypothesis h ϵ { H_{11}, H_{01}, H_{10}, H_{21}, H_{12} }, one can let $r=r(AB,h)$ or $r=r(BA,h)$ in the equation (1) and find the conditional expectation over $r(c_g)$ to determine the observed allele ratio $\boldsymbol{E}[q(r, c_a, r(c_a), c_g, r(c_g))]$. Then, letting $r= \boldsymbol{E}[q(r, c_a, r(c_a), c_g, r(c_g), s_e(A,B), s_e(B,A))]$ in equation (2) one can determine $P(D_s|h,f)$.

Search Algorithm:

[0379] In some embodiments, SNPs with allele ratios that seem to be outliers are ignored (such as by ignoring or eliminating SNPs with allele ratios that are at least 2 or 3 standard deviations above or below the mean value). Note that an advantage identified for this approach is that in the presence of higher mosaicism percentage, the variability in the allele ratios may be high, hence this ensures that SNPs will not be trimmed due to mosaicism.

[0380] Let $F = \{f_1, \ldots, f_N\}$ denote the search space for the mosaicism percentage (such as the tumor fraction). One can determine $P(D_s|h,f)$ at each SNP s and $f \epsilon F$, and combine the likelihood over all SNPs.

[0381] The algorithm goes over each f for each hypothesis. Using a search method, one concludes that mosaicism exists if there is a range F^* of f where the confidence of the deletion or duplication hypothesis is higher than the confidence of the no deletion and no duplication hypotheses. In some embodiments, the maximum likelihood estimate for $P(D_s|h,f)$ in F^* is determined. If desired, the conditional expectation over $f \epsilon F^*$ may be determined. If desired, the confidence for each hypothesis can be determined.

Additional embodiments:

[0382] In some embodiments, a beta binomial distribution is used instead of binomial distribution. In some embodiments, a reference chromosome or chromosome segment is used to determine the sample specific parameters of beta binomial.

Theoretical Performance using Simulations:

[0383] If desired, one can evaluate the theoretical performance of the algorithm by randomly assigning number of reference reads to a SNP with given depth of read (DOR). For the normal case, use $p = 0.5$ for the binomial probability parameter, and for deletions or duplications, p is revised accordingly. Exemplary input parameters for each simulation are as follows: (1) number of SNPs S (2) constant DOR D per SNP, (3) p, and (4) number of experiments.

First Simulation Experiment:

[0384] This experiment focused on $S \in \{500, 1000\}$, $D \in \{500, 1000\}$ and $p \in \{0\%, 1\%, 2\%, 3\%, 4\%, 5\%\}$. We performed 1,000 simulation experiments in each setting (hence 24,000 experiments with phase, and 24,000 without phase). We simulated the number of reads from a binomial distribution (if desired, other distributions can be used). The false positive rate (in the case of $p=0\%$) and false negative rate (in the case of $p>0\%$) were determined both with or without phase information. False positive rates are listed in Figure 26. Note that phase information is very helpful, especially *for* $S=1000$, $D = 1000$. Although for $S=500$, $D=500$, the algorithm has the highest false positive rates with or without phase out of the conditions tested. False negative rates are listed in Figure 27.

[0385] Phase information is particularly useful for low mosaicism percentages ($\leq 3\%$). Without phase information, a high level of false negatives were observed for $p=1\%$ because the confidence on deletion is determined by assigning equal chance to H_{10} and H_{01}, and a small deviation in favor of one hypothesis is not sufficient to compensate for the low likelihood from the other hypothesis. This applies to duplications as well. Note also that the algorithm seems to be more sensitive to depth of read compared to number of SNPs. For the results with phase information, we assume that perfect phase information is available for a high number of consecutive heterozygous SNPs. If desired, haplotype information can be obtained by probabilistically combining haplotypes on smaller segments.

Second Simulation Experiment:

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 250

[0386] This experiment focused on $S \in \{100, 200, 300, 400, 500\}$, $D \in \{1000, 2000, 3000, 4000, 5000\}$ and $p \in \{0\%, 1\%, 1.5\%, 2\%, 2.5\%, 3\%\}$ and 10000 random experiments at each setting. The false positive rate (in the case of p=0%) and false negative rate (in the case of $p>0\%$) were determined both with or without phase information. The false negative rate is below 10% for $D \geq 3000$ and $N \geq 200$ using haplotype information, whereas the same performance is reached for $D=5000$ and $N \geq 400$ (FIGs. 20A and 20B). The difference between the false negative rate was particularly stark for small mosaicism percentages (FIGS. 21A-25B). For example, when $p=1\%$, a less than 20% false negative rate is never reached without haplotype data, whereas it is close to 0% for $N \geq 300$ and $D \geq 3000$. For $p=3\%$, a 0% false negative rate is observed with haplotype data, while $N \geq 300$ and $D \geq 3000$ is needed to reach the same performance without haplotype data.

Exemplary Methods for Detecting Deletions and Duplications Without Phased Data

[0387] In some embodiments, unphased genetic data is used to determine if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of an individual (such as in the genome of one or more cells or in cfDNA or cfRNA). In some embodiments, phased genetic data is used but the phasing is ignored. In some embodiments, the sample of DNA or RNA is a mixed sample of cfDNA or cfRNA from the individual that includes cfDNA or cfRNA from two or more genetically different cells. In some embodiments, the method utilizes the magnitude of the difference between the calculated allele ratio and the expected allele ratio for each of the loci.

[0388] In some embodiments, the method involves obtaining genetic data at a set of polymorphic loci on the chromosome or chromosome segment in a sample of DNA or RNA from one or more cells from the individual by measuring the quantity of each allele at each locus. In some embodiments, allele ratios are calculated for the loci that are heterozygous in at least one cell from which the sample was derived (such as the loci that are heterozygous in the fetus and/or heterozygous in the mother). In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles divided by the total measured quantity of all the alleles for the locus. In some embodiments, the calculated allele ratio for a particular locus is the measured quantity of one of the alleles (such as the allele on the first homologous chromosome segment) divided by the measured quantity of one or more other alleles (such as the allele on the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 251

second homologous chromosome segment) for the locus. The calculated allele ratios and expected allele ratios may be calculated using any of the methods described herein or any standard method (such as any mathematical transformation of the calculated allele ratios or expected allele ratios described herein).

[0389] In some embodiments, a test statistic is calculated based on the magnitude of the difference between the calculated allele ratio and the expected allele ratio for each of the loci. In some embodiments, the test statistic Δ is calculated using the following formula

$$\Delta = \frac{\sum_{All\ Loci}(\delta_i - \mu_i)}{\sqrt{\sum_{All\ Loci}\sigma_i^2}}$$

wherein δ_i is the magnitude of the difference between the calculated allele ratio and the expected allele ratio for the *i*th loci;

wherein μ_i is the mean value of δ_i; and

wherein σ_i^2 is the standard deviation of δ_i.

[0390] For example, we can define δ_i as follows when the expected allele ratio is 0.5:

$$\delta_i \triangleq \left|\frac{1}{2} - R_i\right|.$$

Values for μ_i and σ_i can be computed using the fact that R_i is a Binomial random variable. In some embodiments, the standard deviation is assumed to be the same for all the loci. In some embodiments, the average or weighted average value of the standard deviation or an estimate of the standard deviation is used for the value of σ_i^2. In some embodiments, the test statistic is assumed to have a normal distribution. For example, the central limit theorem implies that the distribution of Δ converges to a standard normal as the number of loci (such as the number of SNPs *T*) grows large.

[0391] In some embodiments, a set of one or more hypotheses specifying the number of copies of the chromosome or chromosome segment in the genome of one or more of the cells are enumerated. In some embodiments, the hypothesis that is most likely based on the test statistic is selected, thereby determining the number of copies of the chromosome or chromosome segment in the genome of one or more of the cells. In some embodiments, a hypotheses is selected if the probability that the test statistic belongs to a distribution of the test statistic for that hypothesis is above an upper threshold; one or more of the hypotheses is rejected if the probability

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 252

that the test statistic belongs to the distribution of the test statistic for that hypothesis is below an lower threshold; or a hypothesis is neither selected nor rejected if the probability that the test statistic belongs to the distribution of the test statistic for that hypothesis is between the lower threshold and the upper threshold, or if the probability is not determined with sufficiently high confidence. In some embodiments, an upper and/or lower threshold is determined from an empirical distribution, such as a distribution from training data (such as samples with a known copy number, such as diploid samples or samples known to have a particular deletion or duplication). Such an empirical distribution can be used to select a threshold for a single hypothesis rejection test.

[0392] Note that the test statistic Δ is independent of S and therefore both can be used independently, if desired.

Exemplary Methods for Detecting Deletions and Duplications Using Allele Distributions or Patterns

[0393] This section includes methods for determining if there is an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment. In some embodiments, the method involves enumerating (i) a plurality of hypotheses specifying the number of copies of the chromosome or chromosome segment that are present in the genome of one or more cells (such as cancer cells) of the individual or (ii) a plurality of hypotheses specifying the degree of overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of one or more cells of the individual. In some embodiments, the method involves obtaining genetic data from the individual at a plurality of polymorphic loci (such as SNP loci) on the chromosome or chromosome segment. In some embodiments, a probability distribution of the expected genotypes of the individual for each of the hypotheses is created. In some embodiments, a data fit between the obtained genetic data of the individual and the probability distribution of the expected genotypes of the individual is calculated. In some embodiments, one or more hypotheses are ranked according to the data fit, and the hypothesis that is ranked the highest is selected. In some embodiments, a technique or algorithm, such as a search algorithm, is used for one or more of the following steps: calculating the data fit, ranking the hypotheses, or selecting the hypothesis that is ranked the highest. In some embodiments, the data fit is a fit

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 253

to a beta-binomial distribution or a fit to a binomial distribution. In some embodiments, the technique or algorithm is selected from the group consisting of maximum likelihood estimation, maximum a-posteriori estimation, Bayesian estimation, dynamic estimation (such as dynamic Bayesian estimation), and expectation-maximization estimation. In some embodiments, the method includes applying the technique or algorithm to the obtained genetic data and the expected genetic data.

[0394] In some embodiments, the method involves enumerating (i) a plurality of hypotheses specifying the number of copies of the chromosome or chromosome segment that are present in the genome of one or more cells (such as cancer cells) of the individual or (ii) a plurality of hypotheses specifying the degree of overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of one or more cells of the individual. In some embodiments, the method involves obtaining genetic data from the individual at a plurality of polymorphic loci (such as SNP loci) on the chromosome or chromosome segment. In some embodiments, the genetic data includes allele counts for the plurality of polymorphic loci. In some embodiments, a joint distribution model is created for the expected allele counts at the plurality of polymorphic loci on the chromosome or chromosome segment for each hypothesis. In some embodiments, a relative probability for one or more of the hypotheses is determined using the joint distribution model and the allele counts measured on the sample, and the hypothesis with the greatest probability is selected.

[0395] In some embodiments, the distribution or pattern of alleles (such as the pattern of calculated allele ratios) is used to determine the presence or absence of a CNV, such as a deletion or duplication. If desired the parental origin of the CNV can be determined based on this pattern. A maternally inherited duplication is an extra copy of a chromosome segment from the mother, and maternally inherited deletion is the absence of the copy of a chromosome segment from the mother such that the only copy of the chromosome segment that is present is from the father. Exemplary patterns are illustrated in FIGs. 15A-19D and are described further below.

[0396] To determine the presence or absence of a deletion of a chromosome segment of interest, the algorithm considers the distribution of sequence counts from each of two possible alleles at large number of SNPs per chromosome. It is important to note that some embodiments of the algorithm use an approach that does not lend itself to visualization. Thus, for the purposes of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 254

illustration, the data is displayed in FIGs. 15A-18 in a simplified fashion as ratios of the two most likely alleles, labeled as A and B, so that the relevant trends can be more readily visualized. This simplified illustration does not take into account some of the possible features of the algorithm. For example, two embodiments for the algorithm that are not possible to illustrate with a method of visualization that displays allele ratios are: 1) the ability to leverage linkage disequilibrium, *i.e.* the influence that a measurement at one SNP has on the likely identity of a neighboring SNP, and 2) the use of non-Gaussian data models that describe the expected distribution of allele measurements at a SNP given platform characteristics and amplification biases. Also note that a simplified version of the algorithm only considers the two most common alleles at each SNP, ignoring other possible alleles.

[0397] Deletions of interest were detected in genomic and maternal blood samples. In some embodiments, the genomic and maternal plasma samples are analyzed using the multiplex-PCR and sequencing method of Example 1. The genomic DNA syndrome samples tested lacked heterozygous SNPs in the targeted regions, confirming the ability of the assays to distinguish monosomy (affected) from disomy (unaffected). Analysis of cfDNA from a maternal blood sample was able to detect 22q11.2 deletion syndrome, Cri-du-Chat deletion syndrome, and Wolf-Hirschhorn deletion syndrome, as well as the other deletion syndromes in FIG. 14 in the fetus.

[0398] FIGs. 15A-15C depict data that indicate the presence of two chromosomes when the sample is entirely maternal (no fetal cfDNA present, Figure 15A), contains a moderate fetal cfDNA fraction of 12% (Figure 15B), or contains a high fetal cfDNA fraction of 26% (Figure 15C). The x-axis represents the linear position of the individual polymorphic loci along the chromosome, and the y-axis represents the number of A allele reads as a fraction of the total (A+B) allele reads. Maternal and fetal genotypes are indicated to the right of the plots. The plots are color-coded according to maternal genotype, such that red indicates a maternal genotype of AA, blue indicates a maternal genotype of BB, and green indicates a maternal genotype of AB. Note that the measurements are made on total cfDNA isolated from maternal blood, and the cfDNA includes both maternal and fetal cfDNA; thus, each spot represents the combination of the fetal and maternal DNA contribution for that SNP. Therefore, increasing the proportion of maternal cfDNA from 0% to 100% will gradually shift some spots up or down within the plots, depending on the maternal and fetal genotype.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 255

[0399] In all cases, SNPs that are homozygous for the A allele (AA) in both the mother and the fetus are found tightly associated with the upper limit of the plots, as the fraction of A allele reads is high because there should be no B alleles present. Conversely, SNPs that are homozygous for the B allele in both the mother and the fetus are found tightly associated with the lower limit of the plots, as the fraction of A allele reads is low because there should be only B alleles. The spots that are not tightly associated with the upper and lower limits of the plots represent SNPs for which the mother, the fetus, or both are heterozygous; these spots are useful for identifying fetal deletions or duplications, but can also be informative for determining paternal versus maternal inheritance. These spots segregate based on both maternal and fetal genotypes and fetal fraction, and as such the precise position of each individual spot along the y-axis depends on both stoichiometry and fetal fraction. For example, loci where the mother is AA and the fetus is AB are expected to have a different fraction of A allele reads, and thus different positioning along the y-axis, depending on the fetal fraction.

[0400] FIG. 15A has data for a non-pregnant woman, and thus represents the pattern when the genotype is entirely maternal. This pattern includes "clusters" of spots: a red cluster tightly associated with the top of the plot (SNPs where the maternal genotype is AA), a blue cluster tightly associated with the bottom of the plot (SNPs where the maternal genotype is BB), and a single, centered green cluster (SNPs where the maternal genotype is AB). For FIG. 15B, the contribution of fetal alleles to the fraction of A allele reads shifts the position of some allele spots up or down along the y-axis. For FIG. 15C, the pattern, including two red and two blue peripheral bands and a trio of central green bands, is readily apparent. The three central green bands correspond to SNPs that are heterozygous in the mother, and two "peripheral" bands each at both the top (red) and bottom (blue) of the plots correspond to SNPs that are homozygous in the mother.

[0401] Analysis of a 22q11.2 deletion carrier (a mother with this deletion) is shown in FIG. 16A. The deletion carrier does not have heterozygous SNPs in this region since the carrier only has one copy of this region. Thus, this deletion is indicated by the absence of the green AB SNPs. The analysis of a paternally inherited 22q11 deletion in a fetus is shown in FIG. 16B. When the fetus only inherits a single copy of a chromosome segment (in the case of a paternally inherited deletion, the copy present in the fetus comes from the mother), and thus only inherits a single allele for each locus in this segment, heterozygosity of the fetus is not possible. As such, the only possible fetal SNP identities are A or B. Note the absence of internal peripheral bands. For a paternally inherited

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 256

deletion, the characteristic pattern includes two central green bands that represent SNPs for which the mother is heterozygous, and only has single peripheral red and blue bands that represent SNPs for which the mother is homozygous, and which remain tightly associated with the upper and lower limits of the plots (1 and 0), respectively.

[0402] Analysis of a maternally inherited Cri-du-Chat deletion syndrome is shown in FIG. 17. There are two central green bands instead of three green bands, and there are two red and two blue peripheral bands. A maternally inherited deletion (such as a maternal carrier of Duchenne's muscular dystrophy) can also be detected based on the small amount of signal in that region of the deletion in a mixed sample of maternal and fetal DNA (such as a plasma sample) due to both the mother and the fetus having the deletion.

[0403] FIG. 18 is a plot of a paternally inherited Wolf-Hirschhorn deletion syndrome, as indicated by the presence of one red and one blue peripheral band.

[0404] If desired, similar plots can be generated for a sample from an individual suspected of having a deletion or duplication, such as a CNV associated with cancer. In such plots, the following color coding can be used based on the genotype of cells without the CNV: red indicates a genotype of AA, blue indicates a genotype of BB, and green indicates a genotype of AB. In some embodiments for a deletion, the pattern includes two central green bands that represent SNPs for which the individual is heterozygous (top green band represents AB from cells without the deletion and A from cells with the deletion, and bottom green band represents AB from cells without the deletion and B from cells with the deletion), and only has single peripheral red and blue bands that represent SNPs for which the individual is homozygous, and which remain tightly associated with the upper and lower limits of the plots (1 and 0), respectively. In some embodiments, the separation of the two green bands increases as the fraction of cells, DNA, or RNA with the deletion increases.

Exemplary Methods for Identifying and Analyzing Multiple Pregnancies

[0405] In some embodiments, any of the methods of the present invention are used to detect the presence of a multiple pregnancy, such as a twin pregnancy, where at least one of the fetuses is genetically different from at least one other fetus. In some embodiments, fraternal twins are identified based on the presence of two fetus with different allele, different allele ratios, or different allele distributions at some (or all) of the tested loci. In some embodiments, fraternal twins are

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 257

identified by determining the expected allele ratio at each locus (such as SNP loci) for two fetuses that may have the same or different fetal fractions in the sample (such as a plasma sample). In some embodiments, the likelihood of a particular pair of fetal fractions (where f1 is the fetal fraction for fetus 1, and f2 is the fetal fraction for fetus 2) is calculated by considering some or all of the possible genotypes of the two fetuses, conditioned on the mother's genotype and genotype population frequencies. The mixture of two fetal and one maternal genotype, combined with the fetal fractions, determine the expected allele ratio at a SNP. For example, if the mother is AA, fetus 1 is AA, and fetus 2 is AB, the overall fraction of B allele at the SNP is one-half of f2. The likelihood calculation asks how well all of the SNPs together match the expected allele ratios based on all of the possible combinations of fetal genotypes. The fetal fraction pair (f1, f2) that best matches the data is selected. It is not necessary to calculated specific genotypes of the fetuses; instead, one can, for example, considered all of the possible genotypes in a statistical combination. In some embodiments, if the method does not distinguish between singleton and identical twins, an ultrasound can be performed to determine whether there is a singleton or identical twin pregnancy. If the ultrasound detects a twin pregnancy it can be assumed that the pregnancy is an identical twin pregnancy because a fraternal twin pregnancy would have been detected based on the SNP analysis discussed above.

[0406] In some embodiments, a pregnant mother is known to have a multiple pregnancy (such as a twin pregnancy) based on prior testing, such as an ultrasound. Any of the methods of the present invention can be used to determine whether the multiple pregnancy includes identical or fraternal twins. For example, the measured allele ratios can be compared to what would be expected for identical twins (the same allele ratios as a singleton pregnancy) or for fraternal twins (such as the calculation of allele ratios as described above). Some identical twins are monochorionic twins, which have a risk of twin-to-twin transfusion syndrome. Thus, twins determined to be identical twins using a method of the invention are desirably tested (such as by ultrasound) to determine if they are monochorionic twins, and if so, these twins can be monitored (such as bi-weekly ultrasounds from 16 weeks) for signs of win-to-twin transfusion syndrome.

[0407] In some embodiments, any of the methods of the present invention are used to determine whether any of the fetuses in a multiple pregnancy, such as a twin pregnancy, are aneuploid. Aneuploidy testing for twins begins with the fetal fraction estimate. In some embodiments, the fetal fraction pair (f1, f2) that best matches the data is selected as described above. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 258

embodiments, a maximum likelihood estimate is performed for the parameter pair (f1, f2) over the range of possible fetal fractions. In some embodiments, the range of f2 is from 0 to f1 because f2 is defined as the smaller fetal fraction. Given a pair (f1, f2), data likelihood is calculated from the allele ratios observed at a set of loci such as SNP loci. In some embodiments, the data likelihood reflects the genotypes of the mother, the father if available, population frequencies, and the resulting probabilities of fetal genotypes. In some embodiments, SNPs are assumed independent. The estimated fetal fraction pair is the one that produces the highest data likelihood. If f2 is 0 then the data is best explained by only one set of fetal genotypes, indicating identical twins, where f1 is the combined fetal fraction. Otherwise f1 and f2 are the estimates of the individual twin fetal fractions. Having established the best estimate of (f1, f2), one can predict the overall fraction of B allele in the plasma for any combination of maternal and fetal genotypes, if desired. It is not necessary to assign individual sequence reads to the individual fetuses. Ploidy testing is performed using another maximum likelihood estimate which compares the data likelihood of two hypotheses. In some embodiments for identical twins, one consider the hypotheses (i) both twins are euploid, and (ii) both twins are trisomic. In some embodiments for fraternal twins, one considers the hypotheses (i) both twins are euploid and (ii) at least one twin is trisomic. The trisomy hypotheses for fraternal twins are based on the lower fetal fraction, since a trisomy in the twin with a higher fetal fraction would also be detected. Ploidy likelihoods are calculated using a method which predicts the expected number of reads at each targeted genome locus conditioned on either the disomy or trisomy hypothesis. There is no requirement for a disomy reference chromosome. The variance model for the expected number of reads takes into account the performance of individual target loci as well as the correlation between loci (see, for example, U.S. Serial No. 62/008,235, filed June 5, 2014, and U.S. Serial No. 62/032,785, filed August 4, 2014, which are each hereby incorporated by reference in its entirety). If the smaller twin has fetal fraction f1, our ability to detect a trisomy in that twin is equivalent to our ability to detect a trisomy in a singleton pregnancy at the same fetal fraction. This is because the part of the method that detects the trisomy in some embodiments does not depend on genotypes and does not distinguish between multiple or singleton pregnancy. It simply looks for an increased number of reads in accordance with the determined fetal fraction.

[0408] In some embodiments, the method includes detecting the presence of twins based on SNP loci (such as described above). If twins are detected, SPNs are used to determine the fetal fraction

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 259

of each fetus (f1, f2) such as described above. In some embodiments, samples that have high confidence disomy calls are used to determine the amplification bias on a per-SNP basis. In some embodiments, these samples with high confidence disomy calls are analyzed in the same run as one or more samples of interest. In some embodiments, the amplification bias on a per-SNP basis is used to model the distribution of reads for one or more chromosomes or chromosome segments of interest such as chromosome 21 that are expected or the disomy hypothesis and the trisomy hypothesis given the lower of the two twin fetal fraction. The likelihood or probability of disomy or trisomy is calculated given the two models and the measured quantity of the chromosome or chromosome segment of interest.

[0409] In some embodiments, the threshold for a positive aneuploidy call (such as a trisomy call) is set based on the twin with the lower fetal fraction. This way, if the other twin is positive, or if both are positive, the total chromosome representation is definitely above the threshold.

Exemplary Counting Methods/Quantitative Methods

[0410] In some embodiments, one or more counting methods (also referred to as quantitative methods) are used to detect one or more CNS, such as deletions or duplications of chromosome segments or entire chromosomes. In some embodiments, one or more counting methods are used to determine whether the overrepresentation of the number of copies of the first homologous chromosome segment is due to a duplication of the first homologous chromosome segment or a deletion of the second homologous chromosome segment. In some embodiments, one or more counting methods are used to determine the number of extra copies of a chromosome segment or chromosome that is duplicated (such as whether there are 1, 2, 3, 4, or more extra copies). In some embodiments, one or more counting methods are used to differentiate a sample has many duplications and a smaller tumor fraction from a sample with fewer duplications and a larger tumor fraction. For example, one or more counting methods may be used to differentiate a sample with four extra chromosome copies and a tumor fraction of 10% from a sample with two extra chromosome copies and a tumor fraction of 20%. Exemplary methods are disclosed, *e.g.* U.S. Publication Nos. 2007/0184467; 2013/0172211; and 2012/0003637; U.S. Patent Nos. 8,467,976; 7,888,017; 8,008,018; 8,296,076; and 8,195,415; U.S. Serial No. 62/008,235, filed June 5, 2014, and U.S. Serial No. 62/032,785, filed August 4, 2014, which are each hereby incorporated by reference in its entirety.

[0411] In some embodiment, the counting method includes counting the number of DNA sequence-based reads that map to one or more given chromosomes or chromosome segments. Some such methods involve creation of a reference value (cut-off value) for the number of DNA sequence reads mapping to a specific chromosome or chromosome segment, wherein a number of reads in excess of the value is indicative of a specific genetic abnormality.

[0412] In some embodiments, the total measured quantity of all the alleles for one or more loci (such as the total amount of a polymorphic or non-polymorphic locus) is compared to a reference amount. In some embodiments, the reference amount is (i) a threshold value or (ii) an expected amount for a particular copy number hypothesis. In some embodiments, the reference amount (for the absence of a CNV) is the total measured quantity of all the alleles for one or more loci for one or more chromosomes or chromosomes segments known or expected to not have a deletion or duplication. In some embodiments, the reference amount (for the presence of a CNV) is the total measured quantity of all the alleles for one or more loci for one or more chromosomes or chromosomes segments known or expected to have a deletion or duplication. In some embodiments, the reference amount is the total measured quantity of all the alleles for one or more loci for one or more reference chromosomes or chromosome segments. In some embodiments, the reference amount is the mean or median of the values determined for two or more different chromosomes, chromosome segments, or different samples. In some embodiments, random (*e.g.*, massively parallel shotgun sequencing) or targeted sequencing is used to determine the amount of one or more polymorphic or non-polymorphic loci.

[0413] In some embodiments utilizing a reference amount, the method includes (a) measuring the amount of genetic material on a chromosome or chromosome segment of interest; (b) comparing the amount from step (a) to a reference amount; and (c) identifying the presence or absence of a deletion or duplication based on the comparison.

[0414] In some embodiments utilizing a reference chromosome or chromosome segment, the method includes sequencing DNA or RNA from a sample to obtain a plurality of sequence tags aligning to target loci. In some embodiments, the sequence tags are of sufficient length to be assigned to a specific target locus (*e.g.*, 15-100 nucleotides in length); the target loci are from a plurality of different chromosomes or chromosome segments that include at least one first chromosome or chromosome segment suspected of having an abnormal distribution in the sample and at least one second chromosome or chromosome segment presumed to be normally distributed

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 261

in the sample. In some embodiments, the plurality of sequence tags are assigned to their corresponding target loci. In some embodiments, the number of sequence tags aligning to the target loci of the first chromosome or chromosome segment and the number of sequence tags aligning to the target loci of the second chromosome or chromosome segment are determined. In some embodiments, these numbers are compared to determine the presence or absence of an abnormal distribution (such as a deletion or duplication) of the first chromosome or chromosome segment.

[0415] In some embodiments, the value of *f* (such as the fetal fraction or tumor fraction) is used in the CNV determination, such as to compare the observed difference between the amount of two chromosomes or chromosome segments to the difference that would be expected for a particular type of CNV given the value of *f* (see, *e.g.,* US Publication No 2012/0190020; US Publication No 2012/0190021; US Publication No 2012/0190557; US Publication No 2012/0191358, which are each hereby incorporated by reference in its entirety). For example, the difference in the amount of a chromosome segment that is duplicated in a fetus compared to a disomic reference chromosome segment in a blood sample from a mother carrying the fetus increases as the fetal fraction increases. Additionally, the difference in the amount of a chromosome segment that is duplicated in a tumor compared to a disomic reference chromosome segment increases as the tumor fraction increases. In some embodiments, the method includes comparing the relative frequency of a chromosome or chromosome segment of interest to a reference chromosomes or chromosome segment (such as a chromosome or chromosome segment expected or known to be disomic) to the value of *f* to determine the likelihood of the CNV. For example, the difference in amounts between the first chromosomes or chromosome segment to the reference chromosome or chromosome segment can be compared to what would be expected given the value of *f* for various possible CNVs (such as one or two extra copies of a chromosome segment of interest).

[0416] The following prophetic examples illustrate the use of a counting method/quantitative method to differentiate between a duplication of the first homologous chromosome segment and a deletion of the second homologous chromosome segment. If one considers the normal disomic genome of the host to be the baseline, then analysis of a mixture of normal and cancer cells yields the average difference between the baseline and the cancer DNA in the mixture. For example, imagine a case where 10% of the DNA in the sample originated from cells with a deletion over a region of a chromosome that is targeted by the assay. In some embodiments, a quantitative

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 262

approach shows that the quantity of reads corresponding to that region is expected to be 95% of what is expected for a normal sample. This is because one of the two target chromosomal regions in each of the tumor cells with a deletion of the targeted region is missing, and thus the total amount of DNA mapping to that region is 90% (for the normal cells) plus ½ x 10% (for the tumor cells) = 95%. Alternately in some embodiments, an allelic approach shows that the ratio of alleles at heterozygous loci averaged 19:20. Now imagine a case where 10% of the DNA in the sample originated from cells with a five-fold focal amplification of a region of a chromosome that is targeted by the assay. In some embodiments, a quantitative approach shows that the quantity of reads corresponding to that region is expected to be 125% of what is expected for a normal sample. This is because one of the two target chromosomal regions in each of the tumor cells with a five-fold focal amplification is copied an extra five times over the targeted region, and thus the total amount of DNA mapping to that region is 90% (for the normal cells) plus (2 + 5) x 10% / 2 (for the tumor cells) = 125%. Alternately in some embodiments, an allelic approach shows that the ratio of alleles at heterozygous loci averaged 25:20. Note that when using an allelic approach alone, a focal amplification of five-fold over a chromosomal region in a sample with 10% cfDNA may appear the same as a deletion over the same region in a sample with 40% cfDNA; in these two cases, the haplotype that is under-represented in the case of the deletion appears to be the haplotype without a CNV in the case with the focal duplication, and the haplotype without a CNV in the case of the deletion appears to be the over-represented haplotype in the case with the focal duplication. Combining the likelihoods produced by this allelic approach with likelihoods produced by a quantitative approach differentiates between the two possibilities.

Exemplary Counting Methods/Quantitative Methods Using Reference Samples

[0417] An exemplary quantitative method that uses one or more reference samples is described in U.S. Serial No. 62/008,235, filed June 5, 2014 and U.S. Serial No. 62/032,785, filed August 4, 2014, which is hereby incorporated by reference in its entirety. In some embodiments, one or more reference samples most likely to not have any CNVs on one or more chromosomes or chromosomes of interest (*e.g.*, a normal sample) are identified by selecting the samples with the highest fraction of tumor DNA, selecting the samples with the z-score closest to zero, selecting the samples where the data fits the hypothesis corresponding to no CNVs with the highest confidence or likelihood, selecting the samples known to be normal, selecting the samples from

individuals with the lowest likelihood of having cancer (*e.g.,* having a low age, being a male when screening for breast cancer, having no family history, *etc.*), selecting the samples with the highest input amount of DNA, selecting the samples with the highest signal to noise ratio, selecting samples based on other criteria believed to be correlated to the likelihood of having cancer, or selecting samples using some combination of criteria. Once the reference set is chosen, one can make the assumption that these cases are disomic, and then estimate the per-SNP bias, that is, the experiment-specific amplification and other processing bias for each locus. Then, one can use this experiment-specific bias estimate to correct the bias in the measurements of the chromosome of interest, such as chromosome 21 loci, and for the other chromosome loci as appropriate, for the samples that are not part of the subset where disomy is assumed for chromosome 21. Once the biases have been corrected for in these samples of unknown ploidy, the data for these samples can then be analyzed a second time using the same or a different method to determine whether the individuals (such as fetuses) are afflicted with trisomy 21. For example, a quantitative method can be used on the remaining samples of unknown ploidy, and a z-score can be calculated using the corrected measured genetic data on chromosome 21. Alternately, as part of the preliminary estimate of the ploidy state of chromosome 21, a fetal fraction (or tumor fraction for samples from an individual suspected of having cancer) can be calculated. The proportion of corrected reads that are expected in the case of a disomy (the disomy hypothesis), and the proportion of corrected reads that are expected in the case of a trisomy (the trisomy hypothesis) can be calculated for a case with that fetal fraction. Alternately, if the fetal fraction was not measured previously, a set of disomy and trisomy hypotheses can be generated for different fetal fractions. For each case, an expected distribution of the proportion of corrected reads can be calculated given expected statistical variation in the selection and measurement of the various DNA loci. The observed corrected proportion of reads can be compared to the distribution of the expected proportion of corrected reads, and a likelihood ratio can be calculated for the disomy and trisomy hypotheses, for each of the samples of unknown ploidy. The ploidy state associated with the hypothesis with the highest calculated likelihood can be selected as the correct ploidy state.

[0418] In some embodiments, a subset of the samples with a sufficiently low likelihood of having cancer may be selected to act as a control set of samples. The subset can be a fixed number, or it can be a variable number that is based on choosing only those samples that fall below a threshold. The quantitative data from the subset of samples may be combined, averaged, or combined using

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 264

a weighted average where the weighting is based on the likelihood of the sample being normal. The quantitative data may be used to determine the per-locus bias for the amplification the sequencing of samples in the instant batch of control samples. The per-locus bias may also include data from other batches of samples. The per-locus bias may indicate the relative over- or under-amplification that is observed for that locus compared to other loci, making the assumption that the subset of samples do not contain any CNVs, and that any observed over or under-amplification is due to amplification and/or sequencing or other bias. The per-locus bias may take into account the GC content of the amplicon. The loci may be grouped into groups of loci for the purpose of calculating a per-locus bias. Once the per-locus bias has been calculated for each locus in the plurality of loci, the sequencing data for one or more of the samples that are not in the subset of the samples, and optionally one or more of the samples that are in the subset of samples, may be corrected by adjusting the quantitative measurements for each locus to remove the effect of the bias at that locus. For example, if SNP 1 was observed, in the subset of patients, to have a depth of read that is twice as great as the average, the adjustment may involve replacing the number of reads corresponding from SNP 1 with a number that is half as great. If the locus in question is a SNP, the adjustment may involve cutting the number of reads corresponding to each of the alleles at that locus in half. Once the sequencing data for each of the loci in one or more samples has been adjusted, it may be analyzed using a method for the purpose of detecting the presence of a CNV at one or more chromosomal regions.

[0419] In an example, sample A is a mixture of amplified DNA originating from a mixture of normal and cancerous cells that is analyzed using a quantitative method. The following illustrates exemplary possible data. A region of the q arm on chromosome 22 is found to only have 90% as much DNA mapping to that region as expected; a focal region corresponding to the HER2 gene is found to have 150% as much DNA mapping to that region as expected; and the p-arm of chromosome 5 is found to have 105% as much DNA mapping to it as expected. A clinician may infer that the sample has a deletion of a region on the q arm on chromosome 22, and a duplication of the HER2 gene. The clinician may infer that since the 22q deletions are common in breast cancer, and that since cells with a deletion of the 22q region on both chromosomes usually do not survive, that approximately 20% of the DNA in the sample came from cells with a 22q deletion on one of the two chromosomes. The clinician may also infer that if the DNA from the mixed sample that originated from tumor cells originated from a set of genetically tumor cells whose

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 265

HER2 region and 22q regions were homogenous, then the cells contained a five-fold duplication of the HER2 region.

[0420] In an example, Sample A is also analyzed using an allelic method. The following illustrates exemplary possible data. The two haplotypes on same region on the q arm on chromosome 22 are present in a ratio of 4:5; the two haplotypes in a focal region corresponding to the HER2 gene are present in ratios of 1:2; and the two haplotypes in the p-arm of chromosome 5 are present in ratios of 20:21. All other assayed regions of the genome have no statistically significant excess of either haplotype. A clinician may infer that the sample contains DNA from a tumor with a CNV in the 22q region, the HER2 region, and the 5p arm. Based on the knowledge that 22q deletions are very common in breast cancer, and/or the quantitative analysis showing an under-representation of the amount of DNA mapping to the 22q region of the genome, the clinician may infer the existence of a tumor with a 22q deletion. Based on the knowledge that HER2 amplifications are very common in breast cancer, and/or the quantitative analysis showing an over-representation of the amount of DNA mapping to the HER2 region of the genome, the clinician may infer the existence of a tumor with a HER2 amplification.

Exemplary Reference Chromosomes or Chromosome Segments

[0421] In some embodiments, any of the methods described herein are also performed on one or more reference chromosomes or chromosomes segments and the results are compared to those for one or more chromosomes or chromosome segments of interest.

[0422] In some embodiments, the reference chromosome or chromosome segment is used as a control for what would be expected for the absence of a CNV. In some embodiments, the reference is the same chromosome or chromosome segment from one or more different samples known or expected to not have a deletion or duplication in that chromosome or chromosome segment. In some embodiments, the reference is a different chromosome or chromosome segment from the sample being tested that is expected to be disomic. In some embodiments, the reference is a different segment from one of the chromosomes of interest in the same sample that is being tested. For example, the reference may be one or more segments outside of the region of a potential deletion or duplication. Having a reference on the same chromosome that is being tested avoids variability between different chromosomes, such as differences in metabolism, apoptosis, histones, inactivation, and/or amplification between chromosomes. Analyzing segments without a CNV on

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 266

the same chromosome as the one being tested can also be used to determine differences in metabolism, apoptosis, histones, inactivation, and/or amplification between homologs, allowing the level of variability between homologs in the absence of a CNV to be determined for comparison to the results from a potential CNV. In some embodiments, the magnitude of the difference between the calculated and expected allele ratios for a potential CNV is greater than the corresponding magnitude for the reference, thereby confirming the presence of a CNV.

[0423] In some embodiments, the reference chromosome or chromosome segment is used as a control for what would be expected for the presence of a CNV, such as a particular deletion or duplication of interest. In some embodiments, the reference is the same chromosome or chromosome segment from one or more different samples known or expected to have a deletion or duplication in that chromosome or chromosome segment. In some embodiments, the reference is a different chromosome or chromosome segment from the sample being tested that is known or expected to have a CNV. In some embodiments, the magnitude of the difference between the calculated and expected allele ratios for a potential CNV is similar to (such as not significantly different) than the corresponding magnitude for the reference for the CNV, thereby confirming the presence of a CNV. In some embodiments, the magnitude of the difference between the calculated and expected allele ratios for a potential CNV is less than (such as significantly less) than the corresponding magnitude for the reference for the CNV, thereby confirming the absence of a CNV. In some embodiments, one or more loci for which the genotype of a cancer cell (or DNA or RNA from a cancer cell such as cfDNA or cfRNA) differs from the genotype of a noncancerous cell (or DNA or RNA from a noncancerous cell such as cfDNA or cfRNA) is used to determine the tumor fraction. The tumor fraction can be used to determine whether the overrepresentation of the number of copies of the first homologous chromosome segment is due to a duplication of the first homologous chromosome segment or a deletion of the second homologous chromosome segment. The tumor fraction can also be used to determine the number of extra copies of a chromosome segment or chromosome that is duplicated (such as whether there are 1, 2, 3, 4, or more extra copies), such as to differentiate a sample with four extra chromosome copies and a tumor fraction of 10% from a sample with two extra chromosome copies and a tumor fraction of 20%. The tumor fraction can also be used to determine how well the observed data fits the expected data for possible CNVs. In some embodiments, the degree of overrepresentation of a CNV is used to select a

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 267

particular therapy or therapeutic regimen for the individual. For example, some therapeutic agents are only effective for at least four, six, or more copies of a chromosome segment.

[0424] In some embodiments, the one or more loci used to determine the tumor fraction are on a reference chromosome or chromosomes segment, such as a chromosome or chromosome segment known or expected to be disomic, a chromosome or chromosome segment that is rarely duplicated or deleted in cancer cells in general or in a particular type of cancer that an individual is known to have or is at increased risk of having, or a chromosome or chromosome segment that is unlikely to be aneuploid (such segment that is expected to lead to cell death if deleted or duplicated). In some embodiments, any of the methods of the invention are used to confirm that the reference chromosome or chromosome segment is disomic in both the cancer cells and noncancerous cells. In some embodiments, one or more chromosomes or chromosomes segments for which the confidence for a disomy call is high are used.

[0425] Exemplary loci that can be used to determine the tumor fraction include polymorphisms or mutations (such as SNPs) in a cancer cell (or DNA or RNA such as cfDNA or cfRNA from a cancer cell) that aren't present in a noncancerous cell (or DNA or RNA from a noncancerous cell) in the individual. In some embodiments, the tumor fraction is determined by identifying those polymorphic loci where a cancer cell (or DNA or RNA from a cancer cell) has an allele that is absent in noncancerous cells (or DNA or RNA from a noncancerous cell) in a sample (such as a plasma sample or tumor biopsy) from an individual; and using the amount of the allele unique to the cancer cell at one or more of the identified polymorphic loci to determine the tumor fraction in the sample. In some embodiments, a noncancerous cell is homozygous for a first allele at the polymorphic locus, and a cancer cell is (i) heterozygous for the first allele and a second allele or (ii) homozygous for a second allele at the polymorphic locus. In some embodiments, a noncancerous cell is heterozygous for a first allele and a second allele at the polymorphic locus, and a cancer cell is (i) has one or two copies of a third allele at the polymorphic locus. In some embodiments, the cancer cells are assumed or known to only have one copy of the allele that is not present in the noncancerous cells. For example, if the genotype of the noncancerous cells is AA and the cancer cells is AB and 5% of the signal at that locus in a sample is from the B allele and 95% is from the A allele, then the tumor fraction of the sample is 10%. In some embodiments, the cancer cells are assumed or known to have two copies of the allele that is not present in the noncancerous cells. For example, if the genotype of the noncancerous cells is AA and the cancer

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 268

cells is BB and 5% of the signal at that locus in a sample is from the B allele and 95% is from the A allele, the tumor fraction of the sample is 5%. In some embodiments, multiple loci for which the cancer cells have an allele not in the noncancerous cells are analyzed to determine which of the loci in the cancer cells are heterozygous and which are homozygous. For example for loci in which the noncancerous cells are AA, if the signal from the B allele is ~5% at some loci and ~10% at some loci, then the cancer cells are assumed to be heterozygous at loci with ~5% B allele, and homozygous at loci with ~10% B allele (indicating the tumor fraction is ~10%).

[0426] Exemplary loci that can be used to determine the tumor fraction include loci for which a cancer cell and noncancerous cell have one allele in common (such as loci in which the cancer cell is AB and the noncancerous cell is BB, or the cancer cell is BB and the noncancerous cell is AB). The amount of A signal, the amount of B signal, or the ratio of A to B signal in a mixed sample (containing DNA or RNA from a cancer cell and a noncancerous cell) is compared to the corresponding value for (i) a sample containing DNA or RNA from only cancer cells or (ii) a sample containing DNA or RNA from only noncancerous cells. The difference in values is used to determine the tumor fraction of the mixed sample.

[0427] In some embodiments, loci that can be used to determine the tumor fraction are selected based on the genotype of (i) a sample containing DNA or RNA from only cancer cells, and/or (ii) a sample containing DNA or RNA from only noncancerous cells. In some embodiments, the loci are selected based on analysis of the mixed sample, such as loci for which the absolute or relative amounts of each allele differs from what would be expected if both the cancer and noncancerous cells have the same genotype at a particular locus. For example, if the cancer and noncancerous cells have the same genotype, the loci would be expected to produce 0% B signal if all the cells are AA, 50% B signal if all the cells are AB, or 100% B signal if all the cells are BB. Other values for the B signal indicate that the genotype of the cancer and noncancerous cells are different at that locus and thus that locus can be used to determine the tumor fraction.

[0428] In some embodiments, the tumor fraction calculated based on the alleles at one or more loci is compared to the tumor fraction calculated using one or more of the counting methods disclosed herein.

Exemplary Methods for Detecting a Phenotype or Analyzing Multiple Mutations

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 269

[0429] In some embodiments, the method includes analyzing a sample for a set of mutations associated with a disease or disorder (such as cancer) or an increased risk for a disease or disorder. There are strong correlations between events within classes (such as M or C cancer classes) which can be used to improve the signal to noise ratio of a method and classify tumors into distinct clinical subsets. For example, borderline results for a few mutations (such as a few CNVs) on one or more chromosomes or chromosomes segments considered jointly may be a very strong signal. In some embodiments, determining the presence or absence of multiple polymorphisms or mutations of interest (such as 2, 3, 4, 5, 8, 10, 12, 15, or more) increases the sensitivity and/or specificity of the determination of the presence or absence of a disease or disorder such as cancer, or an increased risk for with a disease or disorder such as cancer. In some embodiments, the correlation between events across multiple chromosomes is used to more powerfully look at a signal compared to looking at each of them individually. The design of the method itself can be optimized to best categorize tumors. This may be incredibly useful for early detection and screening--vis-a-vis recurrence where sensitivity to one particular mutation/CNV may be paramount. In some embodiments, the events are not always correlated but have a probability of being correlated. In some embodiments, a matrix estimation formulation with a noise covariance matrix that has off diagonal terms is used.

[0430] In some embodiments, the invention features a method for detecting a phenotype (such as a cancer phenotype) in an individual, wherein the phenotype is defined by the presence of at least one of a set of mutations. In some embodiments, the method includes obtaining DNA or RNA measurements for a sample of DNA or RNA from one or more cells from the individual, wherein one or more of the cells is suspected of having the phenotype; and analyzing the DNA or RNA measurements to determine, for each of the mutations in the set of mutations, the likelihood that at least one of the cells has that mutation. In some embodiments, the method includes determining that the individual has the phenotype if either (i) for at least one of the mutations, the likelihood that at least one of the cells contains that mutations is greater than a threshold, or (ii) for at least one of the mutations, the likelihood that at least one of the cells has that mutations is less than the threshold, and for a plurality of the mutations, the combined likelihood that at least one of the cells has at least one of the mutations is greater than the threshold. In some embodiments, one or more cells have a subset or all of the mutations in the set of mutations. In some embodiments, the subset of mutations is associated with cancer or an increased risk for

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 270

cancer. In some embodiments, the set of mutations includes a subset or all of the mutations in the M class of cancer mutations (Ciriello, Nat Genet. 45(10):1127-1133, 2013, doi: 10.1038/ng.2762, which is hereby incorporated by reference in its entirety). In some embodiments, the set of mutations includes a subset or all of the mutations in the C class of cancer mutations (Ciriello, *supra*). In some embodiments, the sample includes cell-free DNA or RNA. In some embodiments, the DNA or RNA measurements include measurements (such as the quantity of each allele at each locus) at a set of polymorphic loci on one or more chromosomes or chromosome segments of interest.

Exemplary Methods for Paternity Testing or Genetic Relatedness Testing

[0431] The methods of the invention can be used to improve the accuracy of paternity testing or other genetic relatedness testing (see, *e.g.*, U.S. Publication No. 2012/0122701, filed December 22, 2011, which is hereby incorporated by reference in its entirety). For example, the multiplex PCR method can allow thousands of polymorphic loci (such as SNPs) to be analyzed for use in the PARENTAL SUPPORT algorithm described herein to determine whether an alleged father in is the biological father of a fetus. In some embodiments, the invention features a method for establishing whether an alleged father is the biological father of a fetus that is gestating in a pregnant mother. In some embodiments, the method involves obtaining phased genetic data for the alleged father (such as by using another of the methods described herein for phasing genetic data), wherein the phased genetic data comprises the identity of the allele present for each locus in a set of polymorphic loci on a first homologous chromosome segment and a second homologous chromosome segment in the alleged father. In some embodiments, the method involves obtaining genetic data at the set of polymorphic loci on the chromosome or chromosome segment in a mixed sample of DNA comprising fetal DNA and maternal DNA from the mother of the fetus by measuring the quantity of each allele at each locus. In some embodiments, the method involves calculating, on a computer, expected genetic data for the mixed sample of DNA from the phased genetic data for the alleged father; determining, on a computer, the probability that the alleged father is the biological father of the fetus by comparing the obtaining genetic data made on the mixed sample of DNA to the expected genetic data for the mixed sample of DNA; and establishing whether the alleged father is the biological father of the fetus using the determined probability that the alleged father is the biological father of the fetus. In some embodiments, the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 271

method involves obtaining phased genetic data for the biological mother of the fetus (such as by using another of the methods described herein for phasing genetic data), wherein the phased genetic data comprises the identity of the allele present for each locus in a set of polymorphic loci on a first homologous chromosome segment and a second homologous chromosome segment in the mother. In some embodiments, the method involves obtaining phased genetic data for the fetus (such as by using another of the methods described herein for phasing genetic data), wherein the phased genetic data comprises the identity of the allele present for each locus in a set of polymorphic loci on a first homologous chromosome segment and a second homologous chromosome segment in the fetus. In some embodiments, the method involves calculating, on a computer, expected genetic data for the mixed sample of DNA using the phased genetic data for the alleged father and using the phased genetic data for the mother and/or the phased genetic data for the fetus.

[0432] In some embodiments, the invention features a method for establishing whether an alleged father is the biological father of a fetus that is gestating in a pregnant mother. In some embodiments, the method involves obtaining phased genetic data for the alleged father (such as by using another of the methods described herein for phasing genetic data), wherein the phased genetic data comprises the identity of the allele present for each locus in a set of polymorphic loci on a first homologous chromosome segment and a second homologous chromosome segment in the alleged father. In some embodiments, the method involves obtaining genetic data at the set of polymorphic loci on the chromosome or chromosome segment in a mixed sample of DNA comprising fetal DNA and maternal DNA from the mother of the fetus by measuring the quantity of each allele at each locus. In some embodiments, the method involves identifying (i) alleles that are present in the fetal DNA but are absent in the maternal DNA at polymorphic loci, and/or identifying (i) alleles that are absent in the fetal DNA and the maternal DNA at polymorphic loci. In some embodiments, the method involves determining, on a computer, the probability that the alleged father is the biological father of the fetus; wherein the determination comprises: (1) comparing (i) the alleles that are present in the fetal DNA but are absent in the maternal DNA at polymorphic loci to (ii) the alleles at the corresponding polymorphic loci in the genetic material from the alleged father, and/or (2) comparing (i) the alleles that are absent in the fetal DNA and the maternal DNA at polymorphic loci to (ii) the alleles at the corresponding polymorphic loci in the genetic material from the alleged father; and establishing whether the alleged father is the

biological father of the fetus using the determined probability that the alleged father is the biological father of the fetus.

[0433] In some embodiments, a method described above for determining whether an alleged father is the biological father of the fetus is used to determine if an alleged relative (such as a grandparent, sibling, aunt, or uncle) of a fetus is an actual biological relative of the fetus (such as by using genetic data of the alleged relative instead of genetic data of the alleged father).

Exemplary Combinations of Methods

[0434] To increase the accuracy of the results, two or more methods (such as any of the methods of the invention or any known method) for detecting the presence or absence of a CNV are performed. In some embodiments, one or more methods for analyzing a factor (such as any of the method described herein or any known method) indicative of the presence or absence of a disease or disorder or an increased risk for a disease or disorder are performed.

[0435] In some embodiments, standard mathematical techniques are used to calculate the covariance and/or correlation between two or more methods. Standard mathematical techniques may also be used to determine the combined probability of a particular hypothesis based on two or more tests. Exemplary techniques include meta-analysis, Fisher's combined probability test for independent tests, Brown's method for combining dependent p-values with known covariance, and Kost's method for combining dependent p-values with unknown covariance. In cases where the likelihoods are determined by a first method in a way that is orthogonal, or unrelated, to the way in which a likelihood is determined for a second method, combining the likelihoods is straightforward and can be done by multiplication and normalization, or by using a formula such as:

$$R_{comb} = R_1R_2 / [R_1R_2 + (1-R_1)(1-R_2)]$$

R_{comb} is the combined likelihood, and R_1 and R_2 are the individual likelihoods. For example, if the likelihood of trisomy from method 1 is 90%, and the likelihood of trisomy from method 2 is 95%, then combining the outputs from the two methods allows the clinician to conclude that the fetus is trisomic with a likelihood of $(0.90)(0.95) / [(0.90)(0.95) + (1 - 0.90)(1 - 0.95)] = 99.42\%$. In cases where the first and the second methods are not orthogonal, that is, where there is a correlation between the two methods, the likelihoods can still be combined.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 273

[0436] Exemplary methods of analyzing multiple factors or variables are disclosed in U.S. Patent No. 8,024,128 issued on September 20, 2011; U.S. Publication No. 2007/0027636, filed July 31, 2006; and U.S. Publication No. 2007/0178501, filed December 6, 2006, which are each hereby incorporated by reference in its entirety).

[0437] In various embodiments, the combined probability of a particular hypothesis or diagnosis is greater than 80, 85, 90, 92, 94, 96, 98, 99, or 99.9%, or is greater than some other threshold value.

Limit of Detection

[0438] In some embodiments, a limit of detection of a mutation (such as an SNV or CNV) of a method of the invention is less than or equal to 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005%. In some embodiments, a limit of detection of a mutation (such as an SNV or CNV) of a method of the invention is between 15 to 0.005%, such as between 10 to 0.005%, 10 to 0.01%, 10 to 0.1%, 5 to 0.005%, 5 to 0.01%, 5 to 0.1%, 1 to 0.005%, 1 to 0.01%, 1 to 0.1%, 0.5 to 0.005%, 0.5 to 0.01%, 0.5 to 0.1%, or 0.1 to 0.01, inclusive. In some embodiments, a limit of detection is such that a mutation (such as an SNV or CNV) that is present in less than or equal to 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules with that locus in a sample (such as a sample of cfDNA or cfRNA) is detected (or is capable of being detected). For example, the mutation can be detected even if less than or equal to 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules that have that locus have that mutation in the locus (instead of, for example, a wild-type or non-mutated version of the locus or a different mutation at that locus). In some embodiments, a limit of detection is such that a mutation (such as an SNV or CNV) that is present in less than or equal to 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules in a sample (such as a sample of cfDNA or cfRNA) is detected (or is capable of being detected). In some embodiments in which the CNV is a deletion, the deletion can be detected even if it is only present in less than or equal to 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules that have a region of interest that may or may not contain the deletion in a sample. In some embodiments in which the CNV is a deletion, the deletion can be detected even if it is only present in less than or equal to 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules in a sample. In some embodiments in which the CNV is a duplication, the duplication can be detected even if the extra duplicated DNA or RNA that is present is less than or equal to

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 274

10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules that have a region of interest that may or may not be duplicated in a sample in a sample. In some embodiments in which the CNV is a duplication, the duplication can be detected even if the extra duplicated DNA or RNA that is present is less than or equal to 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules in a sample. Example 6 provides exemplary methods for calculating the limit of detection. In some embodiments, the "LOD-zs5.0-mr5" method of Example 6 is used.

Exemplary Samples

[0439] In some embodiments of any of the aspects of the invention, the sample includes cellular and/or extracellular genetic material from cells suspected of having a deletion or duplication, such as cells suspected of being cancerous. In some embodiments, the sample comprises any tissue or bodily fluid suspected of containing cells, DNA, or RNA having a deletion or duplication, such as cancer cells, DNA, or RNA. The genetic measurements used as part of these methods can be made on any sample comprising DNA or RNA, for example but not limited to, tissue, blood, serum, plasma, urine, hair, tears, saliva, skin, fingernails, feces, bile, lymph, cervical mucus, semen, or other cells or materials comprising nucleic acids. Samples may include any cell type or DNA or RNA from any cell type may be used (such as cells from any organ or tissue suspected of being cancerous, or neurons). In some embodiments, the sample includes nuclear and/or mitochondrial DNA. In some embodiments, the sample is from any of the target individuals disclosed herein. In some embodiments, the target individual is a born individual, a gestating fetus, a non-gestating fetus such as a products of conception sample, an embryo, or any other individual.

[0440] Exemplary samples include those containing cfDNA or cfRNA. In some embodiments, cfDNA is available for analysis without requiring the step of lysing cells. Cell-free DNA may be obtained from a variety of tissues, such as tissues that are in liquid form, *e.g.*, blood, plasma, lymph, ascites fluid, or cerebral spinal fluid. In some cases, cfDNA is comprised of DNA derived from fetal cells. In some cases, cfDNA is comprised of DNA derived from both fetal and maternal cells. In some cases, the cfDNA is isolated from plasma that has been isolated from whole blood that has been centrifuged to remove cellular material. The cfDNA may be a mixture of DNA derived from target cells (such as cancer cells) and non-target cells (such as non-cancer cells).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 275

[0441] In some embodiments, the sample contains or is suspected to contain a mixture of DNA (or RNA), such as mixture of cancer DNA (or RNA) and noncancerous DNA (or RNA). In some embodiments, at least 0.5, 1, 3, 5, 7, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 92, 94, 95, 96, 98, 99, or 100% of the cells in the sample are cancer cells. In some embodiments, at least 0.5, 1, 3, 5, 7, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 92, 94, 95, 96, 98, 99, or 100% of the DNA (such as cfDNA) or RNA (such as cfRNA) in the sample is from cancer cell(s). In various embodiments, the percent of cells in the sample that are cancerous cells is between 0.5 to 99%, such as between 1 to 95%, 5 to 95%, 10 to 90%, 5 to 70%, 10 to 70%, 20 to 90%, or 20 to 70%, inclusive. In some embodiments, the sample is enriched for cancer cells or for DNA or RNA from cancer cells. In some embodiments in which the sample is enriched for cancer cells, at least 0.5, 1, 2, 3, 4, 5, 6, 7, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 92, 94, 95, 96, 98, 99, or 100% of the cells in the enriched sample are cancer cells. In some embodiments in which the sample is enriched for DNA or RNA from cancer cells, at least 0.5, 1, 2, 3, 4, 5, 6, 7, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 92, 94, 95, 96, 98, 99, or 100% of the DNA or RNA in the enriched sample is from cancer cell(s). In some embodiments, cell sorting (such as Fluorescent Activated Cell Sorting (FACS)) is used to enrich for cancer cells (Barteneva *et. al.*, Biochim Biophys Acta., 1836(1):105-22, Aug 2013. doi: 10.1016/j.bbcan.2013.02.004. Epub 2013 Feb 24, and Ibrahim *et al.*, Adv Biochem Eng Biotechnol. 106:19-39, 2007, which are each hereby incorporated by reference in its entirety).

[0442] In some embodiments of any of the aspects of the invention, the sample comprises any tissue suspected of being at least partially of fetal origin. In some embodiments, the sample includes cellular and/or extracellular genetic material from the fetus, contaminating cellular and/or extracellular genetic material (such as genetic material from the mother of the fetus), or combinations thereof. In some embodiments, the sample comprises cellular genetic material from the fetus, contaminating cellular genetic material, or combinations thereof.

[0443] In some embodiments, the sample is from a gestating fetus. In some embodiments, the sample is from a non-gestating fetus, such as a products of conception sample or a sample from any fetal tissue after fetal demise. In some embodiments, the sample is a maternal whole blood sample, cells isolated from a maternal blood sample, maternal plasma sample, maternal serum sample, amniocentesis sample, placental tissue sample (*e.g.*, chorionic villus, decidua, or placental membrane), cervical mucus sample, or other sample from a fetus. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 276

embodiments, at least 3, 5, 7, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 92, 94, 95, 96, 98, 99, or 100% of the cells in the sample are maternal cells. In various embodiments, the percent of cells in the sample that are maternal cells is between 5 to 99%, such as between 10 to 95%, 20 to 95%, 30 to 90%, 30 to 70%, 40 to 90%, 40 to 70%, 50 to 90%, or 50 to 80%, inclusive.

[0444] In some embodiments, the sample is enriched for fetal cells. In some embodiments in which the sample is enriched for fetal cells, at least 0.5, 1, 2, 3, 4, 5, 6, 7% or more of the cells in the enriched sample are fetal cells. In some embodiments, the percent of cells in the sample that are fetal cells is between 0.5 to 100%, such as between 1 to 99%, 5 to 95%, 10 to 95%, 10 to 95%, 20 to 90%, or 30 to 70%, inclusive. In some embodiments, the sample is enriched for fetal DNA. In some embodiments in which the sample is enriched for fetal DNA, at least 0.5, 1, 2, 3, 4, 5, 6, 7% or more of the DNA in the enriched sample is fetal DNA. In some embodiments, the percent of DNA in the sample that is fetal DNA is between 0.5 to 100%, such as between 1 to 99%, 5 to 95%, 10 to 95%, 10 to 95%, 20 to 90%, or 30 to 70%, inclusive.

[0445] In some embodiments, the sample includes a single cell or includes DNA and/or RNA from a single cell. In some embodiments, multiple individual cells (*e.g.*, at least 5, 10, 20, 30, 40, or 50 cells from the same subject or from different subjects) are analyzed in parallel. In some embodiments, cells from multiple samples from the same individual are combined, which reduces the amount of work compared to analyzing the samples separately. Combining multiple samples can also allow multiple tissues to be tested for cancer simultaneously (which can be used to provide or more thorough screening for cancer or to determine whether cancer may have metastasized to other tissues).

[0446] In some embodiments, the sample contains a single cell or a small number of cells, such as 2, 3, 5, 6, 7, 8, 9, or 10 cells. In some embodiments, the sample has between 1 to 100, 100 to 500, or 500 to 1,000 cells, inclusive. In some embodiments, the sample contains 1 to 10 picograms, 10 to 100 picograms, 100 picograms to 1 nanogram, 1 to 10 nanograms, 10 to 100 nanograms, or 100 nanograms to 1 microgram of RNA and/or DNA, inclusive.

[0447] In some embodiments, the sample is embedded in parafilm. In some embodiments, the sample is preserved with a preservative such as formaldehyde and optionally encased in paraffin, which may cause cross-linking of the DNA such that less of it is available for PCR. In some embodiments, the sample is a formaldehyde fixed-paraffin embedded (FFPE) sample. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 277

embodiments, the sample is a fresh sample (such as a sample obtained with 1 or 2 days of analysis). In some embodiments, the sample is frozen prior to analysis. In some embodiments, the sample is a historical sample.

[0448] These samples can be used in any of the methods of the invention.

Exemplary Sample Preparation Methods

[0449] In some embodiments, the method includes isolating or purifying the DNA and/or RNA. There are a number of standard procedures known in the art to accomplish such an end. In some embodiments, the sample may be centrifuged to separate various layers. In some embodiments, the DNA or RNA may be isolated using filtration. In some embodiments, the preparation of the DNA or RNA may involve amplification, separation, purification by chromatography, liquid liquid separation, isolation, preferential enrichment, preferential amplification, targeted amplification, or any of a number of other techniques either known in the art or described herein. In some embodiments for the isolation of DNA, RNase is used to degrade RNA. In some embodiments for the isolation of RNA, DNase (such as DNase I from Invitrogen, Carlsbad, CA, USA) is used to degrade DNA. In some embodiments, an RNeasy mini kit (Qiagen), is used to isolate RNA according to the manufacturer's protocol. In some embodiments, small RNA molecules are isolated using the mirVana PARIS kit (Ambion, Austin, TX, USA) according to the manufacturer's protocol (Gu *et al*., J. Neurochem. 122:641–649, 2012, , which is hereby incorporated by reference in its entirety). The concentration and purity of RNA may optionally be determined using Nanovue (GE Healthcare, Piscataway, NJ, USA), and RNA integrity may optionally be measured by use of the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) (Gu *et al*., J. Neurochem. 122:641–649, 2012, , which is hereby incorporated by reference in its entirety). In some embodiments, TRIZOL or RNAlater (Ambion) is used to stabilize RNA during storage.

[0450] In some embodiments, universal tagged adaptors are added to make a library. Prior to ligation, sample DNA may be blunt ended, and then a single adenosine base is added to the 3-prime end. Prior to ligation the DNA may be cleaved using a restriction enzyme or some other cleavage method. During ligation the 3-prime adenosine of the sample fragments and the complementary 3-prime tyrosine overhang of adaptor can enhance ligation efficiency. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 278

embodiments, adaptor ligation is performed using the ligation kit found in the AGILENT SURESELECT kit. In some embodiments, the library is amplified using universal primers. In an embodiment, the amplified library is fractionated by size separation or by using products such as AGENCOURT AMPURE beads or other similar methods. In some embodiments, PCR amplification is used to amplify target loci. In some embodiments, the amplified DNA is sequenced (such as sequencing using an ILLUMINA IIGAX or HiSeq sequencer). In some embodiments, the amplified DNA is sequenced from each end of the amplified DNA to reduce sequencing errors. If there is a sequence error in a particular base when sequencing from one end of the amplified DNA, there is less likely to be a sequence error in the complementary base when sequencing from the other side of the amplified DNA (compared to sequencing multiple times from the same end of the amplified DNA).

[0451] In some embodiments, whole genome application (WGA) is used to amplify a nucleic acid sample. There are a number of methods available for WGA: ligation-mediated PCR (LM-PCR), degenerate oligonucleotide primer PCR (DOP-PCR), and multiple displacement amplification (MDA). In LM-PCR, short DNA sequences called adapters are ligated to blunt ends of DNA. These adapters contain universal amplification sequences, which are used to amplify the DNA by PCR. In DOP-PCR, random primers that also contain universal amplification sequences are used in a first round of annealing and PCR. Then, a second round of PCR is used to amplify the sequences further with the universal primer sequences. MDA uses the phi-29 polymerase, which is a highly processive and non-specific enzyme that replicates DNA and has been used for single-cell analysis. In some embodiments, WGA is not performed.

[0452] In some embodiments, selective amplification or enrichment are used to amplify or enrich target loci. In some embodiments, the amplification and/or selective enrichment technique may involve PCR such as ligation mediated PCR, fragment capture by hybridization, Molecular Inversion Probes, or other circularizing probes. In some embodiments, real-time quantitative PCR (RT-qPCR), digital PCR, or emulsion PCR, single allele base extension reaction followed by mass spectrometry are used (Hung et al., J Clin Pathol 62:308–313, 2009, which is hereby incorporated by reference in its entirety). In some embodiments, capture by hybridization with hybrid capture probes is used to preferentially enrich the DNA. In some embodiments, methods for amplification or selective enrichment may involve using probes where, upon correct

hybridization to the target sequence, the 3-prime end or 5-prime end of a nucleotide probe is separated from the polymorphic site of a polymorphic allele by a small number of nucleotides. This separation reduces preferential amplification of one allele, termed allele bias. This is an improvement over methods that involve using probes where the 3-prime end or 5-prime end of a correctly hybridized probe are directly adjacent to or very near to the polymorphic site of an allele. In an embodiment, probes in which the hybridizing region may or certainly contains a polymorphic site are excluded. Polymorphic sites at the site of hybridization can cause unequal hybridization or inhibit hybridization altogether in some alleles, resulting in preferential amplification of certain alleles. These embodiments are improvements over other methods that involve targeted amplification and/or selective enrichment in that they better preserve the original allele frequencies of the sample at each polymorphic locus, whether the sample is pure genomic sample from a single individual or mixture of individuals

[0453] In some embodiments, PCR (referred to as mini-PCR) is used to generate very short amplicons (US Application No. 13/683,604, filed Nov. 21, 2012, U.S. Publication No. 2013/0123120, U.S. Application No. 13/300,235, filed Nov. 18, 2011, U.S. Publication No 2012/0270212, filed Nov. 18, 2011, and U.S. Serial No. 61/994,791, filed May 16, 2014, which are each hereby incorporated by reference in its entirety). cfDNA (such as fetal cfDNA in maternal serum or necroptically- or apoptotically-released cancer cfDNA) is highly fragmented. For fetal cfDNA, the fragment sizes are distributed in approximately a Gaussian fashion with a mean of 160 bp, a standard deviation of 15 bp, a minimum size of about 100 bp, and a maximum size of about 220 bp. The polymorphic site of one particular target locus may occupy any position from the start to the end among the various fragments originating from that locus. Because cfDNA fragments are short, the likelihood of both primer sites being present the likelihood of a fragment of length L comprising both the forward and reverse primers sites is the ratio of the length of the amplicon to the length of the fragment. Under ideal conditions, assays in which the amplicon is 45, 50, 55, 60, 65, or 70 bp will successfully amplify from 72%, 69%, 66%, 63%, 59%, or 56%, respectively, of available template fragment molecules. In certain embodiments that relate most preferably to cfDNA from samples of individuals suspected of having cancer, the cfDNA is amplified using primers that yield a maximum amplicon length of 85, 80, 75 or 70 bp, and in certain preferred embodiments 75 bp, and that have a melting temperature between 50 and 65°C, and in certain preferred embodiments, between 54–60.5°C. The amplicon length is the distance

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 280

between the 5-prime ends of the forward and reverse priming sites. Amplicon length that is shorter than typically used by those known in the art may result in more efficient measurements of the desired polymorphic loci by only requiring short sequence reads. In an embodiment, a substantial fraction of the amplicons are less than 100 bp, less than 90 bp, less than 80 bp, less than 70 bp, less than 65 bp, less than 60 bp, less than 55 bp, less than 50 bp, or less than 45 bp.

[0454] In some embodiments, amplification is performed using direct multiplexed PCR, sequential PCR, nested PCR, doubly nested PCR, one-and-a-half sided nested PCR, fully nested PCR, one sided fully nested PCR, one-sided nested PCR, hemi-nested PCR, hemi-nested PCR, triply hemi-nested PCR, semi-nested PCR, one sided semi-nested PCR, reverse semi-nested PCR method, or one-sided PCR, which are described in US Application No. 13/683,604, filed Nov. 21, 2012, U.S. Publication No. 2013/0123120, U.S. Application No. 13/300,235, filed Nov. 18, 2011, U.S. Publication No 2012/0270212, and U.S. Serial No. 61/994,791, filed May 16, 2014, which are hereby incorporated by reference in their entirety. If desired, any of these methods can be used for mini-PCR.

[0455] If desired, the extension step of the PCR amplification may be limited from a time standpoint to reduce amplification from fragments longer than 200 nucleotides, 300 nucleotides, 400 nucleotides, 500 nucleotides or 1,000 nucleotides. This may result in the enrichment of fragmented or shorter DNA (such as fetal DNA or DNA from cancer cells that have undergone apoptosis or necrosis) and improvement of test performance.

[0456] In some embodiments, multiplex PCR is used. In some embodiments, the method of amplifying target loci in a nucleic acid sample involves (i) contacting the nucleic acid sample with a library of primers that simultaneously hybridize to least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different target loci to produce a reaction mixture; and (ii) subjecting the reaction mixture to primer extension reaction conditions (such as PCR conditions) to produce amplified products that include target amplicons. In some embodiments, at least 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% of the targeted loci are amplified. In various embodiments, less than 60, 50, 40, 30, 20, 10, 5, 4, 3, 2, 1, 0.5, 0.25, 0.1, or 0.05% of the amplified products are primer dimers. In some embodiments, the primers are in solution (such as being dissolved in the liquid phase rather than in a solid phase). In some embodiments, the primers are in solution and are not immobilized on a solid support. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 281

embodiments, the primers are not part of a microarray. In some embodiments, the primers do not include molecular inversion probes (MIPs).

[0457] In some embodiments, two or more (such as 3 or 4) target amplicons (such as amplicons from the miniPCR method disclosed herein) are ligated together and then the ligated products are sequenced. Combining multiple amplicons into a single ligation product increases the efficiency of the subsequent sequencing step. In some embodiments, the target amplicons are less than 150, 100, 90, 75, or 50 base pairs in length before they are ligated. The selective enrichment and/or amplification may involve tagging each individual molecule with different tags, molecular barcodes, tags for amplification, and/or tags for sequencing. In some embodiments, the amplified products are analyzed by sequencing (such as by high throughput sequencing) or by hybridization to an array, such as a SNP array, the ILLUMINA INFINIUM array, or the AFFYMETRIX gene chip. In some embodiments, nanopore sequencing is used, such as the nanopore sequencing technology developed by Genia (see, for example, the world wide web at geniachip.com/technology, which is hereby incorporated by reference in its entirety). In some embodiments, duplex sequencing is used (Schmitt et al., "Detection of ultra-rare mutations by next-generation sequencing," Proc Natl Acad Sci U S A. 109(36): 14508–14513, 2012, which is hereby incorporated by reference in its entirety). This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors result in mutations in only one strand and can thus be discounted as technical error. In some embodiments, the method entails tagging both strands of duplex DNA with a random, yet complementary double-stranded nucleotide sequence, referred to as a Duplex Tag. Double-stranded tag sequences are incorporated into standard sequencing adapters by first introducing a single-stranded randomized nucleotide sequence into one adapter strand and then extending the opposite strand with a DNA polymerase to yield a complementary, double-stranded tag. Following ligation of tagged adapters to sheared DNA, the individually labeled strands are PCR amplified from asymmetric primer sites on the adapter tails and subjected to paired-end sequencing. In some embodiments, a sample (such as a DNA or RNA sample) is divided into multiple fractions, such as different wells (*e.g.*, wells of a WaferGen SmartChip). Dividing the sample into different fractions (such as at least 5, 10, 20, 50, 75, 100, 150, 200, or 300 fractions) can increase the sensitivity of the analysis since the percent of molecules with a

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 282

mutation are higher in some of the wells than in the overall sample. In some embodiments, each fraction has less than 500, 400, 200, 100, 50, 20, 10, 5, 2, or 1 DNA or RNA molecules. In some embodiments, the molecules in each fraction are sequenced separately. In some embodiments, the same barcode (such as a random or non-human sequence) is added to all the molecules in the same fraction (such as by amplification with a primer containing the barcode or by ligation of a barcode), and different barcodes are added to molecules in different fractions. The barcoded molecules can be pooled and sequenced together. In some embodiments, the molecules are amplified before they are pooled and sequenced, such as by using nested PCR. In some embodiments, one forward and two reverse primers, or two forward and one reverse primers are used.

[0458] In some embodiments, a mutation (such as an SNV or CNV) that is present in less than 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, or 0.005% of the DNA or RNA molecules in a sample (such as a sample of cfDNA or cfRNA) is detected (or is capable of being detected). In some embodiments, a mutation (such as an SNV or CNV) that is present in less than 1,000, 500, 100, 50, 20, 10, 5, 4, 3, or 2 original DNA or RNA molecules (before amplification) in a sample (such as a sample of cfDNA or cfRNA from, *e.g.,* a blood sample) is detected (or is capable of being detected). In some embodiments, a mutation (such as an SNV or CNV) that is present in only 1 original DNA or RNA molecule (before amplification) in a sample (such as a sample of cfDNA or cfRNA from, *e.g.,* a blood sample) is detected (or is capable of being detected).

[0459] For example, if the limit of detection of a mutation (such as a single nucleotide variant (SNV)) is 0.1%, a mutation present at 0.01% can be detected by dividing the fraction into multiple, fractions such as 100 wells. Most of the wells have no copies of the mutation. For the few wells with the mutation, the mutation is at a much higher percentage of the reads. In one example, there are 20,000 initial copies of DNA from the target locus, and two of those copies include a SNV of interest. If the sample is divided into 100 wells, 98 wells have the SNV, and 2 wells have the SNV at 0.5%. The DNA in each well can be barcoded, amplified, pooled with DNA from the other wells, and sequenced. Wells without the SNV can be used to measure the background amplification/sequencing error rate to determine if the signal from the outlier wells is above the background level of noise.

[0460] In some embodiments, the amplified products are detected using an array, such as an array especially a microarray with probes to one or more chromosomes of interest (*e.g.*, chromosome 13, 18, 21, X, Y, or any combination thereof). It will be understood for example, that a

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 283

commercially available SNP detection microarray could be used such as, for example, the Illumina (San Diego, CA) GoldenGate, DASL, Infinium, or CytoSNP-12 genotyping assay, or a SNP detection microarray product from Affymetrix, such as the OncoScan microarray. In some embodiments, phased genetic data for one or both biological parents of the embryo or fetus is used to increase the accuracy of analysis of array data from a single cell.

[0461] In some embodiments involving sequencing, the depth of read is the number of sequencing reads that map to a given locus. The depth of read may be normalized over the total number of reads. In some embodiments for depth of read of a sample, the depth of read is the average depth of read over the targeted loci. In some embodiments for the depth of read of a locus, the depth of read is the number of reads measured by the sequencer mapping to that locus. In general, the greater the depth of read of a locus, the closer the ratio of alleles at the locus tend to be to the ratio of alleles in the original sample of DNA. Depth of read can be expressed in variety of different ways, including but not limited to the percentage or proportion. Thus, for example in a highly parallel DNA sequencer such as an Illumina HISEQ, which, *e.g.*, produces a sequence of 1 million clones, the sequencing of one locus 3,000 times results in a depth of read of 3,000 reads at that locus. The proportion of reads at that locus is 3,000 divided by 1 million total reads, or 0.3% of the total reads.

[0462] In some embodiments, allelic data is obtained, wherein the allelic data includes quantitative measurement(s) indicative of the number of copies of a specific allele of a polymorphic locus. In some embodiments, the allelic data includes quantitative measurement(s) indicative of the number of copies of each of the alleles observed at a polymorphic locus. Typically, quantitative measurements are obtained for all possible alleles of the polymorphic locus of interest. For example, any of the methods discussed in the preceding paragraphs for determining the allele for a SNP or SNV locus, such as for example, microarrays, qPCR, DNA sequencing, such as high throughput DNA sequencing, can be used to generate quantitative measurements of the number of copies of a specific allele of a polymorphic locus. This quantitative measurement is referred to herein as allelic frequency data or measured genetic allelic data. Methods using allelic data are sometimes referred to as quantitative allelic methods; this is in contrast to quantitative methods which exclusively use quantitative data from non-polymorphic loci, or from polymorphic loci but without regard to allelic identity. When the allelic data is measured using high-throughput

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 284

sequencing, the allelic data typically include the number of reads of each allele mapping to the locus of interest.

[0463] In some embodiments, non-allelic data is obtained, wherein the non-allelic data includes quantitative measurement(s) indicative of the number of copies of a specific locus. The locus may be polymorphic or non-polymorphic. In some embodiments when the locus is non-polymorphic, the non-allelic data does not contain information about the relative or absolute quantity of the individual alleles that may be present at that locus. Methods using non-allelic data only (that is, quantitative data from non-polymorphic alleles, or quantitative data from polymorphic loci but without regard to the allelic identity of each fragment) are referred to as quantitative methods. Typically, quantitative measurements are obtained for all possible alleles of the polymorphic locus of interest, with one value associated with the measured quantity for all of the alleles at that locus, in total. Non-allelic data for a polymorphic locus may be obtained by summing the quantitative allelic for each allele at that locus. When the allelic data is measured using high-throughput sequencing, the non-allelic data typically includes the number of reads of mapping to the locus of interest. The sequencing measurements could indicate the relative and/or absolute number of each of the alleles present at the locus, and the non-allelic data includes the sum of the reads, regardless of the allelic identity, mapping to the locus. In some embodiments the same set of sequencing measurements can be used to yield both allelic data and non-allelic data. In some embodiments, the allelic data is used as part of a method to determine copy number at a chromosome of interest, and the produced non-allelic data can be used as part of a different method to determine copy number at a chromosome of interest. In some embodiments, the two methods are statistically orthogonal, and are combined to give a more accurate determination of the copy number at the chromosome of interest.

[0464] In some embodiments obtaining genetic data includes (i) acquiring DNA sequence information by laboratory techniques, *e.g.,* by the use of an automated high throughput DNA sequencer, or (ii) acquiring information that had been previously obtained by laboratory techniques, wherein the information is electronically transmitted, *e.g.*, by a computer over the internet or by electronic transfer from the sequencing device.

[0465] Additional exemplary sample preparation, amplification, and quantification methods are described in US Application No. 13/683,604, filed Nov. 21, 2012 (U.S. Publication No. 2013/0123120 and U.S. Serial No. 61/994,791, filed May 16, 2014, which is hereby incorporated

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 285

by reference in its entirety). These methods can be used for analysis of any of the samples disclosed herein.

Exemplary Quantification Methods for Cell-free DNA

[0466] If desired, that amount or concentration of cfDNA or cfRNA can be measured using standard methods. In some embodiments, the amount or concentration of cell-free mitochondrial DNA (cf mDNA) is determined. In some embodiments, the amount or concentration of cell-free DNA that originated from nuclear DNA (cf nDNA) is determined. In some embodiments, the amount or concentration of cf mDNA and cf nDNA are determined simultaneously.

[0467] In some embodiments, qPCR is used to measure cf nDNA and/or cfm DNA (Kohler *et al.* "Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors." Mol Cancer 8:105, 2009, 8:doi:10.1186/1476-4598-8-105, which is hereby incorporated by reference in its entirety). For example, one or more loci from cf nDNA (such as Glyceraldehyd-3-phosphat-dehydrogenase, *GAPDH*) and one or more loci from cf mDNA (ATPase 8, *MTATP 8*) can be measured using multiplex qPCR. In some embodiments, fluorescence-labelled PCR is used to measure cf nDNA and/or cf mDNA (Schwarzenbach *et al.*, "Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease." Mol Biosys 7:2848-2854, 2011, which is hereby incorporated by reference in its entirety). If desired, the normality distribution of the data can be determined using standard methods, such as the Shapiro-Wilk-Test. If desired, cf nDNA and mDNA levels can be compared using standard methods, such as the Mann-Whitney-U-Test. In some embodiments, cf nDNA and/or mDNA levels are compared with other established prognostic factors using standard methods, such as the Mann-Whitney-U-Test or the Kruskal-Wallis-Test.

Exemplary RNA Amplification, Quantification, and Analysis Methods

[0468] Any of the following exemplary methods may be used to amplify and optionally quantify RNA, such as such as cfRNA, cellular RNA, cytoplasmic RNA, coding cytoplasmic RNA, non-coding cytoplasmic RNA, mRNA, miRNA, mitochondrial RNA, rRNA, or tRNA. In some embodiments, the miRNA is any of the miRNA molecules listed in the miRBase database available

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 286

at the world wide web at mirbase.org, which is hereby incorporated by reference in its entirety. Exemplary miRNA molecules include miR-509; miR-21, and miR-146a.

[0469] In some embodiments, reverse-transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) is used to amplify RNA. In some embodiments, each set of hybridizing probes consists of two short synthetic oligonucleotides spanning the SNP and one long oligonucleotide (Li *et al*., Arch Gynecol Obstet. "Development of noninvasive prenatal diagnosis of trisomy 21 by RT-MLPA with a new set of SNP markers," July 5, 2013, DOI 10.1007/s00404-013-2926-5;. Schouten *et al*. "Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification." Nucleic Acids Res 30:e57, 2002; Deng et al. (2011) "Non-invasive prenatal diagnosis of trisomy 21 by reverse transcriptase multiplex ligation-dependent probe amplification," Clin, Chem. Lab Med. 49:641–646, 2011, which are each hereby incorporated by reference in its entirety).

[0470] In some embodiments, RNA is amplified with reverse-transcriptase PCR. In some embodiments, RNA is amplified with real-time reverse-transcriptase PCR, such as one-step real-time reverse-transcriptase PCR with SYBR GREEN I as previously described (Li *et al*., Arch Gynecol Obstet. "Development of noninvasive prenatal diagnosis of trisomy 21 by RT-MLPA with a new set of SNP markers," July 5, 2013, DOI 10.1007/s00404-013-2926-5; Lo et al., "Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection," Nat Med 13:218–223, 2007; Tsui et al., Systematic micro-array based identification of placental mRNA in maternal plasma: towards non-invasive prenatal gene expression profiling. J Med Genet 41:461–467, 2004; Gu *et al*., J. Neurochem. 122:641–649, 2012, which are each hereby incorporated by reference in its entirety).

[0471] In some embodiments, a microarray is used to detect RNA. For example, a human miRNA microarray from Agilent Technologies can be used according to the manufacturer's protocol. Briefly, isolated RNA is dephosphorylated and ligated with pCp-Cy3. Labeled RNA is purified and hybridized to miRNA arrays containing probes for human mature miRNAs on the basis of Sanger miRBase release 14.0. The arrays is washed and scanned with use of a microarray scanner (G2565BA, Agilent Technologies). The intensity of each hybridization signal is evaluated by Agilent extraction software v9.5.3. The labeling, hybridization, and scanning may be performed according to the protocols in the Agilent miRNA microarray system (Gu *et al*., J. Neurochem. 122:641–649, 2012, which is hereby incorporated by reference in its entirety).

[0472] In some embodiments, a TaqMan assay is used to detect RNA. An exemplary assay is the TaqMan Array Human MicroRNA Panel v1.0 (Early Access) (Applied Biosystems), which contains 157 TaqMan MicroRNA Assays, including the respective reverse-transcription primers, PCR primers, and TaqMan probe (Chim et al., "Detection and characterization of placental microRNAs in maternal plasma," Clin Chem. 54(3):482-90, 2008, which is hereby incorporated by reference in its entirety).

[0473] If desired, the mRNA splicing pattern of one or more mRNAs can be determined using standard methods (Fackenthal1 and Godley, Disease Models & Mechanisms 1: 37-42, 2008, doi:10.1242/dmm.000331, which is hereby incorporated by reference in its entirety). For example, high-density microarrays and/or high-throughput DNA sequencing can be used to detect mRNA splice variants.

[0474] In some embodiments, whole transcriptome shotgun sequencing or an array is used to measure the transcriptome.

Exemplary Amplification Methods

[0475] Improved PCR amplification methods have also been developed that minimize or prevent interference due to the amplification of nearby or adjacent target loci in the same reaction volume (such as part of the sample multiplex PCR reaction that simultaneously amplifies all the target loci). These methods can be used to simultaneously amplify nearby or adjacent target loci, which is faster and cheaper than having to separate nearby target loci into different reaction volumes so that they can be amplified separately to avoid interference.

[0476] In some embodiments, the amplification of target loci is performed using a polymerase (*e.g.*, a DNA polymerase, RNA polymerase, or reverse transcriptase) with low 5′→ 3′ exonuclease and/or low strand displacement activity. In some embodiments, the low level of 5′→ 3′ exonuclease reduces or prevents the degradation of a nearby primer (*e.g.*, an unextended primer or a primer that has had one or more nucleotides added to during primer extension). In some embodiments, the low level of strand displacement activity reduces or prevents the displacement of a nearby primer (*e.g.*, an unextended primer or a primer that has had one or more nucleotides added to it during primer extension). In some embodiments, target loci that are adjacent to each other (*e.g.*, no bases between the target loci) or nearby (*e.g.*, loci are within 50, 40, 30, 20, 15, 10,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 288

9, 8, 7, 6, 5, 4, 3, 2, or 1 base) are amplified. In some embodiments, the 3′ end of one locus is within 50, 40, 30, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 base of the 5′ end of next downstream locus.

[0477] In some embodiments, at least 100, 200, 500, 750, 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different target loci are amplified, such as by the simultaneous amplification in one reaction volume. In some embodiments, at least 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% of the amplified products are target amplicons. In various embodiments, the amount of amplified products that are target amplicons is between 50 to 99.5%, such as between 60 to 99%, 70 to 98%, 80 to 98%, 90 to 99.5%, or 95 to 99.5%, inclusive. In some embodiments, at least 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% of the targeted loci are amplified (*e.g.*, amplified at least 5, 10, 20, 30, 50, or 100-fold compared to the amount prior to amplification), such as by the simultaneous amplification in one reaction volume. In various embodiments, the amount target loci that are amplified (*e.g.*, amplified at least 5, 10, 20, 30, 50, or 100-fold compared to the amount prior to amplification) is between 50 to 99.5%, such as between 60 to 99%, 70 to 98%, 80 to 99%, 90 to 99.5%, 95 to 99.9%, or 98 to 99.99% inclusive. In some embodiments, fewer non-target amplicons are produced, such as fewer amplicons formed from a forward primer from a first primer pair and a reverse primer from a second primer pair. Such undesired non-target amplicons can be produced using prior amplification methods if, *e.g.*, the reverse primer from the first primer pair and/or the forward primer from the second primer pair are degraded and/or displaced.

[0478] In some embodiments, these methods allows longer extension times to be used since the polymerase bound to a primer being extended is less likely to degrade and/or displace a nearby primer (such as the next downstream primer) given the low $5' \rightarrow 3'$ exonuclease and/or low strand displacement activity of the polymerase. In various embodiments, reaction conditions (such as the extension time and temperature) are used such that the extension rate of the polymerase allows the number of nucleotides that are added to a primer being extended to be equal to or greater than 80, 90, 95, 100, 110, 120, 130, 140, 150, 175, or 200% of the number of nucleotides between the 3' end of the primer binding site and the 5'end of the next downstream primer binding site on the same strand.

[0479] In some embodiments, a DNA polymerase is used produce DNA amplicons using DNA as a template. In some embodiments, a RNA polymerase is used produce RNA amplicons using

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 289

DNA as a template. In some embodiments, a reverse transcriptase is used produce cDNA amplicons using RNA as a template.

[0480] In some embodiments, the low level of 5′→ 3′ exonuclease of the polymerase is less than 80, 70, 60, 50, 40, 30, 20, 10, 5, 1, or 0.1% of the activity of the same amount of *Thermus aquaticus* polymerase ("Taq" polymerase, which is a commonly used DNA polymerase from a thermophilic bacterium, PDB 1BGX, EC 2.7.7.7, Murali *et al*., "Crystal structure of Taq DNA polymerase in complex with an inhibitory Fab: the Fab is directed against an intermediate in the helix-coil dynamics of the enzyme," Proc. Natl. Acad. Sci. USA 95:12562-12567, 1998, which is hereby incorporated by reference in its entirety) under the same conditions. In some embodiments, the low level of strand displacement activity of the polymerase is less than 80, 70, 60, 50, 40, 30, 20, 10, 5, 1, or 0.1% of the activity of the same amount of Taq polymerase under the same conditions.

[0481] In some embodiments, the polymerase is a PUSHION DNA polymerase, such as PHUSION High Fidelity DNA polymerase (M0530S, New England BioLabs, Inc.) or PHUSION Hot Start Flex DNA polymerase (M0535S, New England BioLabs, Inc.; Frey and Suppman *BioChemica*. 2:34-35, 1995; Chester and Marshak *Analytical Biochemistry*. 209:284-290, 1993, which are each hereby incorporated by reference in its entirety). The PHUSION DNA polymerase is a *Pyrococcus*-like enzyme fused with a processivity-enhancing domain. PHUSION DNA polymerase possesses 5′→ 3′ polymerase activity and 3′→ 5′ exonuclease activity, and generates blunt-ended products. PHUSION DNA polymerase lacks 5′→ 3′ exonuclease activity and strand displacement activity.

[0482] In some embodiments, the polymerase is a Q5® DNA Polymerase, such as Q5® High-Fidelity DNA Polymerase (M0491S, New England BioLabs, Inc.) or Q5® Hot Start High-Fidelity DNA Polymerase (M0493S, New England BioLabs, Inc.). Q5® High-Fidelity DNA polymerase is a high-fidelity, thermostable, DNA polymerase with 3′→ 5′ exonuclease activity, fused to a processivity-enhancing Sso7d domain. Q5® High-Fidelity DNA polymerase lacks 5′→ 3′ exonuclease activity and strand displacement activity.

[0483] In some embodiments, the polymerase is a T4 DNA polymerase (M0203S, New England BioLabs, Inc.; Tabor and Struh. (1989). "DNA-Dependent DNA Polymerases," In Ausebel et al. (Ed.), *Current Protocols in Molecular Biology*. 3.5.10-3.5.12. New York: John Wiley & Sons, Inc., 1989; Sambrook et al. *Molecular Cloning: A Laboratory Manual*. (2nd ed.), 5.44-5.47. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989, which are each hereby incorporated

by reference in its entirety). T4 DNA Polymerase catalyzes the synthesis of DNA in the 5′→ 3′ direction and requires the presence of template and primer. This enzyme has a 3′→ 5′ exonuclease activity which is much more active than that found in DNA Polymerase I. T4 DNA polymerase lacks 5′→ 3′ exonuclease activity and strand displacement activity.

[0484] In some embodiments, the polymerase is a *Sulfolobus* DNA Polymerase IV (M0327S, New England BioLabs, Inc.; (Boudsocq, *et al.* (2001). *Nucleic Acids Res.*, 29:4607-4616, 2001; McDonald, *et al.* (2006). *Nucleic Acids Res.*, 34:1102-1111, 2006, which are each hereby incorporated by reference in its entirety). *Sulfolobus* DNA Polymerase IV is a thermostable Y-family lesion-bypass DNA Polymerase that efficiently synthesizes DNA across a variety of DNA template lesions McDonald, J.P. et al. (2006). *Nucleic Acids Res.*, 34, 1102-1111, which is hereby incorporated by reference in its entirety). *Sulfolobus* DNA Polymerase IV lacks 5′→ 3′ exonuclease activity and strand displacement activity.

[0485] In some embodiments, if a primer binds a region with a SNP, the primer may bind and amplify the different alleles with different efficiencies or may only bind and amplify one allele. For subjects who are heterozygous, one of the alleles may not be amplified by the primer. In some embodiments, a primer is designed for each allele. For example, if there are two alleles (*e.g.*, a biallelic SNP), then two primers can be used to bind the same location of a target locus (*e.g.*, a forward primer to bind the "A" allele and a forward primer to bind the "B" allele). Standard methods, such as the dbSNP database, can be used to determine the location of known SNPs, such as SNP hot spots that have a high heterozygosity rate.

[0486] In some embodiments, the amplicons are similar in size. In some embodiments, the range of the length of the target amplicons is less than 100, 75, 50, 25, 15, 10, or 5 nucleotides. In some embodiments (such as the amplification of target loci in fragmented DNA or RNA), the length of the target amplicons is between 50 and 100 nucleotides, such as between 60 and 80 nucleotides, or 60 and 75 nucleotides, inclusive. In some embodiments (such as the amplification of multiple target loci throughout an exon or gene), the length of the target amplicons is between 100 and 500 nucleotides, such as between 150 and 450 nucleotides, 200 and 400 nucleotides, 200 and 300 nucleotides, or 300 and 400 nucleotides, inclusive.

[0487] In some embodiments, multiple target loci are simultaneously amplified using a primer pair that includes a forward and reverse primer for each target locus to be amplified in that reaction volume. In some embodiments, one round of PCR is performed with a single primer per target

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 291

locus, and then a second round of PCR is performed with a primer pair per target locus. For example, the first round of PCR may be performed with a single primer per target locus such that all the primers bind the same strand (such as using a forward primer for each target locus). This allows the PCR to amplify in a linear manner and reduces or eliminates amplification bias between amplicons due to sequence or length differences. In some embodiments, the amplicons are then amplified using a forward and reverse primer for each target locus.

Exemplary Primer Design Methods

[0488] If desired, multiplex PCR may be performed using primers with a decreased likelihood of forming primer dimers. In particular, highly multiplexed PCR can often result in the production of a very high proportion of product DNA that results from unproductive side reactions such as primer dimer formation. In an embodiment, the particular primers that are most likely to cause unproductive side reactions may be removed from the primer library to give a primer library that will result in a greater proportion of amplified DNA that maps to the genome. The step of removing problematic primers, that is, those primers that are particularly likely to firm dimers has unexpectedly enabled extremely high PCR multiplexing levels for subsequent analysis by sequencing.

[0489] There are a number of ways to choose primers for a library where the amount of non-mapping primer dimer or other primer mischief products are minimized. Empirical data indicate that a small number of 'bad' primers are responsible for a large amount of non-mapping primer dimer side reactions. Removing these 'bad' primers can increase the percent of sequence reads that map to targeted loci. One way to identify the 'bad' primers is to look at the sequencing data of DNA that was amplified by targeted amplification; those primer dimers that are seen with greatest frequency can be removed to give a primer library that is significantly less likely to result in side product DNA that does not map to the genome. There are also publicly available programs that can calculate the binding energy of various primer combinations, and removing those with the highest binding energy will also give a primer library that is significantly less likely to result in side product DNA that does not map to the genome.

[0490] In some embodiments for selecting primers, an initial library of candidate primers is created by designing one or more primers or primer pairs to candidate target loci. A set of candidate target loci (such as SNPs) can selected based on publicly available information about

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 292

desired parameters for the target loci, such as frequency of the SNPs within a target population or the heterozygosity rate of the SNPs. In one embodiment, the PCR primers may be designed using the Primer3 program (the worldwide web at primer3.sourceforge.net; libprimer3 release 2.2.3, which is hereby incorporated by reference in its entirety). If desired, the primers can be designed to anneal within a particular annealing temperature range, have a particular range of GC contents, have a particular size range, produce target amplicons in a particular size range, and/or have other parameter characteristics. Starting with multiple primers or primer pairs per candidate target locus increases the likelihood that a primer or prime pair will remain in the library for most or all of the target loci. In one embodiment, the selection criteria may require that at least one primer pair per target locus remains in the library. That way, most or all of the target loci will be amplified when using the final primer library. This is desirable for applications such as screening for deletions or duplications at a large number of locations in the genome or screening for a large number of sequences (such as polymorphisms or other mutations) associated with a disease or an increased risk for a disease. If a primer pair from the library would produces a target amplicon that overlaps with a target amplicon produced by another primer pair, one of the primer pairs may be removed from the library to prevent interference.

[0491] In some embodiments, an "undesirability score" (higher score representing least desirability) is calculated (such as calculation on a computer) for most or all of the possible combinations of two primers from a library of candidate primers. In various embodiments, an undesirability score is calculated for at least 80, 90, 95, 98, 99, or 99.5% of the possible combinations of candidate primers in the library. Each undesirability score is based at least in part on the likelihood of dimer formation between the two candidate primers. If desired, the undesirability score may also be based on one or more other parameters selected from the group consisting of heterozygosity rate of the target locus, disease prevalence associated with a sequence (*e.g.*, a polymorphism) at the target locus, disease penetrance associated with a sequence (*e.g.*, a polymorphism) at the target locus, specificity of the candidate primer for the target locus, size of the candidate primer, melting temperature of the target amplicon, GC content of the target amplicon, amplification efficiency of the target amplicon, size of the target amplicon, and distance from the center of a recombination hotspot. In some embodiments, the specificity of the candidate primer for the target locus includes the likelihood that the candidate primer will mis-prime by binding and amplifying a locus other than the target locus it was designed to amplify. In some

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 293

embodiments, one or more or all the candidate primers that mis-prime are removed from the library. In some embodiments to increase the number of candidate primers to choose from, candidate primers that may mis-prime are not removed from the library. If multiple factors are considered, the undesirability score may be calculated based on a weighted average of the various parameters. The parameters may be assigned different weights based on their importance for the particular application that the primers will be used for. In some embodiments, the primer with the highest undesirability score is removed from the library. If the removed primer is a member of a primer pair that hybridizes to one target locus, then the other member of the primer pair may be removed from the library. The process of removing primers may be repeated as desired. In some embodiments, the selection method is performed until the undesirability scores for the candidate primer combinations remaining in the library are all equal to or below a minimum threshold. In some embodiments, the selection method is performed until the number of candidate primers remaining in the library is reduced to a desired number.

[0492] In various embodiments, after the undesirability scores are calculated, the candidate primer that is part of the greatest number of combinations of two candidate primers with an undesirability score above a first minimum threshold is removed from the library. This step ignores interactions equal to or below the first minimum threshold since these interactions are less significant. If the removed primer is a member of a primer pair that hybridizes to one target locus, then the other member of the primer pair may be removed from the library. The process of removing primers may be repeated as desired. In some embodiments, the selection method is performed until the undesirability scores for the candidate primer combinations remaining in the library are all equal to or below the first minimum threshold. If the number of candidate primers remaining in the library is higher than desired, the number of primers may be reduced by decreasing the first minimum threshold to a lower second minimum threshold and repeating the process of removing primers. If the number of candidate primers remaining in the library is lower than desired, the method can be continued by increasing the first minimum threshold to a higher second minimum threshold and repeating the process of removing primers using the original candidate primer library, thereby allowing more of the candidate primers to remain in the library. In some embodiments, the selection method is performed until the undesirability scores for the candidate primer combinations remaining in the library are all equal to or below the second

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 294

minimum threshold, or until the number of candidate primers remaining in the library is reduced to a desired number. ,

[0493] If desired, primer pairs that produce a target amplicon that overlaps with a target amplicon produced by another primer pair can be divided into separate amplification reactions. Multiple PCR amplification reactions may be desirable for applications in which it is desirable to analyze all of the candidate target loci (instead of omitting candidate target loci from the analysis due to overlapping target amplicons).

[0494] These selection methods minimize the number of candidate primers that have to be removed from the library to achieve the desired reduction in primer dimers. By removing a smaller number of candidate primers from the library, more (or all) of the target loci can be amplified using the resulting primer library.

[0495] Multiplexing large numbers of primers imposes considerable constraint on the assays that can be included. Assays that unintentionally interact result in spurious amplification products. The size constraints of miniPCR may result in further constraints. In an embodiment, it is possible to begin with a very large number of potential SNP targets (between about 500 to greater than 1 million) and attempt to design primers to amplify each SNP. Where primers can be designed it is possible to attempt to identify primer pairs likely to form spurious products by evaluating the likelihood of spurious primer duplex formation between all possible pairs of primers using published thermodynamic parameters for DNA duplex formation. Primer interactions may be ranked by a scoring function related to the interaction and primers with the worst interaction scores are eliminated until the number of primers desired is met. In cases where SNPs likely to be heterozygous are most useful, it is possible to also rank the list of assays and select the most heterozygous compatible assays. Experiments have validated that primers with high interaction scores are most likely to form primer dimers. At high multiplexing it is not possible to eliminate all spurious interactions, but it is essential to remove the primers or pairs of primers with the highest interaction scores *in silico* as they can dominate an entire reaction, greatly limiting amplification from intended targets. We have performed this procedure to create multiplex primer sets of up to and in some cases more than 10,000 primers. The improvement due to this procedure is substantial, enabling amplification of more than 80%, more than 90%, more than 95%, more than 98%, and even more than 99% on target products as determined by sequencing of all PCR products, as compared to 10% from a reaction in which the worst primers were not removed. When

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 295

combined with a partial semi-nested approach as previously described, more than 90%, and even more than 95% of amplicons may map to the targeted sequences.

[0496] Note that there are other methods for determining which PCR probes are likely to form dimers. In an embodiment, analysis of a pool of DNA that has been amplified using a non-optimized set of primers may be sufficient to determine problematic primers. For example, analysis may be done using sequencing, and those dimers which are present in the greatest number are determined to be those most likely to form dimers, and may be removed. In an embodiment, the method of primer design may be used in combination with the mini-PCR method described herein.

[0497] The use of tags on the primers may reduce amplification and sequencing of primer dimer products. In some embodiments, the primer contains an internal region that forms a loop structure with a tag. In particular embodiments, the primers include a 5' region that is specific for a target locus, an internal region that is not specific for the target locus and forms a loop structure, and a 3' region that is specific for the target locus. In some embodiments, the loop region may lie between two binding regions where the two binding regions are designed to bind to contiguous or neighboring regions of template DNA. In various embodiments, the length of the 3' region is at least 7 nucleotides. In some embodiments, the length of the 3' region is between 7 and 20 nucleotides, such as between 7 to 15 nucleotides, or 7 to 10 nucleotides, inclusive. In various embodiments, the primers include a 5' region that is not specific for a target locus (such as a tag or a universal primer binding site) followed by a region that is specific for a target locus, an internal region that is not specific for the target locus and forms a loop structure, and a 3' region that is specific for the target locus. Tag-primers can be used to shorten necessary target-specific sequences to below 20, below 15, below 12, and even below 10 base pairs. This can be serendipitous with standard primer design when the target sequence is fragmented within the primer binding site or, or it can be designed into the primer design. Advantages of this method include: it increases the number of assays that can be designed for a certain maximal amplicon length, and it shortens the "non-informative" sequencing of primer sequence. It may also be used in combination with internal tagging.

[0498] In an embodiment, the relative amount of nonproductive products in the multiplexed targeted PCR amplification can be reduced by raising the annealing temperature. In cases where one is amplifying libraries with the same tag as the target specific primers, the annealing temperature can be increased in comparison to the genomic DNA as the tags will contribute to the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 296

primer binding. In some embodiments reduced primer concentrations are used, optionally along with longer annealing times. In some embodiments the annealing times may be longer than 3 minutes, longer than 5 minutes, longer than 8 minutes, longer than 10 minutes, longer than 15 minutes, longer than 20 minutes, longer than 30 minutes, longer than 60 minutes, longer than 120 minutes, longer than 240 minutes, longer than 480 minutes, and even longer than 960 minutes. In certain illustrative embodiments, longer annealing times are used along with reduced primer concentrations. In various embodiments, longer than normal extension times are used, such as greater than 3, 5, 8, 10, or 15 minutes. In some embodiments, the primer concentrations are as low as 50 nM, 20 nM, 10 nM, 5 nM, 1 nM, and lower than 1 nM. This surprisingly results in robust performance for highly multiplexed reactions, for example 1,000-plex reactions, 2,000-plex reactions, 5,000-plex reactions, 10,000-plex reactions, 20,000-plex reactions, 50,000-plex reactions, and even 100,000-plex reactions. In an embodiment, the amplification uses one, two, three, four or five cycles run with long annealing times, followed by PCR cycles with more usual annealing times with tagged primers.

[0499] To select target locations, one may start with a pool of candidate primer pair designs and create a thermodynamic model of potentially adverse interactions between primer pairs, and then use the model to eliminate designs that are incompatible with other the designs in the pool.

[0500] In an embodiment, the invention features a method of decreasing the number of target loci (such as loci that may contain a polymorphism or mutation associated with a disease or disorder or an increased risk for a disease or disorder such as cancer) and/or increasing the disease load that is detected (*e.g.*, increasing the number of polymorphisms or mutations that are detected). In some embodiments, the method includes ranking (such as ranking from highest to lowest) loci by frequency or reoccurrence of a polymorphism or mutation (such as a single nucleotide variation, insertion, or deletion, or any of the other variations described herein) in each locus among subjects with the disease or disorder such as cancer. In some embodiments, PCR primers are designed to some or all of the loci. During selection of PCR primers for a library of primers, primers to loci that have a higher frequency or reoccurrence (higher ranking loci) are favored over those with a lower frequency or reoccurrence (lower ranking loci). In some embodiments, this parameter is included as one of the parameters in the calculation of the undesirability scores described herein. If desired, primers (such as primers to high ranking loci) that are incompatible with other designs in the library can be included in a different PCR library/pool. In some embodiments, multiple

libraries/pools (such as 2, 3, 4, 5 or more) are used in separate PCR reactions to enable amplification of all (or a majority) of the loci represented by all the libraries/pools. In some embodiment, this method is continued until sufficient primers are included in one or more libraries/pools such that the primers, in aggregate, enable the desired disease load to be captured for the disease or disorder (*e.g.*, such as by detection of at least 80, 85, 90, 95, or 99% of the disease load).

Exemplary Primer Libraries

[0501] In one aspect, the invention features libraries of primers, such as primers selected from a library of candidate primers using any of the methods of the invention. In some embodiments, the library includes primers that simultaneously hybridize (or are capable of simultaneously hybridizing) to or that simultaneously amplify (or are capable of simultaneously amplifying) at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different target loci in one reaction volume. In various embodiments, the library includes primers that simultaneously amplify (or are capable of simultaneously amplifying) between 100 to 500; 500 to 1,000; 1,000 to 2,000; 2,000 to 5,000; 5,000 to 7,500; 7,500 to 10,000; 10,000 to 20,000; 20,000 to 25,000; 25,000 to 30,000; 30,000 to 40,000; 40,000 to 50,000; 50,000 to 75,000; or 75,000 to 100,000 different target loci in one reaction volume, inclusive. In various embodiments, the library includes primers that simultaneously amplify (or are capable of simultaneously amplifying) between 1,000 to 100,000 different target loci in one reaction volume, such as between 1,000 to 50,000; 1,000 to 30,000; 1,000 to 20,000; 1,000 to 10,000; 2,000 to 30,000; 2,000 to 20,000; 2,000 to 10,000; 5,000 to 30,000; 5,000 to 20,000; or 5,000 to 10,000 different target loci, inclusive. In some embodiments, the library includes primers that simultaneously amplify (or are capable of simultaneously amplifying) the target loci in one reaction volume such that less than 60, 40, 30, 20, 10, 5, 4, 3, 2, 1, 0.5, 0.25, 0.1, or 0.5% of the amplified products are primer dimers. The various embodiments, the amount of amplified products that are primer dimers is between 0.5 to 60%, such as between 0.1 to 40%, 0.1 to 20%, 0.25 to 20%, 0.25 to 10%, 0.5 to 20%, 0.5 to 10%, 1 to 20%, or 1 to 10%, inclusive. In some embodiments, the primers simultaneously amplify (or are capable of simultaneously amplifying) the target loci in one reaction volume such that at least 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% of the amplified products are target amplicons. In various embodiments, the amount of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 298

amplified products that are target amplicons is between 50 to 99.5%, such as between 60 to 99%, 70 to 98%, 80 to 98%, 90 to 99.5%, or 95 to 99.5%, inclusive. In some embodiments, the primers simultaneously amplify (or are capable of simultaneously amplifying) the target loci in one reaction volume such that at least 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% of the targeted loci are amplified (*e.g.*, amplified at least 5, 10, 20, 30, 50, or 100-fold compared to the amount prior to amplification). In various embodiments, the amount target loci that are amplified (*e.g.*, amplified at least 5, 10, 20, 30, 50, or 100-fold compared to the amount prior to amplification) is between 50 to 99.5%, such as between 60 to 99%, 70 to 98%, 80 to 99%, 90 to 99.5%, 95 to 99.9%, or 98 to 99.99% inclusive. In some embodiments, the library of primers includes at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 primer pairs, wherein each pair of primers includes a forward test primer and a reverse test primer where each pair of test primers hybridize to a target locus. In some embodiments, the library of primers includes at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 individual primers that each hybridize to a different target locus, wherein the individual primers are not part of primer pairs.

[0502] In various embodiments, the concentration of each primer is less than 100, 75, 50, 25, 20, 10, 5, 2, or 1 nM, or less than 500, 100, 10, or 1 uM. In various embodiments, the concentration of each primer is between 1 uM to 100 nM, such as between 1 uM to 1 nM, 1 to 75 nM, 2 to 50 nM or 5 to 50 nM, inclusive. In various embodiments, the GC content of the primers is between 30 to 80%, such as between 40 to 70%, or 50 to 60%, inclusive. In some embodiments, the range of GC content of the primers is less than 30, 20, 10, or 5%. In some embodiments, the range of GC content of the primers is between 5 to 30%, such as 5 to 20% or 5 to 10%, inclusive. In some embodiments, the melting temperature (T_m) of the test primers is between 40 to 80 °C, such as 50 to 70 °C, 55 to 65 °C, or 57 to 60.5 °C, inclusive. In some embodiments, the T_m is calculated using the Primer3 program (libprimer3 release 2.2.3) using the built-in SantaLucia parameters (the world wide web at primer3.sourceforge.net). In some embodiments, the range of melting temperature of the primers is less than 15, 10, 5, 3, or 1 °C. In some embodiments, the range of melting temperature of the primers is between 1 to 15 °C, such as between 1 to 10 °C, 1 to 5 °C, or 1 to 3 °C, inclusive. In some embodiments, the length of the primers is between 15 to 100 nucleotides, such as between 15 to 75 nucleotides, 15 to 40 nucleotides, 17 to 35 nucleotides, 18 to 30 nucleotides, or 20 to 65 nucleotides, inclusive. In some embodiments, the range of the length of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 299

the primers is less than 50, 40, 30, 20, 10, or 5 nucleotides. In some embodiments, the range of the length of the primers is between 5 to 50 nucleotides, such as 5 to 40 nucleotides, 5 to 20 nucleotides, or 5 to 10 nucleotides, inclusive. In some embodiments, the length of the target amplicons is between 50 and 100 nucleotides, such as between 60 and 80 nucleotides, or 60 to 75 nucleotides, inclusive. In some embodiments, the range of the length of the target amplicons is less than 50, 25, 15, 10, or 5 nucleotides. In some embodiments, the range of the length of the target amplicons is between 5 to 50 nucleotides, such as 5 to 25 nucleotides, 5 to 15 nucleotides, or 5 to 10 nucleotides, inclusive. In some embodiments, the library does not comprise a microarray. In some embodiments, the library comprises a microarray.

[0503] In some embodiments, some (such as at least 80, 90, or 95%) or all of the adaptors or primers include one or more linkages between adjacent nucleotides other than a naturally-occurring phosphodiester linkage. Examples of such linkages include phosphoramide, phosphorothioate, and phosphorodithioate linkages. In some embodiments, some (such as at least 80, 90, or 95%) or all of the adaptors or primers include a thiophosphate (such as a monothiophosphate) between the last 3' nucleotide and the second to last 3' nucleotide. In some embodiments, some (such as at least 80, 90, or 95%) or all of the adaptors or primers include a thiophosphate (such as a monothiophosphate) between the last 2, 3, 4, or 5 nucleotides at the 3' end. In some embodiments, some (such as at least 80, 90, or 95%) or all of the adaptors or primers include a thiophosphate (such as a monothiophosphate) between at least 1, 2, 3, 4, or 5 nucleotides out of the last 10 nucleotides at the 3' end. In some embodiments, such primers are less likely to be cleaved or degraded. In some embodiments, the primers do not contain an enzyme cleavage site (such as a protease cleavage site).

[0504] Additional exemplary multiplex PCR methods and libraries are described in US Application No. 13/683,604, filed Nov. 21, 2012 (U.S. Publication No. 2013/0123120) and U.S. Serial No. 61/994,791, filed May 16, 2014, which are each hereby incorporated by reference in its entirety). These methods and libraries can be used for analysis of any of the samples disclosed herein and for use in any of the methods of the invention.

Exemplary Primer Libraries for Detection of Recombination

[0505] In some embodiments, primers in the primer library are designed to determine whether or not recombination occurred at one or more known recombination hotspots (such as crossovers

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 300

between homologous human chromosomes). Knowing what crossovers occurred between chromosomes allows more accurate phased genetic data to be determined for an individual. Recombination hotspots are local regions of chromosomes in which recombination events tend to be concentrated. Often they are flanked by "coldspots," regions of lower than average frequency of recombination. Recombination hotspots tend to share a similar morphology and are approximately 1 to 2 kb in length. The hotspot distribution is positively correlated with GC content and repetitive element distribution. A partially degenerated 13-mer motif CCNCCNTNNCCNC plays a role in some hotspot activity. It has been shown that the zinc finger protein called PRDM9 binds to this motif and initiates recombination at its location. The average distance between the centers of recombination hot spots is reported to be ~80 kb. In some embodiments, the distance between the centers of recombination hot spots ranges between ~3 kb to ~100 kb. Public databases include a large number of known human recombination hotspots, such as the HUMHOT and International HapMap Project databases (see, for example, Nishant *et al.*, "HUMHOT: a database of human meiotic recombination hot spots," Nucleic Acids Research, 34: D25–D28, 2006, Database issue; Mackiewicz *et al.*, "Distribution of Recombination Hotspots in the Human Genome – A Comparison of Computer Simulations with Real Data" PLoS ONE 8(6): e65272, doi:10.1371/journal.pone.0065272; and the world wide web at hapmap.ncbi.nlm.nih.gov/downloads/index.html.en, which are each hereby incorporated by reference in its entirety).

[0506] In some embodiments, primers in the primer library are clustered at or near recombination hotspots (such as known human recombination hotspots). In some embodiments, the corresponding amplicons are used to determine the sequence within or near a recombination hotspot to determine whether or not recombination occurred at that particular hotspot (such as whether the sequence of the amplicon is the sequence expected if a recombination had occurred or the sequence expected if a recombination had not occurred). In some embodiments, primers are designed to amplify part or all of a recombination hotspot (and optionally sequence flanking a recombination hotspot). In some embodiments, long read sequencing (such as sequencing using the Moleculo Technology developed by Illumina to sequence up to ~10 kb) or paired end sequencing is used to sequence part or all of a recombination hotspot. Knowledge of whether or not a recombination event occurred can be used to determine which haplotype blocks flank the hotspot. If desired, the presence of particular haplotype blocks can be confirmed using primers

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 301

specific to regions within the haplotype blocks. In some embodiments, it is assumed there are no crossovers between known recombination hotspots. In some embodiments, primers in the primer library are clustered at or near the ends of chromosomes. For example, such primers can be used to determine whether or not a particular arm or section at the end of a chromosome is present. In some embodiments, primers in the primer library are clustered at or near recombination hotspots and at or near the ends of chromosomes.

[0507] In some embodiments, the primer library includes one or more primers (such as at least 5; 10; 50; 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; or 50,000 different primers or different primer pairs) that are specific for a recombination hotspot (such as a known human recombination hotspot) and/or are specific for a region near a recombination hotspot (such as within 10, 8, 5, 3, 2, 1, or 0.5 kb of the 5' or 3' end of a recombination hotspot). In some embodiments, at least 1, 5, 10, 20, 40, 60, 80, 100, or 150 different primer (or primer pairs) are specific for the same recombination hotspot, or are specific for the same recombination hotspot or a region near the recombination hotspot. In some embodiments, at least 1, 5, 10, 20, 40, 60, 80, 100, or 150 different primer (or primer pairs) are specific for a region between recombination hotspots (such as a region unlikely to have undergone recombination); these primers can be used to confirm the presence of haplotype blocks (such as those that would be expected depending on whether or not recombination has occurred). In some embodiments, at least 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the primers in the primer library are specific for a recombination hotspot and/or are specific for a region near a recombination hotspot (such as within 10, 8, 5, 3, 2, 1, or 0.5 kb of the 5' or 3' end of the recombination hotspot). In some embodiments, the primer library is used to determine whether or not recombination has occurred at greater than or equal to 5; 10; 50; 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; or 50,000 different recombination hotspots (such as known human recombination hotspots). In some embodiments, the regions targeted by primers to a recombination hotspot or nearby region are approximately evenly spread out along that portion of the genome. In some embodiments, at least 1, 5, 10, 20, 40, 60, 80, 100, or 150 different primer (or primer pairs) are specific for the a region at or near the end of a chromosome (such as a region within 20, 10, 5, 1, 0.5, 0.1, 0.01, or 0.001 mb from the end of a chromosome). In some embodiments, at least 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the primers in the primer library are specific for the a region at or near the end of a chromosome (such as a region within 20, 10, 5,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 302

1, 0.5, 0.1, 0.01, or 0.001 mb from the end of a chromosome). In some embodiments, at least 1, 5, 10, 20, 40, 60, 80, 100, or 150 different primer (or primer pairs) are specific for a region within a potential microdeletion in a chromosome. In some embodiments, at least 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the primers in the primer library are specific for a region within a potential microdeletion in a chromosome. In some embodiments, at least 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the primers in the primer library are specific for a recombination hotspot, a region near a recombination hotspot, a region at or near the end of a chromosome, or a region within a potential microdeletion in a chromosome.

Exemplary Kits

[0508] In one aspect, the invention features a kit, such as a kit for amplifying target loci in a nucleic acid sample for detecting deletions and/or duplications of chromosome segments or entire chromosomes using any of the methods described herein). In some embodiments, the kit can include any of the primer libraries of the invention. In an embodiment, the kit comprises a plurality of inner forward primers and optionally a plurality of inner reverse primers, and optionally outer forward primers and outer reverse primers, where each of the primers is designed to hybridize to the region of DNA immediately upstream and/or downstream from one of the target sites (*e.g.*, polymorphic sites) on the target chromosome(s) or chromosome segment(s), and optionally additional chromosomes or chromosome segments. In some embodiments, the kit includes instructions for using the primer library to amplify the target loci, such as for detecting one or more deletions and/or duplications of one or more chromosome segments or entire chromosomes using any of the methods described herein.

[0509] In certain embodiments, kits of the invention provide primer pairs for detecting chromosomal aneuploidy and CNV determination, such as primer pairs for massively multiplex reactions for detecting chromosomal aneuploidy such as CNV (CoNVERGe) (Copy Number Variant Events Revealed Genotypically) and/or SNVs. In these embodiments, the kits can include between at least 100, 200, 250, 300, 500, 1000, 2000, 2500, 3000, 5000, 10,000, 20,000, 25,000, 28,000, 50,000, or 75,000 and at most 200, 250, 300, 500, 1000, 2000, 2500, 3000, 5000, 10,000, 20,000, 25,000, 28,000, 50,000, 75,000, or 100,000 primer pairs that are shipped together. The primer pairs can be contained in a single vessel, such as a single tube or box, or multiple tubes or boxes. In certain embodiments, the primer pairs are pre-qualified by a commercial provider and

sold together, and in other embodiments, a customer selects custom gene targets and/or primers and a commercial provider makes and ships the primer pool to the customer neither in one tube or a plurality of tubes. In certain exemplary embodiments, the kits include primers for detecting both CNVs and SNVs, especially CNVs and SNVs known to be correlated to at least one type of cancer.

[0510] Kits for circulating DNA detection according to some embodiments of the present invention, include standards and/or controls for circulating DNA detection. For example, in certain embodiments, the standards and/or controls are sold and optionally shipped and packaged together with primers used to perform the amplification reactions provided herein, such as primers for performing CoNVERGe. In certain embodiments, the controls include polynucleotides such as DNA, including isolated genomic DNA that exhibits one or more chromosomal aneuploidies such as CNV and/or includes one or more SNVs. In certain embodiments, the standards and/or controls are called PlasmArt standards and include polynucleotides having sequence identity to regions of the genome known to exhibit CNV, especially in certain inherited diseases, and in certain disease states such as cancer, as well as a size distribution that reflects that of cfDNA fragments naturally found in plasma. Exemplary methods for making PlasmArt standards are provided in the examples herein. In general, genomic DNA from a source known to include a chromosomal aneuoploidy is isolated, fragmented, purified and size selected.

[0511] Accordingly, artificial cfDNA polynucleotide standards and/or controls can be made by spiking isolated polynucleotide samples prepared as summarized above, into DNA samples known not to exhibit a chromosomal aneuploidy and/or SNVs, at concentrations similar to those observed for cfDNA in vivo, such as between, for example, 0.01% and 20%, 0.1 and 15%, or .4 and 10% of DNA in that fluid. These standards/controls can be used as controls for assay design, characterization, development, and/or validation, and as quality control standards during testing, such as cancer testing performed in a CLIA lab and/or as standards included in research use only or diagnostic test kits.

Exemplary Normalization/Correction Methods

[0512] In some embodiments, measurements for different loci, chromosome segments, or chromosomes are adjusted for bias, such as bias due to differences in GC content or bias due to other differences in amplification efficiency or adjusted for sequencing errors. In some embodiments, measurements for different alleles for the same locus are adjusted for differences in

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 304

metabolism, apoptosis, histones, inactivation, and/or amplification between the alleles. In some embodiments, measurements for different alleles for the same locus in RNA are adjusted for differences in transcription rates or stability between different RNA alleles.

Exemplary Methods for Phasing Genetic Data

[0513] In some embodiments, genetic data is phased using the methods described herein or any known method for phasing genetic data (*see*, *e.g.*, PCT Publ. No. WO2009/105531, filed February 9, 2009, and PCT Publ. No. WO2010/017214, filed August 4, 2009; U.S. Publ. No. 2013/0123120, Nov. 21, 2012; U.S. Publ. No. 2011/ 0033862, filed Oct. 7, 2010; U.S. Publ. No. 2011/0033862, filed August 19, 2010; U.S. Publ. No. 2011/0178719, filed Feb. 3, 2011; U.S. Pat. No. 8,515,679, filed March 17, 2008; U.S. Publ. No. 2007/0184467, filed Nov. 22, 2006; U.S. Publ. No. 2008/0243398, filed March 17, 2008, and U.S. Serial No. 61/994,791, filed May 16, 2014, which are each hereby incorporated by reference in its entirety). In some embodiments, the phase is determined for one or more regions that are known or suspected to contain a CNV of interest. In some embodiments, the phase is also determined for one or more regions flanking the CNV region(s) and/or for one or more reference regions. In one embodiment, genetic data of an individual (*e.g.*, an individual being tested using the methods of the invention or a relative of a gestating fetus or embryo, such as a parent of the fetus or embryo) is phased by inference by measuring tissue from the individual that is haploid, for example by measuring one or more sperm or eggs. In one embodiment, an individual's genetic data is phased by inference using the measured genotypic data of one or more first degree relatives, such as the individual's parents (*e.g.*, sperm from the individual's father) or siblings.

[0514] In one embodiment, an individual's genetic data is phased by dilution where the DNA or RNA is diluted in one or a plurality of wells, such as by using digital PCR. In some embodiments, the DNA or RNA is diluted to the point where there is expected to be no more than approximately one copy of each haplotype in each well, and then the DNA or RNA in the one or more wells is measured. In some embodiments, cells are arrested at phase of mitosis when chromosomes are tight bundles, and microfluidics is used to put separate chromosomes in separate wells. Because the DNA or RNA is diluted, it is unlikely that more than one haplotype is in the same fraction (or tube). Thus, there may be effectively a single molecule of DNA in the tube, which allows the haplotype on a single DNA or RNA molecule to be determined. In some embodiments, the method

includes dividing a DNA or RNA sample into a plurality of fractions such that at least one of the fractions includes one chromosome or one chromosome segment from a pair of chromosomes, and genotyping (*e.g.*, determining the presence of two or more polymorphic loci) the DNA or RNA sample in at least one of the fractions, thereby determining a haplotype. In some embodiments, the genotyping involves sequencing (such as shotgun sequencing or single molecule sequencing), a SNP array to detect polymorphic loci, or multiplex PCR. In some embodiments, the genotyping involves use of a SNP array to detect polymorphic loci, such as at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different polymorphic loci. In some embodiments, the genotyping involves the use of multiplex PCR. In some embodiments, the method involves contacting the sample in a fraction with a library of primers that simultaneously hybridize to at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different polymorphic loci (such as SNPs) to produce a reaction mixture; and subjecting the reaction mixture to primer extension reaction conditions to produce amplified products that are measured with a high throughput sequencer to produce sequencing data. In some embodiments, RNA (such as mRNA) is sequenced. Since mRNA contains only exons, sequencing mRNA allows alleles to be determined for polymorphic loci (such as SNPs) over a large distance in the genome, such as a few megabases. In some embodiments, a haplotype of an individual is determined by chromosome sorting. An exemplary chromosome sorting method includes arresting cells at phase of mitosis when chromosomes are tight bundles and using microfluidics to put separate chromosomes in separate wells. Another method involves collecting single chromosomes using FACS-mediated single chromosome sorting. Standard methods (such as sequencing or an array) can be used to identify the alleles on a single chromosome to determine a haplotype of the individual.

[0515] In some embodiments, a haplotype of an individual is determined by long read sequencing, such as by using the Moleculo Technology developed by Illumina. In some embodiments, the library prep step involves shearing DNA into fragments, such as fragments of ~10 kb size, diluting the fragments and placing them into wells (such that about 3,000 fragments are in a single well), amplifying fragments in each well by long-range PCR and cutting into short fragments and barcoding the fragments, and pooling the barcoded fragments from each well together to sequence them all. After sequencing, the computational steps involve separating the reads from each well based on the attached barcodes and grouping them into fragments, assembling

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 306

the fragments at their overlapping heterozygous SNVs into haplotype blocks, and phasing the blocks statistically based on a phased reference panel and producing long haplotype contigs.

[0516] In some embodiments, a haplotype of the individual is determined using data from a relative of the individual. In some embodiments, a SNP array is used to determine the presence of at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different polymorphic loci in a DNA or RNA sample from the individual and a relative of the individual. In some embodiments, the method involves contacting a DNA sample from the individual and/or a relative of the individual with a library of primers that simultaneously hybridize to at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different polymorphic loci (such as SNPs) to produce a reaction mixture; and subjecting the reaction mixture to primer extension reaction conditions to produce amplified products that are measured with a high throughput sequencer to produce sequencing data.

[0517] In one embodiment, an individual's genetic data is phased using a computer program that uses population based haplotype frequencies to infer the most likely phase, such as HapMap-based phasing. For example, haploid data sets can be deduced directly from diploid data using statistical methods that utilize known haplotype blocks in the general population (such as those created for the public HapMap Project and for the Perlegen Human Haplotype Project). A haplotype block is essentially a series of correlated alleles that occur repeatedly in a variety of populations. Since these haplotype blocks are often ancient and common, they may be used to predict haplotypes from diploid genotypes. Publicly available algorithms that accomplish this task include an imperfect phylogeny approach, Bayesian approaches based on conjugate priors, and priors from population genetics. Some of these algorithms use a hidden Markov model.

[0518] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from genotype data, such as an algorithm that uses localized haplotype clustering (*see, e.g.,* Browning and Browning, "Rapid and Accurate Haplotype Phasing and Missing-Data Inference for Whole-Genome Association Studies By Use of Localized Haplotype Clustering" Am J Hum Genet. Nov 2007; 81(5): 1084–1097, which is hereby incorporated by reference in its entirety). An exemplary program is Beagle version: 3.3.2 or version 4 (available at the world wide web at hfaculty.washington.edu/browning/beagle/beagle.html, which is hereby incorporated by reference in its entirety).

[0519] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from genotype data, such as an algorithm that uses the decay of linkage disequilibrium with distance, the order and spacing of genotyped markers, missing-data imputation, recombination rate estimates, or a combination thereof (*see, e.g.,* Stephens and Scheet, "Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-Data Imputation" Am. J. Hum. Genet. 76:449–462, 2005, which is hereby incorporated by reference in its entirety). An exemplary program is PHASE v.2.1 or v2.1.1. (available at the world wide web at stephenslab.uchicago.edu/software.html, which is hereby incorporated by reference in its entirety).

[0520] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from population genotype data, such as an algorithm that allows cluster memberships to change continuously along the chromosome according to a hidden Markov model. This approach is flexible, allowing for both "block-like" patterns of linkage disequilibrium and gradual decline in linkage disequilibrium with distance (*see, e.g.,* Scheet and Stephens, "A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase." Am J Hum Genet, 78:629-644, 2006, which is hereby incorporated by reference in its entirety). An exemplary program is fastPHASE (available at the world wide web at stephenslab.uchicago.edu/software.html, which is hereby incorporated by reference in its entirety).

[0521] In one embodiment, an individual's genetic data is phased using a genotype imputation method, such as a method that uses one or more of the following reference datasets: HapMap dataset, datasets of controls genotyped on multiple SNP chips, and densely typed samples from the 1,000 Genomes Project. An exemplary approach is a flexible modelling framework that increases accuracy and combines information across multiple reference panels (*see, e.g.,* Howie, Donnelly, and Marchini (2009) "A flexible and accurate genotype imputation method for the next generation of genome-wide association studies." *PLoS Genetics* 5(6): e1000529, 2009, which is hereby incorporated by reference in its entirety). Exemplary programs are IMPUTE or IMPUTE version 2 (also known as IMPUTE2) (available at the world wide web at mathgen.stats.ox.ac.uk/impute/impute_v2.html, which is hereby incorporated by reference in its entirety).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 308

[0522] In one embodiment, an individual's genetic data is phased using an algorithm that infers haplotypes, such as an algorithm that infers haplotypes under the genetic model of coalescence with recombination, such as that developed by Stephens in PHASE v2.1. The major algorithmic improvements rely on the use of binary trees to represent the sets of candidate haplotypes for each individual. These binary tree representations: (1) speed up the computations of posterior probabilities of the haplotypes by avoiding the redundant operations made in PHASE v2.1, and (2) overcome the exponential aspect of the haplotypes inference problem by the smart exploration of the most plausible pathways (*i.e.*, haplotypes) in the binary trees (*see, e.g.,* Delaneau, Coulonges and Zagury, "Shape-IT: new rapid and accurate algorithm for haplotype inference," BMC Bioinformatics 9:540, 2008 doi:10.1186/1471-2105-9-540, which is hereby incorporated by reference in its entirety). An exemplary program is SHAPEIT (available at the world wide web at mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html, which is hereby incorporated by reference in its entirety).

[0523] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from population genotype data, such as an algorithm that uses haplotype-fragment frequencies to obtain empirically based probabilities for longer haplotypes. In some embodiments, the algorithm reconstructs haplotypes so that they have maximal local coherence (*see, e.g.,* Eronen, Geerts, and Toivonen, "HaploRec: Efficient and accurate large-scale reconstruction of haplotypes," *BMC Bioinformatics* 7:542, 2006, which is hereby incorporated by reference in its entirety). An exemplary program is HaploRec, such as HaploRec version 2.3. (available at the world wide web at cs.helsinki.fi/group/genetics/haplotyping.html, which is hereby incorporated by reference in its entirety).

[0524] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from population genotype data, such as an algorithm that uses a partition-ligation strategy and an expectation-maximization-based algorithm (*see, e.g.,* Qin, Niu, and Liu, "Partition-Ligation-Expectation-Maximization Algorithm for Haplotype Inference with Single-Nucleotide Polymorphisms," Am J Hum Genet. 71(5): 1242–1247, 2002, which is hereby incorporated by reference in its entirety). An exemplary program is PL-EM (available at the world wide web at people.fas.harvard.edu/~junliu/plem/click.html, which is hereby incorporated by reference in its entirety).

[0525] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from population genotype data, such as an algorithm for simultaneously phasing genotypes into haplotypes and block partitioning. In some embodiments, an expectation-maximization algorithm is used (*see, e.g.,* Kimmel and Shamir, "GERBIL: Genotype Resolution and Block Identification Using Likelihood," Proceedings of the National Academy of Sciences of the United States of America (PNAS) 102: 158-162, 2005, which is hereby incorporated by reference in its entirety). An exemplary program is GERBIL, which is available as part of the GEVALT version 2 program (available at the world wide web at acgt.cs.tau.ac.il/gevalt/, which is hereby incorporated by reference in its entirety).

[0526] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from population genotype data, such as an algorithm that uses an EM algorithm to calculate ML estimates of haplotype frequencies given genotype measurements which do not specify phase. The algorithm also allows for some genotype measurements to be missing (due, for example, to PCR failure). It also allows multiple imputation of individual haplotypes (*see, e.g.,* Clayton, D. (2002), "SNPHAP: A Program for Estimating Frequencies of Large Haplotypes of SNPs", which is hereby incorporated by reference in its entirety). An exemplary program is SNPHAP (available at the world wide web at gene.cimr.cam.ac.uk/clayton/software/snphap.txt, which is hereby incorporated by reference in its entirety).

[0527] In one embodiment, an individual's genetic data is phased using an algorithm that estimates haplotypes from population genotype data, such as an algorithm for haplotype inference based on genotype statistics collected for pairs of SNPs. This software can be used for comparatively accurate phasing of large number of long genome sequences, *e.g.* obtained from DNA arrays. An exemplary program takes genotype matrix as an input, and outputs the corresponding haplotype matrix (*see, e.g.,* Brinza and Zelikovsky, "2SNP: scalable phasing based on 2-SNP haplotypes," Bioinformatics.22(3):371-3, 2006, which is hereby incorporated by reference in its entirety). An exemplary program is 2SNP (available at the world wide web at alla.cs.gsu.edu/~software/2SNP, which is hereby incorporated by reference in its entirety).

[0528] In various embodiments, an individual's genetic data is phased using data about the probability of chromosomes crossing over at different locations in a chromosome or chromosome segment (such as using recombination data such as may be found in the HapMap database to create

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 310

a recombination risk score for any interval) to model dependence between polymorphic alleles on the chromosome or chromosome segment. In some embodiments, allele counts at the polymorphic loci are calculated on a computer based on sequencing data or SNP array data. In some embodiments, a plurality of hypotheses each pertaining to a different possible state of the chromosome or chromosome segment (such as an overrepresentation of the number of copies of a first homologous chromosome segment as compared to a second homologous chromosome segment in the genome of one or more cells from an individual, a duplication of the first homologous chromosome segment, a deletion of the second homologous chromosome segment, or an equal representation of the first and second homologous chromosome segments) are created (such as creation on a computer); a model (such as a joint distribution model) for the expected allele counts at the polymorphic loci on the chromosome is built (such as building on a computer) for each hypothesis; a relative probability of each of the hypotheses is determined (such as determination on a computer) using the joint distribution model and the allele counts; and the hypothesis with the greatest probability is selected. In some embodiments, building a joint distribution model for allele counts and the step of determining the relative probability of each hypothesis are done using a method that does not require the use of a reference chromosome.

[0529] In one embodiment, genetic data of an individual is phased using genetic data of one or more relatives of the individual (such as one or more parents, siblings, children, fetuses, embryos, grandparents, uncles, aunts, or cousins). In one embodiment, genetic data of an individual is phased using genetic data of one or more genetic offspring of the individual (*e.g.*, 1, 2, 3, or more offspring), such as embryos, fetuses, born children, or a sample of a miscarriage. In one embodiment, genetic data of a parent (such as a parent of a gestating fetus or embryo) is phased using phased haplotypic data for the other parent along with unphased genetic data of one or more genetic offspring of the parents.

[0530] In some embodiments, a sample (*e.g.*, a biopsy such as a tumor biopsy, blood sample, plasma sample, serum sample, or another sample likely to contain mostly or only cells, DNA, or RNA with a CNV of interest) from the individual (such as an individual suspected of having cancer, a fetus, or an embryo) is analyzed to determine the phase for one or more regions that are known or suspected to contain a CNV of interest (such as a deletion or duplication). In some embodiments, the sample has a high tumor fraction (such as 30, 40, 50, 60, 70, 80, 90, 95, 98, 99, or 100%). In some embodiments, a sample (*e.g.*, a maternal whole blood sample, cells isolated

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 311

from a maternal blood sample, maternal plasma sample, maternal serum sample, amniocentesis sample, placental tissue sample (*e.g.*, chorionic villus, decidua, or placental membrane), cervical mucus sample, fetal tissue after fetal demise, other sample from a fetus, or another sample likely to contain mostly or only cells, DNA, or RNA with a CNV of interest) from a fetus or the pregnant mother of a fetus is analyzed to determine the phase for one or more regions that are known or suspected to contain a CNV of interest (such as a deletion or duplication). In some embodiments, the sample has a high fetal fraction (such as 25, 30, 40, 50, 60, 70, 80, 90, 95, 98, 99, or 100%).

[0531] In some embodiments, the sample has a haplotypic imbalance or any aneuploidy. In some embodiments, the sample includes any mixture of two types of DNA where the two types have different ratios of the two haplotypes, and share at least one haplotype. For example, in the fetal-maternal case, the mother is 1:1 and the fetus is 1:0 (plus a paternal haplotype). For example, in the tumor case, the normal tissue is 1:1, and the tumor tissue is 1:0 or 1:2, 1:3, 1:4, *etc.* In some embodiments, at least 10; 100; 500; 1,000; 2,000; 3,000; 5,000; 8,000; or 10,000 polymorphic loci are analyzed to determine the phase of alleles at some or all of the loci. In some embodiments, a sample is from a cell or tissue that was treated to become aneuploidy, such as aneuploidy induced by prolonged cell culture.

[0532] In some embodiments, a large percent or all of the DNA or RNA in the sample has the CNV of interest. In some embodiments, the ratio of DNA or RNA from the one or more target cells that contain the CNV of interest to the total DNA or RNA in the sample is at least 80, 85, 90, 95, or 100%. For samples with a deletion, only one haplotype is present for the cells (or DNA or RNA) with the deletion. This first haplotype can be determined using standard methods to determine the identity of alleles present in the region of the deletion. In samples that only contain cells (or DNA or RNA) with the deletion, there will only be signal from the first haplotype that is present in those cells. In samples that also contain a small amount of cells (or DNA or RNA) without the deletion (such as a small amount of noncancerous cells), the weak signal from the second haplotype in these cells (or DNA or RNA) can be ignored. The second haplotype that is present in other cells, DNA, or RNA from the individual that lack the deletion can be determined by inference. For example, if the genotype of cells from the individual without the deletion is (AB,AB) and the phased data for the individual indicates that the first haplotype is (A,A); then, the other haplotype can be inferred to be (B,B).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 312

[0533] For samples in which both cells (or DNA or RNA) with a deletion and cells (or DNA or RNA) without a deletion are present, the phase can still be determined. For example, plots can be generated similar to FIG. 18 or 29 in which the x-axis represents the linear position of the individual loci along the chromosome, and the y-axis represents the number of A allele reads as a fraction of the total (A+B) allele reads. In some embodiments for a deletion, the pattern includes two central bands that represent SNPs for which the individual is heterozygous (top band represents AB from cells without the deletion and A from cells with the deletion, and bottom band represents AB from cells without the deletion and B from cells with the deletion). In some embodiments, the separation of these two bands increases as the fraction of cells, DNA, or RNA with the deletion increases. Thus, the identity of the A alleles can be used to determine the first haplotype, and the identity of the B alleles can be used to determine the second haplotype.

[0534] For samples with a duplication, an extra copy of the haplotype is present for the cells (or DNA or RNA) with duplication. This haplotype of the duplicated region can be determined using standard methods to determine the identity of alleles present at an increased amount in the region of the duplication, or the haplotype of the region that is not duplicated can be determined using standard methods to determine the identity of alleles present at an decreased amount. Once one haplotype is determined, the other haplotype can be determined by inference.

[0535] For samples in which both cells (or DNA or RNA) with a duplication and cells (or DNA or RNA) without a duplication are present, the phase can still be determined using a method similar to that described above for deletions. For example, plots can be generated similar to FIG. 18 or 29 in which the x-axis represents the linear position of the individual loci along the chromosome, and the y-axis represents the number of A allele reads as a fraction of the total (A+B) allele reads. In some embodiments for a deletion, the pattern includes two central bands that represent SNPs for which the individual is heterozygous (top band represents AB from cells without the duplication and AAB from cells with the duplication, and bottom band represents AB from cells without the duplication and ABB from cells with the duplication). In some embodiments, the separation of these two bands increases as the fraction of cells, DNA, or RNA with the duplication increases. Thus, the identity of the A alleles can be used to determine the first haplotype, and the identity of the B alleles can be used to determine the second haplotype. In some embodiments, the phase of one or more CNV region(s) (such as the phase of at least 50, 60, 70, 80, 90, 95, or 100% of the polymorphic loci in the region that were measured) is determined for a sample (such

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 313

as a tumor biopsy or plasma sample) from an individual known to have cancer and is used for analysis of subsequent samples from the same individual to monitor the progression of the cancer (such as monitoring for remission or reoccurrence of the cancer). In some embodiments, a sample with a high tumor fraction (such as a tumor biopsy or a plasma sample from an individual with a high tumor load) is used to obtain phased data that is used for analysis of subsequent samples with a lower tumor fraction (such as a plasma sample from an individual undergoing treatment for cancer or in remission).

[0536] In another embodiment for prenatal diagnostics, phased parental haplotypic data is to detect the presence of more than one homolog from the father, implying that the genetic material from more than one fetus is present in a maternal blood sample. By focusing on chromosomes that are expected to be euploid in a fetus, one could rule out the possibility that the fetus was afflicted with a trisomy. Also, it is possible to determine if the fetal DNA is not from the current father.

[0537] In some embodiments, two or more of the methods described herein are used to phase genetic data of an individual. In some embodiments, both a bioinformatics method (such as using population based haplotype frequencies to infer the most likely phase) and a molecular biology method (such as any of the molecular phasing methods disclosed herein to obtain actual phased data rather than bioinformatics-based inferred phased data) are used. In some embodiments, phased data from other subjects (such as prior subjects) is used to refine the population data. For example, phased data from other subjects can be added to population data to calculate priors for possible haplotypes for another subject. In some embodiments, phased data from other subjects (such as prior subjects) is used to calculate priors for possible haplotypes for another subject.

[0538] In some embodiments, probabilistic data may be used. For example, due to the probabilistic nature of the representation of DNA molecules in a sample, as well as various amplification and measurement biases, the relative number of molecules of DNA measured from two different loci, or from different alleles at a given locus, is not always representative of the relative number of molecules in the mixture, or in the individual. If one were trying to determine the genotype of a normal diploid individual at a given locus on an autosomal chromosome by sequencing DNA from the plasma of the individual, one would expect to either observe only one allele (homozygous) or about equal numbers of two alleles (heterozygous). If, at that allele, ten molecules of the A allele were observed, and two molecules of the B allele were observed, it would

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 314

not be clear if the individual was homozygous at the locus, and the two molecules of the B allele were due to noise or contamination, or if the individual was heterozygous, and the lower number of molecules of the B allele were due to random, statistical variation in the number of molecules of DNA in the plasma, amplification bias, contamination or any number of other causes. In this case, a probability that the individual was homozygous, and a corresponding probability that the individual was heterozygous could be calculated, and these probabilistic genotypes could be used in further calculations.

[0539] Note that for a given allele ratio, the likelihood that the ratio closely represents the ratio of the DNA molecules in the individual is greater the greater the number of molecules that are observed. For example, if one were to measure 100 molecules of A and 100 molecules of B, the likelihood that the actual ratio was 50% is considerably greater than if one were to measure 10 molecules of A and 10 molecules of B. In one embodiment, one uses Bayesian theory combined with a detailed model of the data to determine the likelihood that a particular hypothesis is correct given an observation. For example, if one were considering two hypotheses – one that corresponds to a trisomic individual and one that corresponds to a disomic individual – then the probability of the disomic hypothesis being correct would be considerably higher for the case where 100 molecules of each of the two alleles were observed, as compared to the case where 10 molecules of each of the two alleles were observed. As the data becomes noisier due to bias, contamination or some other source of noise, or as the number of observations at a given locus goes down, the probability of the maximum likelihood hypothesis being true given the observed data drops. In practice, it is possible to aggregate probabilities over many loci to increase the confidence with which the maximum likelihood hypothesis may be determined to be the correct hypothesis. In some embodiments, the probabilities are simply aggregated without regard for recombination. In some embodiments, the calculations take into account cross-overs.

[0540] In an embodiment, probabilistically phased data is used in the determination of copy number variation. In some embodiments, the probabilistically phased data is population based haplotype block frequency data from a data source such as the HapMap data base. In some embodiments, the probabilistically phased data is haplotypic data obtained by a molecular method, for example phasing by dilution where individual segments of chromosomes are diluted to a single molecule per reaction, but where, due to stochastic noise the identities of the haplotypes may not be absolutely known. In some embodiments, the probabilistically phased data is haplotypic data

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 315

obtained by a molecular method, where the identities of the haplotypes may be known with a high degree of certainty.

[0541] Imagine a hypothetical case where a doctor wanted to determine whether or not an individual had some cells in their body which had a deletion at a particular chromosomal segment by measuring the plasma DNA from the individual. The doctor could make use of the knowledge that if all of the cells from which the plasma DNA originated were diploid, and of the same genotype, then for heterozygous loci, the relative number of molecules of DNA observed for each of the two alleles would fall into one distribution that was centered at 50% A allele and 50% B allele. However, if a fraction of the cells from which the plasma DNA originated had a deletion at a particular chromosome segment, then for heterozygous loci, one would expect that the relative number of molecules of DNA observed for each of the two alleles would fall into two distributions, one centered at above 50% A allele for the loci where there was a deletion of the chromosome segment containing the B allele, and one centered at below 50% for the loci where there was a deletion of the chromosome segment containing the A allele. The greater the proportion of the cells from which the plasma DNA originated contained the deletion, the further from 50% these two distributions would be.

[0542] In this hypothetical case, imagine a clinician who wants to determine if an individual had a deletion of a chromosomal region in a proportion of cells in the individual's body. The clinician may draw blood from the individual into a vacutainer or other type of blood tube, centrifuge the blood, and isolate the plasma layer. The clinician may isolate the DNA from the plasma, enrich the DNA at the targeted loci, possibly through targeted or other amplification, locus capture techniques, size enrichment, or other enrichment techniques. The clinician may analyze such as by measuring the number of alleles at a set of SNPs, in other words generating allele frequency data, the enriched and/or amplified DNA using an assay such as qPCR, sequencing, a microarray, or other techniques that measure the quantity of DNA in a sample. We will consider data analysis for the case where the clinician amplified the cell-free plasma DNA using a targeted amplification technique, and then sequenced the amplified DNA to give the following exemplary possible data at six SNPs found on a chromosome segment that is indicative of cancer, where the individual was heterozygotic at those SNPs:

[0543] SNP 1: 460 reads A allele; 540 reads B allele (46% A)

[0544] SNP 2: 530 reads A allele; 470 reads B allele (53% A)

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 316

[0545] SNP 3: 40 reads A allele; 60 reads B allele (40% A)

[0546] SNP 4: 46 reads A allele; 54 reads B allele (46% A)

[0547] SNP 5: 520 reads A allele; 480 reads B allele (52% A)

[0548] SNP 6: 200 reads A allele; 200 reads B allele (50% A)

[0549] From this set of data, it may be difficult to differentiate between the case where the individual is normal, with all cells being disomic, or where the individual may have a cancer, with some portion of cells whose DNA contributed towards the cell-free DNA found in the plasma having a deletion or duplication at the chromosome. For example, the two hypotheses with the maximum likelihood may be that the individual has a deletion at this chromosome segment, with a tumor fraction of 6%, and where the deleted segment of the chromosome has the genotype over the six SNPs of (A,B,A,A,B,B) or (A,B,A,A,B,A). In this representation of the individual's genotype over a set of SNPs, the first letter in the parentheses corresponds to the genotype of the haplotype for SNP 1, the second to SNP 2, etc.

[0550] If one were to use a method to determine the haplotype of the individual at that chromosome segment, and were to find that the haplotype for one of the two chromosomes was (A,B,A,A,B,B), this would agree with the maximum likelihood hypothesis, and the calculated likelihood that the individual has a deletion at that segment, and therefore may have cancerous or precancerous cells, would be considerably increased. On the other hand, if the individual were found to have the haplotype (A,A,A,A,A,A), then the likelihood that the individual has a deletion at that chromosome segment would be considerably decreased, and perhaps the likelihood of the no-deletion hypothesis would be higher (the actual likelihood values would depend on other parameters such as the measured noise in the system, among others).

[0551] There are many ways to determine the haplotype of the individual, many of which are described elsewhere in this document. A partial list is given here, and is not meant to be exhaustive. One method is a biological method where individual DNA molecules are diluted until approximately one molecule from each chromosomal region is in any given reaction volume, and then methods such as sequencing are used to measure the genotype. Another method is informatically based where population data on various haplotypes coupled with their frequency can be used in a probabilistic manner. Another method is to measure the diploid data of the individual, along with one or a plurality of related individuals who are expected to share haplotype blocks with the individual and to infer the haplotype blocks. Another method would be to take a

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 317

sample of tissue with a high concentration of the deleted or duplicated segment, and determine the haplotype based on allelic imbalance, for example, genotype measurements from a sample of tumor tissue with a deletion can be used to determine the phased data for that deletion region, and this data can then be used to determine if the cancer has regrown post-resection.

[0552] In practice, typically more than 20 SNPs, more than 50 SNPs, more than 100 SNPs, more than 500 SNPs, more than 1,000 SNPs, or more than 5,000 SNPs are measured on a given chromosome segment.

Exemplary Methods for Phasing, Predicting Allele Ratios, and Reconstructing Fetal Genetic Data

[0553] In one aspect, the invention features methods for determining one or more haplotypes of a fetus. In various embodiments, this method allows one to determine which polymorphic loci (such as SNPs) were inherited by the fetus and to reconstruct which homologs (including recombination events) are present in the fetus (and thereby interpolate the sequence between the polymorphic loci). If desired, essentially the entire genome of the fetus can be reconstructed. If there is some remaining ambiguity in the genome of the fetus (such as in intervals with a crossover), this ambiguity can be minimized if desired by analyzing additional polymorphic loci. In various embodiments, the polymorphic loci are chosen to cover one or more of the chromosomes at a density to reduce any ambiguity to a desired level. This method has important applications for the detection of polymorphisms or other mutations of interest (such as deletions or duplications) in a fetus since it enables their detection based on linkage (such as the presence of linked polymorphic loci in the fetal genome) rather than by directing detecting the polymorphism or other mutation of interest in the fetal genome. For example, if a parent is a carrier for a mutation associated with cystic fibrosis (CF), a nucleic acid sample that includes maternal DNA from the mother of the fetus and fetal DNA from the fetus can be analyzed to determine whether the fetal DNA include the haplotype containing the CF mutation. In particular, polymorphic loci can be analyzed to determine whether the fetal DNA includes the haplotype containing the CF mutation without having to detect the CF mutation itself in the fetal DNA. This is useful in screening for one or more mutations, such as disease-linked mutations, without having to directly detect the mutations.

[0554] In some embodiments, the method involves determining a parental haplotype (*e.g.*, a haplotype of the mother or father of the fetus), such as by using any of the methods described

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 318

herein. In some embodiments, this determination is made without using data from a relative of the mother or father. In some embodiments, a parental haplotype is determined using a dilution approach followed by SNP genotyping or sequencing as described herein. In some embodiments, a haplotype of the mother (or father) is determined by any of the methods described herein using data from a relative of the mother (or father). In some embodiments, a haplotype is determined for both the father and the mother.

[0555] This parental haplotype data can be used to determine if the fetus inherited the parental haplotype. In some embodiments, a nucleic acid sample that includes maternal DNA from the mother of the fetus and fetal DNA from the fetus is analyzed using a SNP array to detect at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different polymorphic loci. In some embodiments, a nucleic acid sample that includes maternal DNA from the mother of the fetus and fetal DNA from the fetus is analyzed by contacting the sample with a library of primers that simultaneously hybridize to at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different polymorphic loci (such as SNPs) to produce a reaction mixture. In some embodiments, the reaction mixture is subjected to primer extension reaction conditions to produce amplified products. In some embodiments, the amplified products are measured with a high throughput sequencer to produce sequencing data.

[0556] In various embodiments, a fetal haplotype is determined using data about the probability of chromosomes crossing over at different locations in a chromosome or chromosome segment (such as by using recombination data such as may be found in the HapMap database to create a recombination risk score for any interval) to model dependence between polymorphic alleles on the chromosome or chromosome segment as described above. In some embodiments, the method takes into account physical distance of the SNPs (such as SNPs flanking a gene or mutation of interest) and recombination data from location specific recombination likelihoods and the data observed from the genetic measurements of the maternal plasma to obtain the most likely genotype of the fetus. Then PARENTAL SUPPORT™ may be performed on the targeted sequencing or SPN array data obtained from these SNPs to determine which homologs were inherited by the fetus from both parents (*see, e.g.,* U.S. Application No. 11/603,406 (US Publication No. 20070184467), U.S. Application No. 12/076,348 (US Publication No. 20080243398), U.S. Application 13/110,685 (U.S. Publication No. 2011/0288780), PCT Application PCT/US09/52730

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 319

(PCT Publication No. WO/2010/017214), and PCT Application No. PCT/US10/050824 (PCT Publication No. WO/2011/041485), U.S. Application No. 13/300,235 (U.S. Publication No. 2012/0270212), U.S. Application No. 13/335,043 (U.S. Publication No. 2012/0122701), U.S. Application No. 13/683,604, and U.S. Application No. 13/780,022, which are each hereby incorporated by reference in its entirety).

[0557] Assume a generalized example where the possible alleles at one locus are A and B; assignment of the identity A or B to particular alleles is arbitrary. Parental genotypes for a particular SNP, termed genetic contexts, are expressed as maternal genotype|paternal genotype. Thus, if the mother is homozygous and the father is heterozygous, this would be represented as AA|AB. Similarly, if both parents are homozygous for the same allele, the parental genotypes would be represented as AA|AA. Furthermore, the fetus would never have AB or BB states and the number of sequence reads with the B allele will be low, and thus can be used to determine the noise responses of the assay and genotyping platform, including effects such as low level DNA contamination and sequencing errors; these noise responses are useful for modeling expected genetic data profiles. There are only five possible maternal|paternal genetic contexts: AA|AA, AA|AB, AB|AA, AB|AB, and AA|BB; other contexts are equivalent by symmetry. SNPs where the parents are homozygous for the same allele are only informative for determining noise and contamination levels. SNPs where the parents are not homozygous for the same allele are informative in determining fetal fraction and copy number count.

[0558] Let $N_{A,i}$ and $N_{B,i}$ represent the number of reads of each allele at SNP i, and let Ci represent the parental genetic context at that locus. The data set for a particular chromosome is represented by $N_{AB} = \{N_{A,i}, N_{B,i}\}\ i=1 \ldots N$ and $C=\{C_i\},\ i=1 \ldots N$. For reconstructing part or all of the fetal genome, it can optionally be determined if the fetus has an aneuploidy (such as a missing or extra copy of a chromosome or chromosome segment). For each individual chromosome or chromosome under study, let H represent the set of one or more hypotheses for the total number of chromosomes, the parental origin of each chromosome, and the positions on the parent chromosomes where recombination occurred during formation of the gametes that fertilized to create the child. The probability of a hypothesis $P(H)$ can be computed using the data from the HapMap database and prior information related to each of the ploidy states.

[0559] Furthermore, let F represent the fetal cfDNA fraction in the sample. Given a set of possible H, C, and F, one can compute the probability of N_{AB}, $P(N_{AB}|H,F,C)$ based on modeling the noise

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 320

sources of the molecular assay and the sequencing platform. The goal is to find the hypothesis H and the fetal fraction F that maximizes $P(H,F|N_{AB})$. Using standard Bayesian statistical techniques, and assuming a uniform probability distribution for F from 0 to 1, this can be recast in terms of maximizing the probability of $P(N_{AB}|H,F,C)P(H)$ over H and F, all of which can now be computed. The probability of all hypotheses associated with a particular copy number and fetal fraction, *e.g.*, trisomy and F=10%, but covering all possible parental chromosome origins and crossover locations, are summed. The copy number hypothesis with the highest probability is selected as the test result, the fetal fraction associated with that hypothesis reveals the fetal fraction, and the probability associated with that hypothesis is the calculated accuracy of the result.

[0560] In some embodiments, the algorithm uses *in silico* simulations to generate a very large number of hypothetical sequencing data sets that could result from the possible fetal genetic inheritance patterns, sample parameters, and amplification and measurement artifacts of the method. More specifically, the algorithm first utilizes parental genotypes at a large number of SNPs and crossover frequency data from the HapMap database to predict possible fetal genotypes. It then predicts expected data profiles for the sequencing data that would be measured from mixed samples originating from a mother carrying a fetus with each of the possible fetal genotypes and taking into account a variety of parameters including fetal fraction, expected read depth profile, fetal genome equivalents present in the sample, expected amplification bias at each of the SNPs, and a number of noise parameters. A data model describes how the sequencing or SNP array data is expected to appear for each of these hypotheses given the particular parameter set. The hypothesis with the best data fit between this modeled data and the measured data is selected.

[0561] If desired, expected allele ratios can be calculated for DNA or RNA from the fetus using the results of what haplotypes were inherited by the fetus. The expected allele ratios can also be calculated for a mixed sample containing nucleic acids from both the mother and the fetus (these allele ratios indicate what is expected for measurement of the total amount of each allele, including the amount of the allele from both maternal nucleic acids and fetal nucleic acids in the sample). The expected allele ratios can be calculated for different hypotheses specifying the degree of overrepresentation of the first homologous chromosome segment.

[0562] In some embodiments, the method involves determining whether the fetus has one or more of the following conditions: cystic fibrosis, Huntington's disease, Fragile X, thalassemia, muscular dystrophy (such as Duchenne's muscular dystrophy), Alzheimer, Fanconi Anemia,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 321

Gaucher Disease, Mucolipidosis IV, Niemann-Pick Disease, Tay-Sachs disease, Sickle cell anemia, Parkinson disease, Torsion Dystonia, and cancer. In some embodiments, a fetal haplotype is determined for one or more chromosomes taken from the group consisting of chromosomes 13, 18, 21, X, and Y. In some embodiments, a fetal haplotype is determined for all of the fetal chromosomes. In various embodiments, the method determines essentially the entire genome of the fetus. In some embodiments, the haplotype is determined for at least 30, 40, 50, 60, 70, 80, 90, or 95% of the genome of the fetus. In some embodiments, the haplotype determination of the fetus includes information about which allele is present for at least 100; 200; 500; 750; 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different polymorphic loci. In some embodiments, this method is used to determine a haplotype or allele ratios for an embryo.

Exemplary Methods for Predicting Allele Ratios

[0563] Exemplary methods are described below for calculating expected allele ratios for a sample. Table 1 shows expected allele ratios for a mixed sample (such as a maternal blood sample) containing nucleic acids from both the mother and the fetus. These expected allele ratios indicate what is expected for measurement of the total amount of each allele, including the amount of the allele from both maternal nucleic acids and fetal nucleic acids in the mixed sample. In an example, the mother is heterozygous at two neighboring loci that are expected to cosegregate (*e.g.*, two loci for which no chromosome crossovers are expected between the loci). Thus, the mother is (AB, AB). Now imagine that the phased data for the mother indicates that for one haplotype she is (A, A); thus, for the other haplotype one can infer that she is (B, B). Table 1 gives the expected allele ratios for different hypotheses where the fetal fraction is 20%. For this example, no knowledge of the paternal data is assumed, and the heterozygosity rate is assumed to be 50%. The expected allele ratios are given in terms of (expected proportion of A reads / total number of reads) for each of the two SNPs. These ratios are calculated both using maternal phased data (the knowledge that one haplotype is (A, A) and one is (B, B)) and without using the maternal phased data. Table 1 includes different hypotheses for the number of copies of the chromosome segment in the fetus from each parent.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 322

Table 1: Expected Genetic Data for Mixed Sample of Maternal and Fetal Nucleic Acids

Copy Number Hypothesis	**Expected allele ratios when using maternal phased data**	**Expected allele ratios when not using maternal phased data**
Monosomy (maternal copy missing)	(0.444; 0.444) (0.444; 0.555) (0.555; 0.444) (0.555; 0.555)	(0.444; 0.444) (0.444; 0.555) (0.555; 0.444) (0.555; 0.555)
Monosomy (paternal copy missing)	(0.444; 0.444) (0.555; 0.555)	(0.444; 0.444) (0.444; 0.555) (0.555; 0.444) (0.555; 0.555)
Disomy	(0.40; 0.40) (0.40; 0.50) (0.50; 0.40) (0.50; 0.50) (0.50; 0.60) (0.60; 0.50) (0.60; 0.60)	(0.40; 0.40) (0.40; 0.50) (0.40; 0.60) (0.50; 0.40) (0.50; 0.50) (0.50; 0.60) (0.60; 0.40) (0.60; 0.50) (0.60; 0.60)
Trisomy (extra matching maternal copy)	(0.36; 0.36) (0.36; 0.45) (0.45; 0.36) (0.45; 0.45) (0.54; 0.54) (0.54; 0.63) (0.63; 0.54) (0.63; 0.63)	(0.36; 0.36) (0.36; 0.45) (0.36; 0.54) (0.36; 0.63) (0.45; 0.36) (0.45; 0.45) (0.45; 0.54) (0.45; 0.63) (0.54; 0.36) (0.54; 0.45) (0.54; 0.54)

		(0.54; 0.63) (0.63; 0.36) (0.63; 0.45) (0.63; 0.54) (0.63; 0.63)
Trisomy (extra unmatching maternal copy)	(0.45, 0.45) (0.45; 0.54) (0.54; 0.45) (0.54; 0.54)	(0.36; 0.36) (0.36; 0.45) (0.36; 0.54) (0.36; 0.63) (0.45; 0.36) (0.45; 0.45) (0.45; 0.54) (0.45; 0.63) (0.54; 0.36) (0.54; 0.45) (0.54; 0.54) (0.54; 0.63) (0.63; 0.36) (0.63; 0.45) (0.63; 0.54) (0.63; 0.63)
Trisomy (extra matching paternal copy)	(0.36; 0.36) (0.36; 0.54) (0.54; 0.36) (0.54; 0.54) (0.45; 0.45) (0.45; 0.63) (0.63; 0.45) (0.63; 0.63)	(0.36; 0.36) (0.36; 0.45) (0.36; 0.54) (0.36; 0.63) (0.45; 0.36) (0.45; 0.45) (0.45; 0.54) (0.45; 0.63) (0.54; 0.36) (0.54; 0.45)

		(0.54; 0.54) (0.54; 0.63) (0.63; 0.36) (0.63; 0.45) (0.63; 0.54) (0.63; 0.63)
Trisomy (extra unmatching paternal copy)	(0.36; 0.36) (0.36; 0.45) (0.36; 0.54) (0.36; 0.63) (0.45; 0.36) (0.45; 0.45) (0.45; 0.54) (0.45; 0.63) (0.54; 0.36) (0.54; 0.45) (0.54; 0.54) (0.54; 0.63) (0.63; 0.36) (0.63; 0.45) (0.63; 0.54) (0.63; 0.63)	(0.36; 0.36) (0.36; 0.45) (0.36; 0.54) (0.36; 0.63) (0.45; 0.36) (0.45; 0.45) (0.45; 0.54) (0.45; 0.63) (0.54; 0.36) (0.54; 0.45) (0.54; 0.54) (0.54; 0.63) (0.63; 0.36) (0.63; 0.45) (0.63; 0.54) (0.63; 0.63)

[0564] In addition to the fact that using phased data reduces the number of possible expected allele ratios, it also changes the prior likelihood of each of the expected allele ratios, such that the maximum likelihood result is more likely to be correct. Eliminating expected allele ratios or hypotheses that are not possible increases the likelihood that the correct hypothesis will be chosen. As an example, suppose the measured allele ratios are (0.41, 0.59). Without using phased data, one might assume that the hypothesis with maximum likelihood is a disomy hypothesis (given the similarity of the measured allele ratios to expected allele ratios of (0.40, 0.60) for disomy).

However, using phased data, one can exclude (0.40, 0.60) as expected allele ratios for the disomy hypothesis, and one can select a trisomy hypothesis as more likely.

[0565] Assume the measured allele ratios are (0.4, 0.4). Without any haplotype information, the probability of a maternal deletion at each SNP would be the 0.5 x P(A deleted) + 0.5 x P(B deleted). Therefore, although it looks like A is deleted (missing in the fetus), the likelihood of deletion would be the average of the two. For high enough fetal fraction, one can still determine the most likely hypothesis. For low enough fetal fraction, averaging may work in disfavor of the deletion hypothesis. However, with haplotype information, the probability of homolog 1 being deleted, P (A deleted), is greater and will fit the measured data better. If desired, crossover probabilities between the two loci can also be considered.

[0566] In a further illustrative example of combining likelihoods using phased data, consider two consecutive SNPs s1 and s2, and D1 and D2 denote the allele data in these SNPs. Here we provide an example on how to combine the likelihoods for these two SNPs. Let c denote the probability that two consecutive heterozygous SNPs have the same allele in the same homolog (i.e., both SNPs are AB or both SNPs are BA). Hence 1-c is the probability that one SNP is AB and the other one is BA. For example, consider the hypothesis H10 and allelic imbalance value f. First, assume that all likelihoods are computed assuming that all SNPs are either AB or BA. Then, we can combine the likelihoods in two consecutive SNPs as follows:

$$Lik(D_1, D_2 \,|H_{10}, f) =$$

[0567] $Lik(D_1 \,|H_{10}, f) \times c \times Lik(D_2 \,|H_{10}, f) + Lik(D_1 \,|H_{10}, f) \times (1 - c) \times Lik(D_2 \,|H_{01}, f).$

[0568] We can do this recursively to determine the joint likelihood $Lik(D_1, \ldots, D_N \,|H_{10}, f)$ for all SNPs.

Exemplary Mutations

[0569] Exemplary mutations associated with a disease or disorder such as cancer or an increased risk (such as an above normal level of risk) for a disease or disorder such as cancer include single nucleotide variants (SNVs), multiple nucleotide mutations, deletions (such as deletion of a 2 to 30 million base pair region), duplications, or tandem repeats. In some embodiments, the mutation is in DNA, such as cfDNA, cell-free mitochondrial DNA (cf mDNA), cell-free DNA that originated from nuclear DNA (cf nDNA), cellular DNA, or mitochondrial DNA. In some embodiments, the mutation is in RNA, such as cfRNA, cellular RNA, cytoplasmic RNA, coding

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 326

cytoplasmic RNA, non-coding cytoplasmic RNA, mRNA, miRNA, mitochondrial RNA, rRNA, or tRNA. In some embodiments, the mutation is present at a higher frequency in subjects with a disease or disorder (such as cancer) than subjects without the disease or disorder (such as cancer). In some embodiments, the mutation is indicative of cancer, such as a causative mutation. In some embodiments, the mutation is a driver mutation that has a causative role in the disease or disorder. In some embodiments, the mutation is not a causative mutation. For example, in some cancers, multiple mutations accumulate but some of them are not causative mutations. Mutations (such as those that are present at a higher frequency in subjects with a disease or disorder than subjects without the disease or disorder) that are not causative can still be useful for diagnosing the disease or disorder. In some embodiments, the mutation is loss-of-heterozygosity (LOH) at one or more microsatellites.

[0570] In some embodiments, a subject is screened for one of more polymorphisms or mutations that the subject is known to have (*e.g.*, to test for their presence, a change in the amount of cells, DNA, or RNA with these polymorphisms or mutations, or cancer remission or re-occurrence). In some embodiments, a subject is screened for one of more polymorphisms or mutations that the subject is known to be at risk for (such as a subject who has a relative with the polymorphism or mutation). In some embodiments, a subject is screened for a panel of polymorphisms or mutations associated with a disease or disorder such as cancer (*e.g.*, at least 5, 10, 50, 100, 200, 300, 500, 750, 1,000, 1,500, 2,000, or 5,000 polymorphisms or mutations).

[0571] Many coding variants associated with cancer are described in Abaan *et al.*, "The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology", *Cancer Research,* July 15, 2013, and world wide web at dtp.nci.nih.gov/branches/btb/characterizationNCI60.html, which are each hereby incorporated by reference in its entirety). The NCI-60 human cancer cell line panel consists of 60 different cell lines representing cancers of the lung, colon, brain, ovary, breast, prostate, and kidney, as well as leukemia and melanoma. The genetic variations that were identified in these cell lines consisted of two types: type I variants that are found in the normal population, and type II variants that are cancer-specific.

[0572] Exemplary polymorphisms or mutations (such as deletions or duplications) are in one or more of the following genes: TP53, PTEN, PIK3CA, APC, EGFR, NRAS, NF2, FBXW7, ERBBs, ATAD5, KRAS, BRAF, VEGF, EGFR, HER2, ALK, p53, BRCA, BRCA1, BRCA2, SETD2,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 327

LRP1B, PBRM, SPTA1, DNMT3A, ARID1A, GRIN2A, TRRAP, STAG2, EPHA3/5/7, POLE, SYNE1, C20orf80, CSMD1, CTNNB1, ERBB2. FBXW7, KIT, MUC4, ATM, CDH1, DDX11, DDX12, DSPP, EPPK1, FAM186A, GNAS, HRNR, KRTAP4-11, MAP2K4, MLL3, NRAS, RB1, SMAD4, TTN, ABCC9, ACVR1B, ADAM29, ADAMTS19, AGAP10, AKT1, AMBN, AMPD2, ANKRD30A, ANKRD40, APOBR, AR, BIRC6, BMP2, BRAT1, BTNL8, C12orf4, C1QTNF7, C20orf186, CAPRIN2, CBWD1, CCDC30, CCDC93, CD5L, CDC27, CDC42BPA, CDH9, CDKN2A, CHD8, CHEK2, CHRNA9, CIZ1, CLSPN, CNTN6, COL14A1, CREBBP, CROCC, CTSF, CYP1A2, DCLK1, DHDDS, DHX32, DKK2, DLEC1, DNAH14, DNAH5, DNAH9, DNASE1L3, DUSP16, DYNC2H1, ECT2, EFHB, RRN3P2, TRIM49B, TUBB8P5, EPHA7, ERBB3, ERCC6, FAM21A, FAM21C, FCGBP, FGFR2, FLG2, FLT1, FOLR2, FRYL, FSCB, GAB1, GABRA4, GABRP, GH2, GOLGA6L1, GPHB5, GPR32, GPX5, GTF3C3, HECW1, HIST1H3B, HLA-A, HRAS, HS3ST1, HS6ST1, HSPD1, IDH1, JAK2, KDM5B, KIAA0528, KRT15, KRT38, KRTAP21-1, KRTAP4-5, KRTAP4-7, KRTAP5-4, KRTAP5-5, LAMA4, LATS1, LMF1, LPAR4, LPPR4, LRRFIP1, LUM, LYST, MAP2K1, MARCH1, MARCO, MB21D2, MEGF10, MMP16, MORC1, MRE11A, MTMR3, MUC12, MUC17, MUC2, MUC20, NBPF10, NBPF20, NEK1, NFE2L2, NLRP4, NOTCH2, NRK, NUP93, OBSCN, OR11H1, OR2B11, OR2M4, OR4Q3, OR5D13, OR8I2, OXSM, PIK3R1, PPP2R5C, PRAME, PRF1, PRG4, PRPF19, PTH2, PTPRC, PTPRJ, RAC1, RAD50, RBM12, RGPD3, RGS22, ROR1, RP11-671M22.1, RP13-996F3.4, RP1L1, RSBN1L, RYR3, SAMD3, SCN3A, SEC31A, SF1, SF3B1, SLC25A2, SLC44A1, SLC4A11, SMAD2, SPTA1, ST6GAL2, STK11, SZT2, TAF1L, TAX1BP1, TBP, TGFBI, TIF1, TMEM14B, TMEM74, TPTE, TRAPPC8, TRPS1, TXNDC6, USP32, UTP20, VASN, VPS72, WASH3P, WWTR1, XPO1, ZFHX4, ZMIZ1, ZNF167, ZNF436, ZNF492, ZNF598, ZRSR2, ABL1, AKT2, AKT3, ARAF, ARFRP1, ARID2, ASXL1, ATR, ATRX, AURKA, AURKB, AXL, BAP1, BARD1, BCL2, BCL2L2, BCL6, BCOR, BCORL1, BLM, BRIP1, BTK, CARD11, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD79A, CD79B, CDC73, CDK12, CDK4, CDK6, CDK8, CDKN1B, CDKN2B, CDKN2C, CEBPA, CHEK1, CIC, CRKL, CRLF2, CSF1R, CTCF, CTNNA1, DAXX, DDR2, DOT1L, EMSY (C11orf30), EP300, EPHA3, EPHA5, EPHB1, ERBB4, ERG, ESR1, EZH2, FAM123B (WTX), FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXL2, GATA1, GATA2, GATA3, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GPR124,

GSK3B, HGF, IDH1, IDH2, IGF1R, IKBKE, IKZF1, IL7R, INHBA, IRF4, IRS2, JAK1, JAK3, JUN, KAT6A (MYST3), KDM5A, KDM5C, KDM6A, KDR, KEAP1, KLHL6, MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, MITF, MLH1, MLL, MLL2, MPL, MSH2, MSH6, MTOR, MUTYH, MYC, MYCL1, MYCN, MYD88, NF1, NFKBIA, NKX2-1, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PAK3, PALB2, PAX5, PBRM1, PDGFRA, PDGFRB, PDK1, PIK3CG, PIK3R2, PPP2R1A, PRDM1, PRKAR1A, PRKDC, PTCH1, PTPN11, RAD51, RAF1, RARA, RET, RICTOR, RNF43, RPTOR, RUNX1, SMARCA4, SMARCB1, SMO, SOCS1, SOX10, SOX2, SPEN, SPOP, SRC, STAT4, SUFU , TET2, TGFBR2, TNFAIP3, TNFRSF14, TOP1, TP53, TSC1, TSC2, TSHR, VHL, WISP3, WT1, ZNF217, ZNF703, and combinations thereof (Su *et al.*, J Mol Diagn 2011, 13:74–84; DOI:10.1016/j.jmoldx.2010.11.010; and Abaan *et al.*, "The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology", *Cancer Research,* July 15, 2013, which are each hereby incorporated by reference in its entirety). In some embodiments, the duplication is a chromosome 1p ("Chr1p") duplication associated with breast cancer. In some embodiments, one or more polymorphisms or mutations are in BRAF, such as the V600E mutation. In some embodiments, one or more polymorphisms or mutations are in K-ras. In some embodiments, there is a combination of one or more polymorphisms or mutations in K-ras and APC. In some embodiments, there is a combination of one or more polymorphisms or mutations in K-ras and p53. In some embodiments, there is a combination of one or more polymorphisms or mutations in APC and p53. In some embodiments, there is a combination of one or more polymorphisms or mutations in K-ras, APC, and p53. In some embodiments, there is a combination of one or more polymorphisms or mutations in K-ras and EGFR. Exemplary polymorphisms or mutations are in one or more of the following microRNAs: miR-15a, miR-16-1, miR-23a, miR-23b, miR-24-1, miR-24-2, miR-27a, miR-27b, miR-29b-2, miR-29c, miR-146, miR-155, miR-221, miR-222, and miR-223 (Calin *et al.* "A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia." N Engl J Med 353:1793– 801, 2005, which is hereby incorporated by reference in its entirety).

[0573] In some embodiments, the deletion is a deletion of at least 0.01 kb, 0.1 kb, 1 kb, 10 kb, 100 kb, 1 mb, 2 mb, 3 mb, 5 mb, 10 mb, 15 mb, 20 mb, 30 mb, or 40 mb. In some embodiments, the deletion is a deletion of between 1 kb to 40 mb, such as between 1 kb to 100 kb, 100 kb to 1

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 329

mb, 1 to 5 mb, 5 to 10 mb, 10 to 15 mb, 15 to 20 mb, 20 to 25 mb, 25 to 30 mb, or 30 to 40 mb, inclusive.

[0574] In some embodiments, the duplication is a duplication of at least 0.01 kb, 0.1 kb, 1 kb, 10 kb, 100 kb, 1 mb, 2 mb, 3 mb, 5 mb, 10 mb, 15 mb, 20 mb, 30 mb, or 40 mb. In some embodiments, the duplication is a duplication of between 1 kb to 40 mb, such as between 1 kb to 100 kb, 100 kb to 1 mb, 1 to 5 mb, 5 to 10 mb, 10 to 15 mb, 15 to 20 mb, 20 to 25 mb, 25 to 30 mb, or 30 to 40 mb, inclusive.

[0575] In some embodiments, the tandem repeat is a repeat of between 2 and 60 nucleotides, such as 2 to 6, 7 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, or 50 to 60 nucleotides, inclusive. In some embodiments, the tandem repeat is a repeat of 2 nucleotides (dinucleotide repeat). In some embodiments, the tandem repeat is a repeat of 3 nucleotides (trinucleotide repeat).

[0576] In some embodiments, the polymorphism or mutation is prognostic. Exemplary prognostic mutations include K-ras mutations, such as K-ras mutations that are indicators of post-operative disease recurrence in colorectal cancer (Ryan *et al."* A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up," Gut 52:101-108, 2003; and Lecomte T *et al.* Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis," Int J Cancer 100:542-548, 2002, which are each hereby incorporated by reference in its entirety).

[0577] In some embodiments, the polymorphism or mutation is associated with altered response to a particular treatment (such as increased or decreased efficacy or side-effects). Examples include K-ras mutations are associated with decreased response to EGFR-based treatments in non-small cell lung cancer (Wang *et al.* "Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer," Clin Canc Res16:1324-1330, 2010, which is hereby incorporated by reference in its entirety).

[0578] K-ras is an oncogene that is activated in many cancers. Exemplary K-ras mutations are mutations in codons 12, 13, and 61. K-ras cfDNA mutations have been identified in pancreatic, lung, colorectal, bladder, and gastric cancers (Fleischhacker & Schmidt "Circulating nucleic acids (CNAs) and caner – a survey," Biochim Biophys Acta 1775:181-232, 2007, which is hereby incorporated by reference in its entirety).

[0579] p53 is a tumor suppressor that is mutated in many cancers and contributes to tumor progression (Levine & Oren "The first 30 years of p53: growing ever more complex. Nature Rev

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 330

Cancer," 9:749–758, 2009, which is hereby incorporated by reference in its entirety). Many different codons can be mutated, such as Ser249. p53 cfDNA mutations have been identified in breast, lung, ovarian, bladder, gastric, pancreatic, colorectal, bowel, and hepatocellular cancers (Fleischhacker & Schmidt "Circulating nucleic acids (CNAs) and caner – a survey," Biochim Biophys Acta 1775:181-232, 2007, which is hereby incorporated by reference in its entirety).

[0580] BRAF is an oncogene downstream of Ras. BRAF mutations have been identified in glial neoplasm, melanoma, thyroid, and lung cancers (Dias-Santagata *et al.* BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLOS ONE 2011;6:e17948, 2011; Shinozaki *et al.* Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Canc Res 13:2068-2074, 2007; and Board *et al.* Detection of BRAF mutations in the tumor and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Brit J Canc 2009;101:1724-1730, which are each hereby incorporated by reference in its entirety). The BRAF V600E mutation occurs, *e.g.*, in melanoma tumors, and is more common in advanced stages. The V600E mutation has been detected in cfDNA.

[0581] EGFR contributes to cell proliferation and is misregulated in many cancers (Downward J. Targeting RAS signaling pathways in cancer therapy. Nature Rev Cancer 3:11–22, 2003; and Levine & Oren "The first 30 years of p53: growing ever more complex. Nature Rev Cancer," 9:749–758, 2009, which is hereby incorporated by reference in its entirety). Exemplary EGFR mutations include those in exons 18-21, which have been identified in lung cancer patients. EGFR cfDNA mutations have been identified in lung cancer patients (Jia *et al.* "Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer," J Canc Res Clin Oncol 2010;136:1341-1347, 2010, which is hereby incorporated by reference in its entirety).

[0582] Exemplary polymorphisms or mutations associated with breast cancer include LOH at microsatellites (Kohler *et al.* "Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors," Mol Cancer 8:doi:10.1186/1476-4598-8-105, 2009, which is hereby incorporated by reference in its entirety), p53 mutations (such as mutations in exons 5-8)(Garcia *et al.*" Extracellular tumor DNA in plasma and overall survival in breast cancer patients," Genes, Chromosomes & Cancer 45:692-701, 2006, which is hereby incorporated by reference in its entirety), HER2 (Sorensen *et al.* "Circulating *HER2* DNA after trastuzumab

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 331

treatment predicts survival and response in breast cancer," Anticancer Res30:2463-2468, 2010, which is hereby incorporated by reference in its entirety), PIK3CA, MED1, and GAS6 polymorphisms or mutations (Murtaza *et al.* "Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA," Nature 2013;doi:10.1038/nature12065, 2013, which is hereby incorporated by reference in its entirety).

[0583] Increased cfDNA levels and LOH are associated with decreased overall and disease-free survival. p53 mutations (exons 5-8) are associated with decreased overall survival. Decreased circulating HER2 cfDNA levels are associated with a better response to HER2-targeted treatment in HER2-positive breast tumor subjects. An activating mutation in PIK3CA, a truncation of MED1, and a splicing mutation in GAS6 result in resistance to treatment.

[0584] Exemplary polymorphisms or mutations associated with colorectal cancer include p53, APC, K-ras, and thymidylate synthase mutations and p16 gene methylation (Wang *et al.* "Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers," World J Surg 28:721-726, 2004; Ryan *et al.* "A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up," Gut 52:101-108, 2003; Lecomte *et al.* "Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis," Int J Cancer 100:542-548, 2002; Schwarzenbach *et al.* "Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma," Int J Cancer 127:881-888, 2009, which are each hereby incorporated by reference in its entirety). Post-operative detection of K-ras mutations in serum is a strong predictor of disease recurrence. Detection of K-ras mutations and p16 gene methylation are associated with decreased survival and increased disease recurrence. Detection of K-ras, APC, and/or p53 mutations is associated with recurrence and/or metastases. Polymorphisms (including LOH, SNPs, variable number tandem repeats, and deletion) in the thymidylate synthase (the target of fluoropyrimidine-based chemotherapies) gene using cfDNA may be associated with treatment response.

[0585] Exemplary polymorphisms or mutations associated with lung cancer (such as non-small cell lung cancer) include K-ras (such as mutations in codon 12) and EGFR mutations. Exemplary prognostic mutations include EGFR mutations (exon 19 deletion or exon 21 mutation) associated with increased overall and progression-free survival and K-ras mutations (in codons 12 and 13)

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 332

are associated with decreased progression-free survival (Jian *et al.* "Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer," J Canc Res Clin Oncol 136:1341-1347, 2010; Wang *et al.* "Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer," Clin Canc Res 16:1324-1330, 2010, which are each hereby incorporated by reference in its entirety). Exemplary polymorphisms or mutations indicative of response to treatment include EGFR mutations (exon 19 deletion or exon 21 mutation) that improve response to treatment and K-ras mutations (codons 12 and 13) that decrease the response to treatment. A resistance-conferring mutation in EFGR has been identified (Murtaza *et al.* "Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA," Nature doi:10.1038/nature12065, 2013, which is hereby incorporated by reference in its entirety).

[0586] Exemplary polymorphisms or mutations associated with melanoma (such as uveal melanoma) include those in GNAQ, GNA11, BRAF, and p53. Exemplary GNAQ and GNA11 mutations include R183 and Q209 mutations. Q209 mutations in GNAQ or GNA11 are associated with metastases to bone. BRAF V600E mutations can be detected in patients with metastatic/advanced stage melanoma. BRAF V600E is an indicator of invasive melanoma. The presence of the BRAF V600E mutation after chemotherapy is associated with a non-response to the treatment

[0587] Exemplary polymorphisms or mutations associated with pancreatic carcinomas include those in K-ras and p53 (such as p53 Ser249). p53 Ser249 is also associated with hepatitis B infection and hepatocellular carcinoma, as well as ovarian cancer, and non-Hodgkin's lymphoma.

[0588] Even polymorphisms or mutations that are present in low frequency in a sample can be detected with the methods of the invention. For example, a polymorphism or mutation that is present at a frequency of 1 in a million can be observed 10 times by performing 10 million sequencing reads. If desired, the number of sequencing reads can be altered depending of the level of sensitivity desired. In some embodiments, a sample is re-analyzed or another sample from a subject is analyzed using a greater number of sequencing reads to improve the sensitivity. For example, if no or only a small number (such as 1, 2, 3, 4, or 5) polymorphisms or mutations that are associated with cancer or an increased risk for cancer are detected, the sample is re-analyzed or another sample is tested.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 333

[0589] In some embodiments, multiple polymorphisms or mutations are required for cancer or for metastatic cancer. In such cases, screening for multiple polymorphisms or mutations improves the ability to accurately diagnose cancer or metastatic cancer. In some embodiments when a subject has a subset of multiple polymorphisms or mutations that are required for cancer or for metastatic cancer, the subject can be re-screened later to see if the subject acquires additional mutations.

[0590] In some embodiments in which multiple polymorphisms or mutations are required for cancer or for metastatic cancer, the frequency of each polymorphism or mutation can be compared to see if they occur at similar frequencies. For example, if two mutations required for cancer (denoted "A" and "B"), some cells will have none, some cells with A, some with B, and some with A and B. If A and B are observed at similar frequencies, the subject is more likely to have some cells with both A and B. If observer A and B at dissimilar frequencies, the subject is more likely to have different cell populations.

[0591] In some embodiments in which multiple polymorphisms or mutations are required for cancer or for metastatic cancer, the number or identity of such polymorphisms or mutations that are present in the subject can be used to predict how likely or soon the subject is likely to have the disease or disorder. In some embodiments in which polymorphisms or mutations tend to occur in a certain order, the subject may be periodically tested to see if the subject has acquired the other polymorphisms or mutations.

[0592] In some embodiments, determining the presence or absence of multiple polymorphisms or mutations (such as 2, 3, 4, 5, 8, 10, 12, 15, or more) increases the sensitivity and/or specificity of the determination of the presence or absence of a disease or disorder such as cancer, or an increased risk for with a disease or disorder such as cancer.

[0593] In some embodiments, the polymorphism(s) or mutation(s) are directly detected. In some embodiments, the polymorphism(s) or mutation(s) are indirectly detected by detection of one or more sequences (*e.g.*, a polymorphic locus such as a SNP) that are linked to the polymorphism or mutation.

Exemplary Nucleic Acid Alterations

[0594] In some embodiments, there is a change to the integrity of RNA or DNA (such as a change in the size of fragmented cfRNA or cfDNA or a change in nucleosome composition) that is

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 334

associated with a disease or disorder such as cancer, or an increased risk for a disease or disorder such as cancer. In some embodiments, there is a change in the methylation pattern RNA or DNA that is associated with a disease or disorder such as cancer, or an increased risk for with a disease or disorder such as cancer (*e.g.*, hypermethylation of tumor suppressor genes). For example, methylation of the CpG islands in the promoter region of tumor-suppressor genes has been suggested to trigger local gene silencing. Aberrant methylation of the p16 tumor suppressor gene occurs in subjects with liver, lung, and breast cancer. Other frequently methylated tumor suppressor genes, including APC, Ras association domain family protein 1A (RASSF1A), glutathione S-transferase P1 (GSTP1), and DAPK, have been detected in various type of cancers, for example nasopharyngeal carcinoma, colorectal cancer, lung cancer, esophageal cancer, prostate cancer, bladder cancer, melanoma, and acute leukemia. Methylation of certain tumor-suppressor genes, such as p16, has been described as an early event in cancer formation, and thus is useful for early cancer screening.

[0595] In some embodiments, bisulphite conversion or a non-bisulphite based strategy using methylation sensitive restriction enzyme digestion is used to determine the methylation pattern (Hung *et al.,* J Clin Pathol 62:308–313, 2009, which is hereby incorporated by reference in its entirety). On bisulphite conversion, methylated cytosines remain as cytosines while unmethylated cytosines are converted to uracils. Methylation-sensitive restriction enzymes (*e.g.*, BstUI) cleaves unmethylated DNA sequences at specific recognition sites (*e.g.*, 5′-CG ∨ CG-3′ for BstUI), while methylated sequences remain intact. In some embodiments, the intact methylated sequences are detected. In some embodiments, stem-loop primers are used to selectively amplify restriction enzyme-digested unmethylated fragments without co-amplifying the non-enzyme-digested methylated DNA.

Exemplary Changes in mRNA Splicing

[0596] In some embodiments, a change in mRNA splicing is associated with a disease or disorder such as cancer, or an increased risk for a disease or disorder such as cancer. In some embodiments, the change in mRNA splicing is in one or more of the following nucleic acids associated with cancer or an increased risk for cancer: DNMT3B, BRCA1, KLF6, Ron, or Gemin5. In some embodiments, the detected mRNA splice variant is associated with a disease or disorder, such as cancer. In some embodiments, multiple mRNA splice variants are produced by healthy cells (such

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 335

as non-cancerous cells), but a change in the relative amounts of the mRNA splice variants is associated with a disease or disorder, such as cancer. In some embodiments, the change in mRNA splicing is due to a change in the mRNA sequence (such as a mutation in a splice site), a change in splicing factor levels, a change in the amount of available splicing factor (such as a decrease in the amount of available splicing factor due to the binding of a splicing factor to a repeat), altered splicing regulation, or the tumor microenvironment.

[0597] The splicing reaction is carried out by a multi-protein/RNA complex called the spliceosome (Fackenthall and Godley, Disease Models & Mechanisms 1: 37-42, 2008, doi:10.1242/dmm.000331, which is hereby incorporated by reference in its entirety). The spliceosome recognizes intron-exon boundaries and removes intervening introns via two transesterification reactions that result in ligation of two adjacent exons. The fidelity of this reaction must be exquisite, because if the ligation occurs incorrectly, normal protein-encoding potential may be compromised. For example, in cases where exon-skipping preserves the reading frame of the triplet codons specifying the identity and order of amino acids during translation, the alternatively spliced mRNA may specify a protein that lacks crucial amino acid residues. More commonly, exon-skipping will disrupt the translational reading frame, resulting in premature stop codons. These mRNAs are typically degraded by at least 90% through a process known as nonsense-mediated mRNA degradation, which reduces the likelihood that such defective messages will accumulate to generate truncated protein products. If mis-spliced mRNAs escape this pathway, then truncated, mutated, or unstable proteins are produced.

[0598] Alternative splicing is a means of expressing several or many different transcripts from the same genomic DNA and results from the inclusion of a subset of the available exons for a particular protein. By excluding one or more exons, certain protein domains may be lost from the encoded protein, which can result in protein function loss or gain. Several types of alternative splicing have been described: exon skipping; alternative 5′ or 3′ splice sites; mutually exclusive exons; and, much more rarely, intron retention. Others have compared the amount of alternative splicing in cancer versus normal cells using a bioinformatic approach and determined that cancers exhibit lower levels of alternative splicing than normal cells. Furthermore, the distribution of the types of alternative splicing events differed in cancer versus normal cells. Cancer cells demonstrated less exon skipping, but more alternative 5′ and 3′ splice site selection and intron retention than normal cells. When the phenomenon of exonization (the use of sequences as exons

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 336

that are used predominantly by other tissues as introns) was examined, genes associated with exonization in cancer cells were preferentially associated with mRNA processing, indicating a direct link between cancer cells and the generation of aberrant mRNA splice forms.

Exemplary Changes in DNA or RNA Levels

[0599] In some embodiments, there is a change in the total amount or concentration of one or more types of DNA (such as cfDNA cf mDNA, cf nDNA, cellular DNA, or mitochondrial DNA) or RNA (cfRNA, cellular RNA, cytoplasmic RNA, coding cytoplasmic RNA, non-coding cytoplasmic RNA, mRNA, miRNA, mitochondrial RNA, rRNA, or tRNA). In some embodiments, there is a change in the amount or concentration of one or more specific DNA (such as cfDNA cf mDNA, cf nDNA, cellular DNA, or mitochondrial DNA) or RNA (cfRNA, cellular RNA, cytoplasmic RNA, coding cytoplasmic RNA, non-coding cytoplasmic RNA, mRNA, miRNA, mitochondrial RNA, rRNA, or tRNA) molecules. In some embodiments, one allele is expressed more than another allele of a locus of interest. Exemplary miRNAs are short 20–22 nucleotide RNA molecules that regulate the expression of a gene. In some embodiments, there is a change in the transcriptome, such as a change in the identity or amount of one or more RNA molecules.

[0600] In some embodiments, an increase in the total amount or concentration of cfDNA or cfRNA is associated with a disease or disorder such as cancer, or an increased risk for a disease or disorder such as cancer. In some embodiments, the total concentration of a type of DNA (such as cfDNA cf mDNA, cf nDNA, cellular DNA, or mitochondrial DNA) or RNA (cfRNA, cellular RNA, cytoplasmic RNA, coding cytoplasmic RNA, non-coding cytoplasmic RNA, mRNA, miRNA, mitochondrial RNA, rRNA, or tRNA) increases by at least 2, 3, 4, 5, 6, 7, 8, 9, 10-fold, or more compared to the total concentration of that type of DNA or RNA in healthy (such as non-cancerous) subjects. In some embodiments, a total concentration of cfDNA between 75 to 100 ng/mL, 100 to 150 ng/mL, 150 to 200 ng/mL, 200 to 300 ng/mL, 300 to 400 ng/mgL, 400 to 600 ng/mL, 600 to 800 ng/mL, 800 to 1,000 ng/mL, inclusive, or a total concentration of cfDNA of more than 100 ng, mL, such as more than 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 ng/mL is indicative of cancer, an increased risk for cancer, an increased risk of a tumor being malignant rather than benign, a decreased probably of the cancer going into remission, or a worse prognosis for the cancer. In some embodiments, the amount of a type of DNA (such as cfDNA cf mDNA,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 337

cf nDNA, cellular DNA, or mitochondrial DNA) or RNA (cfRNA, cellular RNA, cytoplasmic RNA, coding cytoplasmic RNA, non-coding cytoplasmic RNA, mRNA, miRNA, mitochondrial RNA, rRNA, or tRNA) having one or more polymorphisms/mutations (such as deletions or duplications) associated with a disease or disorder such as cancer or an increased risk for a disease or disorder such as cancer is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, or 25% of the total amount of that type of DNA or RNA. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, or 25% of the total amount of a type of DNA (such as cfDNA cf mDNA, cf nDNA, cellular DNA, or mitochondrial DNA) or RNA (cfRNA, cellular RNA, cytoplasmic RNA, coding cytoplasmic RNA, non-coding cytoplasmic RNA, mRNA, miRNA, mitochondrial RNA, rRNA, or tRNA) has a particular polymorphism or mutation (such as a deletion or duplication) associated with a disease or disorder such as cancer or an increased risk for a disease or disorder such as cancer.

[0601] In some embodiments, the cfDNA is encapsulated. In some embodiments, the cfDNA is not encapsulated.

[0602] In some embodiments, the fraction of tumor DNA out of total DNA (such as fraction of tumor cfDNA out of total cfDNA or fraction of tumor cfDNA with a particular mutation out of total cfDNA) is determined. In some embodiments, the fraction of tumor DNA may be determined for a plurality of mutations, where the mutations can be single nucleotide variants, copy number variants, differential methylation, or combinations thereof. In some embodiments, the average tumor fraction calculated for one or a set of mutations with the highest calculated tumor fraction is taken as the actual tumor fraction in the sample. In some embodiments, the average tumor fraction calculated for all of the mutations is taken as the actual tumor fraction in the sample. In some embodiments, this tumor fraction is used to stage a cancer (since higher tumor fractions can be associated with more advanced stages of cancer). In some embodiments, the tumor fraction is used to size a cancer, since larger tumors may be correlated with the fraction of tumor DNA in the plasma. In some embodiments, the tumor fraction is used to size the proportion of a tumor that is afflicted with a single or plurality of mutations, since there may be a correlation between the measured tumor fraction in a plasma sample and the size of tissue with a given mutation(s) genotype. For example, the size of tissue with a given mutation(s) genotype may be correlated with the fraction of tumor DNA that may be calculated by focusing on that particular mutation(s).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 338

Exemplary Databases

[0603] The invention also features databases containing one or more results from a method of the invention. For example, the database may include records with any of the following information for one or more subjects: any polymorphisms/mutations (such as CNVs) identified, any known association of the polymorphisms/mutations with a disease or disorder or an increased risk for a disease or disorder, effect of the polymorphisms/mutations on the expression or activity level of the encoded mRNA or protein, fraction of DNA, RNA, or cells associated with a disease or disorder (such as DNA, RNA, or cells having polymorphism/mutation associated with a disease or disorder) out of the total DNA, RNA, or cells in sample, source of sample used to identify the polymorphisms/mutations (such as a blood sample or sample from a particular tissue), number of diseased cells, results from later repeating the test (such as repeating the test to monitor the progression or remission of the disease or disorder), results of other tests for the disease or disorder, type of disease or disorder the subject was diagnosed with, treatment(s) administered, response to such treatment(s), side-effects of such treatment(s), symptoms (such as symptoms associated with the disease or disorder), length and number of remissions, length of survival (such as length of time from initial test until death or length of time from diagnosis until death), cause of death, and combinations thereof.

[0604] In some embodiments, the database includes records with any of the following information for one or more subjects: any polymorphisms/mutations identified, any known association of the polymorphisms/mutations with cancer or an increased risk for cancer, effect of the polymorphisms/mutations on the expression or activity level of the encoded mRNA or protein, fraction of cancerous DNA, RNA or cells out of the total DNA, RNA, or cells in sample, source of sample used to identify the polymorphisms/mutations (such as a blood sample or sample from a particular tissue), number of cancerous cells, size of tumor(s), results from later repeating the test (such as repeating the test to monitor the progression or remission of the cancer), results of other tests for cancer, type of cancer the subject was diagnosed with, treatment(s) administered, response to such treatment(s), side-effects of such treatment(s), symptoms (such as symptoms associated with cancer), length and number of remissions, length of survival (such as length of time from initial test until death or length of time from cancer diagnosis until death), cause of death, and combinations thereof. In some embodiments, the response to treatment includes any of the following: reducing or stabilizing the size of a tumor (*e.g.*, a benign or cancerous tumor),

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 339

slowing or preventing an increase in the size of a tumor, reducing or stabilizing the number of tumor cells, increasing the disease-free survival time between the disappearance of a tumor and its reappearance, preventing an initial or subsequent occurrence of a tumor, reducing or stabilizing an adverse symptom associated with a tumor, or combinations thereof. In some embodiments, the results from one or more other tests for a disease or disorder such as cancer are included, such as results from screening tests, medical imaging, or microscopic examination of a tissue sample.

[0605] In one such aspect, the invention features an electronic database including at least 5, 10, 10^2, 10^3, 10^4, 10^5, 10^6, 10^7, 10^8 or more records. In some embodiments, the database has records for at least 5, 10, 10^2, 10^3, 10^4, 10^5, 10^6, 10^7, 10^8 or more different subjects.

[0606] In another aspect, the invention features a computer including a database of the invention and a user interface. In some embodiments, the user interface is capable of displaying a portion or all of the information contained in one or more records. In some embodiments, the user interface is capable of displaying (i) one or more types of cancer that have been identified as containing a polymorphism or mutation whose record is stored in the computer, (ii) one or more polymorphisms or mutations that have been identified in a particular type of cancer whose record is stored in the computer, (iii) prognosis information for a particular type of cancer or a particular a polymorphism or mutation whose record is stored in the computer (iv) one or more compounds or other treatments useful for cancer with a polymorphism or mutation whose record is stored in the computer, (v) one or more compounds that modulate the expression or activity of an mRNA or protein whose record is stored in the computer, and (vi) one or more mRNA molecules or proteins whose expression or activity is modulated by a compound whose record is stored in the computer. The internal components of the computer typically include a processor coupled to a memory. The external components usually include a mass-storage device, *e.g.,* a hard disk drive; user input devices, *e.g.*, a keyboard and a mouse; a display, *e.g.,* a monitor; and optionally, a network link capable of connecting the computer system to other computers to allow sharing of data and processing tasks. Programs may be loaded into the memory of this system during operation.

[0607] In another aspect, the invention features a computer-implemented process that includes one or more steps of any of the methods of the invention.

Exemplary Risk Factors

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 340

[0608] In some embodiments, the subject is also evaluated for one or more risk factors for a disease or disorder, such as cancer. Exemplary risk factors include family history for the disease or disorder, lifestyle (such as smoking and exposure to carcinogens) and the level of one or more hormones or serum proteins (such as alpha-fetoprotein (AFP) in liver cancer, carcinoembryonic antigen (CEA) in colorectal cancer, or prostate-specific antigen (PSA) in prostate cancer). In some embodiments, the size and/or number of tumors is measured and use in determining a subject's prognosis or selecting a treatment for the subject.

Exemplary Screening Methods

[0609] If desired, the presence or absence of a disease or disorder such cancer can be confirmed, or the disease or disorder such as cancer can be classified using any standard method. For example, a disease or disorder such as cancer can be detected in a number of ways, including the presence of certain signs and symptoms, tumor biopsy, screening tests, or medical imaging (such as a mammogram or an ultrasound). Once a possible cancer is detected, it may be diagnosed by microscopic examination of a tissue sample. In some embodiments, a subject diagnosed undergoes repeat testing using a method of the invention or known testing for the disease or disorder at multiple time points to monitor the progression of the disease or disorder or the remission or reoccurrence of the disease or disorder.

Exemplary Cancers

[0610] Exemplary cancers that can be diagnosed, prognosed, stabilized, treated, or prevented using any of the methods of the invention include solid tumors, carcinomas, sarcomas, lymphomas, leukemias, germ cell tumors, or blastomas. In various embodiments, the cancer is an acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancer, AIDS-related lymphoma, anal cancer, appendix cancer, astrocytoma (such as childhood cerebellar or cerebral astrocytoma), basal-cell carcinoma, bile duct cancer (such as extrahepatic bile duct cancer) bladder cancer, bone tumor (such as osteosarcoma or malignant fibrous histiocytoma), brainstem glioma, brain cancer (such as cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymo, medulloblastoma, supratentorial primitive neuroectodermal tumors, or visual pathway and hypothalamic glioma), glioblastoma, breast cancer, bronchial adenoma or carcinoid, burkitt's lymphoma, carcinoid tumor (such as a childhood or gastrointestinal carcinoid tumor),

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 341

carcinoma central nervous system lymphoma, cerebellar astrocytoma or malignant glioma (such as childhood cerebellar astrocytoma or malignant glioma), cervical cancer, childhood cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous t-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, ewing's sarcoma, tumor in the ewing family of tumors, extracranial germ cell tumor (such as a childhood extracranial germ cell tumor), extragonadal germ cell tumor, eye cancer (such as intraocular melanoma or retinoblastoma eye cancer), gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor (such as extracranial, extragonadal, or ovarian germ cell tumor), gestational trophoblastic tumor, glioma (such as brain stem, childhood cerebral astrocytoma, or childhood visual pathway and hypothalamic glioma), gastric carcinoid, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, hodgkin lymphoma, hypopharyngeal cancer, hypothalamic and visual pathway glioma (such as childhood visual pathway glioma), islet cell carcinoma (such as endocrine or pancreas islet cell carcinoma), kaposi sarcoma, kidney cancer, laryngeal cancer, leukemia (such as acute lymphoblastic, acute myeloid, chronic lymphocytic, chronic myelogenous, or hairy cell leukemia), lip or oral cavity cancer, liposarcoma, liver cancer (such as non-small cell or small cell cancer), lung cancer, lymphoma (such as AIDS-related, burkitt, cutaneous T cell, Hodgkin, non-hodgkin, or central nervous system lymphoma), macroglobulinemia (such as waldenström macroglobulinemia, malignant fibrous histiocytoma of bone or osteosarcoma, medulloblastoma (such as childhood medulloblastoma), melanoma, merkel cell carcinoma, mesothelioma (such as adult or childhood mesothelioma), metastatic squamous neck cancer with occult, mouth cancer, multiple endocrine neoplasia syndrome (such as childhood multiple endocrine neoplasia syndrome), multiple myeloma or plasma cell neoplasm. mycosis fungoides, myelodysplastic syndrome, myelodysplastic or myeloproliferative disease, myelogenous leukemia (such as chronic myelogenous leukemia), myeloid leukemia (such as adult acute or childhood acute myeloid leukemia), myeloproliferative disorder (such as chronic myeloproliferative disorder), nasal cavity or paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma or malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer (such as islet cell pancreatic cancer), paranasal sinus or nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 342

pheochromocytoma, pineal astrocytoma, pineal germinoma. pineoblastoma or supratentorial primitive neuroectodermal tumor (such as childhood pineoblastoma or supratentorial primitive neuroectodermal tumor), pituitary adenoma, plasma cell neoplasia, pleuropulmonary blastoma, primary central nervous system lymphoma, cancer, rectal cancer, renal cell carcinoma, renal pelvis or ureter cancer (such as renal pelvis or ureter transitional cell cancer, retinoblastoma, rhabdomyosarcoma (such as childhood rhabdomyosarcoma), salivary gland cancer, sarcoma (such as sarcoma in the ewing family of tumors, Kaposi, soft tissue, or uterine sarcoma), sézary syndrome, skin cancer (such as nonmelanoma, melanoma, or merkel cell skin cancer), small intestine cancer, squamous cell carcinoma, supratentorial primitive neuroectodermal tumor (such as childhood supratentorial primitive neuroectodermal tumor), T-cell lymphoma (such as cutaneous T-cell lymphoma), testicular cancer, throat cancer, thymoma (such as childhood thymoma), thymoma or thymic carcinoma, thyroid cancer (such as childhood thyroid cancer), trophoblastic tumor (such as gestational trophoblastic tumor), unknown primary site carcinoma (such as adult or childhood unknown primary site carcinoma), urethral cancer (such as endometrial uterine cancer), uterine sarcoma, vaginal cancer, visual pathway or hypothalamic glioma (such as childhood visual pathway or hypothalamic glioma), vulvar cancer, waldenström macroglobulinemia, or wilms tumor (such as childhood wilms tumor). In various embodiments, the cancer has metastasized or has not metastasized.

[0611] The cancer may or may not be a hormone related or dependent cancer (*e.g.*, an estrogen or androgen related cancer). Benign tumors or malignant tumors may be diagnosed, prognosed, stabilized, treated, or prevented using the methods and/or compositions of the present invention.

[0612] In some embodiments, the subject has a cancer syndrome. A cancer syndrome is a genetic disorder in which genetic mutations in one or more genes predispose the affected individuals to the development of cancers and may also cause the early onset of these cancers. Cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors. Many of these syndromes are caused by mutations in tumor suppressor genes, genes that are involved in protecting the cell from turning cancerous. Other genes that may be affected are DNA repair genes, oncogenes and genes involved in the production of blood vessels (angiogenesis). Common examples of inherited cancer syndromes are hereditary breast-ovarian cancer syndrome and hereditary non-polyposis colon cancer (Lynch syndrome).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 343

[0613] In some embodiments, a subject with one or more polymorphisms or mutations n K-ras, p53, BRA, EGFR, or HER2 is administered a treatment that targets K-ras, p53, BRA, EGFR, or HER2, respectively.

[0614] The methods of the invention can be generally applied to the treatment of malignant or benign tumors of any cell, tissue, or organ type.

Exemplary Treatments

[0615] If desired, any treatment for stabilizing, treating, or preventing a disease or disorder such as cancer or an increased risk for a disease or disorder such as cancer can be administered to a subject (*e.g.*, a subject identified as having cancer or an increased risk for cancer using any of the methods of the invention). In various embodiments, the treatment is a known treatment or combination of treatments for a disease or disorder such as cancer, such as cytotoxic agents, targeted therapy, immunotherapy, hormonal therapy, radiation therapy, surgical removal of cancerous cells or cells likely to become cancerous, stem cell transplantation, bone marrow transplantation, photodynamic therapy, palliative treatment, or a combination thereof. In some embodiments, a treatment (such as a preventative medication) is used to prevent, delay, or reduce the severity of a disease or disorder such as cancer in a subject at increased risk for a disease or disorder such as cancer.

[0616] In some embodiments, the targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells while limiting damage to normal cells, usually leading to fewer side effects than other cancer medications.

[0617] One of the more successful approaches has been to target angiogenesis, the new blood vessel growth around a tumor. Targeted therapies such as bevacizumab (Avastin), lenalidomide (Revlimid), sorafenib (Nexavar), sunitinib (Sutent), and thalidomide (Thalomid) interfere with angiogenesis. Another example is the use of a treatment that targets HER2, such as trastuzumab or lapatinib, for cancers that overexpress HER2 (such as some breast cancers). In some embodiments, a monoclonal antibody is used to block a specific target on the outside of cancer cells. Examples include alemtuzumab (Campath-1H), bevacizumab, cetuximab (Erbitux), panitumumab (Vectibix), pertuzumab (Omnitarg), rituximab (Rituxan), and trastuzumab. In some embodiments, the monoclonal antibody tositumomab (Bexxar) is used to deliver radiation to the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 344

tumor. In some embodiments, an oral small molecule inhibits a cancer process inside of a cancer cell. Examples include dasatinib (Sprycel), erlotinib (Tarceva), gefitinib (Iressa), imatinib (Gleevec), lapatinib (Tykerb), nilotinib (Tasigna), sorafenib, sunitinib, and temsirolimus (Torisel). In some embodiments, a proteasome inhibitor (such as the multiple myeloma drug, bortezomib (Velcade)) interferes with specialized proteins called enzymes that break down other proteins in the cell.

[0618] In some embodiments, immunotherapy is designed to boost the body's natural defenses to fight the cancer. Exemplary types of immunotherapy use materials made either by the body or in a laboratory to bolster, target, or restore immune system function.

[0619] In some embodiments, hormonal therapy treats cancer by lowering the amounts of hormones in the body. Several types of cancer, including some breast and prostate cancers, only grow and spread in the presence of natural chemicals in the body called hormones. In various embodiments, hormonal therapy is used to treat cancers of the prostate, breast, thyroid, and reproductive system.

[0620] In some embodiments, the treatment includes a stem cell transplant in which diseased bone marrow is replaced by highly specialized cells, called hematopoietic stem cells. Hematopoietic stem cells are found both in the bloodstream and in the bone marrow.

[0621] In some embodiments, the treatment includes photodynamic therapy, which uses special drugs, called photosensitizing agents, along with light to kill cancer cells. The drugs work after they have been activated by certain kinds of light.

[0622] In some embodiments, the treatment includes surgical removal of cancerous cells or cells likely to become cancerous (such as a lumpectomy or a mastectomy). For example, a woman with a breast cancer susceptibility gene mutation (*BRCA1* or *BRCA2* gene mutation) may reduce her risk of breast and ovarian cancer with a risk reducing salpingo-oophorectomy (removal of the fallopian tubes and ovaries) and/or a risk reducing bilateral mastectomy (removal of both breasts). Lasers, which are very powerful, precise beams of light, can be used instead of blades (scalpels) for very careful surgical work, including treating some cancers.

[0623] In addition to treatment to slow, stop, or eliminate the cancer (also called disease-directed treatment), an important part of cancer care is relieving a subject's symptoms and side effects, such as pain and nausea. It includes supporting the subject with physical, emotional, and social needs,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 345

an approach called palliative or supportive care. People often receive disease-directed therapy and treatment to ease symptoms at the same time.

[0624] Exemplary treatments include actinomycin D, adcetris, Adriamycin, aldesleukin, alemtuzumab, alimta, amsidine, amsacrine, anastrozole, aredia, arimidex, aromasin, asparaginase, avastin, bevacizumab, bicalutamide, bleomycin, bondronat, bonefos, bortezomib, busilvex, busulphan, campto, capecitabine, carboplatin, carmustine, casodex, cetuximab, chimax, chlorambucil, cimetidine, cisplatin, cladribine, clodronate, clofarabine, crisantaspase, cyclophosphamide, cyproterone acetate, cyprostat, cytarabine, cytoxan, dacarbozine, dactinomycin, dasatinib, daunorubicin, dexamethasone, diethylstilbestrol, docetaxel, doxorubicin, drogenil, emcyt, epirubicin, eposin, Erbitux, erlotinib, estracyte, estramustine, etopophos, etoposide, evoltra, exemestane, fareston, femara, filgrastim, fludara, fludarabine, fluorouracil, flutamide, gefinitib, gemcitabine, gemzar, gleevec, glivec. gonapeptyl depot, goserelin, halaven, herceptin, hycamptin, hydroxycarbamide, ibandronic acid, ibritumomab, idarubicin, ifosfomide, interferon, imatinib mesylate, iressa, irinotecan, jevtana, lanvis, lapatinib, letrozole, leukeran, leuprorelin, leustat, lomustine, mabcampath, mabthera, megace, megestrol, methotrexate, mitozantrone, mitomycin, mutulane, myleran, navelbine, neulasta, neupogen, nexavar, nipent, nolvadex D, novantron, oncovin, paclitaxel, pamidronate, PCV, pemetrexed, pentostatin, perjeta, procarbazine, provenge, prednisolone, prostrap, raltitrexed, rituximab, sprycel, sorafenib, soltamox, streptozocin, stilboestrol, stimuvax, sunitinib, sutent, tabloid, tagamet, tamofen, tamoxifen, tarceva, taxol, taxotere, tegafur with uracil, temodal, temozolomide, thalidomide, thioplex, thiotepa, tioguanine, tomudex, topotecan, toremifene, trastuzumab, tretinoin, treosulfan, triethylenethiophorsphoramide, triptorelin, tyverb, uftoral, velcade, vepesid, vesanoid, vincristine, vinorelbine, xalkori, xeloda, yervoy, zactima, zanosar, zavedos, zevelin, zoladex, zoledronate, zometa zoledronic acid, and zytiga.

[0625] For subjects that express both a mutant form (*e.g.*, a cancer-related form) and a wild-type form (*e.g.*, a form not associated with cancer) of an mRNA or protein, the therapy preferably inhibits the expression or activity of the mutant form by at least 2, 5, 10, or 20-fold more than it inhibits the expression or activity of the wild-type form. The simultaneous or sequential use of multiple therapeutic agents may greatly reduce the incidence of cancer and reduce the number of treated cancers that become resistant to therapy. In addition, therapeutic agents that are used as part of a combination therapy may require a lower dose to treat cancer than the corresponding dose

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 346

required when the therapeutic agents are used individually. The low dose of each compound in the combination therapy reduces the severity of potential adverse side-effects from the compounds.

[0626] In some embodiments, a subject identified as having an increased risk of cancer may invention or any standard method), avoid specific risk factors, or make lifestyle changes to reduce any additional risk of cancer.

[0627] In some embodiments, the polymorphisms, mutations, risk factors, or any combination thereof are used to select a treatment regimen for the subject. In some embodiments, a larger dose or greater number of treatments is selected for a subject at greater risk of cancer or with a worse prognosis.

Other Compounds for Inclusion in Individual or Combination Therapies

[0628] If desired, additional compounds for stabilizing, treating, or preventing a disease or disorder such as cancer or an increased risk for a disease or disorder such as cancer may be identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field or drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the methods of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened for their effect on cells from a particular type of cancer or from a particular subject or screened for their effect on the activity or expression of cancer related molecules (such as cancer related molecules known to have altered activity or expression in a particular type of cancer). When a crude extract is found to modulate the activity or expression of a cancer related molecule, further fractionation of the positive lead extract may be performed to isolate chemical constituent responsible for the observed effect using methods known in the art.

Exemplary Assays and Animal Models for the Testing of Therapies

[0629] If desired, one or more of the treatment disclosed herein can be tested for their effect on a disease or disorder such as cancer using a cell line (such as a cell line with one or more of the mutations identified in the subject who has been diagnosed with cancer or an increased risk of cancer using the methods of the invention) or an animal model of the disease or disorder, such as a SCID mouse model (Jain *et al.,* Tumor Models In Cancer Research, ed. Teicher, Humana Press Inc., Totowa, N.J., pp. 647-671, 2001, which is hereby incorporated by reference in its entirety).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 347

Additionally, there are numerous standard assays and animal models that can be used to determine the efficacy of particular therapies for stabilizing, treating, or preventing a disease or disorder such as cancer or an increased risk for a disease or disorder such as cancer. Therapies can also be tested in standard human clinical trials.

[0630] For the selection of a preferred therapy for a particular subject, compounds can be tested for their effect on the expression or activity on one or more genes that are mutated in the subject. For example, the ability of a compound to modulate the expression of particular mRNA molecules or proteins can be detected using standard Northern, Western, or microarray analysis. In some embodiments, one or more compounds are selected that (i) inhibit the expression or activity of mRNA molecules or proteins that promote cancer that are expressed at a higher than normal level or have a higher than normal level of activity in the subject (such as in a sample from the subject) or (ii) promote the expression or activity of mRNA molecules or proteins that inhibit cancer that are expressed at a lower than normal level or have a lower than normal level of activity in the subject. An individual or combination therapy that (i) modulates the greatest number of mRNA molecules or proteins that have mutations associated with cancer in the subject and (ii) modulates the least number of mRNA molecules or proteins that do not have mutations associated with cancer in the subject. In some embodiments, the selected individual or combination therapy has high drug efficacy and produces few, if any, adverse side-effects.

[0631] As an alternative to the subject-specific analysis described above, DNA chips can be used to compare the expression of mRNA molecules in a particular type of early or late-stage cancer (*e.g.*, breast cancer cells) to the expression in normal tissue (Marrack *et al.*, Current Opinion in Immunology 12, 206-209, 2000; Harkin, Oncologist. 5:501-507, 2000; Pelizzari *et al.*, Nucleic Acids Res. 28(22):4577-4581, 2000, which are each hereby incorporated by reference in its entirety). Based on this analysis, an individual or combination therapy for subjects with this type of cancer can be selected to modulate the expression of the mRNA or proteins that have altered expression in this type of cancer.

[0632] In addition to being used to select a therapy for a particular subject or group of subjects, expression profiling can be used to monitor the changes in mRNA and/or protein expression that occur during treatment. For example, expression profiling can be used to determine whether the expression of cancer related genes has returned to normal levels. If not, the dose of one or more compounds in the therapy can be altered to either increase or decrease the effect of the therapy on

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 348

the expression levels of the corresponding cancer related gene(s). In addition, this analysis can be used to determine whether a therapy affects the expression of other genes (*e.g.*, genes that are associated with adverse side-effects). If desired, the dose or composition of the therapy can be altered to prevent or reduce undesired side-effects.

Exemplary Formulations and Methods of Administration

[0633] For stabilizing, treating, or preventing a disease or disorder such as cancer or an increased risk for a disease or disorder such as cancer, a composition may be formulated and administered using any method known to those of skill in the art (see, *e.g.*, U.S. Pat. Nos. 8,389,578 and 8,389,557, which are each hereby incorporated by reference in its entirety). General techniques for formulation and administration are found in "Remington: The Science and Practice of Pharmacy," 21st Edition, Ed. David Troy, 2006, Lippincott Williams & Wilkins, Philadelphia, Pa., which is hereby incorporated by reference in its entirety). Liquids, slurries, tablets, capsules, pills, powders, granules, gels, ointments, suppositories, injections, inhalants, and aerosols are examples of such formulations. By way of example, modified or extended release oral formulation can be prepared using additional methods known in the art. For example, a suitable extended release form of an active ingredient may be a matrix tablet or capsule composition. Suitable matrix forming materials include, for example, waxes (*e.g.*, carnauba, bees wax, paraffin wax, ceresin, shellac wax, fatty acids, and fatty alcohols), oils, hardened oils or fats (*e.g.*, hardened rapeseed oil, castor oil, beef tallow, palm oil, and soya bean oil), and polymers (*e.g.,* hydroxypropyl cellulose, polyvinylpyrrolidone, hydroxypropyl methyl cellulose, and polyethylene glycol). Other suitable matrix tableting materials are microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, ethyl cellulose, with other carriers, and fillers. Tablets may also contain granulates, coated powders, or pellets. Tablets may also be multi-layered. Optionally, the finished tablet may be coated or uncoated.

[0634] Typical routes of administering such compositions include, without limitation, oral, sublingual, buccal, topical, transdermal, inhalation, parenteral (*e.g.*, subcutaneous, intravenous, intramuscular, intrasternal injection, or infusion techniques), rectal, vaginal, and intranasal. In preferred embodiments, the therapy is administered using an extended release device. Compositions of the invention are formulated so as to allow the active ingredient(s) contained therein to be bioavailable upon administration of the composition. Compositions may take the

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 349

form of one or more dosage units. Compositions may contain 1, 2, 3, 4, or more active ingredients and may optionally contain 1, 2, 3, 4, or more inactive ingredients.

Alternate Embodiments

[0635] Any of the methods described herein may include the output of data in a physical format, such as on a computer screen, or on a paper printout. Any of the methods of the invention may be combined with the output of the actionable data in a format that can be acted upon by a physician. Some of the embodiments described in the document for determining genetic data pertaining to a target individual may be combined with the notification of a potential chromosomal abnormality (such as a deletion or duplication), or lack thereof, with a medical professional, optionally combined with the decision to abort, or to not abort, a fetus in the context of prenatal diagnosis. Some of the embodiments described herein may be combined with the output of the actionable data, and the execution of a clinical decision that results in a clinical treatment, or the execution of a clinical decision to make no action.

[0636] In some embodiments, a method is disclosed herein for generating a report disclosing a result of any method of the invention (such as the presence or absence of a deletion or duplication). A report may be generated with a result from a method of the invention, and it may be sent to a physician electronically, displayed on an output device (such as a digital report), or a written report (such as a printed hard copy of the report) may be delivered to the physician. In addition, the described methods may be combined with the actual execution of a clinical decision that results in a clinical treatment, or the execution of a clinical decision to make no action.

[0637] In certain embodiments, the present invention provides reagents, kits, and methods, and computer systems and computer media with encoded instructions for performing such methods, for detecting both CNVs and SNVs from the same sample using the multiplex PCR methods disclosed herein. In certain preferred embodiments the sample is a single cell sample or a plasma sample suspected of containing circulating tumor DNA. These embodiments take advantage of the discovery that by interrogating DNA samples from single cells or plasma for CNVs and SNVs using the highly sensitive multiplex PCR methods disclosed herein, improved cancer detection can be achieved, versus interrogating for either CNVs or SNVs alone, especially for cancers exhibiting CNV such as breast, ovarian, and lung cancer. The methods in certain illustrative embodiments for analyzing CNVs interrogate for between 50 and 100,000 or 50 and 10,000, or 50 and 1,000

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 350

SNPs and for SNVs interrogate for between 50 and 1000 SNVs or for between 50 and 500 SNVs or for between 50 and 250 SNVs. The methods provided herein for detecting CNVs and/or SNVs in plasma of subjects suspected of having cancer, including for example, cancers known to exhibit CNVs and SNVs, such as breast, lung, and ovarian cancer, provide the advantage of detecting CNVs and/or SNVs from tumors that often are composed of heterogeneous cancer cell populations in terms of genetic compositions. Thus, traditional methods, which focus on analyzing only certain regions of the tumors can often miss CNVs or SNVs that are present in cells in other regions of the tumor. The plasma samples act as liquid biopsies that can be interrogated to detect any of the CNVs and/or SNVs that are present in only subpopulations of tumor cells.

Example Computer Architecture

[0638] FIG. 69 shows an example system architecture X00 useful for performing embodiments of the present invention. System architecture X00 includes an analysis platform X08 connected to one or more laboratory information systems ("LISs") X04. As shown in FIG. 69, analysis platform X08 may be connected to LIS X04 over a network X02. Network X02 may include one or more networks of one or more network types, including any combination of LAN, WAN, the Internet, etc. Network X02 may encompass connections between any or all components in system architecture X00. Analysis platform X08 may alternatively or additionally be connected directly to LIS X06. In an embodiment, analysis platform X08 analyzes genetic data provided by LIS X04 in a software-as-a-service model, where LIS X04 is a third-party LIS, while analysis platform X08 analyzes genetic data provided by LIS X06 in a full-service or in-house model, where LIS X06 and analysis platform X08 are controlled by the same party. In an embodiment where analysis platform X08 is providing information over network X02, analysis platform X08 may be a server.

[0639] In an example embodiment, laboratory information system X04 includes one or more public or private institutions that collect, manage, and/or store genetic data. A person having skill in the relevant art(s) would understand that methods and standards for securing genetic data are known and can be implemented using various information security techniques and policies, e.g., username/password, Transport Layer Security (TLS), Secure Sockets Layer (SSL), and/or other cryptographic protocols providing communication security.

[0640] In an example embodiment, system architecture X00 operates as a service-oriented architecture and uses a client-server model that would be understood by one of skill in the relevant

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 351

art(s) to enable various forms of interaction and communication between LIS X04 and analysis platform X08. System architecture X00 may be distributed over various types of networks X02 and/or may operate as cloud computing architecture. Cloud computing architecture may include any type of distributed network architecture. By way of example and not of limitation, cloud computing architecture is useful for providing software as a service (SaaS), infrastructure as a service (IaaS), platform as a service (PaaS), network as a service (NaaS), data as a service (DaaS), database as a service (DBaaS), backend as a service (BaaS), test environment as a service (TEaaS), API as a service (APIaaS), integration platform as a service (IPaaS) etc.

[0641] In an example embodiment, LISs X04 and X06 each include a computer, device, interface, etc. or any sub-system thereof. LISs X04 and X06 may include an operating system (OS), applications installed to perform various functions such as, for example, access to and/or navigation of data made accessible locally, in memory, and/or over network X02. In an embodiment, LIS X04 accesses analysis platform X08 through an application programming interface ("API"). LIS X04 may also include one or more native applications that may operate independently of an API.

[0642] In an example embodiment, analysis platform X08 includes one or more of an input processor X12, a hypothesis manager X14, a modeler X16, an error correction unit X18, a machine learning unit X20, and an output processor X18. Input processor X12 receives and processes inputs from LISs X04 and/or X06. Processing may include but is not limited to operations such as parsing, transcoding, translating, adapting, or otherwise handling any input received from LISs X04 and/or X06. Inputs may be received via one or more streams, feeds, databases, or other sources of data, such as may be made accessible by LISs X04 and X06. Data errors may be corrected by error correction unit X18 through performance of the error correction mechanisms described above.

[0643] In an example embodiment, hypothesis manager X14 is configured to receive the inputs passed from input processor X12 in a form ready to be processed in accordance with hypotheses for genetic analysis that are represented as models and/or algorithms. Such models and/or algorithms may be used by modeler X16 to generate probabilities, for example, based on dynamic, real-time, and/or historical statistics or other indicators. Data used to derive and populate such strategy models and/or algorithms are available to hypothesis manager X14 via, for example, genetic data source X10. Genetic data source X10 may include, for example, a nucleic acid sequencer. Hypothesis manager X14 may be configured to formulate hypotheses based on, for

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 352

example, the variables required to populate its models and/or algorithms. Models and/or algorithms, once populated, may be used by modeler X16 to generate one or more hypotheses as described above. Hypothesis manager X14 may select a particular value, range of values, or estimate based on a most-likely hypothesis as an output as described above. Modeler X16 may operate in accordance with models and/or algorithms trained by machine learning unit X20. For example, machine learning unit X20 may develop such models and/or algorithms by applying a classification algorithm as described above to a training set database (not shown). In certain embodiments, the machine learning unit analyzes one or more control samples to generate training data sets useful in SNV detections methods provided herein.

[0644] Once hypothesis manager X14 has identified a particular output, such output may be returned to the particular LIS 104 or 106 requesting the information by output processor X22.

[0645] Various aspects of the disclosure can be implemented on a computing device by software, firmware, hardware, or a combination thereof. FIG. 70 illustrates an example computer system Y00 in which the contemplated embodiments, or portions thereof, can be implemented as computer-readable code. Various embodiments are described in terms of this example computer system Y00.

[0646] Processing tasks in the embodiment of FIG. 70 are carried out by one or more processors Y02. However, it should be noted that various types of processing technology may be used here, including programmable logic arrays (PLAs), application-specific integrated circuits (ASICs), multi-core processors, multiple processors, or distributed processors. Additional specialized processing resources such as graphics, multimedia, or mathematical processing capabilities may also be used to aid in certain processing tasks. These processing resources may be hardware, software, or an appropriate combination thereof. For example, one or more of processors Y02 may be a graphics-processing unit (GPU). In an embodiment, a GPU is a processor that is a specialized electronic circuit designed to rapidly process mathematically intensive applications on electronic devices. The GPU may have a highly parallel structure that is efficient for parallel processing of large blocks of data, such as mathematically intensive data. Alternatively or in addition, one or more of processors Y02 may be a special parallel processing without the graphics optimization, such parallel processors performing the mathematically intensive functions described herein. One or more of processors Y02 may include a processing accelerator (e.g., DSP or other special-purpose processor).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 353

[0647] Computer system Y00 also includes a main memory Y30, and may also include a secondary memory Y40. Main memory Y30 may be a volatile memory or non-volatile memory, and divided into channels. Secondary memory Y40 may include, for example, non-volatile memory such as a hard disk drive Y50, a removable storage drive Y60, and/or a memory stick. Removable storage drive Y60 may comprise a floppy disk drive, a magnetic tape drive, an optical disk drive, a flash memory, or the like. The removable storage drive Y60 reads from and/or writes to a removable storage unit 470 in a well-known manner. Removable storage unit Y70 may comprise a floppy disk, magnetic tape, optical disk, etc. which is read by and written to by removable storage drive Y60. As will be appreciated by persons skilled in the relevant art(s), removable storage unit Y70 includes a computer usable storage medium having stored therein computer software and/or data.

[0648] In alternative implementations, secondary memory Y40 may include other similar means for allowing computer programs or other instructions to be loaded into computer system Y00. Such means may include, for example, a removable storage unit Y70 and an interface (not shown). Examples of such means may include a program cartridge and cartridge interface (such as that found in video game devices), a removable memory chip (such as an EPROM, or PROM) and associated socket, and other removable storage units Y70 and interfaces which allow software and data to be transferred from the removable storage unit Y70 to computer system Y00.

[0649] Computer system Y00 may also include a memory controller Y75. Memory controller Y75 controls data access to main memory Y30 and secondary memory Y40. In some embodiments, memory controller Y75 may be external to processor Y10, as shown in FIG. 70. In other embodiments, memory controller Y75 may also be directly part of processor Y10. For example, many AMDTM and IntelTM processors use integrated memory controllers that are part of the same chip as processor Y10 (not shown in FIG. 70).

[0650] Computer system Y00 may also include a communications and network interface Y80. Communication and network interface Y80 allows software and data to be transferred between computer system Y00 and external devices. Communications and network interface Y80 may include a modem, a communications port, a PCMCIA slot and card, or the like. Software and data transferred via communications and network interface Y80 are in the form of signals which may be electronic, electromagnetic, optical, or other signals capable of being received by communication and network interface Y80. These signals are provided to communication and

network interface Y80 via a communication path Y85. Communication path Y85 carries signals and may be implemented using wire or cable, fiber optics, a phone line, a cellular phone link, an RF link or other communications channels.

[0651] The communication and network interface Y80 allows the computer system Y00 to communicate over communication networks or mediums such as LANs, WANs the Internet, etc. The communication and network interface Y80 may interface with remote sites or networks via wired or wireless connections.

[0652] In this document, the terms "computer program medium," "computer-usable medium" and "non-transitory medium" are used to generally refer to tangible media such as removable storage unit Y70, removable storage drive Y60, and a hard disk installed in hard disk drive Y50. Signals carried over communication path Y85 can also embody the logic described herein. Computer program medium and computer usable medium can also refer to memories, such as main memory Y30 and secondary memory Y40, which can be memory semiconductors (e.g. DRAMs, etc.). These computer program products are means for providing software to computer system Y00.

[0653] Computer programs (also called computer control logic) are stored in main memory Y30 and/or secondary memory Y40. Computer programs may also be received via communication and network interface Y80. Such computer programs, when executed, enable computer system Y00 to implement embodiments as discussed herein. In particular, the computer programs, when executed, enable processor Y10 to implement the disclosed processes. Accordingly, such computer programs represent controllers of the computer system Y00. Where the embodiments are implemented using software, the software may be stored in a computer program product and loaded into computer system Y00 using removable storage drive Y60, interfaces, hard drive Y50 or communication and network interface Y80, for example.

[0654] The computer system Y00 may also include input/output/display devices Y90, such as keyboards, monitors, pointing devices, touchscreens, etc.

[0655] It should be noted that the simulation, synthesis and/or manufacture of various embodiments may be accomplished, in part, through the use of computer readable code, including general programming languages (such as C or C++), hardware description languages (HDL) such as, for example, Verilog HDL, VHDL, Altera HDL (AHDL), or other available programming tools. This computer readable code can be disposed in any known computer-usable medium

including a semiconductor, magnetic disk, optical disk (such as CD-ROM, DVD-ROM). As such, the code can be transmitted over communication networks including the Internet.

[0656] The embodiments are also directed to computer program products comprising software stored on any computer-usable medium. Such software, when executed in one or more data processing devices, causes a data processing device(s) to operate as described herein. Embodiments employ any computer-usable or -readable medium, and any computer-usable or –readable storage medium known now or in the future. Examples of computer-usable or computer-readable mediums include, but are not limited to, primary storage devices (e.g., any type of random access memory), secondary storage devices (e.g., hard drives, floppy disks, CD ROMS, ZIP disks, tapes, magnetic storage devices, optical storage devices, MEMS, nano-technological storage devices, etc.), and communication mediums (e.g., wired and wireless communications networks, local area networks, wide area networks, intranets, etc.). Computer-usable or computer-readable mediums can include any form of transitory (which include signals) or non-transitory media (which exclude signals). Non-transitory media comprise, by way of non-limiting example, the aforementioned physical storage devices (e.g., primary and secondary storage devices).

[0657] It will be understood that any of the embodiments disclosed herein can be used in combination with any other embodiment disclosed herein.

Experimental Section

[0658] The presently disclosed embodiments are described in the following Examples, which are set forth to aid in the understanding of the disclosure, and should not be construed to limit in any way the scope of the disclosure as defined in the claims which follow thereafter. The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to use the described embodiments, and is not intended to limit the scope of the disclosure nor is it intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (*e.g.*, amounts, temperature, *etc.*) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by volume, and temperature is in degrees Centigrade. It should be understood that variations in the methods as described may be made without changing the fundamental aspects that the experiments are meant to illustrate.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 356

Example 1

[0659] Exemplary sample preparation and amplification methods are described in US Application No. 13/683,604, filed Nov. 21, 2012; U.S. Publication No. 2013/0123120, and U.S. Serial No. 61/994,791, filed May 16, 2014, which is hereby incorporated by reference in its entirety. These methods can be used for analysis of any of the samples disclosed herein.

[0660] In one experiment, plasma samples were prepared and amplified using a hemi-nested 19,488-plex protocol. The samples were prepared in the following way: up to 20 mL of blood were centrifuged to isolate the buffy coat and the plasma. The genomic DNA in the blood sample was prepared from the buffy coat. Genomic DNA can also be prepared from a saliva sample. Cell-free DNA in the plasma was isolated using the QIAGEN CIRCULATING NUCLEIC ACID kit and eluted in 50 uL TE buffer according to manufacturer's instructions. Universal ligation adapters were appended to the end of each molecule of 40 uL of purified plasma DNA and libraries were amplified for 9 cycles using adaptor specific primers. Libraries were purified with AGENCOURT AMPURE beads and eluted in 50 ul DNA suspension buffer.

[0661] 6 ul of the DNA was amplified with 15 cycles of STAR 1 (95˚C for 10 min for initial polymerase activation, then 15 cycles of 96˚C for 30s; 65˚C for 1 min; 58˚C for 6 min; 60˚C for 8 min; 65˚C for 4 min and 72˚C for 30s; and a final extension at 72˚C for 2 min) using 7.5 nM primer concentration of 19,488 target-specific tagged reverse primers and one library adaptor specific forward primer at 500 nM.

[0662] The hemi-nested PCR protocol involved a second amplification of a dilution of the STAR 1 product for 15 cycles (STAR 2) (95˚C for 10 min for initial polymerase activation, then 15 cycles of 95˚C for 30s; 65˚C for 1 min; 60˚C for 5 min; 65˚C for 5 min and 72˚C for 30s; and a final extension at 72˚C for 2 min) using reverse tag concentration of 1000 nM, and a concentration of 20 nM for each of 19,488 target-specific forward primers.

[0663] An aliquot of the STAR 2 products was then amplified by standard PCR for 12 cycles with 1 uM of tag-specific forward and barcoded reverse primers to generate barcoded sequencing libraries. An aliquot of each library was mixed with libraries of different barcodes and purified using a spin column.

[0664] In this way, 19,488 primers were used in the single-well reactions; the primers were designed to target SNPs found on chromosomes 1, 2, 13, 18, 21, X and Y. The amplicons were

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 357

then sequenced using an ILLUMINA GAIIX sequencer. If desired, the number of sequencing reads can be increased to increase the number of targeted SNPs that are amplified and sequenced.

[0665] Relevant genomic DNA samples amplified using a semi-nested 19,488 outer forward primers and tagged reverse primers at 7.5 nM in the STAR 1. Thermocycling conditions and composition of STAR 2, and the barcoding PCR were the same as for the hemi-nested protocol.

Example 2

[0666] Exemplary primer selection methods are described in US Application No. 13/683,604, filed Nov. 21, 2012 (U.S. Publication No. 2013/0123120) and U.S. Serial No. 61/994,791, filed May 16, 2014, which is hereby incorporated by reference in its entirety). These methods can be used for analysis of any of the samples disclosed herein.

[0667] The following experiment illustrates an exemplary method for designing and selecting a library of primers that can be used in any of the multiplexed PCR methods of the invention. The goal is to select primers from an initial library of candidate primers that can be used to simultaneously amplify a large number of target loci (or a subset of target loci) in a single reaction volume. For an initial set of candidate target loci, primers did not have to be designed or selected for each target locus. Preferably, primers are designed and selected for a large portion of the most desirable target loci.

Step 1

[0668] A set of candidate target loci (such as SNPs) were selected based on publicly available information about desired parameters for the target loci, such as frequency of the SNPs within a target population or heterozygosity rate of the SNPs (worldwide web at ncbi.nlm.nih.gov/projects/SNP/; Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001 Jan 1;29(1):308-11, which are each incorporated by reference in its entirety). For each candidate locus, one or more PCR primer pairs were designed using the Primer3 program (the worldwide web at primer3.sourceforge.net; libprimer3 release 2.2.3, which is hereby incorporated by reference in its entirety). If there were no feasible designs for PCR primers for a particular target locus, then that target locus was eliminated from further consideration.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 358

[0669] If desired, a "target locus score" (higher score representing higher desirability) can be calculated for most or all of the target loci, such as a target locus score calculated based on a weighted average of various desired parameters for the target loci. The parameters may be assigned different weights based on their importance for the particular application that the primers will be used for. Exemplary parameters include the heterozygosity rate of the target locus, the disease prevalence associated with a sequence (*e.g.*, a polymorphism) at the target locus, the disease penetrance associated with a sequence (*e.g.*, a polymorphism) at the target locus, the specificity of the candidate primer(s) used to amplify the target locus, the size of the candidate primer(s) used to amply the target locus, and the size of the target amplicon. In some embodiments, the specificity of the candidate primer for the target locus includes the likelihood that the candidate primer will mis-prime by binding and amplifying a locus other than the target locus it was designed to amplify. In some embodiments, one or more or all the candidate primers that mis-prime are removed from the library.

Step 2

[0670] A thermodynamic interaction score was calculated between each primer and all primers for all other target loci from Step 1 (*see, e.g.*, Allawi, H. T. & SantaLucia, J., Jr. (1998), "Thermodynamics of Internal C-T Mismatches in DNA", *Nucleic Acids Res. 26*, 2694-2701; Peyret, N., Seneviratne, P. A., Allawi, H. T. & SantaLucia, J., Jr. (1999), "Nearest-Neighbor Thermodynamics and NMR of DNA Sequences with Internal A-A, C-C, G-G, and T-T Mismatches", *Biochemistry 38*, 3468-3477; Allawi, H. T. & SantaLucia, J., Jr. (1998), "Nearest-Neighbor Thermodynamics of Internal A-C Mismatches in DNA: Sequence Dependence and pH Effects", *Biochemistry 37*, 9435-9444.; Allawi, H. T. & SantaLucia, J., Jr. (1998), "Nearest Neighbor Thermodynamic Parameters for Internal G-A Mismatches in DNA", *Biochemistry 37*, 2170-2179; and Allawi, H. T. & SantaLucia, J., Jr. (1997), "Thermodynamics and NMR of Internal G-T Mismatches in DNA", *Biochemistry 36*, 10581-10594; MultiPLX 2.1 (Kaplinski L, Andreson R, Puurand T, Remm M. MultiPLX: automatic grouping and evaluation of PCR primers. Bioinformatics. 2005 Apr 15;21(8):1701-2, which are each hereby incorporated by reference in its entirety). This step resulted in a 2D matrix of interaction scores. The interaction score predicted the likelihood of primer-dimers involving the two interacting primers. The score was calculated as follows:

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 359

interaction_score = max(- deltaG_2, 0.8 * (- deltaG_1))

where

deltaG_2 = Gibbs energy (energy required to break the dimer) for a dimer that is extensible by PCR on both ends, *i.e.*, the 3' end of each primer anneals to the other primer; and

deltaG_1 = Gibbs energy for a dimer that is extensible by PCR on at least one end.

Step 3:

[0671] For each target locus, if there was more than one primer-pair design, then one design was selected using the following method:

1 For each primer-pair design for the locus, find the worst-case (highest) interaction score for the two primers in that design and all primers from all designs for all other target loci.
2 Pick the design with the best (lowest) worst-case interaction score.

Step 4

[0672] A graph was built such that each node represented one locus and its associated primer-pair design (*e.g.*, a Maximal Clique problem). One edge was created between every pair of nodes. A weight was assigned to each edge equal to the worst-case (highest) interaction score between the primers associated with the two nodes connected by the edge.

Step 5

[0673] If desired, for every pair of designs for two different target loci where one of the primers from one design and one of the primers from the other design would anneal to overlapping target regions, an additional edge was added between the nodes for the two design. The weight of these

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 360

edges was set equal to the highest weight assigned in Step 4. Thus, Step 5 prevents the library from having primers that would anneal to overlapping target regions, and thus interfere with each other during a multiplex PCR reaction.

Step 6

[0674] An initial interaction score threshold was calculated as follows:

weight_threshold = max(edge_weight) - 0.05 * (max(edge_weight) - min(edge_weight))

where

max(edge_weight) is the maximum edge weight in the graph; and

min(edge_weight) is the minimum edge weight in the graph.

The initial bounds for the threshold were set as follows:

max_weight_threshold = max(edge_weight)

min_weight_threshold = min(edge_weight)

Step 7

[0675] A new graph was constructed consisting of the same set of nodes as the graph from Step 5, only including edges with weights that exceed weight_threshold. Thus, step ignores interactions with scores equal to or below weight_threshold.

Step 8

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 361

[0676] Nodes (and all of the edges connected to the removed nodes) were removed from the graph of Step 7 until there were no edges left. Nodes were removed by applying the following procedure repeatedly:

1 Find the node with the highest degree (highest number of edges). If there is more than one then pick one arbitrarily.

2 Define the set of nodes consisting of the node picked above and all of the nodes connected to it, but excluding any nodes that have degree less than the node picked above.

3 Choose the node from the set that has the lowest target locus score (lower score representing lower desirability) from Step 1. Remove that node from the graph.

Step 9

[0677] If the number of nodes remaining in the graph satisfies the required number of target loci for the multiplexed PCR pool (within an acceptable tolerance), then the method was continued at Step 10.

[0678] If there were too many or too few nodes remaining in the graph, then a binary search was performed to determine what threshold values would result in the desired number of nodes remaining in the graphs. If there were too many nodes in the graph then, the weight threshold bounds were adjusted as follows:

max_weight_threshold = weight_threshold

Otherwise (if there are two few nodes in the graph), then the weight threshold bounds were adjusted as follows:

min_weight_threshold = weight_threshold

Then, the weight threshold was adjusted follows:

weight_threshold = (max_weight_threshold + min_weight_threshold) / 2

Steps 7-9 were repeated.

Step 10

[0679] The primer-pair designs associated with the nodes remaining in the graph were selected for the library of primers. This primer library can be used in any of the methods of the invention.

[0680] If desired, this method of designing and selecting primers can be performed for primer libraries in which only one primer (instead of a primer pair) is used for amplification of a target locus. In this case, a node presents one primer per target locus (rather than a primer pair).

Example 3

[0681] If desired, methods of the invention can be tested to evaluate their ability to detect a deletion or duplication of a chromosome or chromosome segment. The following experiment was performed to demonstrate the detection of an overrepresentation of the X chromosome or a segment from the X chromosome inherited from the father compared to the X chromosome or X chromosome segment from the mother. This assay is designed to mimic a deletion or duplication of a chromosome or chromosome segment. Different amounts of DNA from a father (with XY sex chromosomes) were mixed with DNA from a daughter (with XX sex chromosomes) of the father for analysis of the extra amount of X chromosome from the father (FIGS. 19A-19D).

[0682] DNA from father and daughter cells lines was extracted and quantified using Qubit. Father cell line AG16782, cAG16782-2-F and daughter cell line AG16777, cAG16777-2-P were used. To determine the father's haplotype for the X chromosome, SNPs were detected that are present on the X chromosome but not on the Y chromosome, so there would be a signal from the father's X chromosome but not Y chromosome. The daughter inherited this haplotype from the father. The haplotype from the other X chromosome in the daughter was inherited from her mother. This haplotype from the mother can be determined by assigning the SNPs in the DNA from the daughter cell line that were not inherited from the father to the haplotype from the mother.

[0683] To determine whether an overrepresentation of the X chromosome from the father could be detected, different amounts DNA from the father cell line were mixed with DNA from the daughter cell line. The total DNA input was approximately 75 ng (~25k copies) of genomic DNA. Approximately 3,456 SNPs were amplified using direct multiplex PCR for X and Y chromosome assays. The amplified products were sequenced using 50 bp single run sequencing with 7 bp barcodes using the Rapid/HT mode. The number of reads was approximately 10K per SNP.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 363

[0684] As shown in FIGs. 19A-19D, mosaicism from the father's DNA could be detected. These figures indicate that chromosomes segments or entire chromosomes that are overrepresented can be detected.

[0685] All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. While the methods of the present disclosure have been described in connection with the specific embodiments thereof, it will be understood that it is capable of further modification. Furthermore, this application is intended to cover any variations, uses, or adaptations of the methods of the present disclosure, including such departures from the present disclosure as come within known or customary practice in the art to which the methods of the present disclosure pertain, and as fall within the scope of the appended claims. Any of the embodiments of the invention can be performed by analyzing the DNA and/or RNA in a sample. For example, any of the methods disclosed herein for DNA can be readily adapted for RNA, for example, by including a reverse transcription step to convert the RNA into DNA.

Example 4

[0686] This example describes an exemplary method for non-invasive cell-free tumor DNA-based detection of breast cancer-related copy number variations. Breast cancer screening involves mammography, which results in a high false positive rate and misses some cancers. Analysis of tumor-derived circulating cell-free DNA (ctDNA) for cancer-associated CNVs may allow for earlier, safer, and more accurate screening. A SNP-based massively multiplex PCR (mmPCR) approach was used to screen for CNVs in ctDNA isolated from the plasma of breast cancer patients. The mmPCR assay was designed to target 3,168 SNPs on chromosomes 1, 2, and 22, which often have CNVs in cancer (*e.g.*, 49% of breast cancer samples have a 22q deletion). Six plasma samples from breast cancer patients - one stage IIa, four stage IIb, and one stage IIIb – were analyzed. Each sample had CNVs on one or more of the targeted chromosomes. The assay identified CNVs in all six plasma samples, including in one stage IIb sample that was correctly called at a ctDNA fraction of 0.58% (FIGs. 30, 31B, 32A, 32B, and 33); detection only required 86 heterozygous SNPs. A stage IIa sample was also corrected called at a ctDNA fraction of 4.33% using approximately 636 heterozygous SNPs (FIGs. 29, 31A, and 32A). This demonstrates that focal or whole chromosome arm CNVs, both common in cancer, can be readily detected.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 364

[0687] To further evaluate sensitivity, 22 artificial mixtures containing a 3Mb 22q CNV from a cancer cell line were mixed with DNA from a normal cell line (5:95) to simulate a ctDNA fraction of between 0.43% and ***7.35%*** (FIGs. 28A-28C). The method correctly detected CNVs in 100% of these samples. Thus, artificial cfDNA polynucleotide standards/controls can be made by spiking isolated polynucleotide samples that include fragmented polynucleotide mixtures generated by non-cfDNA sources known to exhibit CNV, such as tumor cell lines, into other DNA samples at concentrations similar to those observed for cfDNA in vivo, such as between, for example, 0.01% and 20%, 0.1 and 15%, or .4 and 10% of DNA in that fluid. These standards/controls can be used as controls for assay design, characterization, development, and/or validation, and as quality control standards during testing, such as cancer testing performed in a CLIA lab and/or as standards included in research use only or diagnostic test kits. Significantly, in numerous cancers - including breast and ovarian - CNVs are more prevalent relative to point mutations. Together, this supports that this SNP-based mmPCR approach offers a cost-effective, non- invasive method for detecting these cancers.

Example 5

[0688] This example describes an exemplary method for detection of copy number variations in breast cancer samples using SNP-targeted massively multiplexed PCR. Evaluation of CNV in tumor tissues typically involves SNP microarray or aCGH. These methods have high whole-genome resolution, but require large amounts of input material, have high fixed costs, and do not work well on formaldehyde fixed-paraffin embedded (FFPE) samples. For this example, 28,000-plex SNP-targeted PCR with next generation sequencing (NGS) was used to target 1p, 1q, 2p, 2q, 4p16, 5p15, 7q11, 15q, 17p, 22q11, 22q13 and chromosomes 13, 18, 21 and X for detection of CNVs in breast cancer samples. Accuracy was validated on 96 samples with aneuploidies or microdeletions. Single-molecule sensitivity was established by analyzing single cells. Of 17 breast cancer samples (15 fresh frozen and 2 FFPE tumor tissues, 5 pairs of matched tumor and normal cell lines) analyzed, 16 (including both FFPEs) were observed with full or partial CNVs in one to 15 targets (average: 7.8); evidence of tumor heterogeneity was observed. The three tissues with one CNV all had a 1q duplication, the most frequent cytogenetic abnormality in breast carcinoma. The most frequent regions with CNVs were 1q, 7p, and 22q1. Only one tumor tissue (with 9 CNVs) had a region with LOH; this LOH was also detected in adjacent putatively normal

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 365

tissue that lacked the other 8 CNVs. By contrast, 5 or more regions with LOH and a high total CNV incidence (average: 12.8) was detected in cell lines. Thus, massively multiplexed PCR offers an economical high-throughput approach to investigate CNVs in a targeted manner, and is applicable to difficult-to-analyze samples, such as FFPE tissues.

Example 6

[0689] This example illustrates exemplary methods for calculating the limit of detection for any of the methods of the invention. These methods were used to calculate the limit of detection for single nucleotide variants (SNVs) in a tumor biopsy (FIG. 34) and a plasma sample (FIG. 35).

[0690] The first method (denoted "LOD-mr5" in FIGs. 34 and 35) calculates the limit of detection based on a minimum of 5 reads being chosen as the minimum number of times a SNV is observed in the sequencing data to have sufficient confidence the SNV is actually present. The limit of detection is based on whether the observed the depth of read (DOR) is above this minimum of 5. The gray lines in FIGs. 34 and 35 indicate SNVs for which the limit of detection is limited by the DOR. In these cases, not enough reads were measured to reach the error limit of the assay. If desired, the limit of detection can be improved (resulting in a lower numerical value) for these SNVs by increasing the DOR.

[0691] The second method (denoted "LOD-zs5.0" in FIGs. 34 and 35) calculates the limit of detection based on the z-score. The Z-score is the number of standard deviations an observed error percentage is away from the background mean error. If desired, outliers can be removed and the z-score can be recalculated and this process can be repeated. The final weighted mean and the standard deviation of the error rate are used to calculate the z-score. The mean is weighted by the DOR since the accuracy is higher when the DOR is higher.

[0692] For the exemplary z-score calculation used for this example, the background mean error and standard deviation were calculated from all the other samples of the same sequencing run weighted by their depth of read, for each genomic locus and substitution type. Samples were not considered in the background distribution if they were 5 standard deviations away from the background mean. The orange lines in FIGs. 34 and 35 indicate SNVs for which the limit of detection is limited by the error rate. For these SNV's enough reads were taken to reach the 5 read minimum, and the limit of detection was limited by the error rate. If desired, the limit of detection can be improved by optimizing the assay to reduce the error rate.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 366

[0693] The third method (denoted "LOD-zs5.0-mr5" in FIGs. 34 and 35) calculates the limit of detection based on the maximum value of the above two metrics.

[0694] For the analysis of a tumor sample shown in FIG. 34, the mean limit of detection was 0.36%, and the median limit of detection was 0.28%. The number of DOR limited (gray lines) SNVs was 934. The number of error rate limited (orange lines) SNVs was 738.

[0695] For the analysis of cDNA in a plasma sample shown in FIG. 35, the mean limit of detection was 0.24%, and the median limit of detection was 0.09%. The number of DOR limited (gray lines) SNVs was 732. The number of error rate limited (orange lines) SNVs was 921.

Example 7

[0696] This example illustrates the detection of CNVs and SNVs from the same single cell. The following primer libraries were used: a library of ~28,000 primers for detecting CNVs, a library of ~3,000 primers for detecting CNVs, and library of primers for detecting SNVs. For analysis of a single cell, cells were serial diluted until there were 3 or 4 cells per droplet. An individual cell was pipetted and placed into a PCR tube. The cell was lysed using Protease K, salt, and DTT using the following conditions: 56°C for 20 minutes, 95°C for 10 minutes, and then a 4°C hold. For analysis of genomic DNA, DNA from the same cell line as the analyzed single cell was either purchased or obtained by growing the cells and extracting the DNA.

[0697] For amplification with the library of ~28,000 primers, the following PCR conditions were used: a 40uL reaction volume, 7.5nM of each primer, and 2x master mix (MM). In some embodiments QIAGEN Multiplex PCR Kit is used for the master mix (QIAGEN catalog No. 206143; *see, e.g.*, information available at the world wide web at qiagen.com/products/catalog/assay-technologies/end-point-pcr-and-rt-pcr-reagents/qiagen-multiplex-pcr-kit, is which is hereby incorporated by reference in its entirety). The kit includes 2x QIAGEN Multiplex PCR Master Mix (providing a final concentration of 3 mM $MgCl_2$, 3 x 0.85 ml), 5x Q-Solution (1 x 2.0 ml), and RNase-Free Water (2 x 1.7 ml). The QIAGEN Multiplex PCR Master Mix (MM) contains a combination of KCl and $(NH_4)_2SO_4$ as well as the PCR additive, Factor MP, which increases the local concentration of primers at the template. Factor MP stabilizes specifically bound primers, allowing efficient primer extension by, *e.g.,* HotStarTaq DNA Polymerase. HotStarTaq DNA Polymerase is a modified form of *Taq* DNA polymerase and has no polymerase activity at ambient temperatures. The following thermocycling conditions were

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 367

used for the first round of PCR: 95°C for 10 minutes; 25 cycles of 96°C for 30 seconds, 65°C for 29 minutes, and 72°C for 30 seconds; and then 72°C for 2 minutes, and a 4°C hold. For the second round of PCR a 10ul reaction volume, 1xMM, and 5nM of each primer was used. The following thermocycling conditions were used: 95°C for 15 minutes; 25 cycles of 94°C for 30 seconds, 65°C for 1 minute, 60°C for 5 minutes, 65°C for 5 minutes, and 72°C for 30 seconds; and then 72°C for 2 minutes, and a 4°C hold.

[0698] For the library of ~3,000 primers, exemplary reaction conditions include a 10ul reaction volume, 2x MM, 70mM TMAC, and 2nM primer of each primer. For the library of primers for detecting SNVs, exemplary reaction conditions include a 10ul reaction volume, 2x MM, 4mM EDTA, and 7.5nM primer of each primer. Exemplary thermocycling conditions include 95°C for 15 minutes, 20 cycles of 94°C for 30 seconds, 65°C for 15 minutes, and 72°C for 30 seconds; and then 72°C for 2 minutes, and a 4°C hold.

[0699] The amplified products were barcoded. One run of sequencing was performed with an approximately equal number of reads per sample.

[0700] FIGs. 36A and 36B show results from analysis of genomic DNA (FIG. 36A) or DNA from a single cell (FIG. 36B) using a library of approximately 28,000 primers designed to detect CNVs. Approximately 4 million reads were measured per sample. The presence of two central bands instead of one central band indicates the presence of a CNV. For three samples of DNA from a single cell, the percent of mapped reads was 89.9%, 94.0%, and 93.4%, respectively. For two samples of genomic DNA the percent of mapped reads was 99.1% for each sample.

[0701] FIGs. 37A and 37B show results from analysis of genomic DNA (FIG. 37A) or DNA from a single cell (FIG. 37B) using a library of approximately 3,000 primers designed to detect CNVs. Approximately 1.2 million reads were measured per sample. The presence of two central bands instead of one central band indicates the presence of a CNV. For three samples of DNA from a single cell, the percent of mapped reads was 98.2%, 98.2%, and 97.9%, respectively. For two samples of genomic DNA the percent of mapped reads was 98.8% for each sample. FIG. 38 illustrates the uniformity in DOR for these ~3,000 loci.

[0702] For calling SNVs, the call percent for true positive mutations was similar for DNA from a single cell and genomic DNA. A graph of call percent for true positive mutations for single cells on the y-axis versus that for genomic DNA on the x- axis yielded a curve fit of $y = 1.0076x - 0.3088$ with $R^2 = 0.9834$. FIG. 39 shows similar error call metrics for genomic DNA and DNA

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 368

from a single cell. FIG. 40 shows that the error rate for detecting transition mutations was greater than for detecting transversion mutations, indicating it may be desirable to select transversion mutations for detection rather than transition mutations when possible.

Example 8

[0703] This example further validates a massively multiplexed PCR methodology for chromosomal aneuploidy and CNV determination disclosed herein, called CoNVERGe (Copy Number Variant Events Revealed Genotypically), and further illustrates the development and use of "PlasmArt" standards for PCR of ctDNA samples. PlasmArt standards include polynucleotides having sequence identity to regions of the genome known to exhibit CNV and a size distribution that reflects that of cfDNA fragments naturally found in plasma.

Sample Collection

[0704] Human breast cancer cell lines (HCC38, HCC1143, HCC1395, HCC1937, HCC1954, and HCC2218) and matched normal cell lines (HCC38BL, HCC1143BL, HCC1395BL, HCC1937BL, HCC1954BL, and HCC2218BL) were obtained from the American Type Culture Collection (ATCC). Trisomy 21 B-lymphocyte (AG16777) and paired father / child DiGeorge Syndrome (DGS) cell lines (GM10383 and GM10382, respectively) were from the Coriell Cell Repository (Camden, NJ). GM10382 cells only have the paternal 22q11.2 region.

[0705] We procured tumour tissues from 16 breast cancer patients, including 11 fresh frozen (FF) samples from Geneticist (Glendale, CA) and five formalin-fixed paraffin-embedded (FFPE) samples from North Shore-LIJ (Manhasset, NY). We acquired matched buffy coat samples for eight patients and matched plasma samples for nine patients. FF tumour tissues and matched buffy coat and plasma samples from five ovarian cancer patients were from North Shore-LIJ. For eight breast tumour FF samples, tissue subsections were resected for analysis. Institutional review board approvals from Northshore/LIJ IRB and Kharkiv National Medical University Ethics Committee were obtained for sample collection and informed consent was obtained from all subjects.

[0706] Blood samples were collected into EDTA tubes. Circulating tumour DNA was isolated from 1 mL plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Valencia, CA).

[0707] To make the PlasmArt standards according to one exemplary method, first, 9 □ 106 cells were lysed with hypotonic lysis buffer (20 mM Tris-Cl (pH 7.5), 10 mM NaCl, and 3 mM MgCl2) for 15 min on ice. Then, 10% IGEPAL CA-630 (Sigma, St. Louis, MO) was added to a final concentration of 0.5%. After centrifugation at 3,000 g for 10 min at 4°C, pelleted nuclei were

resuspended in 1X micrococcal nuclease (MNase) Buffer (New England BioLabs, Ipswich, MA) before adding 1000 U of MNase (New England BioLabs), and then incubated for 5 min at 37°C. Reactions were stopped by adding EDTA to a final concentration of 15 mM. Undigested chromatin was removed by centrifugation at 2,000 g for 1 min. Fragmented DNA was purified with the DNA Clean & Concentrator™-500 kit (Zymo Research, Irvine, CA). Mononucleosomal DNA produced by MNase digestion was also purified and size-selected using AMPure XP magnetic beads (Beckman Coulter, Brea, CA). DNA fragments were sized and quantified with a Bioanalyzer DNA 1000 chip (Agilent, Santa Clara, CA).

[0708] To model ctDNA at different concentrations, different fractions of PlasmArts from HCC1954 and HCC2218 cancer cells were mixed with those from the corresponding matched normal cell line (HCC1954BL and HCC2218BL, respectively). Three samples at each concentration were analyzed. Similarly, to model allelic imbalances in plasma DNA in a focal 3.5 Mb region, we generated PlasmArts from DNA mixtures containing different ratios of DNA from a child with a maternal 22q11.2 deletion and DNA from the father. Samples containing only the father's DNA were used as negative controls. Eight samples at each concentration were analyzed.

[0709] Accordingly, to evaluate the sensitivity and reproducibility of CoNVERGe, especially when the proportion of abnormal DNA for a CNV, or average allelic imbalance (AAI), is low, we used it to detect CNVs in DNA mixtures comprised of a previously characterized abnormal sample titrated into a matched normal sample. The mixtures consisted of artificial cfDNA, termed "PlasmArt", with fragment size distribution approximating natural cfDNA (see above). FIG. 42 graphically displays the size distribution of an exemplary PlasmArt prepared from a cancer cell line compared to the size distribution of cfDNA, looking at CNVs on chromosome arms 1p, 1q, 2p, and 2q. In the first pair, a son's tumor DNA sample having a 3 Mb Focal CNV deletion of the 22q11.2 region was titrated into a matched normal sample from the father at between 0–1.5% total cfDNA (FIG. 41a). CoNVERGe reproducibly identified CNVs corresponding to the known abnormality with estimated AAI of >0.35% in mixtures of ≥0.5% +/-0.2% AAI, failed to detect the CNV in 6/8 replicates at 0.25% abnormal DNA, and reported a value of ≤0.05% for all eight negative control samples. The AAI values estimated by CoNVERGe showed high linearity (R2 = 0.940) and reproducibility (error variance = 0.087). The assay was sensitive to different levels of amplification within the same sample. Based on these data a conservative detection threshold of 0.45% AAI could be used for subsequent analyses. Using this cutoff another experiment was

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 370

performed in which Plasmart synthetic ctDNA was spiked at known concentrations to create synthetic cancer plasma at between around 0.5% and around 3.5%. Negative plasma was also included as a control. All of the synthetic cancer plasma yielded estimates above 0.45% and the reading for the negative plasma was well below 0.45% (FIG. 43A-D). FIG. 43A shows the maximum likelihood of tumor, and FIG. 43B shows an estimate of DNA fraction results as an odds ratio plot. FIG. 43C is a plot for the detection of transversion events. FIG 43D is a plot for the detection of Transition events.

[0710] Two additional PlasmArt titrations, prepared from pairs of matched tumor and normal cell line samples and having CNVs on chromosome 1 or chromosome 2, were also evaluated (FIG. 41b, 41c). Among negative controls, all values were <0.45%, and high linearity (R2 = 0.952 for HCC1954 1p, R2 = 0.993 for HCC1954 1q, R2 = 0.977 for HCC2218 2p, R2 = 0.967 for HCC2218 2q) and reproducibility (error variance = 0.190 for HCC1954 1p, 0.029 for HCC1954 1q, 0.250 for HCC2218 2p, and 0.350 for HCC2218 2q) were observed between the known input DNA amount and that calculated by CoNVERGe. The difference in the slopes of the regressions for regions 1p and 1q of one sample pair correlates with the relative difference in copy number observed in the B-allelic frequencies (BAFs) of regions 1p and 1q of the same sample, demonstrating the relative precision of the AAI estimate calculated by CoNVERGe (FIG. 41c, 41d).

[0711] The workflow for processing samples is illustrated in FIG. 63. CoNVERge has application to a variety of sample sources including FFPE, Fresh Frozen, Single Cell, Germline control and cfDNA. We applied CoNVERGe to six human breast cancer cell lines and matched normal cell lines to assess whether it can detect somatic CNVs. Arm-level and focal CNVs were present in all six tumour cell lines, but were absent from their matched normal cell lines, with the exception of chromosome 2 in HCC1143 in which the normal cell line exhibits a deviation from the 1:1 homolog ratio (FIG. 63b). To validate these results on a different platform, we performed CytoSNP-12 microarray analyses, which produced consistent results for all samples (FIG. 63d, 63e). Moreover, the maximum homolog ratios for CNVs identified by CoNVERGe and CytoSNP-12 microarrays exhibited a strong linear correlation (R2 = 0.987, P < 0.001) (FIG. 63f).

[0712] We next applied CoNVERGe to fresh-frozen (FF) (FIG. 64a) and formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue samples (FIG. 64b, 64d). In both sample types, several arm-level and focal CNVs were present; however, no CNVs were detected in DNA from

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 371

matched buffy coat samples. CoNVERGe results were highly correlated with those from microarray analyses of the same samples (FIG. 64e-h; R2 = 0.909, P < 0.001 for CytoSNP-12 on FF; R2 = 0.992, P < 0.001 for OncoScan on FFPE). CoNVERGe also produces consistent results on small quantities of DNA extracted from laser capture microdissection (LCM) samples, for which microarray methods are not suitable.

Detection of CNVs in single cells with CoNVERGe

[0713] To test the limits of the applicability of this mmPCR approach, we isolated single cells from the six aforementioned cancer cell lines and from a B-lymphocyte cell line that had no CNVs in the target regions. The CNV profiles from these single-cell experiments were consistent between three replicates and with those from genomic DNA (gDNA) extracted from a bulk sample of about 20,000 cells (FIG. 65). On the basis of the number of SNPs with no sequencing reads, the average assay drop-out rate for bulk samples was 0.48% (range: 0.41–0.60%), which is attributable to either synthesis or assay design failure. For single cells, the additional average assay drop-out rate observed was 0.39% (range: 0.19–0.67%). For single cell assays that did not fail (i.e. no assay drop-out occurred), the average single ADO rate calculated using heterozygous SNPs only was 0.05% (range: 0.00–0.43%). Additionally, the percentage of SNPs with high confidence genotypes (i.e. SNP genotypes determined with at least 98% confidence) was similar for both single cell and bulk samples and the genotype in the single cell samples matched those in the bulk sample (average 99.52%, range: 92.63–100.00%).

[0714] In single cells, allele frequencies are expected to directly reflect chromosome copy numbers, unlike in tumour samples where this may be confounded by TH and non-tumour cell contamination. BAFs of 1/n and (n - 1)/n indicate n chromosome copies in a region. Chromosome copy numbers are indicated on the allele frequency plots for both single cells and matched gDNA samples (FIG. 65).

Application of CoNVERGe to plasma samples

[0715] To investigate the ability of CoNVERGe to detect CNVs in real plasma samples, we applied our approach to cfDNA paired with a matched tumour biopsy from each of two stage II breast cancer patients and five late-stage ovarian cancer. In all seven patients, CNVs were detected in both FF tumour tissues and in the corresponding plasma samples (FIG. 66). FIG. 67 provides a list of SNV breast cancer mutations. A total of 32 CNVs, at a level of ≥0.45% AAI, were detected in the seven plasma samples (range: 0.48–12.99% AAI) over the five regions assayed, which

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 372

represent about 20% of the genome. Note that the presence of CNVs in plasma cannot be confirmed due to the lack of alternative orthogonal methods.

[0716] Although AAI estimates may appear correlated with BAFs in tumour, direct proportionality should not necessarily be expected due to tumour heterogeneity. For example, in sample BC5 (FIG. 66a), the ovals at the upper left area of FIG. 66a indicate regions that have BAFs compatible with N = 11; combining this with the AAI calculation from the plasma sample leads to estimates for c of 2.33% and 2.67% for the two regions. Estimating c using the other regions in the sample give values between 4.46% and 9.53%, which clearly demonstrates the presence of tumor heterogeneity.

[0717] These data demonstrate that CNVs can be detected in plasma in a substantial fraction of samples, and suggest that the more prevalent a CNV is within a tumour, the more likely it is to be observed in cfDNA. Furthermore, CoNVERGe detected CNVs from a liquid biopsy that may have otherwise gone unobserved in a traditional tumour biopsy.

Example 9

[0718] This example provides details regarding certain exemplary sample preparation methods used for CoNVERGe analysis of different types of samples.

Single Cell CNV Protocol for 28,000-plex PCR

[0719] Multiplexed PCR allows simultaneous amplification of many targets in a single reaction. Target SNPs were identified in each genomic region with 10% minimum population minor allele frequency (1000 Genomes Project data; April 30, 2012 release). For each SNP, multiple primers, semi-nested, were designed to have an amplicon length of a maximum length of 75 bp and a melting temperature between 54–60.5°C. Primer interaction scores for all possible combinations of primers were calculated; primers with high scores were eliminated to reduce the likelihood of primer dimer product formation. Candidate PCR assays were ranked and selected on the basis of target SNP minor allele frequency, observed heterozygosity rate (from dbSNP), presence in HapMap, and amplicon length.

[0720] In certain experiments, single cell samples were prepared and amplified using a mmPCR 28,000-plex protocol. The samples were prepared in the following way: For analysis of a single cell, cells were serial diluted until there were 3 or 4 cells per droplet. An individual cell was

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 373

pipetted and placed into a PCR tube. The cell was lysed using Protease K, salt, and DTT using the following conditions: 56°C for 20 minutes, 95°C for 10 minutes, and then a 4°C hold. For analysis of genomic DNA, DNA from the same cell line as the analyzed single cell was either purchased or obtained by growing the cells and extracting the DNA. The DNA was amplified in a 40uL reaction volume containing Qiagen mp-PCR master mix (2XMM final conc), 7.5nM primer conc. for 28K primer pairs having a hemi-nested Rev primers under the following conditions: 95C 10min, 25x [96C 30sec, 65C 29min, 72C 30sec], 72C 2min, 4C hold. The amplification product was diluted 1:200 in water and 2 ul added to STAR 2 (10 ul reaction volume) 1XMM, 5nM primer conc. and PCR was performed using hemi-nested inner Fwd primer and tag specific Rev primer: 95C 15min, 25x [94C 30sec, 65C 1min, 60C 5min, 65C 5min, 72C 30sec], 72C 2min, 4C hold.

[0721] Full sequence tags and barcodes were attached to the amplification products and amplified for 9 cycles using adaptor specific primers. Prior to sequencing, the barcoded library product were pooled, purified with the QIAquick PCR Purification Kit (Qiagen), and quantified using the Qubit® dsDNA BR Assay Kit (Life Technologies). Amplicons were sequenced using an Illumina HiSeq 2500 sequencer.

Extraction of DNA from a Blood/Plasma Sample

[0722] Blood samples were collected into EDTA tubes. The whole blood sample was centrifuged and separated into three layers: the upper layer, 55% of the blood sample, was plasma and contains cell-free DNA (cfDNA); the buffy coat middle layer contained leucocytes having DNA, <1% of total; and the bottom layer, 45% of the collected blood sample, contained erythrocytes, no DNA was present in this fraction as erythrocytes are enucleated. Circulating tumor DNA was isolated from at least 1 mL plasma using the QIAamp Circulating Nucleic Acid Kit, Qia-Amp (Qiagen, Valencia, CA), according to the manufacture's protocol.

Plasma CNV Protocol for 3,168-plex for Chromosomes 1p, 1q, 2p, 2q, and 22q11

[0723] Plasma DNA libraries were prepared and amplified using a mmPCR 3,168-plex protocol. The samples were prepared in the following way: Up to 20 mL of blood was centrifuged to isolate the buffy coat and the plasma. Plasma extraction of cfDNA and library preparation was performed. DNA was eluted in 50 uL TE buffer. The input for mmPCR was 6.7 uL of amplified and purified Natera plasma library at an input amount of approximately 1200 ng. The plasma DNA was amplified in a 20uL reaction volume containing Qiagen mp-PCR master mix (2XMM final conc), 2 nM tagged primer conc. (total 12.7 uM) in 3,168-plex primer pools and PCR amplified: 95C

10min, 25x [96C 30sec, 65C 20min, 72C 30sec], 72C 2min, 4C hold. The amplification product was diluted 1:2,000 in water and 1 ul added to the Barcoding-PCR in a 10 uL reaction volume. The barcodes are attached to the amplification products via PCR amplification for 12 cycles using tag specific primers. Products of multiple samples are pooled and then purified with QIAquick PCR Purification Kit (Qiagen) and eluted in 50 ul DNA suspension buffer. Samples are sequenced by NGS as described for the Single Cell CNV Protocol for 28,000-plex PCR.

Breast cancer feasibility SNV panel from plasma

[0724] cfDNA from breast cancer patient blood samples was prepared and amplified using 336 primer pairs that were distributed into four 84-plex pools. Natera plasma libraries were prepared as described for Plasma CNV Protocol for 3,168-plex for Chromosomes 1p, 1q, 2p, 2q, and 22q11. DNA was eluted in 50 uL TE buffer. The input for mPCR was 2.5uL of amplified and purified Natera plasma library at an input amount of approximately 600 ng. FIG. 68A-B represents the major and minor allele frequencies of the SNPs used in a 3168 mmPCR reaction. The X-axis represents the number of SNPs, from left to right, for chromosome 1q, 1p, 2q, 2p and 22q. SNPs were selected from the 1000 Genomes map for Humans, Group 19 and dbSNP to pick targets, but only SNPs from the 1000 Genomes were used to screen for minor allele frequencies. The plasma DNA was amplified in four parallel reactions of 84-plex primer pools, a 10uL reaction volume containing Qiagen mp-PCR master mix (2XMM final conc.), 4mM EDTA, 7.5 nM primer concentration (total 1.26 uM) and PCR amplified: 95C 15min, 25x [94C 30sec, 65C 15min, 72C 30sec], 72C 2min, 4C hold. The amplification product of the 4 subpools were each diluted 1:200 in water and 1 ul added to the Barcoding-PCR reaction in a 10 uL reaction volume containing Q5 HS HF master mix (1xfinal), and 1 uM each barcoding primer and each of the pools were amplified in the following reaction: 98C 1min, 25x [98C 10sec, 70C 10sec, 60C 30sec, 65C 15sec, 72C 15sec], 72C 2min, 4C hold. Libraries were purified with QIAquick PCR Purification Kit (Qiagen) and eluted in 50 ul DNA suspension buffer. Samples were sequenced by paired end sequencing.

Example 10

[0725] This example provides details regarding certain exemplary methods for analyzing sequencing data to identify SNVs.

[0726] **SNV METHOD 1:** For this embodiment**, a** background error model was constructed using normal plasma samples, which were sequenced on the same sequencing run to account for

run-specific artifacts. In certain embodiments, 5, 10, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, or more than 250 normal plasma samples were analyzed on the same sequencing run. In certain illustrative embodiments, 20, 25, 40, or 50 normal plasma samples are analyzed on the same sequencing run. Noisy positions with normal median variant allele frequency greater than a cutoff are removed. For example this cutoff in certain embodiments is > 0.1%, 0.2%, 0.25%, 0.5%, 1%, 2%, 5%, or 10%. In certain illustrative embodiments noisy positions with normal medial variant allele frequency greater than 0.5% are removed. Outlier samples were iteratively removed from the model to account for noise and contamination. In certain embodiments, samples with a Z score of greater than 5, 6, 7, 8, 9, or 10 were removed from the data analysis. For each base substitution of every genomic loci, the depth of read weighted mean and standard deviation of the error were calculated. Tumor or cell-free plasma samples' positions with at least 5 variant reads and a Z-score of 10 against the background error model were called as a candidate mutation.

[0727] SNV METHOD 2: For this embodiment we aim to determine Single Nucleotide Variants (SNVs) using plasma ctDNA data. We model the PCR process as a stochastic process, estimate the parameters using a training set and make the final SNV calls using a separate testing set. The main idea is to determine the propagation of the error across multiple PCR cycles, calculate the mean and the variance of the background error, and differentiate the background error from real mutations.

The following parameters are estimated for each base:

p = efficiency (probability that each read is replicated in each cycle)

p_e = error rate per cycle for mutation type e (probability that an error of type e occurs)

X_0 = initial number of molecules

As a read is replicated over the course of PCR process, the more errors occur. Hence, the error profile of the reads is determined by the degrees of separation from the original read. We refer to a read as k^{th} generation if it has gone through k replications until it has been generated.

Let us define the following variables for each base:

X_{ij} = number of generation i reads generated in the PCR cycle j

Y_{ij} = total number of generation i reads at the end of cycle j

X_{ij}^{e} = number of generation i reads with mutation e generated in the PCR cycle j

Moreover, in addition to normal molecules X_0, if there are additional $f_e X_0$ molecules with the mutation e at the beginning of the PCR process (hence $fe/(1+fe)$ will be the fraction of mutated molecules in the initial mixture).

Given the total number of generation i-1 reads at cycle j-1, the number of generation i reads generated at cycle j has a binomial distribution with a sample size of $Y_{i-1,j-1}$ and probability parameter of p. Hence, $\mathbf{E}(X_{ij,} | Y_{i-1,j-1}, p) = p\ Y_{i-1,j-1}$ and $\mathbf{Var}(X_{ij,} | Y_{i-1,j-1}, p) = p(1-p)\ Y_{i-1,j-1}$.

We also have $Y_{ij} = \sum_{k=i}^{j} X_{ik}$. Hence, by recursion, simulation or similar methods, we can determine $\mathbf{E}(X_{ij,})$. Similarly, we can determine $\mathbf{Var}(X_{ij}) = \mathbf{E}(\mathbf{Var}(X_{ij,} | p)) + \mathbf{Var}(\mathbf{E}(X_{ij,} | p))$ using the distribution of p.

finally, $\mathbf{E}(X_{ij}^{e} | Y_{i-1,j-1}, p_e) = p_e\ Y_{i-1,j-1}$ and $\mathbf{Var}(X_{ij}^{e} | Y_{i-1,j-1}, p) = p_e\ (1-p_e)\ Y_{i-1,j-1}$, and we can use these to compute $\mathbf{E}(X_{ij}^{e})$ and $\mathbf{Var}(X_{ij}^{e})$.

[0728] **20.**

[0729] **6+.2 Algorithm**

[0730] The algorithm starts by estimating the efficiency and error rate per cycle using the training set. Let n denote the total number of PCR cycles.

[0731] The number of reads R_b at each base b can be approximated by $(1+p_b)^n X_0$, where p_b is the efficiency at base b. Then $(R_b/X_0)^{1/n}$ can be used to approximate $1+p_b$. Then, we can determine the mean and the standard variation of p_b across all training samples, to estimate the parameters of the probability distribution (such as normal, beta, or similar distributions) for each base.

[0732] Similarly, the number of error e reads R_b^{e} at each base b can be used to estimate p_e. After determining the mean and the standard deviation of the error rate across all training samples,

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 377

we approximate its probability distribution (such as normal, beta, or similar distributions) whose parameters are estimated using this mean and standard deviation values.

[0733] Next, for the testing data, we estimate the initial starting copy at each base as $\int_0^1 \frac{R_b}{(1+p_b)^n} f(\boldsymbol{p_b}) d\boldsymbol{p_b}$ where f(.) is an estimated distribution from the training set.

[0734] $\int_0^1 \frac{R_b}{(1+p_b)^n} f(\boldsymbol{p_b}) d\boldsymbol{p_b}$ where f(.) is an estimated distribution from the training set.

[0735] Hence, we have estimated the parameters that will be used in the stochastic process. Then, by using these estimates, we can estimate the mean and the variance of the molecules created at each cycle (note that we do this separately for normal molecules, error molecules, and mutation molecules).

[0736] Finally, by using a probabilistic method (such as maximum likelihood or similar methods), we can determine the best $\boldsymbol{f_e}$ value that fits the distribution of the error, mutation, and normal molecules the best. More specifically, we estimate the expected ratio of the error molecules to total molecules for various $\boldsymbol{f_e}$ values in the final reads, and determine the likelihood of our data for each of these values, and then select the value with the highest likelihood.

[0737] In certain embodiments, Method 2 above is performed as follows:

[0738] a) Estimate a PCR efficiency and a per cycle error rate using a training data set;

[0739] b) Estimate a number of starting molecules for the testing data set at each base using the distribution of the efficiency estimated in step (a);

[0740] c) If needed, update the estimate of the efficiency for the testing data set using the starting number of molecules estimated in step (b);

[0741] d) Estimate the mean and variance for the total number of molecules, background error molecules and real mutation molecules (for a search space consisting of an initial percentage of real mutation molecules) using testing set data and parameters estimated in steps (a), (b) and (c);

[0742] e) Fit a distribution to the number of total error molecules (background error and real mutation) in the total molecules, and calculate the likelihood for each real mutation percentage in the search space; and

[0743] f) Determine the most likely real mutation percentage and calculate the confidence using the data from in step (e).

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 378

Example 11

[0744] This example provides results using the multiplexed PCR CoNVERGe methods provided herein, for the detection of cancer by detecting CNV in circulating DNA. The Plasma CNV Protocol for 3,168-plex for Chromosomes 1p, 1q, 2p, 2q, and 22q11 provided herein, was used. Plasma from 21 breast cancer patients (stage I-IIIB) was analyzed. The results shown in FIG. 44 demonstrate that CNVs were detected in all samples using an AAI >= 0.45% and required as few as 62 heterozygous SNPs. A similar protocol was used to analyze plasma from ovarian cancer patients. Using a 0.45% cutoff, a 100% ovarian cancer detection rate was achieved, as shown in FIG. 45. Each of the five samples also had a matched tumor sample.

Example 12

[0745] This example demonstrates that a dramatic improvement in the ability to detect cancer is achieved by testing plasma for the presence of CNVs and SNVs. CNVs and SNVs were detected using the methods provided in the Examples above. Samples were prepared according to the appropriate protocols in Example 9. SNVs were identified using SNV Method 1 above. As shown in FIG. 46, the sensitivity of detecting breast and lung cancer are greatly improved by analyzing plasma from Stage I-III cancer patients for both CNVs and SNVs versus testing for SNVs alone. Analyzing SNVs only, 71% of cancers were detected in plasma samples. However by analyzing for the presence of SNVs and/or CNVs the detection rate goes up to 83% for breast and 92% for lung in the patient populations analyzed. If one considers all of the SNVs and CNVs that have been identified in the TCGA and COSMIC data sets, the expected diagnostic load would be greater than 97% for breast cancer and >98% for lung cancer.

[0746] Further analysis was performed on samples from 41 patient samples with different stages of cancer using the plasma sample prep methods provided in Example 9 and SNV Method 1 provided above. As shown in FIG. 47, when assaying for CNVs and SNVs in circulating tumor DNA from breast cancer patients 60% of Stage I, 88% of Stage II and 100% of Stage III breast cancers were detected using a limit of quantification of 0.2% ctDNA for SNVs and 0.45% ctDNA for CNVs. As shown in FIG. 48, when assaying for CNVs and SNVs in ctDNA and looking at 41 patient samples with different substages of breast cancer, 60% of Stage I, 100% of Stage II, 90% of Stage IIA, 80% of Stage IIB, and 100% of Stage III, IIIA, and IIIB breast cancers were detected using a limit of quantification of 0.2% ctDNA for SNVs and 0.45% ctDNA for CNVs. As shown

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 379

in FIG. 49, when assaying for CNVs and SNVs in 24 circulating tumor DNA from lung cancer patient samples 88% of Stage I, 100% of Stage II and 100% of Stage III lung cancers were detected using a limit of quantification of 0.2% ctDNA for SNVs and 0.45% ctDNA for CNVs. As shown in FIG. 50, when assaying for CNVs and SNVs in ctDNA and looking at 24 patient samples with different substages of lung cancer, 100% detection rate was achieved for all substages except that an 82% detection rate was achieved for the patients with stage IB lung cancer using a limit of quantification of 0.2% ctDNA for SNVs and 0.45% ctDNA for CNVs.

Example 13

[0747] This example demonstrates that detection of SNV in ctDNA overcomes the limitations in identifying variant alleles in biopsied samples due to tumor heterogeneity. TRACERx samples of three small cell lung cancer patient samples and one adenocarcinoma lung cancer patient sample for which tumor biopsies and corresponding pre-operative blood plasma samples had been collected were used for analysis of tumor heterogeneity. Samples were obtained from the Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6BT, UK. Samples were primary lung cancer samples for analysis of SNV mutations. Two to three biopsies from various regions from the entire cancerous lung were taken from each patient (FIG. 51A). Each biopsied sample was assayed by whole exome sequencing (Illumina HiSeq200; Illumina, San Diego, CA), followed by AmpliSeq® sequencing (Ion Torrent, South San Francisco, CA) on a PGM® for identification of underlying clonal heterogeneity. Following sequencing and SNV analyses, the variant allele frequency (VAF) was determined for each biopsy sample (FIG. 51B).

[0748] Plasma samples from each of the four patients were used to isolate ctDNA and identify both clonal and subclonal SNV mutations in plasma to overcome tumor heterogeneity (FIG. 52). Clonal populations had VAF allele calls in all biopsied samples assayed and in plasma while subclonal populations had VAF allele calls in at least one biopsy sample, but not all biopsy samples. The plasma was considered to be a cumulative representative of the SNV's found in the ctDNA of each patient. Not all SNV's identified by sequencing were able to have corresponding PCR assays designed.

[0749] To compare the AmpliSeq (Swanton) and mmPCR/NGS assay methods for identifying tumor heterogeneity, Natera designed PCR assays for each SNV mutation for VAF detection in

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 380

both biopsied and corresponding ctDNA from plasma (FIG. 53). Blank cells represent no biopsy sample available and a zero value represents no VAF detected. The following 11 genes were initially identified as a negative (false VAF call) by the AmpliSeq FP or FN assays but were called correctly by the Natera TP or TN assays and mmPCR/NGS assay methods: L12: CYFIP1, FAT1, MLLT4, and RASA1; L13: HERC4, JAK2, MSH2, MTOR, and PLCG2; L15: GABRG1; L17: TRIM67. Surprisingly, when the AmpliSeq raw sequencing data was re-examined these results were verified. The raw AmpliSeq data sequencing files revealed that the data fell below the PGM or Illumina detectable threshold setting. The data identified 16/38 variants were detected in plasma and that there were several biopsy samples in the L12 patient samples that had predominant clonal SNV mutations: L12: BRIP1, CARS, FAT1, MLLT4, NFE2L2, TP53, TP53 as well as patients L13: EGFR, EGFR, TP53 and L15: KDM6A, ROS1. An additional two patients were found to have a total of four subclonal variant mutations in plasma: L12: CIC, KDM6A and L17; NF1, TRIM67. These results are summarized in FIG. 54A which is a whisker plot of the mean VAF for each sample listed in FIG. 53 by each assay method and FIG. 54B is a direct comparison represented by a linear regression plot of each assay's VAF sample mean.

Example 14

[0750] This example demonstrates that by using low primer concentrations such that primer amount is the limiting reactant in multiplex PCR in a workflow that is followed by next generation sequencing, uniformity of density of reads, and therefore limits of detection, across a pool of amplification reactions is improved. Some experiments were carried out for plasma CNV using the 3,168-plex panel according to Example 9 above except that the total reaction volume was 10 uL instead of 20 uL. Furthermore, PCR was carried out for 15, 20, or 25 cycles. Other experiments were carried out using the four 84-plex pools on breast cancer samples according to the protocol of Example 9 except that primer concentrations were 2 nM and PCR amplification was carried out for 15, 20, or 25 cycles.

[0751] Not to be limited by theory, it is believed that primer limited multiplex PCR provides improved depth of read uniformity for multiplex PCR before multi-read sequencing, such as sequencing on an Illumina HiSeq or MiSeq system or an Ion Torrent PGM or Proton system, based on the following considerations: If some of the amplifications in a multiplex PCR have lower efficiencies than others, then with normal multiplex PCR we will end up with a wide range of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 381

depth of read ("DOR") values. However, if the amount of primer is limited, and the multiplex PCR is cycled more times than what it takes to exhaust the primers, then the more efficient amplifications will stop doubling (because they have no more primers to use) and the less efficient ones will continue to double; this will result in a more similar amount of amplification product for all of the amplification products. This will translate into a much more uniform distribution of the DOR.

[0752] The following calculations are used to determine the number of cycles that would exact a given amount of primer and starting nucleic acid template:

[0753] -assume a given starting DNA input level: 100k copies of each target (10^5; this is easily achieved with using amplified library)

[0754] -assume we use 2 nM of each primer as an exemplary concentration, although other concentrations such as, for example, 0.2, 0.5, 1, 1.5, 2, 2.5, 5, or 10 nM could work too.

[0755] -calculate the number of primer molecules for each primer: 2*10^-9 (molar concentration, 2 nM) x 10*10^-6 (reaction volume, 10 ul) X 6*10^23 (number of molecules per mole, Avogadro's number) = 12*10^9

[0756] -calculate the amplification fold needed to consume all primers: 12*10^9 (number of primer molecules) / 10^5 (number of copies of each target) = 12*10^4

[0757] -calculate the number of cycles needed to achieve this amplification fold, assuming 100% efficiency at each cycle: log2(12*10^4) = 17 cycles. (this is log2 because at each cycle, the number of copies doubles).

[0758] So for these conditions (100k copies input, 2 nM primers, 10 ul reaction volume, assuming 100% PCR efficiency at each cycle), the primers would be consumed after 17 PCR cycles.

[0759] However, the key assumption is that some of the products DO NOT have 100% efficiency, so without measuring their efficiencies (which is only practicable for a small number of them anyway), it would take more than 17 cycles to consume them.

[0760] FIGs. 55-58 show results for the four 84-plex SNV PCR primer pools. For each of the pools we observed improved DOR efficiency with increasing cycles from 15 to 20 to 25. Similar results were obtained for experiments using the 3,168-plex panel (FIGs. 59-61). The limit of detection decreased (i.e. SNV sensitivity increased) with increasing depth of read. Furthermore, the sensitivity was consistently better when detecting transversion mutations than transition

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 382

mutations. It is likely that additional increases in DOR efficiency can be obtained with additional cycles when using primer-limiting multiplex PCR before multi-read sequencing.

[0761] Accordingly, in one aspect provided herein is a method of amplifying a plurality of target loci in a nucleic acid sample that includes (i) contacting the nucleic acid sample with a library of primers and other primer extension reaction components to provide a reaction mixture, wherein the relative amount of each primer in the reaction mixture compared to the other primer extension reaction components creates a reaction wherein the primers are present at a limiting concentration, and wherein the primers hybridize to a plurality of different target loci; and (ii) subjecting the reaction mixture to primer extension reaction conditions for sufficient number of cycles to consume or exhaust the primers in the library of primers, to produce amplified products that include target amplicons. For example, the plurality of different target loci can include at least 2, 3, 5, 10, 25, 50, 100, 200, 250, 500, 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; or 100,000 different target loci, and at most, 50, 100, 200, 250, 500, 1,000; 2,000; 5,000; 7,500; 10,000; 20,000; 25,000; 30,000; 40,000; 50,000; 75,000; 100,000, 200,000, 250,000, 500,000, and 1,000,000 different target loci to produce a reaction mixture.

[0762] The method in illustrative embodiments, includes determining an amount of primer that will be a rate limiting amount. This calculation typically includes estimating and/or determining the number of target molecules and involves analyzing and/or determining the number of amplification cycles performed. For example, in illustrative embodiments, the concentration of each primer is less than 100, 75, 50, 25, 10, 5, 2, 1, 0.5, 0.25, 0.2 or 0.1 nM. In various embodiments, the GC content of the primers is between 30 to 80%, such as between 40 to 70% or 50 to 60%, inclusive. In some embodiments, the range of GC content (*e.g.,* the maximum GC content minus minimum GC content, such as 80% - 60% = a range of 20%) of the primers is less than 30, 20, 10, or 5%. In some embodiments, the melting temperature (T_m) of the primers is between 40 to 80 °C, such as 50 to 70 °C, 55 to 65 °C, or 57 to 60.5 °C, inclusive. In some embodiments, the range of melting temperatures of the primers is less than 20, 15, 10, 5, 3, or 1 °C. In some embodiments, the length of the primers is between 15 to 100 nucleotides, such as between 15 to 75 nucleotides, 15 to 40 nucleotides, 17 to 35 nucleotides, 18 to 30 nucleotides, 20 to 65 nucleotides, inclusive. In some embodiments, the primers include a tag that is not target specific, such as a tag that forms an internal loop structure. In some embodiments, the tag is between two DNA binding regions. In various embodiments, the primers include a 5' region that

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 383

is specific for a target locus, an internal region that is not specific for the target locus and forms a loop structure, and a 3' region that is specific for the target locus. In various embodiments, the length of the 3' region is at least 7 nucleotides. In some embodiments, the length of the 3' region is between 7 and 20 nucleotides, such as between 7 to 15 nucleotides, or 7 to 10 nucleotides, inclusive. In various embodiments, the test primers include a 5' region that is not specific for a target locus (such as a tag or a universal primer binding site) followed by a region that is specific for a target locus**,** an internal region that is not specific for the target locus and forms a loop structure, and a 3' region that is specific for the target locus. In some embodiments, the range of the length of the primers is less than 50, 40, 30, 20, 10, or 5 nucleotides. In some embodiments, the length of the target amplicons is between 50 and 100 nucleotides, such as between 60 and 80 nucleotides, or 60 to 75 nucleotides, inclusive. In some embodiments, the range of the length of the target amplicons is less than 100, 75, 50, 25, 15, 10, or 5 nucleotides.

[0763] In various embodiments of any of the aspects of the invention, the primer extension reaction conditions are polymerase chain reaction conditions (PCR). In various embodiments, the length of the annealing step is greater than 3, 5, 8, 10, or 15 minutes but less than 240, 120, 60, or 30 minutes. In various embodiments, the length of the extension step is greater than 3, 5, 8, 10, or 15 minutes but less than 240, 120, 60 or 30 minutes.

Example 15

[0764] This Example demonstrates the ability of the SNV detection methods of the present invention to identify mosaicism in single cell analysis also referred to as single molecule analysis. FIG. 62 shows multiplex PCR results from tumor cell genomic DNA and single cell/molecule inputs using the 28K-plex primer set according to the 28K single cell method provided in Example 9. Using this method, greater than 85% of reads were mapped – over 4.7M reads (about 167 reads per target). The lower portion of the figure shows that mosaicism was observed among cells.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 384

Doc Code: TRACK1.REQ
Document Description: TrackOne Request

PTO/AIA/424 (04-14)

CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION UNDER 37 CFR 1.102(e) (Page 1 of 1)

First Named Inventor:	Joshua BABIARZ	Nonprovisional Application Number (if known):	To be assigned
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS		

APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR THE ABOVE-IDENTIFIED APPLICATION.

1. The processing fee set forth in 37 CFR 1.17(i)(1) and the prioritized examination fee set forth in 37 CFR 1.17(c) have been filed with the request. The publication fee requirement is met because that fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee, and examination fee are filed with the request or have been already been paid. I understand that any required excess claims fees or application size fee must be paid for the application.

2. I understand that the application may not contain, or be amended to contain, more than four independent claims, more than thirty total claims, or any multiple dependent claims, and that any request for an extension of time will cause an outstanding Track I request to be dismissed.

3. The applicable box is checked below:

I. ☑ Original Application (Track One) - Prioritized Examination under § 1.102(e)(1)

i. (a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a). This certification and request is being filed with the utility application via EFS-Web.

---OR---

(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a). This certification and request is being filed with the plant application in paper.

ii. An executed inventor's oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each inventor, **or** the application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is filed with the application.

II. ☐ Request for Continued Examination - Prioritized Examination under § 1.102(e)(2)

i. A request for continued examination has been filed with, or prior to, this form.
ii. If the application is a utility application, this certification and request is being filed via EFS-Web.
iii. The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is a national stage entry under 35 U.S.C. 371.
iv. This certification and request is being filed prior to the mailing of a first Office action responsive to the request for continued examination.
v. No prior request for continued examination has been granted prioritized examination status under 37 CFR 1.102(e)(2).

Signature /Tianran Yan/	Date 5-6-2022
Name (Print/Typed) Tianran Yan	Practitioner Registration Number 67,162

Note: *This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. Submit multiple forms if more than one signature is required.**

☑ *Total of 1 forms are submitted.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 17/738,354

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	320
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	700
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	800
TOTAL CLAIMS (37 CFR 1.16(i))	15 minus 20 =	*			OR	x 100 =	0.00
INDEPENDENT CLAIMS (37 CFR 1.16(h))	1 minus 3 =	*				x 480 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						1680
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	3500

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/738,354	05/06/2022		3500	N.012.US.44	15	1

CONFIRMATION NO. 8319

FILING RECEIPT

110711
Natera, Inc.
201 Industrial Road
Suite 410
San Carlos, CA 94070

OC000000134045341

Date Mailed: 05/24/2022

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Joshua BABIARZ, Castro Valley, CA;
Tudor Pompiliu CONSTANTIN, Berkeley, CA;
Lane A. EUBANK, San Carlos, CA;
George GEMELOS, Portland, OR;
Matthew Micah HILL, Belmont, CA;
Huseyin Eser KIRKIZLAR, Los Angeles, CA;
Matthew RABINOWITZ, San Francisco, CA;
Onur SAKARYA, Redwood City, CA;
Styrmir SIGURJONSSON, San Jose, CA;
Bernhard ZIMMERMANN, Manteca, CA;

Applicant(s)

Natera, Inc., San Carlos, CA;

Assignment For Published Patent Application

Natera, Inc., San Carlos, CA

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 17/692,469 03/11/2022
which is a CON of 15/898,145 02/15/2018 PAT 11319595
which is a CON of 14/692,703 04/21/2015 PAT 10179937
which claims benefit of 61/982,245 04/21/2014
and claims benefit of 61/987,407 05/01/2014

and claims benefit of 61/994,791 05/16/2014
and claims benefit of 62/066,514 10/21/2014
and claims benefit of 62/146,188 04/10/2015
and claims benefit of 62/147,377 04/14/2015
and claims benefit of 62/148,173 04/15/2015

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 05/23/2022
The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/738,354**
Projected Publication Date: 09/01/2022
Non-Publication Request: No
Early Publication Request: No
Title

DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

Preliminary Class

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application

serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/738,354	05/06/2022	Joshua BABIARZ	N.012.US.44	8319

110711 7590 06/17/2022

Natera, Inc.
201 Industrial Road
Suite 410
San Carlos, CA 94070

EXAMINER
CENTRAL, DOCKET

ART UNIT	PAPER NUMBER
OPAP	

NOTIFICATION DATE	DELIVERY MODE
06/17/2022	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

IP@natera.com

PTOL-90A (Rev. 04/07)

Decision Granting Request for Prioritized Examination (Track I)	**Application No.** 17/738,354	**Applicant(s)** BABIARZ et al.	
	Examiner FIKIRTE A GEREMEW	**Art Unit** OMBL	**AIA (FITF) Status** Yes

1. THE REQUEST FILED 06 May 2022 IS **GRANTED** .

The above-identified application has met the requirements for prioritized examination

A. ☑ for an original nonprovisional application (Track I).
B. ☐ for an application undergoing continued examination (RCE).

2. **The above-identified application will undergo prioritized examination**. The application will be accorded special status throughout its entire course of prosecution until one of the following occurs:

A. filing a **petition for extension of time** to extend the time period for filing a reply;

B. filing an **amendment to amend the application to contain more than four independent claims, more than thirty total claims** , or a multiple dependent claim;

C. filing a **request for continued examination** ;

D. filing a notice of appeal;

E. filing a request for suspension of action;

F. mailing of a notice of allowance;

G. mailing of a final Office action;

H. completion of examination as defined in 37 CFR 41.102; or

I. abandonment of the application.

Telephone inquiries with regard to this decision should be directed to FIKIRTE GEREMEW at (703) 756-1930. In his/her absence, calls may be directed to Petition Help Desk at (571) 272-3282.

/FIKIRTE A GEREMEW/ PROGRAM SUPPORT ASSISTANT, OMBL	

Web Search History

date, time	web site	search string
6/29/2022 2:21:38 PM	Google Scholar	[after:2000] [before:2013] tumor cell free dna snp amplify OR pcr
6/29/2022 2:26:46 PM	Google Scholar	tumor cell free dna snp amplify OR pcr [after:2000] [before:2013]
6/29/2022 3:52:22 PM	Google Scholar	illumina read depth
6/29/2022 3:59:46 PM	Google Scholar	marker density read depth
6/29/2022 4:00:11 PM	Google Scholar	illumina "read depth"
6/29/2022 4:01:07 PM	Google Scholar	illumina "read depth" [after:2013] [before:2020]
6/29/2022 4:01:22 PM	Google Scholar	illumina "read depth" [after:2020] [before:2013]
6/29/2022 4:08:25 PM	Google Scholar	[after:2000] [before:2013] illumina "read level"
6/29/2022 4:08:25 PM	Google Scholar	illumina "read depth" [after:2000] [before:2013]
6/29/2022 4:16:52 PM	Google Scholar	[after:2000] [before:2013] illumina "read count"
6/29/2022 4:41:58 PM	Google Scholar	cfDNA tumor biopsy
6/29/2022 4:42:34 PM	Google Scholar	cfDNA tumor biopsy [after:2000] [before:2013]
6/29/2022 5:02:53 PM	Google Scholar	tumor clonal heterogeneity
6/29/2022 5:03:05 PM	Google Scholar	tumor clonal heterogeneity [after:2000] [before:2013]
6/29/2022 5:29:34 PM	Google Scholar	detectable fraction cell free DNA
6/29/2022 5:30:20 PM	Google Scholar	detectable fraction cell free DNA [after:2000] [before:2013]
6/29/2022 5:36:03 PM	Google Scholar	[after:2000] [before:2013] sensitivity cell free DNA tumor
6/29/2022 5:36:03 PM	Google Scholar	[after:2000] [before:2013] sensitivity cell free DNA
6/29/2022 5:37:42 PM	Google Scholar	[after:2000] [before:2013] mutation percent cell free DNA tumor
6/29/2022 5:40:29 PM	Google Scholar	[after:2000] [before:2013] fraction cell free DNA tumor
6/30/2022 1:12:54 PM	Google Scholar	targeted sequencing depth
6/30/2022 1:13:07 PM	Google Scholar	mutation sequencing depth

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L244	4803	tumor SAME cell free SAME (amplif$ OR PCR)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/06/29 02:49 PM
L245	2345	L244 AND ((C12Q1/6886 OR C12Q2600/156 OR C12Q1/6806 OR C12Q1/686 OR C12Q2600/16).cpc.)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/06/29 02:50 PM
L246	613	L245 AND @ay<"2014"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/06/29 02:50 PM
L247	283	L246 AND multiplex	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU,	ADJ	ON	ON	2022/06/29 02:50 PM

			CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L248	532	tumor SAME cell free SAME (amplif$ OR PCR) SAME multiplex	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/06/29 02:51 PM
L249	383	L248 AND ((C12Q1/6886 OR C12Q2600/156 OR C12Q2600/16 OR C12Q1/686 OR C12Q1/6827).cpc.)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/06/29 02:52 PM
L250	89	L249 AND @ay<"2014"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN,	ADJ	ON	ON	2022/06/29 02:52 PM

			WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 397

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/738,354	BABIARZ et al.
	Examiner	Art Unit
	JOHN S BRUSCA	1631

CPC - Searched*		
Symbol	Date	Examiner

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
Global Dossier reviewed Parent Application No. 15/898,145 reviewed Consulted with Stephanie Mummert Inventor name search-PE2P-DAV Google Scholar and PE2E-SEARCH-see search history printouts	06/30/2022	/JSB/

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner

/JOHN S BRUSCA/ Primary Examiner, Art Unit 1631	

Notice of References Cited	Application/Control No. 17/738,354	Applicant(s)/Patent Under Reexamination BABIARZ et al.	
	Examiner JOHN S BRUSCA	Art Unit 1631	Page 1 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
	A					
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N	WO-2004051218-A2	06-2004	WO	ANDERSEN M	C12Q1/6806
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Forshew et al. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA Science Translational Medicine vol. 4 article 136ra68 and Supplementary Material (Year: 2012)
	V	Benesova et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients Analytical Biochemistry vol. 433, pages 227-234 (Year: 2013)
	W	Marusyk et al. Tumor heterogeneity: Causes and consequences Biochimica et Biophysica Acta vol. 1805, pages 105-117 (Year: 2010)
	X	Diehl et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors Proceedings of the National Academy of Sciences USA vol. 102 pages 16368-16373 (Year: 2005)

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 17/738,354	Applicant(s)/Patent Under Reexamination BABIARZ et al.	
	Examiner JOHN S BRUSCA	Art Unit 1631	Page 2 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-11319596-B2	05-2022	Babiarz; Joshua	G16B40/20	1/1
*	B	US-11371100-B2	06-2022	Babiarz; Joshua	C12Q1/6886	1/1
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ku et al. Exome versus transcriptome sequencing in identifying coding region variants Expert Review of Molecular Diagnostics vol. 12, pages 241-251 (Year: 2012)
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/738,354	05/06/2022	Joshua BABIARZ	N.012.US.44	8319

110711 7590 07/07/2022

Natera, Inc.
201 Industrial Road
Suite 410
San Carlos, CA 94070

EXAMINER
BRUSCA, JOHN S

ART UNIT	PAPER NUMBER
1631	

NOTIFICATION DATE	DELIVERY MODE
07/07/2022	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

IP@natera.com

PTOL-90A (Rev. 04/07)

Office Action Summary	**Application No.** 17/738,354	**Applicant(s)** BABIARZ et al.	
	Examiner JOHN S BRUSCA	**Art Unit** 1631	**AIA (FITF) Status** Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL.** 2b) ☑ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-15 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1-15 is/are rejected.

8) ☑ Claim(s) 1 is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☑ The drawing(s) filed on 06 May 2022 is/are: a)☑ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Status of the Claims

2. Claims 1-15 are pending.

Claim 1 is objected to.

Claims 1-15 are rejected.

Priority

3. Claims 1-15 are given the benefit of the claim to priority to Provisional Application No. 61/982,245 filed 21 April 2014.

Drawings

4. The drawings were received on 06 May 2022. These drawings are accepted.

Claim Objections

5. Claim 1 is objected to because of the following informalities: In line 6 the claim recites "the cell-free DNA" and should recite "cell-free DNA" because the first recitation of a term should not use a definite article. Appropriate correction is required.

Claim Interpretation

6. The terms "clonal SNV mutations" and "subclonal SNV mutations" in claims 4-6 are interpreted as discussed in the specification at paragraphs 111 and 748. Paragraph 48 states that plasma has a cumulative representation of SNV mutations. Plasma samples are therefore interpreted as comprising both clonal and subclonal SNV mutations.

Claim Rejections - 35 USC § 112

7. The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.

The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.

Claim 1 is indefinite for recitation in lines 6-7 of the phrase "from the cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom" because it is not clear how cell-free DNA is different than DNA derived therefrom. For the purpose of examination claim 1 has been interpreted to be limited to cell-free DNA isolated from a plasma sample.

Claims 2-15 are rejected for the same reason as claim 1 because they depend from claim 1 and fail to remedy the indefiniteness of claim 1.

Claims 1, 2, and 12 are indefinite for recitation of the phrase "high throughput sequencing" because the metes and bounds are not clear and the specification does not provide a limiting definition of the phrase. For the purpose of examination the claims have been interpreted as being limited to sequencing.

Claims 3-7 are rejected for the same reason as claim 2 because they depend from claim 2 and fail to remedy the indefiniteness of claim 2.

Claim 11 is indefinite for recitation of the phrase "patient-specific PCR primers" because the phrase is not defined in the specification and it is not clear if the primers are not capable of

hybridizing to DNA of any other individual or merely capable of hybridizing to DNA of a particular patient. For the purpose of examination claim 11 has been interpreted as being limited to primers that are capable of hybridizing to DNA of a patient.

Claim Rejections - 35 USC § 103

8. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

9. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

> A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.

10. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.

11. Claims 1, 3, 7, 9, and 11-14 are rejected under 35 U.S.C. 103 as being unpatentable over Forshew et al. (Science Translational Medicine vol. 4, article 136ra68 plus supplementary material (2012)) in view of Benesova et al. (Analytical Biochemistry vol. 433, pages 227-234 (2013)).

Independent claim 1 recites a process of identifying single nucleotide variant (SNV) mutations in a tumor sample of a subject by sequencing, performing at least a 20 multiplex amplification to generate amplicons using cell-free DNA from a plasma sample of the subject, and sequencing the amplicons to detect SNV mutations. Dependent claim 3 further recites a process of analyzing cell-free DNA that comprises circulating tumor DNA. Dependent claim 7 further recites a process of analyzing mutations in a tumor tissue sample of a subject. Dependent claim 9 further recites a process of a 20-50 multiplex amplification. Dependent claim 11 further recites a process of use of primers that hybridize to DNA of the subject. Dependent claim 12 further recites a process of using barcoding in the amplification. Dependent claim 13 further recites a process of detecting recurrence of cancer. An embodiment of dependent claim 14 further recites a process of analysis of colorectal cancer.

Forshew et al. shows in the abstract and throughout analysis of cell-free DNA of individuals with tumors for mutation analysis by multiplex amplification using a pool of primer pairs followed by sequencing of amplicons. Forshew et al. outlines the process in Figure 1, which shows a preamplification step that uses a single multiplex amplification of regions of interest followed by a second amplification followed by barcoded amplification and sequencing. Forshew et al. shows on page 3 use of 48 primer pairs to amplify regions of interest. Forshew et al. shows on pages 3-9 identification of mutations in the amplified regions of interest. Forshew et al. shows in Figure 4 data of time series of observations to identify recurrences of cancer, for example see Figure 4-B.

Forshew et al. does not show an initial step of identifying SNV mutations in a tumor sample or tumor tissue of a subject by sequencing. Forshew et al. does not show analysis of colon cancer.

Benesova et al. shows analysis of cell-free DNA to analyze tumor DNA in a patient on pages 228-232. Benesova et al. shows in the first column of page 230 a process of initially determining a tumor-specific mutation in a primary tumor, followed by detection of the same mutation in cell-free DNA. Benesova et al. notes in the first column of page 228 that Figure 1 shows colon tumor analysis through cell-free DNA, as illustrated in Figure 1. Analysis of colorectal cancer is further discussed on pages 230-232

It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the process of Forshew et al. by first identifying a mutation in tumor tissue because Benesova et al. provides guidance to first identify a mutation in tumor tissue followed by analysis of the mutation using cell-free DNA. It would have been further obvious to analyze colorectal cancer using cell-free DNA because Benesova et al. provides guidance to do so.

12. Claims 4-6 and 8 are rejected under 35 U.S.C. 103 as being unpatentable over Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above, and further in view of Marusyk et al. (Biochimica et Biophysica Acta vol. 1805 pages 105-117 (2010)).

Dependent claim 4 further recites a process of analyzing clonal SNV mutations. Dependent claim 5 further recites a process of analyzing subclonal SNV mutations. Dependent claim 6 further recites a process of analyzing both clonal and subclonal SNV mutations. Dependent claim 8 further recites a process of determining clonal heterogeneity of a sample.

Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above does not explicitly discuss analysis of clonal and subclonal mutations.

Marusyk et al. reviews tumor clonal heterogeneity. Marusyk et al. shows intra tumor clonal diversity at section 3.1. Analysis of clonal heterogeneity and subclonal changes by sequencing of specific genes is discussed in section 4.1.

It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the process of Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above by analysis of clonal and subclonal mutations because as discussed in the interpretation above plasma samples (as analyzed in Forshew et al. and Benesova et al.) comprise clonal and subclonal mutations and Marusyk et al. provides explicit guidance to analyze tumor heterogeneity comprising clonal and subclonal variations.

13. Claim 10 is rejected under 35 U.S.C. 103 as being unpatentable over Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above, and further in view of Anderson et al. (WO 2004/051218).

Dependent claim 10 further recites a process of a 50-100 multiplex amplification.

Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above does not show a process of a 50-100 multiplex amplification.

Anderson et al. shows multiplex amplifications in the abstract and throughout. Anderson et al. shows in the example at pages 36-39 examples of a multiplex amplification of 95 samples using low primer concentrations.

It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the process of Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above by use of the 95 multiplex process of Anderson et al. to allow for analysis of a greater number of loci in a single amplification saving time and expense.

14. Claims 14 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above, and further in view of Diehl et al. (Proceedings of the National Academy of Sciences USA vol. 102, pages 16368-16373 (2005)).

An embodiment of dependent claim 14 further recites a process of analysis of colorectal cancer. Dependent claim 15 further recites a process of analyzing a mutation that is less than or equal to 0.015% of the cell-free DNA.

Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above show analysis of colorectal cancer in Benesova et al., but do not show analyzing a mutation that is less than or equal to 0.015% of the cell-free DNA.

Diehl et al. analyzes cell-free DNA for colorectal cancer DNA in the abstract and throughout. Diehl et al. shows sensitivity of the assay (detailed in figure 2) of amplified colorectal cancer DNA in Table 1 of as low as 0.001%.

It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the process of Forshew et al. in view of Benesova et al. as applied to claims 1, 3, 7, 9, and 11-14 above by use of the assay of Diehl et al. because Diehl et al. shows an assay with high sensitivity.

Double Patenting

15. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not

patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 *et seq.* for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

16. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 11 and 18 of U.S. Patent No. 11,319,596. Although the claims at issue are not

identical, they are not patentably distinct from each other because claims 11 and 18 of U.S. Patent No. 11,319,596 is anticipatory of instant claim 1 in view of claiming a species of the instant claim 1 regarding multiplex amplifications of 10-50 target loci relative to the instant at least 20 target loci. Regarding the instant claim 1 limitation of sequencing a tumor sample by whole exome sequencing or whole genome sequencing, the type of sequencing is obvious over issued claim 18 limited to whole exome sequencing of a tumor biopsy sample.

17. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 16 of copending Application No. 16/288,416 in view of Ku et al. (Expert Reviews in Molecular Diagnostics vol. 12, pages 241-251 (2012)). Claim 16 of Application No. 16/288,416 claims a species of the instant claim 1 regarding multiplex amplifications of 10-50 target loci relative to the instant at least 20 target loci. Regarding the limitation in instant claim 1 of sequencing by whole exome sequencing, such sequencing is obvious over Ku et al. which shows advantages of whole exome sequencing for targeting expressed genomic regions at page 243.

This is a provisional nonstatutory double patenting rejection.

18. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 13 and 10 of U.S. Patent No. 11,371,100. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 13 and 10 of U.S. Patent No. 11,371,100 is anticipatory of instant claim 1 in view of claiming a species of the instant claim 1 regarding multiplex amplifications of 10-50 target loci relative to the instant at least 20 target loci. Regarding the instant claim 1 limitation of sequencing a tumor sample by whole exome sequencing or whole genome sequencing, the type of sequencing is obvious over issued claim 10 limited to whole exome sequencing of a tumor biopsy sample.

19. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 18 and 19 of copending Application No. 16/359,917 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claim 18 of Application No. 16/359,917 shows a method of performing whole exome sequencing of a tumor sample of a subject and performing multiplex amplification of a cell-free sample of the subject followed by sequencing of the amplicons. Copending claim 19 shows a species of the limitation of instant claim 1 of at least 20 target loci targeted in a multiplex amplification by claiming at least 50 target loci targeted in a multiplex amplification. The combination of claim 18 and 19 makes instant claim 1 obvious.

This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.

20. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 14 of copending Application No. 17/018,966 in view of Ku et al. (Expert Reviews in Molecular Diagnostics vol. 12, pages 241-251 (2012)). Claim 14 of Application No. 17/018,966 claims a species of the instant claim 1 regarding multiplex amplifications of at least 25 target loci relative to the instant at least 20 target loci. Regarding the limitation in instant claim 1 of sequencing by whole exome sequencing, such sequencing is obvious over Ku et al. which shows advantages of whole exome sequencing for targeting expressed genomic regions at page 243.

This is a provisional nonstatutory double patenting rejection.

21. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process... may obtain a patent therefor..." (Emphasis added). Thus, the term "same

invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

22. Claims 1-15 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-15 of copending Application No. 17/692,469 (reference application). This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

Conclusion

23. This Office action is a Non-Final action. A shortened statutory period for reply to this action is set to expire THREE MONTHS from the mailing date of this action.

24. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN S. BRUSCA whose telephone number is (571)272-0714. The examiner's fax number is (571) 273-0714.The examiner can normally be reached M-F 8:30 AM-5:00PM.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Karlheinz Skowronek can be reached on (571) 272-9047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/JOHN S BRUSCA/
Primary Examiner, Art Unit 1631

Electronic Acknowledgement Receipt	
EFS ID:	46241694
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	21-JUL-2022
Filing Date:	06-MAY-2022
Time Stamp:	13:18:02
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Internet Communications Authorization	N012US44-Internet-Communication.pdf	78969 2d6b12459c1a90509dc25abb3f42c7d61e9620a7	no	2
Warnings:					

Information:	
Total Files Size (in bytes):	78969

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: ECOMM.AUTH/ECOMM.WTDW
Doc Description: Internet Communications Authorized/Internet Communications Authorization Withdrawn

PTO/SB/439 (11-15)

AUTHORIZATION FOR INTERNET COMMUNICATIONS IN A PATENT APPLICATION OR REQUEST TO WITHDRAW AUTHORIZATION FOR INTERNET COMMUNICATIONS		
	Application No.	17/738,354
	Filing Date	5/6/2022
	First Named Inventor	Joshua BABIARZ
	Art Unit	1631
	Examiner Name	BRUSCA, JOHN S
	Practitioner Docket No.	N.012.US.44

To: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I. To authorize permission for Internet Communications.

☑ Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application via video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file. (MPEP 502.03)

II. To withdraw authorization for Internet Communications.

☐ The authorization given on _____, to the USPTO to communicate with the undersigned and any practitioner in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application via Internet communications such as video conferencing, instant messaging, or electronic mail is hereby withdrawn. I understand that the withdrawal is effective when approved rather than when received.

I am the

☐ applicant.

☑ attorney or agent of record. Registration number 67,162.

☐ attorney or agent acting under 37 CFR 1.34. Registration number _____.

/Tianran Yan/ — Signature

7/20/2022 — Date

Tianran Yan — Typed or printed name

(202) 295-4781 — Telephone Number

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. Juristic entities must be represented by a patent practitioner (see 37 CFR 1.31, which is applicable to any paper filed on or after September 16, 2012, that is presented on behalf of a juristic entity, regardless of application filing date). Submit multiple forms if more than one signature is required, see below*.

☐ * Total of _____ forms are submitted.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Inventor Name:	Joshua BABIARZ
Title:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
Application No.:	17/738,354
Filing Date:	5/6/2022
Examiner:	BRUSCA, JOHN S
Art Unit:	1631
Conf. No.:	8319

AMENDMENT AND REPLY UNDER 37 CFR 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

This communication is responsive to the non-final Office Action mailed July 7, 2022, concerning the above-referenced patent application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks begin on page 6 of this document.

Please amend the application as follows:

DRAFT

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (**Currently Amended**) A method for preparing a plasma sample of a subject having cancer or suspected of having cancer useful for detecting one or more single nucleotide variant (SNV) mutations in [[a]]the plasma sample ~~of a subject having cancer or suspected of having cancer~~, the method comprising:

performing whole exome sequencing or whole genome sequencing on a tumor sample of the subject to identify[[ing]] a plurality of tumor-specific SNV mutations ~~in a tumor sample of the subject by whole exome sequencing or whole genome sequencing~~;

performing targeted multiplex amplification to amplify ~~at least 20~~ 10 to 500 target loci each encompassing a different tumor-specific SNV mutation from ~~the~~ cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom to obtain amplicons, wherein the target loci are amplified together in the same reaction volume; and

performing high-throughput sequencing to sequence the amplicons to obtain sequence reads, and detecting one or more of the tumor-specific SNV mutations present in the cell-free DNA from the sequence reads, wherein the high-throughput sequencing has a depth of read of at least 50,000 per target locus.

2. (Cancelled)

3. (Original) The method of claim 1, wherein the cell-free DNA comprises circulating tumor DNA.

4. (Original) The method of claim 1, wherein the SNV mutations comprise one or more clonal SNV mutations.

5. (Original) The method of claim 1, wherein the SNV mutations comprise one or more subclonal SNV mutations.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 420

6. (Original) The method of claim 1, wherein the SNV mutations comprise one or more clonal SNV mutations and one or more subclonal SNV mutations.

7. (Original) The method of claim 1, wherein the tumor sample of the subject is a tumor tissue sample.

8. (Original) The method of claim 1, wherein the method further comprises determining clonal heterogeneity of the tumor sample.

9. (Original) The method of claim 1, wherein the targeted multiplex amplification amplifies 20 to 50 target loci each encompassing a different tumor-specific SNV mutation.

10. (Original) The method of claim 1, wherein the targeted multiplex amplification amplifies 50 to 100 target loci each encompassing a different tumor-specific SNV mutation.

11. (**Currently Amended**) The method of claim 1, wherein the method further comprises designing ~~patient-specific~~ PCR primers or hybrid capture probes targeting the plurality of SNV mutations identified in the tumor sample.

12. (Original) The method of claim 1, wherein the method further comprises performing barcoding PCR prior to the high-throughput sequencing.

13. (Original) The method of claim 1, wherein the method further comprises detecting recurrence and/or metastases of the cancer from the SNV mutations detected in the cell-free DNA.

14. (Original) The method of claim 1, wherein the cancer is colorectal cancer, lung cancer, bladder cancer, or breast cancer.

15. (**Currently Amended**) ~~The method of claim 1, wherein~~ A method for preparing a plasma sample of a subject having cancer or suspected of having cancer useful for detecting one or more single nucleotide variant (SNV) mutations in the plasma sample, the method comprising:

performing whole exome sequencing or whole genome sequencing on a tumor sample of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 421

the subject to identify a plurality of tumor-specific SNV mutations;

performing targeted multiplex amplification to amplify 10 to 500 target loci each encompassing a different tumor-specific SNV mutation from cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom to obtain amplicons, wherein the target loci are amplified together in the same reaction volume; and

performing high-throughput sequencing to sequence the amplicons to obtain sequence reads, and detecting one or more of the tumor-specific SNV mutations present in the cell-free DNA from the sequence reads, wherein the method is capable of detecting an SNV mutation that is present in less than or equal to 0.015% of the cell-free DNA comprising the SNV locus ~~is detected from the sequence reads~~.

16. (New) The method of claim 15, wherein the high-throughput sequencing has a depth of read of at least 50,000 per target locus.

17. (New) The method of claim 15, wherein the cell-free DNA comprises circulating tumor DNA.

18. (New) The method of claim 15, wherein the SNV mutations comprise one or more clonal SNV mutations.

19. (New) The method of claim 15, wherein the SNV mutations comprise one or more subclonal SNV mutations.

20. (New) The method of claim 15, wherein the SNV mutations comprise one or more clonal SNV mutations and one or more subclonal SNV mutations.

21. (New) The method of claim 15, wherein the tumor sample of the subject is a tumor tissue sample.

22. (New) The method of claim 15, wherein the method further comprises determining clonal heterogeneity of the tumor sample.

DRAFT

23. (New) The method of claim 15, wherein the targeted multiplex amplification amplifies 20 to 50 target loci each encompassing a different tumor-specific SNV mutation.

24. (New) The method of claim 15, wherein the targeted multiplex amplification amplifies 50 to 100 target loci each encompassing a different tumor-specific SNV mutation.

25. (New) The method of claim 15, wherein the method further comprises designing PCR primers or hybrid capture probes targeting the plurality of SNV mutations identified in the tumor sample.

26. (New) The method of claim 15, wherein the method further comprises performing barcoding PCR prior to the high-throughput sequencing.

27. (New) The method of claim 15, wherein the method further comprises detecting recurrence and/or metastases of the cancer from the SNV mutations detected in the cell-free DNA.

28. (New) The method of claim 15, wherein the cancer is colorectal cancer, lung cancer, bladder cancer, or breast cancer.

29. (New) The method of claim 15, wherein the method is capable of detecting an SNV mutation that is present in 0.005% to 0.015% of the cell-free DNA comprising the SNV locus.

DRAFT

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 423

REMARKS

Applicant respectfully requests reconsideration of the present application in view of the foregoing amendments and the reasons that follow.

Status of Claims

Claims 1-15 were pending in the subject case. With this submission, claims 1, 11 and 15 are amended to more clearly and particularly describe the claimed invention; claim 2 is cancelled without prejudice or disclaimer thereof; claims 16-29 are added. Support for the amendments to claim 1 can be found in claim 2 as well as paragraph 0761 of the as-filed specification; support for the amendments to claim 15 can be found in claim 1; support for new claims 16-29 can be found in claims 2-14 as well as paragraphs 0438 and 0458 of the as-filed specification. No new matter has been introduced.

After amending the claims as set forth above, claims 1 and 3-29 will be pending in this application.

Claim Objection

Claim 1 is objected to for grammatical informalities. For the sole purpose of expediting prosecution, Applicant has amended claim 1 pursuant to the Examiner's suggestion on page 2 of the Office Action, thereby resolving the issue.

Claim Rejections Under 35 U.S.C. § 112

Claims 1-15 are rejected under 35 U.S.C. § 112(b) for alleged indefiniteness in reciting "cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom." Applicant respectfully traverses this rejection. As described throughout the as-filed specification, the isolated cell-free DNA can be subject to optional library preparation steps prior to performing targeted multiplex amplification. See, e.g., Example 1 ("*Universal ligation adapters were appended to the end of each molecule of 40 uL of purified plasma DNA and*

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 424

libraries were amplified for 9 cycles using adaptor specific primers."). Thus, a person skilled in the art would understand that the targeted multiplex amplification step can be performed on the isolated cell-free DNA or on DNA derived from the cell-free DNA.

Claims 1, 2 and 12 are rejected under 35 U.S.C. § 112(b) for alleged indefiniteness in reciting "high-throughput sequencing." Applicant respectfully traverses this rejection at least because high-throughput sequencing, also known as next-generation sequencing (NGS), is a term of art that is well understood by a person skilled in the art.

Claim 11 is rejected under 35 U.S.C. § 112(b) for alleged indefiniteness in reciting "patient-specific PCR primers." Applicant respectfully traverses this rejection. For the sole purpose of expediting prosecution and without acquiescing to the rejection, Applicant has amended claim 11 to recite "PCR primers…targeting the plurality of SNV mutations identified in the tumor sample," thereby resolving the issue.

For at least these reasons, Applicant respectfully requests reconsideration and withdrawal of the subject rejections.

Claim Rejections Under 35 U.S.C. § 103

Claim 1, 3, 7, 9 and 11-14 are rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew *et al.* 2012 ("Forshew") in view of Benesova *et al.* 2013 ("Benesova"). Claims 4-6 and 8 are rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew in view of Benesova, and further in view of Marusky *et al.* 2010 ("Marusky"). Claim 10 is rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew in view of Benesova, and further in view of WO2004/051218 ("Anderson"). Claims 14 and 15 are rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew in view of Benesova, and further in view of Diehl *et al.* 2005 ("Diehl"). Applicant respectfully traverses these rejections.

Claim 2 stands free of the subject rejections. For the sole purpose of expediting prosecution and without acquiescing to the rejection, Applicant has amended independent claim

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 425

1 to incorporate the limitation of previous claim 2, thereby rendering the rejections moot. None of the cited references teaches or suggests sequencing each of the target loci with a depth of read of at least 50,000 per target locus. For at least these reasons, Applicant respectfully request withdrawal of the subject rejections against claims 1 and 3-14.

Applicant further submits that amended claim 15 and claims dependent therefrom are also unobvious over the cited references. As amended, claim 15 recites:

> 15. A method for preparing a plasma sample of a subject having cancer or suspected of having cancer useful for detecting one or more single nucleotide variant (SNV) mutations in the plasma sample, the method comprising:
>
> performing whole exome sequencing or whole genome sequencing on a tumor sample of the subject to identify a plurality of tumor-specific SNV mutations;
>
> performing targeted multiplex amplification to amplify 10 to 200 target loci each encompassing a different tumor-specific SNV mutation from cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom to obtain amplicons, wherein the target loci are amplified together in the same reaction volume; and
>
> performing high-throughput sequencing to sequence the amplicons to obtain sequence reads, and detecting one or more of the tumor-specific SNV mutations present in the cell-free DNA from the sequence reads, wherein the method is capable of detecting an SNV mutation that is present in less than or equal to 0.015% of the cell-free DNA comprising the SNV locus.

In contrast to the presently claimed method which is capable of "detecting an SNV mutation that is present in less than or equal to 0.015% of the cell-free DNA comprising the SNV locus", Forshew's TAm-Seq workflow was only able to achieve a detection limit of 2% (see abstract). Forshew also expressly acknowledged that "*[a] current limitation of TAm-Seq is the detection limit compared to assays that target individual loci, which have been shown to detect two to three orders of magnitude lower frequencies*" (pg. 10). There was no teaching or suggestion in Forshew about detecting an SNV mutation having a variant allele frequency of less than or equal to 0.015% in the cell-free DNA sample, and there was no teaching or suggestion in Forshew that such detection limit could be achieved by the TAm-Seq method disclosed therein.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 426

The Office cites Diehl for allegedly showing a sensitivity of as low as 0.001% in detection of colorectal cancer DNA. Diehl, however, performs neither targeted multiplex amplification of 10 to 200 target loci in the same reaction nor high-throughput sequencing of the amplicons. Instead, Diehl relies on bead-based digital PCR in emulsions (BEAMing) to amplify in a single target locus to detect adenomatous polyposis coli (APC) mutations. Because the workflow of BEAMing is completely different from the workflow of TAm-Seq, the sensitivity of BEAMing reported by Diehl is not applicable to the Forshew's TAm-Seq method.

Moreover, Forshew already considered Diehl's BEAMing method and pointed out its limitation in detecting cancer mutations outside of well-defined hotspot regions (see Forshew, p.9). There is no teaching or suggestion in the cited references about whether or how the detection limit of Forshew's TAm-Seq method could be improved by Diehl's BEAMing method.

Furthermore, Forshew's TAm-Seq process was rationally and deliberately designed to rely on single-plex, "*individual amplification to purify and select for intended targets*" (pg. 3). In fact, Forshew had considered but dismissed multiplex targeted amplification – "*Multiplex amplification using a large set of primers could result in nonspecific amplification products and biased coverage*" (Fig. 1B, pg. 3). Forshew deliberately resorted to parallel single-plex amplification on Access Array, which physically separate individual primer pairs and individual reaction volumes to avoid issues such as nonspecific amplification and primer dimer formation. There was no reason or motivation for one of ordinary skill in the art to alter Forshew's TAm-Seq process by substituting a step rationally and deliberately designed by Forshew for purpose of addressing the issue of nonspecific amplification, for a step already considered but dismissed by Forshew.

Benesova is cited for allegedly teaching identification of a tumor-specific mutation in a primary tumor. Marusky is cited for allegedly teaching analysis of clonal heterogeneity. Anderson is cited for allegedly teaching a 95-plex amplification using low primer concentrations. None of Benesova, Marusky, and Anderson could cure the aforementioned deficiencies of Forshew and Diehl. Accordingly, so far as the combined disclosure of the cited references still

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 427

fails to meet each and every limitation of the claimed invention, the *prima facie* case of obviousness cannot be sustained. Reconsideration and withdrawal of the subject rejection are therefore respectfully requested.

Double Patenting

Claim 1 is rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Pat. No. 11,319,596. Claim 1 is rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Pat. No. 11,371,100. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Appl. No. 16/288,416. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Appl. No. 16/359,917.

Applicant respectfully traverses these rejections. For the sole purpose of expediting prosecution and without acquiescing to the rejections, Applicant submits herewith a terminal disclaimer over U.S. Pat. Nos. 11,319,596 and 11,371,100, and U.S. Appl. Nos. 16/288,416 and 16/399,941, to overcome the subject rejections.

Claim 1 is also provisionally rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Appl. No. 17/018,966. Claims 1-15 are also provisionally rejected on the ground of statutory double patenting for allegedly claiming the same invention as claims 1-15 of U.S. Appl. No. 17/692,469.

Applicant respectfully traverses these rejections. For the sole purpose of expediting prosecution and without acquiescing to the rejections, Applicant has amended the claims of U.S. Appl. Nos. 17/018,966 and 17/692,469 to be patentably distinct from the pending claims of the instant application, thereby resolving the issue.

For at least these reasons, Applicant respectfully requests reconsideration and withdrawal of the subject rejections.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 428

Concluding Remarks

Applicant believes that the application is in condition for allowance. Favorable reconsideration is respectfully requested. The Examiner is invited to contact the undersigned to advance prosecution.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-6075. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extension fees to Deposit Account No. 50-6075.

Respectfully submitted,

Date

By /DRAFT/

Tianran Yan
Registration No. 67162
Customer No. 110711
202-295-4781
IP@natera.com
Attorney for Applicant

DRAFT

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/738,354	05/06/2022	Joshua BABIARZ	N.012.US.44	8319

110711 7590 07/28/2022

Natera, Inc.
201 Industrial Road
Suite 410
San Carlos, CA 94070

EXAMINER
BRUSCA, JOHN S

ART UNIT	PAPER NUMBER
1631	

NOTIFICATION DATE	DELIVERY MODE
07/28/2022	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

IP@natera.com

PTOL-90A (Rev. 04/07)

Applicant-Initiated Interview Summary	**Application No.** 17/738,354	**Applicant(s)** BABIARZ et al.		
	Examiner JOHN S BRUSCA	**Art Unit** 1631	**AIA (First Inventor to File) Status** Yes	**Page** 1 of 1

All Participants (applicant, applicants representative, PTO personnel)	**Title**	**Type**
JOHN S BRUSCA	Primary Examiner	Video Conference
Tianran Yan	Attorney	

Date of Interview: 22 July 2022

Issues Discussed:

35 U.S.C. 112

The metes and bounds of high throughput sequencing was discussed without agreement

35 U.S.C. 103

The examiner stated that the limitations of a depth of read of at least 50,000 per target locus in independent clam 1 and detection of an SNV at 0.015% of cell-free DNA comprising the SNV in proposed independent claim 15 would require further search to determine obviousness of the claims.

Proposed Amendment(s)

See attached draft amendment and comments

☑ Attachment

/JOHN S BRUSCA/ Primary Examiner, Art Unit 1631	

Applicant is reminded that a complete written statement as to the substance of the interview must be made of record in the application file. It is the applicants responsibility to provide the written statement, unless the interview was initiated by the Examiner and the Examiner has indicated that a written summary will be provided. See MPEP 713.04
Please further see:
MPEP 713.04
Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews, paragraph (b)
37 CFR § 1.2 Business to be transacted in writing

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/738,354	05/06/2022	Joshua BABIARZ	N.012.US.44

CONFIRMATION NO. 8319

110711
Natera, Inc.
201 Industrial Road
Suite 410
San Carlos, CA 94070

PUBLICATION NOTICE



Title:DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

Publication No.US-2022-0282335-A1
Publication Date:09/08/2022

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently https://portal.uspto.gov/pair/PublicPair. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/738,354	Filing Date 05/06/2022	☐ To be Mailed

ENTITY: ☑ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

	(Column 1)	(Column 2)			
FOR	NUMBER FILED	NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $100 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $480 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	10/07/2022	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 28	Minus	** 29	= 0		x $100 =	0
	Independent (37 CFR 1.16(h))	* 2	Minus	*** 3	= 0		x $480 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	SLIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/MONIQUE BENJAMIN/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt	
EFS ID:	46779956
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	07-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	18:11:33
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		N012US44-Response-SIGNED.pdf	69631 f7fabdb4b31940a3b89a37bb60b0182c850b7033	yes	11

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment/Request for Reconsideration-After Non-Final Rejection	1	1
	Claims	2	5
	Applicant Arguments/Remarks Made in an Amendment	6	11
Warnings:			
Information:			
	Total Files Size (in bytes):	69631	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

REMARKS

Applicant respectfully requests reconsideration of the present application in view of the foregoing amendments and the reasons that follow.

Statement of the Substance of an Interview

Applicant thanks Examiner Brusca for the courtesy extended in conducting an interview on July 22, 2022. During the interview, the outstanding rejections and proposed claim amendments to overcome the rejections were discussed. The official interview summary dated July 28, 2022 accurately reflects the contents of this discussion. If the Examiner believes that more review in the record is needed about this interview, he can notify the undersigned.

Status of Claims

Claims 1-15 were pending in the subject case. With this submission, claims 1, 11, 12, and 15 are amended to more clearly and particularly describe the claimed invention; claim 2 is cancelled without prejudice or disclaimer thereof; claims 16-29 are added. Support for the amendments to claim 1 can be found in claim 2 as well as paragraphs 0453, 0457 and 0761 of the as-filed specification; support for the amendments to claim 15 can be found in claim 1; support for new claims 16-29 can be found in claims 2-14 as well as paragraphs 0438 and 0458 of the as-filed specification. No new matter has been introduced.

After amending the claims as set forth above, claims 1 and 3-29 will be pending in this application.

Claim Objection

Claim 1 is objected to for grammatical informalities. For the sole purpose of expediting prosecution, Applicant has amended claim 1 pursuant to the Examiner's suggestion on page 2 of the Office Action, thereby resolving the issue.

Claim Rejections Under 35 U.S.C. § 112

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 436

Claims 1-15 are rejected under 35 U.S.C. § 112(b) for alleged indefiniteness in reciting "cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom." Applicant respectfully traverses this rejection. As described throughout the as-filed specification, the isolated cell-free DNA can be subject to optional library preparation steps prior to performing targeted multiplex amplification. See, e.g., Example 1 ("*Universal ligation adapters were appended to the end of each molecule of 40 uL of purified plasma DNA and libraries were amplified for 9 cycles using adaptor specific primers*."). Thus, a person skilled in the art would understand that the targeted multiplex amplification step can be performed on the isolated cell-free DNA or on DNA derived from the cell-free DNA.

Claims 1, 2 and 12 are rejected under 35 U.S.C. § 112(b) for alleged indefiniteness in reciting "high-throughput sequencing." Applicant respectfully traverses this rejection. For the sole purpose of expediting prosecution and without acquiescing to the rejection, Applicant has amended claims 1 and 12 to recite "sequencing" instead, thereby resolving the issue.

Claim 11 is rejected under 35 U.S.C. § 112(b) for alleged indefiniteness in reciting "patient-specific PCR primers." Applicant respectfully traverses this rejection. For the sole purpose of expediting prosecution and without acquiescing to the rejection, Applicant has amended claim 11 to recite "PCR primers…targeting the plurality of SNV mutations identified in the tumor sample," thereby resolving the issue.

For at least these reasons, Applicant respectfully requests reconsideration and withdrawal of the subject rejections.

Claim Rejections Under 35 U.S.C. § 103

Claim 1, 3, 7, 9 and 11-14 are rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew *et al.* 2012 ("Forshew") in view of Benesova *et al.* 2013 ("Benesova"). Claims 4-6 and 8 are rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew in view of Benesova, and further in view of Marusky *et al.* 2010 ("Marusky"). Claim 10 is rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew in view of Benesova, and further in view of WO2004/051218 ("Anderson"). Claims 14 and 15 are rejected under 35 U.S.C. § 103 for allegedly being unpatentable over Forshew in view

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 437

of Benesova, and further in view of Diehl *et al.* 2005 ("Diehl"). Applicant respectfully traverses these rejections.

Claim 2 stands free of the subject rejections. For the sole purpose of expediting prosecution and without acquiescing to the rejection, Applicant has amended independent claim 1 to incorporate the limitation of previous claim 2, thereby rendering the rejections moot. None of the cited references teaches or suggests sequencing each of the target loci with a depth of read of at least 50,000 per target locus. For at least these reasons, Applicant respectfully request withdrawal of the subject rejections against claims 1 and 3-14.

Applicant further submits that amended claim 15 and claims dependent therefrom are also unobvious over the cited references. As amended, claim 15 recites:

> 15. A method for preparing a plasma sample of a subject having cancer or suspected of having cancer useful for detecting one or more single nucleotide variant (SNV) mutations in the plasma sample, the method comprising:
>
> performing whole exome sequencing or whole genome sequencing on a tumor sample of the subject to identify a plurality of tumor-specific SNV mutations;
>
> performing targeted multiplex amplification to amplify 10 to 200 target loci each encompassing a different tumor-specific SNV mutation from cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom to obtain amplicons having a length of 50-150 bases, wherein the target loci are amplified together in the same reaction volume; and
>
> sequencing the amplicons to obtain sequence reads, and detecting one or more of the tumor-specific SNV mutations present in the cell-free DNA from the sequence reads, wherein the method is capable of detecting an SNV mutation that is present in less than or equal to 0.015% of the cell-free DNA comprising the SNV locus.

In contrast to the presently claimed method which is capable of "detecting an SNV mutation that is present in less than or equal to 0.015% of the cell-free DNA comprising the SNV locus", Forshew's TAm-Seq workflow was only able to achieve a detection limit of 2% (see abstract). Forshew also expressly acknowledged that "*[a] current limitation of TAm-Seq is the detection limit compared to assays that target individual loci, which have been shown to detect two to three orders of magnitude lower frequencies*" (pg. 10). There was no teaching or

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 438

suggestion in Forshew about detecting an SNV mutation having a variant allele frequency of less than or equal to 0.015% in the cell-free DNA sample, and there was no teaching or suggestion in Forshew that such detection limit could be achieved by the TAm-Seq method disclosed therein.

The Office cites Diehl for allegedly showing a sensitivity of as low as 0.001% in detection of colorectal cancer DNA. Diehl, however, performs neither targeted multiplex amplification of 10 to 200 target loci in the same reaction nor high-throughput sequencing of the amplicons. Instead, Diehl relies on bead-based digital PCR in emulsions (BEAMing) to amplify in a single target locus to detect adenomatous polyposis coli (APC) mutations. Because the workflow of BEAMing is completely different from the workflow of TAm-Seq, the sensitivity of BEAMing reported by Diehl is not applicable to the Forshew's TAm-Seq method.

Moreover, Forshew already considered Diehl's BEAMing method and pointed out its limitation in detecting cancer mutations outside of well-defined hotspot regions (see Forshew, p.9). There is no teaching or suggestion in the cited references about whether or how the detection limit of Forshew's TAm-Seq method could be improved by Diehl's BEAMing method.

Furthermore, Forshew's TAm-Seq process was rationally and deliberately designed to rely on single-plex, "*individual amplification to purify and select for intended targets*" (pg. 3). In fact, Forshew had considered but dismissed multiplex targeted amplification – "*Multiplex amplification using a large set of primers could result in nonspecific amplification products and biased coverage*" (Fig. 1B, pg. 3). Forshew deliberately resorted to parallel single-plex amplification on Access Array, which physically separate individual primer pairs and individual reaction volumes to avoid issues such as nonspecific amplification and primer dimer formation. There was no reason or motivation for one of ordinary skill in the art to alter Forshew's TAm-Seq process by substituting a step rationally and deliberately designed by Forshew for purpose of addressing the issue of nonspecific amplification, for a step already considered but dismissed by Forshew.

Benesova is cited for allegedly teaching identification of a tumor-specific mutation in a primary tumor. Marusky is cited for allegedly teaching analysis of clonal heterogeneity. Anderson is cited for allegedly teaching a 95-plex amplification using low primer concentrations. None of Benesova, Marusky, and Anderson could cure the aforementioned deficiencies of

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 439

Forshew and Diehl. Accordingly, so far as the combined disclosure of the cited references still fails to meet each and every limitation of the claimed invention, the *prima facie* case of obviousness cannot be sustained. Reconsideration and withdrawal of the subject rejection are therefore respectfully requested.

Double Patenting

Claim 1 is rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Pat. No. 11,319,596. Claim 1 is rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Pat. No. 11,371,100. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Appl. No. 16/288,416. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Appl. No. 16/359,917.

Applicant respectfully traverses these rejections. For the sole purpose of expediting prosecution and without acquiescing to the rejections, Applicant submits herewith a terminal disclaimer over U.S. Pat. Nos. 11,319,596 and 11,371,100, and U.S. Appl. Nos. 16/288,416 and 16/359,917, to overcome the subject rejections.

Claim 1 is also provisionally rejected on the ground of nonstatutory double patenting for allegedly being unpatentable over claims of U.S. Appl. No. 17/018,966. Applicant respectfully traverses this rejection. For the sole purpose of expediting prosecution and without acquiescing to the rejections, Applicant has amended the claims of U.S. Appl. No. 17/018,966 to be patentably distinct from the pending claims of the instant application, thereby resolving the issue.

Claims 1-15 are provisionally rejected on the ground of statutory double patenting for allegedly claiming the same invention as claims 1-15 of U.S. Appl. No. 17/692,469. Applicant respectfully traverses this rejection. For the sole purpose of expediting prosecution and without acquiescing to the rejections, Applicant has amended the claims of U.S. Appl. No. 17/692,469 to claim a different invention. In addition, Applicant submits herewith a terminal disclaimer over U.S. Appl. No. 17/692,469 to expedite prosecution.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 440

For at least these reasons, Applicant respectfully requests reconsideration and withdrawal of the subject rejections.

Concluding Remarks

Applicant believes that the application is in condition for allowance. Favorable reconsideration is respectfully requested. The Examiner is invited to contact the undersigned to advance prosecution.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-6075. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extension fees to Deposit Account No. 50-6075.

Respectfully submitted,

Date 10-7-2022

By /Tianran Yan/

Tianran Yan
Registration No. 67162
Customer No. 110711
202-295-4781
IP@natera.com
Attorney for Applicant

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (**Currently Amended**) A method for preparing a plasma sample of a subject having cancer or suspected of having cancer useful for detecting one or more single nucleotide variant (SNV) mutations in [[a]]the plasma sample ~~of a subject having cancer or suspected of having cancer~~, the method comprising:

performing whole exome sequencing or whole genome sequencing on a tumor sample of the subject to identify[[ing]] a plurality of tumor-specific SNV mutations ~~in a tumor sample of the subject by whole exome sequencing or whole genome sequencing~~;

performing targeted multiplex amplification to amplify ~~at least 20~~ 10 to 500 target loci each encompassing a different tumor-specific SNV mutation from ~~the~~ cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom to obtain amplicons having a length of 50-150 bases, wherein the target loci are amplified together in the same reaction volume; and

~~performing high throughput~~ sequencing ~~to sequence~~ the amplicons to obtain sequence reads, and detecting one or more of the tumor-specific SNV mutations present in the cell-free DNA from the sequence reads, wherein the sequencing has a depth of read of at least 50,000 per target locus.

2. (Cancelled)

3. (Original) The method of claim 1, wherein the cell-free DNA comprises circulating tumor DNA.

4. (Original) The method of claim 1, wherein the SNV mutations comprise one or more clonal SNV mutations.

5. (Original) The method of claim 1, wherein the SNV mutations comprise one or more subclonal SNV mutations.

6. (Original) The method of claim 1, wherein the SNV mutations comprise one or more clonal SNV mutations and one or more subclonal SNV mutations.

7. (Original) The method of claim 1, wherein the tumor sample of the subject is a tumor tissue sample.

8. (Original) The method of claim 1, wherein the method further comprises determining clonal heterogeneity of the tumor sample.

9. (Original) The method of claim 1, wherein the targeted multiplex amplification amplifies 20 to 50 target loci each encompassing a different tumor-specific SNV mutation.

10. (Original) The method of claim 1, wherein the targeted multiplex amplification amplifies 50 to 100 target loci each encompassing a different tumor-specific SNV mutation.

11. (**Currently Amended**) The method of claim 1, wherein the method further comprises designing ~~patient-specific~~ PCR primers or hybrid capture probes targeting the plurality of SNV mutations identified in the tumor sample.

12. (**Currently Amended**) The method of claim 1, wherein the method further comprises performing barcoding PCR prior to the ~~high-throughput~~ sequencing.

13. (Original) The method of claim 1, wherein the method further comprises detecting recurrence and/or metastases of the cancer from the SNV mutations detected in the cell-free DNA.

14. (Original) The method of claim 1, wherein the cancer is colorectal cancer, lung cancer, bladder cancer, or breast cancer.

15. (**Currently Amended**) ~~The method of claim 1, wherein~~ A method for preparing a plasma sample of a subject having cancer or suspected of having cancer useful for detecting one or more single nucleotide variant (SNV) mutations in the plasma sample, the method comprising:

performing whole exome sequencing or whole genome sequencing on a tumor sample of the subject to identify a plurality of tumor-specific SNV mutations;

performing targeted multiplex amplification to amplify 10 to 500 target loci each

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 443

encompassing a different tumor-specific SNV mutation from cell-free DNA isolated from a plasma sample of the subject or DNA derived therefrom to obtain amplicons, wherein the target loci are amplified together in the same reaction volume; and

sequencing the amplicons to obtain sequence reads, and detecting one or more of the tumor-specific SNV mutations present in the cell-free DNA from the sequence reads, wherein the method is capable of detecting an SNV mutation that is present in less than or equal to 0.015% of the cell-free DNA comprising the SNV locus ~~is detected from the sequence reads~~.

16. (New) The method of claim 15, wherein the sequencing has a depth of read of at least 50,000 per target locus.

17. (New) The method of claim 15, wherein the cell-free DNA comprises circulating tumor DNA.

18. (New) The method of claim 15, wherein the SNV mutations comprise one or more clonal SNV mutations.

19. (New) The method of claim 15, wherein the SNV mutations comprise one or more subclonal SNV mutations.

20. (New) The method of claim 15, wherein the SNV mutations comprise one or more clonal SNV mutations and one or more subclonal SNV mutations.

21. (New) The method of claim 15, wherein the tumor sample of the subject is a tumor tissue sample.

22. (New) The method of claim 15, wherein the method further comprises determining clonal heterogeneity of the tumor sample.

23. (New) The method of claim 15, wherein the targeted multiplex amplification amplifies 20 to 50 target loci each encompassing a different tumor-specific SNV mutation.

24. (New) The method of claim 15, wherein the targeted multiplex amplification amplifies 50 to 100 target loci each encompassing a different tumor-specific SNV mutation.

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 444

25. (New) The method of claim 15, wherein the method further comprises designing PCR primers or hybrid capture probes targeting the plurality of SNV mutations identified in the tumor sample.

26. (New) The method of claim 15, wherein the method further comprises performing barcoding PCR prior to the sequencing.

27. (New) The method of claim 15, wherein the method further comprises detecting recurrence and/or metastases of the cancer from the SNV mutations detected in the cell-free DNA.

28. (New) The method of claim 15, wherein the cancer is colorectal cancer, lung cancer, bladder cancer, or breast cancer.

29. (New) The method of claim 15, wherein the method is capable of detecting an SNV mutation that is present in 0.005% to 0.015% of the cell-free DNA comprising the SNV locus.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Inventor Name:	Joshua BABIARZ
Title:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
Application No.:	17/738,354
Filing Date:	5/6/2022
Examiner:	BRUSCA, JOHN S
Art Unit:	1631
Conf. No.:	8319

AMENDMENT AND REPLY UNDER 37 CFR 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

This communication is responsive to the non-final Office Action mailed July 7, 2022, concerning the above-referenced patent application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks begin on page 6 of this document.

Please amend the application as follows:

NATERA EX2003
NeoGenomics v. Natera, IPR2024-00346
Page 446

Electronic Acknowledgement Receipt	
EFS ID:	46780255
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	07-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	18:47:40
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Power of Attorney	N012US44-POA-82AB-SIGNED.pdf	198377 d4d0981d551b495b1269a98d5453687765 9460b4	no	2
Warnings:					

Information:	
Total Files Size (in bytes):	198377

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82A (07-13)
Approved for use through 01/31/2018. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	17/738,354
Filing Date	May 6, 2022
First Named Inventor	BABIARZ, et al.
Title	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
Art Unit	1631
Examiner Name	BRUSCA, JOHN S
Attorney Docket Number	N.012.US.44

SIGNATURE of Applicant or Patent Practitioner

Signature	/Nishita Doshi/	Date (Optional)	
Name	Nishita Doshi	Registration Number	61,573
Title (if Applicant is a juristic entity)	Chief IP Counsel and Vice President		
Applicant Name (if Applicant is a juristic entity)	Natera, Inc.		

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☑ *Total of 2 forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 11/30/2014. OMB 0651-0051
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

☑ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 110711

OR

☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

☑ The address associated with the above-mentioned Customer Number

OR

☐ The address associated with Customer Number:

OR

Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Natera, Inc.

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☑ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	DocuSigned by: Nishita Doshi	Date (Optional)	
Name	Nishita Doshi		
Title	Chief IP Counsel and Vice President		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☑ Total of 2 forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt	
EFS ID:	46780306
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	07-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	18:54:13
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$900
RAM confirmation Number	E202207I54560049
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Fee Worksheet (SB06)	fee-info.pdf	38216 487a4c16deaa0c24716d4184edf1c6b4a2e9d5b9	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	38216		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Patent Application Fee Transmittal

Application Number:	17738354
Filing Date:	06-May-2022
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Filer:	Nishita Alka Doshi/Jeremy Johnston
Attorney Docket Number:	N.012.US.44

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
CLAIMS IN EXCESS OF 20	1202	9	100	900
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
		Total in USD ($)		**900**

Electronic Acknowledgement Receipt	
EFS ID:	46780454
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	07-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	19:16:05
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$1020
RAM confirmation Number	E202207J16340241
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Terminal Disclaimer Filed	TD_application_16288416.pdf	245205 930b47689fe09f64617d563a969c4bec8db7dc8f	no	2
Warnings:					
Information:					
2	Terminal Disclaimer Filed	TD_application_16359917.pdf	250136 51ae849a95d77bdac4ed06c5c2b940a9eb46a8dc	no	2
Warnings:					
Information:					
3	Terminal Disclaimer Filed	TD_application_17692469.pdf	250932 bafb0590c086af735c2a6e372a77d8046b5c4d62	no	2
Warnings:					
Information:					
4	Terminal Disclaimer Filed	TD_application_17959543.pdf	250931 0e92e3828ffb7ebf81268b0478dd7a8746fc2b46	no	2
Warnings:					
Information:					
5	Terminal Disclaimer Filed	TD_patent_11319596.pdf	160209 31169f4adacaec8cc0f0b751e4756b1d7f07dc8c	no	2
Warnings:					
Information:					
6	Terminal Disclaimer Filed	TD_patent_11371100.pdf	165049 191602dd288729a80ed957d5c27d4a315e282358	no	2
Warnings:					
Information:					

7	Fee Worksheet (SB06)	fee-info.pdf	37962 f2bab712bcbbfeb1dfd00050b1ed9f001e426745	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	1360424	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Patent Application Fee Transmittal

Application Number:	17738354
Filing Date:	06-May-2022
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Filer:	Nishita Alka Doshi/Jeremy Johnston
Attorney Docket Number:	N.012.US.44

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
STATUTORY OR TERMINAL DISCLAIMER	1814	6	170	1020
		Total in USD ($)		**1020**

PTO/AIA/26 (04-14)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) N.012.US.44

In re Application of: BABIARZ, et al.

Application No.: 17/738,354

Filed: May 6, 2022

For: DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

The applicant, Natera, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 11,371,100 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☑ The undersigned is an attorney or agent of record. Reg. No. 67162

/Tianran Yan/ — Signature
10-7-2022 — Date

Tianran Yan — Typed or printed name

Agent for Applicant — Title
Telephone Number

☑ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/26 (04-14)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) N.012.US.44

In re Application of: BABIARZ, et al.

Application No.: 17/738,354

Filed: May 6, 2022

For: DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

The applicant, Natera, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 11,319,596 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☑ The undersigned is an attorney or agent of record. Reg. No. 67162

/Tianran Yan/ — Signature
10-7-2022 — Date

Tianran Yan — Typed or printed name

Agent for Applicant — Title
Telephone Number

☑ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/25 (04-13)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) N.012.US.44

In re Application of: BABIARZ, et al.

Application No.: 17/738,354

Filed: May 6, 2022

For: DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

The applicant, Natera, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending **reference** Application Number 17/959,543, filed, Oct 4, 2022, as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of any patent granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent granted on the pending **reference** application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☑ The undersigned is an attorney or agent of record. Reg. No. 67162

/Tianran Yan/	10-7-2022
Signature	Date
Tianran Yan	
Typed or printed name	
Agent for Applicant	
Title	Telephone Number

☑ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/25 (04-13)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) N.012.US.44

In re Application of: BABIARZ, et al.

Application No.: 17/738,354

Filed: May 6, 2022

For: DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

The applicant, Natera, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending **reference** Application Number 17/692,469, filed, Mar 11, 2022, as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of any patent granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent granted on the pending **reference** application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☑ The undersigned is an attorney or agent of record. Reg. No. 67162

/Tianran Yan/ — Signature
10-7-2022 — Date

Tianran Yan — Typed or printed name

Agent for Applicant — Title
Telephone Number

☑ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/25 (04-13)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) N.012.US.44

In re Application of: BABIARZ, et al.

Application No.: 17/738,354

Filed: May 6, 2022

For: DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

The applicant, Natera, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending **reference** Application Number 16/359,917, filed, Feb 28, 2019, as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of any patent granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent granted on the pending **reference** application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☑ The undersigned is an attorney or agent of record. Reg. No. 67162

/Tianran Yan/	10-7-2022
Signature	Date
Tianran Yan	
Typed or printed name	
Agent for Applicant	
Title	Telephone Number

☑ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/25 (04-13)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional)

In re Application of: BABIARZ, et al.

Application No.: 17/738,354

Filed: May 6, 2022

For: DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS

The applicant, Natera, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending **reference** Application Number 16/288,416, filed, Feb 28, 2019, as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of any patent granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent granted on the pending **reference** application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☑ The undersigned is an attorney or agent of record. Reg. No. 67162

/Tianran Yan/ — Signature
10-7-2022 — Date

Tianran Yan — Typed or printed name

Agent for Applicant — Title
Telephone Number

☑ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Application Number * 17/738,354 *	Application/Control No. 17/738,354	Applicant(s)/Patent under Reexamination BABIARZ et al.	
	Examiner BRUSCA, JOHN S	Art Unit 1672	

Document Code - DISQ	Internal Document - DO NOT MAIL

TERMINAL DISCLAIMER	☑ APPROVED	☐ DISAPPROVED
Date Filed: 07 October 2022	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:

/JEAN PROCTOR/

Technology Center: OPLC

Telephone: (571)272-1040

6 td's

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/738,354	05/06/2022	Joshua BABIARZ	N.012.US.44

CONFIRMATION NO. 8319

110711
Natera, Inc.
201 Industrial Road
Suite 410
San Carlos, CA 94070

POA ACCEPTANCE LETTER

OC000000136598025

Date Mailed: 10/20/2022

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 10/07/2022.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/tnguyen/

Electronic Acknowledgement Receipt	
EFS ID:	46902175
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:16:55
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	BODENREIDER_2004.pdf	747008 e19ed6a48bf6a4d0dcef929225a068b10b85e069	no	4
Warnings:					

Information:					
2	Non Patent Literature	BOLOTIN_2015_p380_NPL.pdf	220848 35a6371aef567d512a89e9afc86c93299f643efe	no	2
Warnings:					
Information:					
3	Non Patent Literature	BORDONI_2008_p8_NPL.pdf	240664 eff1b2b7828e0e3f09433f3a071d7c313a86f121	no	8
Warnings:					
Information:					
4	Non Patent Literature	BOUDSOCQ_p4607_2001_NPL.pdf	12871514 8bbd128215ee19a724b8ac2f7a9f0f477535ed32	no	10
Warnings:					
Information:					
5	Non Patent Literature	BOUMA_1977_p6432_NPL.pdf	1803010 cd17123a95a5b218316bc7f44413176acff4250c	no	6
Warnings:					
Information:					
6	Non Patent Literature	BRASTIANOS_2015_p1164_NPL.pdf	2503203 ca3a92f64c961978a68fd61504954d67289b9180	no	15
Warnings:					
Information:					
7	Non Patent Literature	BREITHAUPT_2001.pdf	729290 6d7fcf48256fcf2fbd21fa7c6a0546e268d0a558	no	3
Warnings:					
Information:					
8	Non Patent Literature	BRINZA_2006_p371_NPL.pdf	98672 90e8650a1fe9e1cba614643486b61343a3086c43	no	3
Warnings:					
Information:					

9	Non Patent Literature	BROCHET_2008_pW503_NPL.pdf	896055 fc5b2ed96c3e3aa89241647a0e36fc664dff349e	no	7
Warnings:					
Information:					
10	Non Patent Literature	BROCKMAN_2008_p770_NPL.pdf	274075 4c485a8e7c70c54d54bede66f19a393d912fca65	no	8
Warnings:					
Information:					
11	Non Patent Literature	Broude_2001_p206_NPL.pdf	176827 992c5ea38b00282795033822 6d2a654bebcd7d2c	no	6
Warnings:					
Information:					
12	Non Patent Literature	Broude_2001_p327_NPL.pdf	2782317 5c4a4e83cb8b57ea595094404e36222393e0a35d	no	6
Warnings:					
Information:					
13	Non Patent Literature	Broude_2004_p61_NPL.pdf	721905 8aadbc53729656932f44438d90bd8853f12b5516	no	16
Warnings:					
Information:					
14	Non Patent Literature	Brownie.pdf	667997 847a19866e92014b2c01eff1d8583fcfd62cdc5d	no	7
Warnings:					
Information:					
15	Non Patent Literature	BROWNING_2007_p1084_NPL.pdf	286235 705d11613fc06c09d16e4ded56a3a27eebb667d2	no	14
Warnings:					
Information:					

16	Non Patent Literature	BRYANT_1933_p231_NPL.pdf	2101302 0630cb78c66d9992c3581e2e621aaf7b05f7ba69	no	1
Warnings:					
Information:					
17	Non Patent Literature	BUNNAPRADIST_INCLUDES_NATERA_AUTHORS_2021_p2439_NPL.pdf	246766 8065f66f9e8629b48e50afd00192d8bfa83c1ee1	no	3
Warnings:					
Information:					
18	Non Patent Literature	BURKEY_1992_p1517_NPL.pdf	15265852 1dc4ab9f93aa41a9f8ac76dbabb428c48610ac40	no	10
Warnings:					
Information:					
19	Non Patent Literature	BURKOVA_2014_26pgs_NPL.pdf	1946937 b06f33aa12d2fe62e97f00e30ceba975323d43be	no	26
Warnings:					
Information:					
20	Non Patent Literature	BURNHAM_2016_9pgs_NPL.pdf	1068367 9237dfcf0cf014874ddcdf8db18b02d9e89c6dd8	no	9
Warnings:					
Information:					
21	Non Patent Literature	BURNHAM_2017_S237_NPL.pdf	745720 0fb69318629b4a69ce37e934f3a648d1daf67f3e	no	5
Warnings:					
Information:					
22	Non Patent Literature	BUSTAMANTE-ARAGONES_2008_p510_NPL.pdf	308497 4bc55ea81b002da4fdf1ce004cc4c0c52a183c3c	no	6
Warnings:					
Information:					

23	Non Patent Literature	Butler_2003.pdf	669705 3323549c4bb13fd9d767f1a51071fb16f7d39d7a	no	11
Warnings:					
Information:					
24	Non Patent Literature	BUTLER_2009_p11_NPL.pdf	1503577 d2e0c310e9967bb1b543a2240f26de1398a1a69c	no	11
Warnings:					
Information:					
25	Non Patent Literature	BUTT_2008_236_NPL.pdf	555818 3f5a412294d93bbcef22264ee1d6c859a04c9886	no	7
Warnings:					
Information:					
26	Non Patent Literature	Cairns.pdf	323832 8efea8f1a51f941d6665793dbbf2dc2cb7fe5a99	no	4
Warnings:					
Information:					
27	Non Patent Literature	Caliendo.pdf	122838 0e44e0bab84b8cfe55d7ac3fb63d2ee27b5cf251	no	5
Warnings:					
Information:					
28	Non Patent Literature	CALIN_2005_p1793_NPL.pdf	246325 97259e1cf397a943eba2a087e4cd40928b7a4d5d	no	10
Warnings:					
Information:					
29	Non Patent Literature	CAMPBELL_2008_p13081_NPL.pdf	1195314 3141e2673e7d7cfb8ab52745ab30f0b0915b6760	no	6
Warnings:					
Information:					

30	Non Patent Literature	CANICK_2013_p667_NPL.pdf	1050983 aff5a4b448818 5ff5fed9b696cc41c50bcd55c40	no	8
Warnings:					
Information:					
31	Non Patent Literature	CANSAR_2018_50pgs_NPL.pdf	5122878 72af3a908854216a2c42e6f8696e7bd2decd6d6e	no	50
Warnings:					
Information:					
32	Non Patent Literature	CAO_1995_p353_NPL.pdf	15898499 8912462c59530cead69e412a7cce2e911df9d2ec	no	9
Warnings:					
Information:					
33	Non Patent Literature	CARNEVALE_1998.pdf	1347513 579dd3606124dc46e3e26909408b5ed31fee1ad7	no	6
Warnings:					
Information:					
34	Non Patent Literature	CARVALHO_2007_485_NPL.pdf	734555 3b9346f134b2b9fd396a5d91a759e60ee4df9fb8	no	15
Warnings:					
Information:					
35	Non Patent Literature	CASBON_2011.pdf	774155 54ca82a4ab72a7f9cb1f33a582692b347251635a	no	8
Warnings:					
Information:					
36	Non Patent Literature	CASTLEBERRY_2011_1pg_NPL.pdf	159043 474f85e302297918a2ef704c2316bc24d6684dd2	no	1
Warnings:					
Information:					

37	Non Patent Literature	Cawkwell_1993_NPL.pdf	2682799 14105365ee9f442a3cb12e1945541bd23f9743fa	no	6
Warnings:					
Information:					
38	Non Patent Literature	CHAKRABORTY_1996.pdf	724739 2d2dce6d8f168dcf935e8d3f45207d8ff2259ec5	no	7
Warnings:					
Information:					
39	Non Patent Literature	CHAN_2003_p122_NPL.pdf	5312395 6350d0c12fe450564f81d67e6e451dac1469b273	no	9
Warnings:					
Information:					
40	Non Patent Literature	CHAN_2004_88_NPL.pdf	199998 ab45891062eebc70b2693d6150db96bad8ff3d38	no	5
Warnings:					
Information:					
41	Non Patent Literature	CHANG_2002_1697_NPL.pdf	651626 2942ca5a02c267a43db1531895dba90a697e0b2f	no	7
Warnings:					
Information:					
42	Non Patent Literature	CHAVALI_2005_p3918_NPL.pdf	957334 424d0e71f113d90d4998d9f87c92ee98943d35ae	no	8
Warnings:					
Information:					
43	Non Patent Literature	CHEN_1996_1033_NPL.pdf	544757 41bf20d2126637b3b9673382f45847bc697a7d98	no	3
Warnings:					
Information:					

44	Non Patent Literature	CHEN_2000_p353_NPL.pdf	1166300 0fa2d40e65eb326e2f56a03a62bf36044c120c0e	no	4
Warnings:					
Information:					
45	Non Patent Literature	CHEN_2002_NPL.pdf	4038051 2579b2d3ef96f941e2331862f331a140b2a70074	no	11
Warnings:					
Information:					
46	Non Patent Literature	CHEN_2011.pdf	1476286 b3f3034ae9c9dc4fdb0466e8d162ae60d1e7d161	no	7
Warnings:					
Information:					
47	Non Patent Literature	CHEN_2015_1-8_NPL.pdf	1233399 5529c25e00f7722dc7b9a2795230077025a68cb1	no	8
Warnings:					
Information:					
48	Non Patent Literature	CHETTY.pdf	84993 4d9774ced27ee5209e9091715a66fdc7a6c42729	no	5
Warnings:					
Information:					
49	Non Patent Literature	CHEUNG_1996_14676_NPL.pdf	457868 aedb235491494529 54b2aa7790860ef64b466191	no	4
Warnings:					
Information:					
50	Non Patent Literature	CHEUNG_2007_1679_NPL.pdf	698785 293042431b13e663f1bdc4eb5412ec8240610709	no	8
Warnings:					
Information:					

51	Non Patent Literature	CHIM_2008_p482_NPL.pdf	332467 218878acc8dcacd8e31ac2f61c73ad6434428430	no	10
Warnings:					
Information:					
52	Non Patent Literature	CHINNAPAPAGARI_2005_p653_NPL.pdf	7880052 169d4be3aec9f8b8d645d697a5cd24cff5ed75aa	no	4
Warnings:					
Information:					
53	Non Patent Literature	CHITTY_2015_20pgs_NPL.pdf	785852 609e0cada692b50cef6274879629e7243fc60ea8	no	20
Warnings:					
Information:					
54	Non Patent Literature	CHIU_2001.pdf	795605 c9977501887d5c00b3c2aaf8c3252c935021b8dd	no	7
Warnings:					
Information:					
55	Non Patent Literature	CHIU_2007_p941_NPL.pdf	3032465 38c5bcc9aa1b6ef2368cd10cfec841cdf1141c44	no	10
Warnings:					
Information:					
56	Non Patent Literature	CHIU_2008.pdf	4231225 3aa4c626f3689c7af7d609d86f8e0275cdbdf278	no	23
Warnings:					
Information:					
57	Non Patent Literature	CHIU_2009_TIG.pdf	1807178 8085a54caf07b54e584b5c64fd9dea9496a863a3	no	8
Warnings:					
Information:					

58	Non Patent Literature	CHIU_2010_CC.pdf	821720 d25b61abf82c92a16cd6a470e0dbdff8a8de9667	no	5
Warnings:					
Information:					
59	Non Patent Literature	CHIU_2011.pdf	1639620 754b5d0cd752bd9c091124db97ca92067ad39027	no	9
Warnings:					
Information:					
60	Non Patent Literature	CHOI_2009_19096_NPL.pdf	1066973 86bfeda14da039b6fd565c68ce1a9b81f52b1494	no	6
Warnings:					
Information:					
		Total Files Size (in bytes):	119030583		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt	
EFS ID:	46902181
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:19:22
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	CHOI_2018_26pgs_NPL.pdf	2121088 3a9c172285b25cdba85809b46b908b299722ef69	no	26
Warnings:					

Information:					
2	Non Patent Literature	CHOTHIA_1987_p901_NPL.pdf	1710171 84e5d9f07cbf7ed6f26db27eb0d88577179e0277	no	17
Warnings:					
Information:					
3	Non Patent Literature	CHU_2009.pdf	1396032 426d28667fab80a7d3dab18d33d0bbe14c8eaac6	no	7
Warnings:					
Information:					
4	Non Patent Literature	CHU_2010_BIOINFORMATICS.pdf	966028 276358f34e4f0e304ac936a72bbc7fe98732cd22	no	4
Warnings:					
Information:					
5	Non Patent Literature	CHU_2010_PD.pdf	716726 78256c9ecd076de47f67d9aaba38d8c6ebef1306	no	4
Warnings:					
Information:					
6	Non Patent Literature	CHUN_2007_NPL.pdf	910984 6a05d8771f536c062fd76e7062a0c1f92b2d3f03	no	6
Warnings:					
Information:					
7	Non Patent Literature	CHUNG_2005_p655_NPL.pdf	8190632 04c419b4aa92b9a49570a8d0d3d46e2f5afdf6eb	no	4
Warnings:					
Information:					
8	Non Patent Literature	CHURCH_1988_p188_NPL.pdf	1420123 ae6149f6a2ceed0adf24848f423ca3ec1e86519e	no	4
Warnings:					
Information:					

9	Non Patent Literature	CIRIELLO_2013_p1127_NPL.pdf	2049644 0f0804477ee5feae8cb66860bd9cf62608811e9c	no	10
Warnings:					
Information:					
10	Non Patent Literature	CLAUSEN_2007_p6_NPL.pdf	384645 e4bf1637a07b2f6dc34739e0a7a6179a99e3fec7	no	5
Warnings:					
Information:					
11	Non Patent Literature	CNAPS_VII_2011_2pgs_NPL.pdf	43899 e1a04c9cf86df4d02c27310e9e54bd966e7d07f1	no	2
Warnings:					
Information:					
12	Non Patent Literature	COLE_2008.pdf	220216 12593ac368e9f2c846fee05f5da82e19381f5910	no	6
Warnings:					
Information:					
13	Non Patent Literature	COLELLA_2007.pdf	1724178 bd6927959e132778aa0f8288fa91ce68f1e71f01	no	13
Warnings:					
Information:					
14	Non Patent Literature	CONLIN_2010_1263_NPL.pdf	2020163 74884a4cc6a579ca74532f9c78215865b8095273	no	13
Warnings:					
Information:					
15	Non Patent Literature	COOMBES_2018_3pgs_NPL.pdf	147139 84496ec0f900da1d1a55bc2766a0afd9fab736a6	no	4
Warnings:					
Information:					

16	Non Patent Literature	COSSU_1996.pdf	1056398 a5d667b413563419af28b483b644fb08b7f46fe9	no	5
Warnings:					
Information:					
17	Non Patent Literature	COSTA_2002_p255_NPL.pdf	452913 5bb2f83d3cad5f4754d2819aa4c1e0afd01a0bf5	no	6
Warnings:					
Information:					
18	Non Patent Literature	COURAUD_2014_p4613_NPL.pdf	2273160 08eaf4777194d9642c383b97f56076960445e6a0	no	13
Warnings:					
Information:					
19	Non Patent Literature	COURAUD_Supplemental_Data_2014_13pgs_NPL.pdf	402736 e44c03c32d8dd5f2d211e82596f38f088680bcc8	no	13
Warnings:					
Information:					
20	Non Patent Literature	COYLE.pdf	3021801 1f369f9ff00b3d598edee2fdfcbdde1fc59aae5b	no	18
Warnings:					
Information:					
21	Non Patent Literature	CRAIG_2008_887.pdf	1575289 0848001e13a884f2b509bcdd8e85e00519c45388	no	16
Warnings:					
Information:					
22	Non Patent Literature	CRESPO-LEIRO_2009_p2243_NPL.pdf	61410 1c6651a4a15d07af5450965806 1ed6d9ba7e5b7b	no	4
Warnings:					
Information:					

23	Non Patent Literature	CRONN_2008_11pgs_NPL.pdf	1755196 453911a7e20847f246f3146ce7d525f8eb7a09c4	no	11
Warnings:					
Information:					
24	Non Patent Literature	CROSS_2007.pdf	2246172 e2051d6f582d6a399b7d4058910c85445dda1500	no	8
Warnings:					
Information:					
25	Non Patent Literature	CUNNINGHAM_2006_p121_NPL.pdf	702181 65a21b8d6683feae10f084c219bcc10cea60d8bf	no	9
Warnings:					
Information:					
26	Non Patent Literature	DAHL_2007_p9392_NPL.pdf	616978 f293fe81868a9f9e930addab22e5b0137c9f1ba4	no	6
Warnings:					
Information:					
27	Non Patent Literature	DAMBRIN_1999_p531_NPL.pdf	695565 634d0e66532226b77f6ef7128dfc58a4a7d14a26	no	8
Warnings:					
Information:					
28	Non Patent Literature	DANIELS_2004_p225_NPL.pdf	946571 1680f7f65abf8c7bf49d4a7739adefe291848359	no	8
Warnings:					
Information:					
29	Non Patent Literature	DAquila.pdf	226834 d72d98bae975917940165430 7faceabecbbbdecb	no	1
Warnings:					
Information:					

30	Non Patent Literature	DARUWALA.pdf	1463301 58536c9a7554fca2eecb6c7321661cd06ef1c208	no	6
Warnings:					
Information:					
31	Non Patent Literature	DAWSON_2013_1199_NPL.pdf	1370647 d53e59514fce03fa6e78af1b4fdf764c8c04b85d	no	11
Warnings:					
Information:					
32	Non Patent Literature	dbSNP2015.pdf	172986 29f54123c5236cb343d5e42335c99800bf6f3bff	no	3
Warnings:					
Information:					
33	Non Patent Literature	DE_BRUIN_2014_251_NPL.pdf	1478180 c4c1be5ac3c0b19126be2c07bb669133e942a461	no	12
Warnings:					
Information:					
34	Non Patent Literature	DE_JONG_2009_p225_NPL.pdf	3303804 dbe954e19ea5c28a1cd6db42758ba9a78b7a08fb	no	18
Warnings:					
Information:					
35	Non Patent Literature	DEANGELIS.pdf	584702 6701cc27712b8e6a72943e03bc84f93d06fef394	no	2
Warnings:					
Information:					
36	Non Patent Literature	DEB_2008_p17_NPL.pdf	1144626 0c94c677066911b73e1c852927ff33c57463cb77	no	8
Warnings:					
Information:					

37	Non Patent Literature	Declaration_Zimmerman2014.pdf	190968 91540bfbf8b18eab15b79b8d1af490562bb98374	no	4
Warnings:					
Information:					
38	Non Patent Literature	DELANEAU_2008_14pgs_NPL.pdf	329581 738a5b6ca2a949ec44273af8c88c33d966b036fd	no	14
Warnings:					
Information:					
39	Non Patent Literature	DELGADO_2013_p983_NPL.pdf	442772 8b91d03db69d2e313443a0bd80135e134ce78676	no	4
Warnings:					
Information:					
40	Non Patent Literature	DENG_2017_12pgs_NPL.pdf	1372615 3cda26a0ee7c604fe82837afa39b8214f39b0fcd	no	12
Warnings:					
Information:					
41	Non Patent Literature	DEUTSCH_2004_908_NPL.pdf	169916 d2f9563bd044aa64f4bb6c727d3cc13515f8fd9b	no	8
Warnings:					
Information:					
42	Non Patent Literature	DEVANEY.pdf	2925577 d7df11326feea57c999eab43b94e37ee63e20c28	no	10
Warnings:					
Information:					
43	Non Patent Literature	deVries2005.pdf	1579976 078a740897efeac370fb9b6febc9d104e4c9a16c	no	11
Warnings:					
Information:					

44	Non Patent Literature	DHALLAN_2004.pdf	1486382 da57c78d5ec0cad6f04f39ad9f56e2707c26b212	no	6
Warnings:					
Information:					
45	Non Patent Literature	DHALLAN_2007.pdf	1707569 517cd333a37908c8a330fe35b59a94d1341c3aa3	no	8
Warnings:					
Information:					
46	Non Patent Literature	DI_2005_p1958_NPL.pdf	286295 6b231f725cf13693e8366feb1d9a70bc6576cfc3	no	6
Warnings:					
Information:					
47	Non Patent Literature	DIAS_SANTAGATA_2011_9pgs_NPL.pdf	525491 252ac565beb23548102c4e1780a5a4b37d520406	no	9
Warnings:					
Information:					
48	Non Patent Literature	DIAZ_VOL-32-2014_NPL.pdf	1323277 b40f744188962472c8638b5d72934c91cb87088a	no	9
Warnings:					
Information:					
49	Non Patent Literature	DICKOVER_1998_p1070_NPL.pdf	93903 c185e2a4cb8edfbe9d70e99598aea4dac2b30ab3	no	4
Warnings:					
Information:					
50	Non Patent Literature	Dieffenbach.pdf	573625 aec193e1b39ccecb719ee44e8784b8bfeba46815	no	9
Warnings:					
Information:					

51	Non Patent Literature	DIEHL_16368-16373-2005_NPL.pdf	1097350 31921407757c2278509f9518f8b11597418f35aa	no	6
Warnings:					
Information:					
52	Non Patent Literature	DIEHL_2005_p16368_NPL.pdf	1648535 84f9adc48cd21aa4de5f24ef5c4c35fcd64a2573	no	12
Warnings:					
Information:					
53	Non Patent Literature	DIEHL_2008_985_NPL.pdf	527551 399a02f715ca7d1aef39cf1d45d1f793d2c4b052	no	6
Warnings:					
Information:					
54	Non Patent Literature	DIETMAIER_1999_83_NPL.pdf	785026 440caea4ac7b620700edfc69f8f41f53068aef3a	no	13
Warnings:					
Information:					
55	Non Patent Literature	DING_2003.pdf	233094 a847d37de3064e58acd9ff18649274aba73997ff	no	5
Warnings:					
Information:					
56	Non Patent Literature	DING_2004_p10762_NPL.pdf	336755 5f24dd961846a285e6090a9e8225fe2adb161b93	no	7
Warnings:					
Information:					
57	Non Patent Literature	DING_2004_p10762_NPL3.pdf	4252586 7ee897f11846b6d1d597d5f2d62bf395ed52069a	no	7
Warnings:					
Information:					

58	Non Patent Literature	DODGE_2008_31_NPL.pdf	238154 3de2732630aae6095b97762b1fbcb5d0f88c83ca	no	4
Warnings:					
Information:					
59	Non Patent Literature	DOHM.pdf	3394141 df418686086126503cc26d8eaed955c09909a19f	no	10
Warnings:					
Information:					
60	Non Patent Literature	Dolganov.pdf	2314272 a619c554f7c6717b4da27ec4dde8dd8e20b894fc	no	12
Warnings:					
Information:					
		Total Files Size (in bytes):	77408529		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt	
EFS ID:	46902156
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:12:29
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	WO2011057061A1.pdf	623338 fee3a43da97f93bd442c74ae4c2ce9932316bc06	no	42
Warnings:					

Information:					
2	Foreign Reference	WO2011057094.pdf	6323453 fb87d7cf12c5ca6f5e8653776c971ba601c266a4	no	125
Warnings:					
Information:					
3	Foreign Reference	WO2011087760.pdf	24130761 cf52e7988d96424d42229c152380271a02f3eb50	no	529
Warnings:					
Information:					
4	Foreign Reference	WO2011090556A1.pdf	1190670 eca16467a0fe81fba9468533933b3d710b49a8eb	no	94
Warnings:					
Information:					
5	Foreign Reference	WO2011118603A1_EFS.pdf	3147323 8f91f216fb6d7c92e6ec3363f32d9e49c6b1b3ab	no	57
Warnings:					
Information:					
6	Foreign Reference	WO2011146632.pdf	17804009 e2b81a75d034f031b85fdc741e3a36ceb6ac5e27	no	141
Warnings:					
Information:					
7	Foreign Reference	WO2012019200A2.pdf	1328559 1a90c68e4a4473ffd483be4e97c65b693f50a18c	no	147
Warnings:					
Information:					
8	Foreign Reference	WO2012028746A1.pdf	5599952 1d9e65e81a3faa4639819716 2c0a0d421378b093	no	128
Warnings:					
Information:					

9	Foreign Reference	WO2012042374A2.pdf	508316 b7b6c3b93499afda9f3c2fb609715965b7e0a372	no	65
Warnings:					
Information:					
10	Foreign Reference	WO2012058488A9.pdf	1117391 fa0f6353eefd82429f1b58a40f418a236a3a157d	no	99
Warnings:					
Information:					
11	Foreign Reference	WO2012071621A1.pdf	5633474 622be4a5197a0f244a003b9c50ff8bef302f9abc	no	103
Warnings:					
Information:					
12	Foreign Reference	WO2012083250.pdf	3866594 9823d19a0dc29b777a48d5edd522efeb659c37a8	no	71
Warnings:					
Information:					
13	Foreign Reference	WO2012088456.pdf	13985368 168bd2593b004d1f0bb39ec44fdab6a00647f3d0	no	98
Warnings:					
Information:					
14	Foreign Reference	WO2012108920A1.pdf	14997756 97b8eaea868a7636125993d772620e9c26eaf8d7	no	197
Warnings:					
Information:					
15	Foreign Reference	WO2012142531A2.pdf	9127920 11c96889205be27f590bc9a39787b3bb1a4298e9	no	94
Warnings:					
Information:					

16	Foreign Reference	WO2013030577.pdf	3023115 c2f042f51a6b2f9f93d269c0401680bc21f96ffd	no	71
Warnings:					
Information:					
17	Foreign Reference	WO2013045432.pdf	6809883 8aedcd671c806175e227df9123aaca832758f981	no	90
Warnings:					
Information:					
18	Foreign Reference	WO2013049892A1.pdf	1416080 614bd284316a07eb2c87134e14e302dfbca8034c	no	68
Warnings:					
Information:					
19	Foreign Reference	WO2013052557A2.pdf	13996375 400a1c7313d4e464fb2d80114ac04a277800e599	no	91
Warnings:					
Information:					
20	Foreign Reference	WO2013078470A2.pdf	1368103 ff21e093a79a6b10e9607b0ac772ccc9a25626d9	no	29
Warnings:					
Information:					
21	Foreign Reference	WO2013086464A1.pdf	10998281 41c06ee29924564914df1f04778924cf5e5d8352	no	218
Warnings:					
Information:					
22	Foreign Reference	WO2013123220A1.pdf	1023343 1b253d3050ed24fe46aace5a0a80b326fe4ee5a1	no	117
Warnings:					
Information:					

23	Foreign Reference	WO2013130848.pdf	13360184 ae028b1cd691fc4983294b11b3634fc3e92768d0	no	221
Warnings:					
Information:					
24	Foreign Reference	WO2013138510A1.pdf	2104791 001830f941a0db82aa48fc3b6e2432b63e9eec77	no	101
Warnings:					
Information:					
25	Foreign Reference	WO2013138510A9.pdf	2110140 63f04280b9eb7f4bb8b6dd175cf9d5a915ec8409	no	102
Warnings:					
Information:					
26	Foreign Reference	WO2013159035A2.pdf	4637359 009b68f69f10c13bb0b0499af37b50f566a507b6	no	95
Warnings:					
Information:					
27	Foreign Reference	WO2013169339A1.pdf	3867543 3085e9635eb2b301fb47b4527fa117eb4b8d0049	no	69
Warnings:					
Information:					
28	Foreign Reference	WO2013177220A1.pdf	859732 a74d50646f4b2eae0563526b04a1f76621aeb3da	no	107
Warnings:					
Information:					
29	Foreign Reference	WO2013181651A1.pdf	774267 749644e1711c357be05b56d486abc9ce4207efeb	no	31
Warnings:					
Information:					

30	Foreign Reference	WO2014004726A1.pdf	9818421 1bc5d72db6ad2fd18ab65ea0218121f77fe48946	no	93
Warnings:					
Information:					
31	Foreign Reference	WO2014014497.pdf	4665974 1969b71fb3e2e715d0ad25de4520ba28753dab0d	no	473
Warnings:					
Information:					
32	Foreign Reference	WO2014018080.pdf	16775357 5ddece6be1d2f51e211e4b076f0e9a25de65cb85	no	288
Warnings:					
Information:					
33	Foreign Reference	WO2014035986A1.pdf	1362758 dac9bf7b113321a664a5b1faa22c9bcf35fae107	no	74
Warnings:					
Information:					
34	Foreign Reference	WO2014122288A1.pdf	4522469 0316c6a03ef9662888881e3f67bbd16c885ad9c9	no	60
Warnings:					
Information:					
35	Foreign Reference	WO2014145078A1.pdf	2733604 fb20047606b09a490c856c863812a9b2706f3032	no	144
Warnings:					
Information:					
36	Foreign Reference	WO2014145232A2.pdf	591738 e0db38fb753017886310ffa52516936706a884de	no	62
Warnings:					
Information:					

37	Foreign Reference	WO2014149134A2.pdf	6834989 52c23d89e5ee3f03985bee9403db56a7dc288d11	no	133
Warnings:					
Information:					
38	Foreign Reference	WO2014150300A2.pdf	917060 402f3a922475def508bbba72059e5300181b416c	no	113
Warnings:					
Information:					
39	Foreign Reference	WO2014151117A1.pdf	4354412 df8601f372cfa211d3d2ffb40488548c0a31db26	no	547
Warnings:					
Information:					
40	Foreign Reference	WO2014194113A2.pdf	770778 d4c6585afac57a36e8fa1793ad6df72e3e2fc0fa	no	48
Warnings:					
Information:					
41	Foreign Reference	WO2015048535A1.pdf	357993 2e8e910a5080d8e2d321a17dffb1459c5366f3c3	no	43
Warnings:					
Information:					
42	Foreign Reference	WO2015070086A1_EFS.pdf	3644646 de11816726705ccb341ef12ca21f652dcacb09c6	no	66
Warnings:					
Information:					
43	Foreign Reference	WO2015100427A1.pdf	6032867 34ee45c467c916a6808e9e425979259f285f92ef	no	113
Warnings:					
Information:					

44	Foreign Reference	WO2015134552A1.pdf	8025182 5dc8e701008f6d3aa76b4c8c81d3219b0f6b6457	no	163
Warnings:					
Information:					
45	Foreign Reference	WO2015148494A1.pdf	2903009 ab7715582adb93c4a5ff35f501d455f6f882946c	no	51
Warnings:					
Information:					
46	Foreign Reference	WO2015164432.pdf	17937171 e79d2872a63ad866958decb4cb96edf2d1e3460c	no	352
Warnings:					
Information:					
47	Foreign Reference	WO2016009059.pdf	8605360 6294ad6296d055d3694263b352efb04be6745ff5	no	80
Warnings:					
Information:					
48	Foreign Reference	WO2016009224A1.pdf	4873217 19143089b81d4a7b1f97c61ea849cabc841792c1	no	71
Warnings:					
Information:					
49	Foreign Reference	WO2016063122A1.pdf	631668 1e3a8f3d9b691c8c657068df70a30377655fb4f0	no	77
Warnings:					
Information:					
50	Foreign Reference	WO2016065295.pdf	4444020 a31a47812a6b5a8f5a51a9228dfa5b15b32d6a34	no	76
Warnings:					
Information:					

51	Foreign Reference	WO2016077313A1_EFS.pdf	1572625 14b0e024bef8368c4fc818d3497f54c4c9d5f3cc	no	34
Warnings:					
Information:					
52	Foreign Reference	WO2016123698A1.pdf	770653 d2e4826db791ad041776bd7900d020b3835babcc	no	28
Warnings:					
Information:					
53	Foreign Reference	WO2016138080A1.pdf	1629064 72da124c1be4e9fdc74c30482db949515f1698b	no	105
Warnings:					
Information:					
54	Foreign Reference	WO2016176662A1.pdf	3801736 2b60bc4ce4f9085bbed3991e2d5aae4adcec87af	no	84
Warnings:					
Information:					
55	Foreign Reference	WO2016183106A1.pdf	2327521 350831938a65eca7f1f885e0697ba47bbf25b725	no	209
Warnings:					
Information:					
56	Foreign Reference	WO2016193490A1.pdf	3718396 1c4da72fb9bdd1f94bbde6b36ae8d0b24b9f8593	no	76
Warnings:					
Information:					
57	Foreign Reference	WO2017058784A1.pdf	892636 77933015ddd81b16929c2f37241b0e96cc88418b	no	43
Warnings:					
Information:					

58	Foreign Reference	WO2017181146A1.pdf	2445003 afb63913167aab1b1d013c57c936f095064 1d16f	no	126
Warnings:					
Information:					
59	Foreign Reference	WO2017181202A2.pdf	6236077 71e0686fb8aed70ed8f6e73f41c40df72b71 486e	no	221
Warnings:					
Information:					
60	Foreign Reference	WO2017190106A1.pdf	4054450 1a7551f089d60f3386d900e0c3b546964c7 49a48	no	83
Warnings:					
Information:					
		Total Files Size (in bytes):	313984934		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt	
EFS ID:	46902193
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:29:49
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	Frohman_1994_p540_NPL.pdf	4103690 6d760e3cc52b4883f524e84d74856f5c29378617	no	20
Warnings:					

Information:					
2	Non Patent Literature	FROST2012.pdf	6599881 24b5a56aeaa0f88bb1e4da87a7998ab11a2800dd	no	6
Warnings:					
Information:					
3	Non Patent Literature	FU_2006_p482_NPL.pdf	699570 9dc159dc1eddb99c4e5c444a7f0acfaeceeb3937	no	6
Warnings:					
Information:					
4	Non Patent Literature	FU_2011_9026.pdf	799896 489bd933d9d755912fba25ac304f45b74774bcc0	no	6
Warnings:					
Information:					
5	Non Patent Literature	FU_2014_2867.pdf	469704 dc68507f8917fcb0313c23ecf77f616d889a3652	no	4
Warnings:					
Information:					
6	Non Patent Literature	GADI_2006_p379_NPL.pdf	836569 a1026755bfb0e751eaf4b90df84c068c2a711897	no	4
Warnings:					
Information:					
7	Non Patent Literature	GANSHIRT-AHLERT_1987.pdf	903844 d042739c8fd39704a7c89460ba9e1d69cd116293	no	4
Warnings:					
Information:					
8	Non Patent Literature	GANSHIRT-AHLERT_1990.pdf	954264 1203a8e176dddd41381ce1f7f56c5d309034670d	no	6
Warnings:					
Information:					

9	Non Patent Literature	GANSHIRT-AHLERT_1992.pdf	577022 17d3dc4c2354472480058 2ae938754 1813f422cd	no	3
Warnings:					
Information:					
10	Non Patent Literature	GAO_1997_p629_NPL.pdf	132958 1fc371c43f735326734b1a231f961bbc8a0ae6dc	no	7
Warnings:					
Information:					
11	Non Patent Literature	GAO_1998_p399_NPL.pdf	736392 06373798999df0b32e9d6d19be4177180d048d2b	no	14
Warnings:					
Information:					
12	Non Patent Literature	GAO_2013_8pgs_NPL.pdf	1576699 9ff0039b034068b365b201868d511f73e64ff6e6	no	8
Warnings:					
Information:					
13	Non Patent Literature	GARCIA_MOREIRA_2009_p1958_NPL.pdf	1125826 359335bbe0cbd20fbf5bb5318c9541f9b5f6366a	no	9
Warnings:					
Information:					
14	Non Patent Literature	GARCIA_MURILLAS_2015_34pgs_NPL.pdf	2035955 1aa23f6b3860c2c817a794d86be09370b53cb075	no	34
Warnings:					
Information:					
15	Non Patent Literature	GARDINA.pdf	3472581 7235c33fbc880d34de5ca45b5d51e7e2745e7ffb	no	16
Warnings:					
Information:					

16	Non Patent Literature	GAUTIER_2005_p666_NPL.pdf	4228866 37476f9fa7f2594fcf42fecc5dcefc358fec833a	no	4
Warnings:					
Information:					
17	Non Patent Literature	GEIFMAN-HOLTZMAN_2008_p751_NPL.pdf	542379 0e6fd6cc2fd9d00ac99359b1673a0b82d8287681	no	25
Warnings:					
Information:					
18	Non Patent Literature	GEISS_2008_317_NPL.pdf	390193 239bb7868a9d36659ee545404f1162316f7fab99	no	10
Warnings:					
Information:					
19	Non Patent Literature	Genetics-Home-reference.pdf	229539 b5a465dbddd4e9a5d8f6be6127e03ba7278d72ec	no	2
Warnings:					
Information:					
20	Non Patent Literature	GHANTA.pdf	1957181 a4f47f00f0616fcafd86a260ad41a6259a94a29f	no	10
Warnings:					
Information:					
21	Non Patent Literature	GHOLAMI_p635_2012_NPL.pdf	1379516 35fac72939234f9b1250b392cd0abab3f0c4959a	no	11
Warnings:					
Information:					
22	Non Patent Literature	GIELIS_2015_p2541_NPL.pdf	1015055 1d6357fc8724584c088786ccd88989fad746c255	no	12
Warnings:					
Information:					

23	Non Patent Literature	GIELIS_2018_16pgs_NPL.pdf	1319713 50f9d26a27238239a865d85a31da0d48737 57c1d	no	16
Warnings:					
Information:					
24	Non Patent Literature	GINEIKIENE_2009_p74_NPL.pdf	337973 86ab74efebe90ddc581998590159a2528ea d8ab7	no	9
Warnings:					
Information:					
25	Non Patent Literature	GINGERAS_2005_p671_NPL. pdf	944996 54d23aa2963b9a8f8631a9f51332017d9c70 6bdf	no	11
Warnings:					
Information:					
26	Non Patent Literature	GIRNITA_2006_p1780_NPL.pdf	186791 642891b5fb6e5104f26a62705b443d3ae84 73386	no	7
Warnings:					
Information:					
27	Non Patent Literature	GJERTSON.pdf	1850380 fea766098a6f2eaad407f82bd96cc6bd85e9 fce0	no	10
Warnings:					
Information:					
28	Non Patent Literature	GLAAB_1999_12pgs_NPL.pdf	1486109 e5c60d6334346ecc8c894e1da49480643c1 95d4f	no	12
Warnings:					
Information:					
29	Non Patent Literature	GNIRKE_2009_p182_NPL.pdf	780604 ccc216e9e6d1f28c2595a9ed6514a72c03b5 7280	no	8
Warnings:					
Information:					

30	Non Patent Literature	GO_2011_p372_NPL.pdf	1521953 8ea7165d386d35b49412deac69ab8480e8e06db5	no	11
Warnings:					
Information:					
31	Non Patent Literature	Gonecalves_Primo_2014_1260_NPL.pdf	2965486 ad5751f7a49fa68666bc411dc692475e3301c6bc	no	6
Warnings:					
Information:					
32	Non Patent Literature	GORDON_2009_p556_NPL.pdf	175938 3f162acb4f399d0f685a9901451ee8ba58fd8727	no	7
Warnings:					
Information:					
33	Non Patent Literature	GOUYA_2009_p385_NPL.pdf	276012 7e51af2d0c4082477f6fef8654556607a017c09b	no	9
Warnings:					
Information:					
34	Non Patent Literature	GREENWALT.pdf	677474 7e2fc7866d7182fa941ce4659abad011ad452a16	no	4
Warnings:					
Information:					
35	Non Patent Literature	GREGORY_2006_p884_NPL.pdf	364931 07c77c08932387955f45ca876a8728961030ecb8	no	8
Warnings:					
Information:					
36	Non Patent Literature	GRENDA_2021_3pgs_NPL.pdf	315760 e89215c4eedaebb5e8bcc3a5770a3952a23ecccb	no	3
Warnings:					
Information:					

37	Non Patent Literature	GRIFFITHS_1996_5pgs_NPL.pdf	4267168 39a27c4e9aacfb61f2815246f2c3b3374dabe30a	no	5
Warnings:					
Information:					
38	Non Patent Literature	GRSKOVIC_2016_890_NPL.pdf	845992 7771101ff8bb7e8b44f190102ab7719137f2d3be	no	108
Warnings:					
Information:					
39	Non Patent Literature	GRUNENWALD_2003_p89_NPL.pdf	1125095 c73a617a3480a3ecda53005e3d09f247954629 09	no	11
Warnings:					
Information:					
40	Non Patent Literature	GU_2012_p641_NPL.pdf	451908 290a767e90e098da804e8848b8e13612462c1309	no	9
Warnings:					
Information:					
41	Non Patent Literature	GUERRA.pdf	113795 8ef7ef455f375ef309a1f64b4dac0f2ed814ee74	no	8
Warnings:					
Information:					
42	Non Patent Literature	GUETTA_2004.pdf	1699268 64ac59bf0cf88f946c4621280d4b96af25bbf34a	no	7
Warnings:					
Information:					
43	Non Patent Literature	Guichoux.pdf	903239 dd0772b010ef32afa7fd9292f1a3a19b8141bd9c	no	22
Warnings:					
Information:					

44	Non Patent Literature	Guidelinerelatedtogeneticexamination.pdf	231528 aaca5d7c3f8ec114d956e734cccdb45831ecec2d	no	15
Warnings:					
Information:					
45	Non Patent Literature	GUNDERSON_2005_549_NPL.pdf	5380801 703cc5202deed07a1a118d061499f08ee0bf6f67	no	7
Warnings:					
Information:					
46	Non Patent Literature	GUNDRY_2008_p3401_NPL.pdf	1040096 3da9d96ff1be065276b757146d77ded8e9ee412a	no	8
Warnings:					
Information:					
47	Non Patent Literature	Guo_2006_p18_NPL.pdf	229770 3f32322b2cce459995b8525f9eb91f2ca9eb4be9	no	6
Warnings:					
Information:					
48	Non Patent Literature	Gusella_1979_PNAS_NPL.pdf	3310515 e8516eae5abceb1cb40af80d6014f9aba53fb044	no	5
Warnings:					
Information:					
49	Non Patent Literature	HAHN_2000_p96_NPL.pdf	13453020 307aa23ae8f6e34e99dfcf27580f12418babe819	no	11
Warnings:					
Information:					
50	Non Patent Literature	HAHN_2001_p1577_NPL.pdf	145875 4de0b16b5d6dc1557238c9a21e21143cb8f30960	no	2
Warnings:					
Information:					

51	Non Patent Literature	HAHN_2012_p528_NPL.pdf	237074 90adc8f8c2e377cf0f91c331870ab0e4863e2a46	no	12
Warnings:					
Information:					
52	Non Patent Literature	HAINER-FAZZIO_2019_e85_NPL.pdf	2066572 35d793ad20852b1e547b524b9342a3d419ae283f	no	22
Warnings:					
Information:					
53	Non Patent Literature	HALFORD_1999_p835_NPL.pdf	2133834 be3852d77f66de1af81b326fd38b1e58123fee94	no	1
Warnings:					
Information:					
54	Non Patent Literature	HALLPanoramaMicrodeletionsWhitePaper.pdf	272189 5658d4de05461f476f0ee9f60488dbf907b991b3	no	5
Warnings:					
Information:					
55	Non Patent Literature	HAN_2005_2493_NPL.pdf	1211320 5578234bd1536726a334fdd376f8e22d9b087f5a	no	9
Warnings:					
Information:					
56	Non Patent Literature	HANDLEY_2010_p581_NPL.pdf	2060421 1bca080d16067baedaeba1383c677bb16412fb1e	no	12
Warnings:					
Information:					
57	Non Patent Literature	HANDYSIDE_2004.pdf	665275 b62f337ca92a7a0116d4ac578ea31bb1398395c5	no	6
Warnings:					
Information:					

58	Non Patent Literature	HAO_2014_p1482_NPL.pdf	548765 3df832fc7f1406725d6e39bcf3cf2eb06bae0e57	no	8
Warnings:					
Information:					
59	Non Patent Literature	Hara.pdf	911786 db348e10f4fb4708af5b0f61758a0f06ca2e2b58	no	8
Warnings:					
Information:					
60	Non Patent Literature	Hardenbol_genotyping.pdf	1443154 ece4eab3edddb700c4e2395b3a9fb256258f455	no	6
Warnings:					
Information:					
		Total Files Size (in bytes):	92720160		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt	
EFS ID:	46902139
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:06:46
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	CN101675169A_WO2007147079.pdf	15323797 02e7c7ca2c7fa19c65eb126b4e796dce1ee9af40	no	230
Warnings:					

Information:					
2	Foreign Reference	CN104736722A_WO2013177220A1.pdf	2404339 75143f7250c287c892fef25009e606eed1edf468	no	184
Warnings:					
Information:					
3	Foreign Reference	CN105229175A_WO2014150300A2.pdf	10796943 a40a961f0726f8bec747ca15b2373d62d5c570f8	no	384
Warnings:					
Information:					
4	Foreign Reference	CN1650032A_WO03074723A2_1of2.pdf	17005481 0c849da6e851b677ac2a1ff1cb6067d16266e524	no	329
Warnings:					
Information:					
5	Foreign Reference	CN1650032A_WO03074723A2_2of2.pdf	22119819 2a1f80d7ad80795014bcf6ce8fb3ecafdd0a8945	no	282
Warnings:					
Information:					
6	Foreign Reference	CN1674028A_US2005216208A1.pdf	2629988 db3261f5d6c4f50b782a7fa29cd7071a1669accc	no	53
Warnings:					
Information:					
7	Foreign Reference	EP0270017A2.pdf	1039060 44f6d2eca18880db4f8b1e10a8166dad8f4ff160	no	15
Warnings:					
Information:					
8	Foreign Reference	EP1524321A1.pdf	428171 f9fd23733a5ba9f3fecd9b8107d2923d671525cc	no	9
Warnings:					
Information:					

9	Foreign Reference	EP1524321B1.pdf	609418 bef0de63058f16f7cdc15758c4bf9a75968f1514	no	12
Warnings:					
Information:					
10	Foreign Reference	EP1702990A1.pdf	394662 b320eb7060d4baf3a6d4965cde2c15ac902be514	no	29
Warnings:					
Information:					
11	Foreign Reference	EP2128169A1_US2011130558A1.pdf	7263574 af9d08989bf18275d30ea2c61c608745ccf15191	no	49
Warnings:					
Information:					
12	Foreign Reference	EP2163622A1_US2010221788A1.pdf	2200629 8d2ef8f646167aa243fde6fb1412ec4db1a6959d	no	42
Warnings:					
Information:					
13	Foreign Reference	EP2315849B1_EFS.pdf	3301996 65defa3f7a17068e69653053d2c81347c44232de	no	81
Warnings:					
Information:					
14	Foreign Reference	EP2653562A1_EFS.pdf	1473242 b7566f8e30d6764400eda5931d98515c6ae14b4f	no	27
Warnings:					
Information:					
15	Foreign Reference	EP2902500A1.pdf	9562335 ae0dddb48f56f2d30b605aaf2a5ccd88e28e100c	no	111
Warnings:					
Information:					

16	Foreign Reference	EP3026124A1.pdf	11382005 37438158a414ac6bbd6c5ee0ed4461daccd17020	no	39
Warnings:					
Information:					
17	Foreign Reference	EP3134541B1.pdf	19027627 4fd2799ad010c87dee67b9f5a4413650b48ea637	no	190
Warnings:					
Information:					
18	Foreign Reference	EP3187597B1.pdf	2430509 85946d4e1aca0fc0f84e131535addc9ad128f8f3	no	106
Warnings:					
Information:					
19	Foreign Reference	EP3285193A1.pdf	982808 cb6433e71bfff03743 4f6b4c2c2e75213e7b7f19	no	27
Warnings:					
Information:					
20	Foreign Reference	EP3443119B1.pdf	16006939 323e40ff3988619d6541f9a4ddaddf77e6a78259	no	194
Warnings:					
Information:					
21	Foreign Reference	EP3760730A1.pdf	3324566 e64d846ef64e59cebe1d349b65a79f884f6cb1b0	no	110
Warnings:					
Information:					
22	Foreign Reference	EP3760731A1.pdf	3429074 113d4d2d6ddccf2bb2925134c17a923073d94b8d	no	111
Warnings:					
Information:					

23	Foreign Reference	EP3760732A1.pdf	3576194 edcf49967bdc6d2c7d31cd2810b5d0db297e2cbd	no	113
Warnings:					
Information:					
24	Foreign Reference	EP3824470.pdf	9041867 2a4c5882bc1faa337356fd1bc8f14eb34d40e15a	no	89
Warnings:					
Information:					
25	Foreign Reference	GB2488358.pdf	1353761 58a9ad993c6ecfffa777a28a11e394e15e051840	no	32
Warnings:					
Information:					
26	Foreign Reference	JP2002300894_US2002182622A1.pdf	18787496 d877d5ebfff940167a444a4508da04f50eafb733	no	101
Warnings:					
Information:					
27	Foreign Reference	JP2002530121A_WO2000031306A.pdf	9476046 e9d8d038bbe450f6ac1eddfc657b05e0da013873	no	192
Warnings:					
Information:					
28	Foreign Reference	JP2003521252A_WO2001057269A2.pdf	9215742 0fcc3b1aaad954e9af3bcab4dcfbc3dc162add1c	no	122
Warnings:					
Information:					
29	Foreign Reference	JP2004502466_WO200204672.pdf	4986624 0f37e159f2500c5503acb2ff6edf140a60822f14	no	112
Warnings:					
Information:					

30	Foreign Reference	JP2004533243_US20120053073.pdf	14368737 867660d5fc79e87583d6d32795c71bef0f3f5c83	no	140
Warnings:					
Information:					
31	Foreign Reference	JP2005160470_EP1524321A1.pdf	1098016 7d1c65c081bc1356506f7ebb0a0f62ab9702ca9f	no	20
Warnings:					
Information:					
32	Foreign Reference	JP2005514956_WO2003062441.pdf	3590301 f6c4c24f7d52b6d6bb14b3676cdcd8f38d38c22b	no	53
Warnings:					
Information:					
33	Foreign Reference	JP2006254912A_EP1702990A.pdf	5244552 d964570223c8722350564182d92d043ea07f43f6	no	63
Warnings:					
Information:					
34	Foreign Reference	JP2008263974A_US20082867 83A1.pdf	16002976 aa65f0fec8bb675fc891bc857301fac227cb3b2a	no	138
Warnings:					
Information:					
35	Foreign Reference	JP2008271980A_WO2002070751A1.pdf	5187388 078c7617c3a766b2f8481d3337ca8d04a761dadd	no	196
Warnings:					
Information:					
36	Foreign Reference	JP2010509922A_WO2008061213A2.pdf	2573565 10f8c94847327aa7ed9ae1456f4f0b0c0cbed313	no	101
Warnings:					
Information:					

37	Foreign Reference	JP2011508662A_US20110064824A1.pdf	3763111 b66d2a96bd2512f4a846d41de93b04f9f0a060a2	no	66
Warnings:					
Information:					
38	Foreign Reference	JP2011516069_WO2009124293.pdf	3702907 3d241907fbdc41d97dcec0707ed723d8d14a9f3f	no	47
Warnings:					
Information:					
39	Foreign Reference	JP2015535681_US10041127.pdf	14296710 7a11447014cb41d18722d70354806a1fc00b2035	no	162
Warnings:					
Information:					
40	Foreign Reference	JP2965699_WO9114768.pdf	16316964 274fad0f2a69ecb70d03be993f9146995fea522b	no	70
Warnings:					
Information:					
41	Foreign Reference	RU2290078C1.pdf	228262 ea27132cccaa6190f290d0c0c5eb57681a0649b5	no	7
Warnings:					
Information:					
42	Foreign Reference	WO2000018957A1.pdf	4474552 ae9cecaabcaebaba2c647c958ce326c62c3791e1	no	104
Warnings:					
Information:					
43	Foreign Reference	WO2000031306A2.pdf	3003347 62be9da0f3176a89707e620e64900d79549ffdad	no	90
Warnings:					
Information:					

44	Foreign Reference	WO0107640A2.pdf	4182348 9f3f9f43e38862104078b1acbe18a9ea4bc1 1335	no	92
Warnings:					
Information:					
45	Foreign Reference	WO2001034844A1.pdf	2697570 e37c334f5ae953f704af869deed050cfe6d64 75d	no	66
Warnings:					
Information:					
46	Foreign Reference	WO2001057269A2.pdf	4295463 a74b1cb3e8585e89e2f4e121063a39f9f43a 3e76	no	87
Warnings:					
Information:					
47	Foreign Reference	WO0179851A1.pdf	3482190 e5769008f2bd75b01c829abedfdba9a1d15 1320f	no	28
Warnings:					
Information:					
48	Foreign Reference	WO0190419A2.pdf	7641904 6c1fc1d2c1a1125221f579fa982d05a37bc4 2128	no	166
Warnings:					
Information:					
49	Foreign Reference	WO0204672A2.pdf	1666736 99c007c0af250fe1886c958d11d62b064691 a229	no	42
Warnings:					
Information:					
50	Foreign Reference	WO02055985A2.pdf	13018312 1bffcc622af24b3875a6b34eb9c8880b1657 8ef1	no	142
Warnings:					
Information:					

51	Foreign Reference	WO2002070751A1.pdf	6255981 a227540c044410e4afbdfb3d91e86dace210837b	no	141
Warnings:					
Information:					
52	Foreign Reference	WO02076377A2.pdf	3447066 13af96ebb35e4f1f088b1e05a4827801c5a3102d	no	76
Warnings:					
Information:					
53	Foreign Reference	WO02090505A2.pdf	2298315 615ded5f5bedc53314267d896fc9fa3da64725d6	no	46
Warnings:					
Information:					
54	Foreign Reference	WO2002044411A1.pdf	8548758 a5ff489f0c9117f0bba5653f000cffbde11e0631	no	137
Warnings:					
Information:					
55	Foreign Reference	WO2003000919.pdf	2329781 f0b6a9cb4a41667cbb62552464b91eb371ae382c	no	52
Warnings:					
Information:					
56	Foreign Reference	WO2003018757A3.pdf	139087 28615e6b7bdb9d96ee8b3b8b99d8b34846984a21	no	3
Warnings:					
Information:					
57	Foreign Reference	WO2003020974A3.pdf	234751 c105034000ddb4deb1faca90c3d7d04950451a76	no	6
Warnings:					
Information:					

58	Foreign Reference	WO03031646A1.pdf	7088482 bc61e8c6bb194a15163f0f97e7d2fc9dfe9920fc	no	60
Warnings:					
Information:					
59	Foreign Reference	WO03050532A1.pdf	5455644 96bc9595256f321e49b60de760ed89892e677faa	no	38
Warnings:					
Information:					
60	Foreign Reference	WO03062441A1.pdf	1362793 9f0c1a5daa2bb0a477732387422020 67ec11af5e	no	31
Warnings:					
Information:					
		Total Files Size (in bytes):	377571281		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt	
EFS ID:	46902168
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:15:52
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	ASHOOR_2012.pdf	1298457 ad899c58fd041695c13655bbe48f2c04cc3d8ef7	no	5
Warnings:					

Information:					
2	Non Patent Literature	ASHOOR_2013_26_NPL.pdf	769519 30eb02f86269d538031ab7bf4d99c7817107a06f	no	7
Warnings:					
Information:					
3	Non Patent Literature	Ashoor-fetal-fraction.pdf	1448022 d0893e0e4b97346723d017041b399b9c6fb3fcc7	no	7
Warnings:					
Information:					
4	Non Patent Literature	AULD_1988_p110_NPL.pdf	4771009 44852b4f80240294 6287d886fb445aad36312cfc	no	5
Warnings:					
Information:					
5	Non Patent Literature	AVENT_2009_p179_NPL.pdf	2299305 fa03479b3938cd7e9f90d1b3e18fff2170163c26	no	5
Warnings:					
Information:					
6	Non Patent Literature	AVGIDOU_2005_p1761_NPL.pdf	1279809 960a5b51fcdd23d26753961dbb7e6868945c9339	no	13
Warnings:					
Information:					
7	Non Patent Literature	AYALA_2009_p591_NPL.pdf	291030 75e98e66144c4cc8e0a4dbc60d03676f613a2b1f	no	11
Warnings:					
Information:					
8	Non Patent Literature	BADA.pdf	3312681 0c45cf1493bfdcdbf8e9ff534b1bdd9d6abaabd5	no	23
Warnings:					
Information:					

9	Non Patent Literature	BAI_2013_7pgs_NPL.pdf	845177 013846a54c355a8e2ff7d54b7ad3d150163a10f2	no	7
Warnings:					
Information:					
10	Non Patent Literature	BALAVOINE_1996_p1547_NPL.pdf	1026790 0e314fa211179d4f793f7c9fdec5a4328ebabf2b	no	8
Warnings:					
Information:					
11	Non Patent Literature	BALDUINI_2003_p3078_NPL.pdf	96020 7e5fe3b727bcf2f0736c42d75c62bb63e32d2081	no	4
Warnings:					
Information:					
12	Non Patent Literature	BALE_2003_270pgs_NPL.pdf	2186101 539d0a07bfaa698cbf15cab73e4d85295d86d234	no	270
Warnings:					
Information:					
13	Non Patent Literature	BALLIF_2006_2757_NPL.pdf	1218630 98e1a1088d5dca679f3db510fbe4e2db61bce4e9	no	11
Warnings:					
Information:					
14	Non Patent Literature	BANFI_2007_p565_NPL.pdf	218608 8be6938d308c0bc2e8bfeb3069ea5260c596a750	no	13
Warnings:					
Information:					
15	Non Patent Literature	BARBAZUK_2007_p918_NPL.pdf	144424 df51d39df315c5935513c6cf24d836bf45d4df97	no	9
Warnings:					
Information:					

16	Non Patent Literature	BARRA_2015_p976_NPL.pdf	659130 ccefe0fe40d9439c1faefa782fd513381af889dc	no	6
Warnings:					
Information:					
17	Non Patent Literature	BARSKI_2007_p823_NPL.pdf	4558898 a4a16775a8deff579e192351e22efbe1a3808b20	no	16
Warnings:					
Information:					
18	Non Patent Literature	BARTLETT_2003_NPL.pdf	2065328 bdead83297302502787b8ae20d0e9f6938ea1c49	no	5
Warnings:					
Information:					
19	Non Patent Literature	BASHASHATI_2013_p21_NPL.pdf	1914753 352d83c46e86a43bd493485b02397bc605aab400	no	14
Warnings:					
Information:					
20	Non Patent Literature	BAU_2009_171-175_NPL.pdf	595252 6754c581c610dd9d17a74967ea063ae7df2081c1	no	5
Warnings:					
Information:					
21	Non Patent Literature	BAUER_2006_p831_NPL.pdf	3796781 2871247ab11c9130eeaa2674f7c8a7c9bdcf0288	no	6
Warnings:					
Information:					
22	Non Patent Literature	BAXTER_2000_p195_NPL.pdf	611094 0a0659d7c2009f3c61ff8a594a94c9f0d2c0fee6	no	9
Warnings:					
Information:					

23	Non Patent Literature	BAXTER-LOWE_2006_p561_NPL.pdf	53211 8399c77a842bee30cb9dc1ba7524f6eb06fa05ca	no	3
Warnings:					
Information:					
24	Non Patent Literature	BEAUMONT_2004.pdf	2576060 0fe0335a896438c3f6711219bd1c97137e71d7a9	no	11
Warnings:					
Information:					
25	Non Patent Literature	BECK_2009_p730_NPL.pdf	1178978 b8f9f438b0771713653 8b932e5704f80d6ea3de	no	9
Warnings:					
Information:					
26	Non Patent Literature	BECK_2010_p342_NPL.pdf	263201 971448c0be0d8222e8fc1e574f50e47c76907230	no	9
Warnings:					
Information:					
27	Non Patent Literature	BECK_2013_1732_npl.pdf	3386668 063aee769ed9c455d91127e5a018ab19fef32cd6	no	10
Warnings:					
Information:					
28	Non Patent Literature	BEER.pdf	2225517 daaeab1b65113ef69f338bee3a955e9dec27e79a	no	15
Warnings:					
Information:					
29	Non Patent Literature	BEERENWINKEL_2003_BIOINFORMATICS.pdf	1961087 4e968b1004b723b241ac36c6e4fcc3783333a299	no	10
Warnings:					
Information:					

30	Non Patent Literature	BEERENWINKEL_2003_NAR.pdf	1192488 84b0603af3f451172e882393fa086bd3e1e76644	no	6
Warnings:					
Information:					
31	Non Patent Literature	BELOSTOTSKY_2009_p408_NPL_Part1.pdf	17515893 c380042ed3bf0483d453cb132175fa153cb0f320	no	200
Warnings:					
Information:					
32	Non Patent Literature	BELOSTOTSKY_2009_p408_NPL_Part2.pdf	19795376 68ff1c07190cde174144f916ae5a24c8f0d28b01	no	207
Warnings:					
Information:					
33	Non Patent Literature	BENDER_2006_p75_NPL.pdf	112697 166ef68f937b215b84d9980215853309492 6d4ec	no	3
Warnings:					
Information:					
34	Non Patent Literature	BENESOVA_227-234_2013_NPL.pdf	848656 57bf14b674fe4c575429fc8c5bfa66e8df109a84	no	8
Warnings:					
Information:					
35	Non Patent Literature	BENJAMINI_1995_p289_NPL.pdf	1354956 7477aecc49ce5397229cf363187fa6eb8ce6bd32	no	13
Warnings:					
Information:					
36	Non Patent Literature	BENN_2012.pdf	77565 3e89e69ec0c95264b7f34db251b06659d36ea7bd	no	4
Warnings:					
Information:					

37	Non Patent Literature	BENN_2013.pdf	269987 90406d60a7dd59d21c721a2472787ddc278086fa	no	19
Warnings:					
Information:					
38	Non Patent Literature	BENNETT_2005_p373_NPL.pdf	6786519 fcf198cfc66089c9bff66639c1164e00b81116b2	no	10
Warnings:					
Information:					
39	Non Patent Literature	BENTLEY_2008.pdf	572263 9176d9304b613b3d7d6da1a84d2445f7d16b5643	no	20
Warnings:					
Information:					
40	Non Patent Literature	BENTLEY_2009_p403_NPL.pdf	448148 42a424c83ab34709ef2ba10d9125c18bc01ec66a	no	11
Warnings:					
Information:					
41	Non Patent Literature	BERGEN_2005_11pgs_NPL.pdf	3961220 45d749915225207950b2ac24acb10745c82ab95e	no	11
Warnings:					
Information:					
42	Non Patent Literature	BERMUDEZ.pdf	341039 d8c6581b9ccaa9db9ba625cbf429ce4cf8397fc2	no	9
Warnings:					
Information:					
43	Non Patent Literature	BEROUD_2003_1013_NPL.pdf	2821619 dd27b9221d8ccd0db317997803b90b2a6c06cab4	no	2
Warnings:					
Information:					

44	Non Patent Literature	Bevinetto5Foods.pdf	900753 d25365e40d26fabe2b053e7e5a5113b8052f0f5e	no	8
Warnings:					
Information:					
45	Non Patent Literature	BIANCHI_1999_574_NPL.pdf	998689 567291b464eb77b2d04d76a22b1b8fce98ec45d9	no	10
Warnings:					
Information:					
46	Non Patent Literature	BIANCHI_2002.pdf	2156924 44d5b41081eb4d82c92d94a1d2ee053516279892	no	7
Warnings:					
Information:					
47	Non Patent Literature	BIANCHI_2004_S93_NPL.pdf	119830 2dd3248f3bbae693a9940aaadbd001e3fab3d574	no	9
Warnings:					
Information:					
48	Non Patent Literature	Bianchi_2010_p747_NPL.pdf	328492 6476be254529bfbc9bb424fe7434885cc570f033	no	11
Warnings:					
Information:					
49	Non Patent Literature	BIANCHI_2012_890_NPL.pdf	1451368 cd6e70919845a6cae5fb683a154b3d7e9ae1956e	no	12
Warnings:					
Information:					
50	Non Patent Literature	BINLADEN_2007_9pgs_NPL.pdf	836435 39dd833b5c1174688dbc4f9fdfebf47be5388508	no	9
Warnings:					
Information:					

51	Non Patent Literature	BIRCH.pdf	386535 7e923788abb1fe060204357457172f2cdd4ce2c9	no	9
Warnings:					
Information:					
52	Non Patent Literature	BIRKENKAMP-DEMTRODER_2018_3653_NPL.pdf	155863 c0208f9ed4e2b4160c4fb4d64e0ed2943e12c9c1	no	4
Warnings:					
Information:					
53	Non Patent Literature	BIRKENKAMP-DEMTRODER_Vol-29-2018_NPL.pdf	71686 3ea6d4431493fb3cb8dfaf50dd1b6ca95351b69f	no	2
Warnings:					
Information:					
54	Non Patent Literature	BISCHOFF_2003_p139_NPL.pdf	2451599 0ebe8ad4c58707d63dd5d769f49a24dd62518a94	no	2
Warnings:					
Information:					
55	Non Patent Literature	BISCHOFF_2005_p59_NPL.pdf	12510990 a4b29e48355da0254b18c2ac1d5ff3cf8f1a656a	no	9
Warnings:					
Information:					
56	Non Patent Literature	BISIGNANO_2011.pdf	1947371 8e1357257c7821e8584f3ba371dbbb113fcbd5b6	no	9
Warnings:					
Information:					
57	Non Patent Literature	Blast2015.pdf	420094 a4118612a810cfc33bcf7aa72da2677cf94f6168	no	9
Warnings:					
Information:					

58	Non Patent Literature	Blomquist_2013_14pgs_NPL.pdf	2109936 cb1aa77618c0db8418e1acad20d6a9a2ac5ff492	no	14
Warnings:					
Information:					
59	Non Patent Literature	BLOW_2007_p627_NPL.pdf	6010455 4dcb207d856ac10852f98a7282f4f74f1cf6b9f5	no	4
Warnings:					
Information:					
60	Non Patent Literature	BOARD_2009_p1724_NPL.pdf	197081 e053095b67eef1037ced1815806ea224149cb18c	no	8
Warnings:					
Information:					
		Total Files Size (in bytes):	136204067		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

<u>New Applications Under 35 U.S.C. 111</u>
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
<u>National Stage of an International Application under 35 U.S.C. 371</u>
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
<u>New International Application Filed with the USPTO as a Receiving Office</u>
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt

EFS ID:	46902224
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:35:15
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	KIBBE_2007_pW43_NPL.pdf	5153073 e31bef58ea57546e66cfe58e85fd02997996198a	no	4
Warnings:					

Information:					
2	Non Patent Literature	KIERNAN_2000_p8_NPL.pdf	169911 10840ab516dae8b3aa1f5c6df0bff00a855b db7c	no	7
Warnings:					
Information:					
3	Non Patent Literature	KIJAK.pdf	1361225 1ff588889ee9a278777aebe80050ae087fbfc 365	no	7
Warnings:					
Information:					
4	Non Patent Literature	KIM_2015_316_NPL.pdf	3045963 0d999ae9c47b18b29d2d053626b7a404de a24f1e	no	13
Warnings:					
Information:					
5	Non Patent Literature	KIMMEL_2005_p158_NPL.pdf	189215 e11766672e31f49c3dcee697086e7402b17 4ab83	no	5
Warnings:					
Information:					
6	Non Patent Literature	KINDE_2011.pdf	1768909 ec1af082ccccfd6f0e13bba6e2a342bec383 6425	no	16
Warnings:					
Information:					
7	Non Patent Literature	KINNINGS_2015_816.pdf	718580 057d6c01ac64ecb7aaa11e514986540becb 73205	no	7
Warnings:					
Information:					
8	Non Patent Literature	KIRCHER_2009_p83_9_NPL.pdf	3873667 02727b370dfbcc7aa6a5c71ba6663cb6d0a 1d5de	no	9
Warnings:					
Information:					

9	Non Patent Literature	KIRKIZLAR_2015_407.pdf	509286 8cad85080f686643b2e2b11f43197b21ecc6d522	no	10
Warnings:					
Information:					
10	Non Patent Literature	KIRKNESS_2013_p826_NPL.pdf	818149 3deaf29dbb7e193ca419f60e91a20c87f7a6907a	no	8
Warnings:					
Information:					
11	Non Patent Literature	Kittler_2002_Anal_Biochem_NPL.pdf	445132 220591825ed3fb236a25a8c2b044e9f56e1ca001	no	8
Warnings:					
Information:					
12	Non Patent Literature	KIVIOJA_2011.pdf	517473 16011b920db4f9c6443ba707207c910f86e3f599	no	5
Warnings:					
Information:					
13	Non Patent Literature	Kivioja_2011_18pgs_NPL.pdf	515640 2d11ce2d6aa600482deaf4a7aadc286e1086c72b	no	18
Warnings:					
Information:					
14	Non Patent Literature	Kivioja_2012_p72_NPL.pdf	756937 46499bc006038277debb75cd7e555e0d6287cecd	no	5
Warnings:					
Information:					
15	Non Patent Literature	KOBASHIGAWA_2005_p1537_NPL.pdf	108985 c9831001a4f6c3d5e782d648d305543c5e5d3c12	no	6
Warnings:					
Information:					

16	Non Patent Literature	KOBOLDT_2009_p2285_NPL.pdf	204256 10aaa803ed36a1e4a6d8f1499d8db50534478b71	no	3
Warnings:					
Information:					
17	Non Patent Literature	KOELMAN_2000_p64_NPL.pdf	173480 0200bec73d6e6253b362dc2febcad317fa55fd40	no	8
Warnings:					
Information:					
18	Non Patent Literature	KOHLER_2009_9pgs_NPL.pdf	455205 dece594a331bc2c169ad7f6242c27926a8439fa3	no	9
Warnings:					
Information:					
19	Non Patent Literature	KOIDE_2005_p604_NPL.pdf	404739 74688445f7a77857d34fcbb1fe0fe360daf900e5	no	4
Warnings:					
Information:					
20	Non Patent Literature	KOLDEHOFF_2006_p746_NPL.pdf	319794 fe1343085895425c15441379d029fdeffbde593c	no	12
Warnings:					
Information:					
21	Non Patent Literature	KONFORTOV.pdf	206227 b2cbcafcd3ad9947cc6e05be8d3f64f9a9854f10	no	8
Warnings:					
Information:					
22	Non Patent Literature	Konfortov_2000_p1737_NPL.pdf	147803 afbd4cc7050ff4ebe0500e60425f091e33fa8929	no	8
Warnings:					
Information:					

23	Non Patent Literature	KOPRESKI_1997_p12393_NPL.pdf	688451 ac943f5004207e3a03f32050c9a6307cd97733d1	no	7
Warnings:					
Information:					
24	Non Patent Literature	KORESSAAR_2007_p1289_NPL.pdf	3590144 5fe824cd63d3029a01160e1565f30cd2cbd3b8cc	no	3
Warnings:					
Information:					
25	Non Patent Literature	KORN_2008_p1260_NPL.pdf	684582 855f17aa0f062462dc61f9e09b8cb6cd98117842	no	8
Warnings:					
Information:					
26	Non Patent Literature	KRJUTSKOV.pdf	1340899 bfd56f63538b3aabbb0485a6874324bd3289d4a	no	7
Warnings:					
Information:					
27	Non Patent Literature	KU_241-251_2012_NPL.pdf	2151664 3848d09c02bb548385f0760b55cff249120d7a6d	no	16
Warnings:					
Information:					
28	Non Patent Literature	KUHN_2002_p574_NPL.pdf	1274224 314ba443e729bf4671f5d7325de3c59a36a8673e	no	7
Warnings:					
Information:					
29	Non Patent Literature	KUKITA_2015_p269_NPL.pdf	802136 98eed6bebc4703f5dc13dd569c410aad329c2eb2	no	9
Warnings:					
Information:					

30	Non Patent Literature	KULIEV.pdf	1943140 265b2b1f260960a2507bc24a57869cb0cd5fe626	no	7
Warnings:					
Information:					
31	Non Patent Literature	KULIFAJ_2018_p118_NPL.pdf	770405 0e847cfeafdcc6ca997a3aa5070f0f223edd742e	no	10
Warnings:					
Information:					
32	Non Patent Literature	KUMAR_2000_p578_NPL.pdf	152153 3aba32fc9720543a80702f92714ec27e2c906434	no	6
Warnings:					
Information:					
33	Non Patent Literature	KUNISHIMA_2005_360_NPL.pdf	560899 96fbd1e2d0ef50fc806065612f66f1c791a66a3c	no	6
Warnings:					
Information:					
34	Non Patent Literature	KWOK_2000_5pgs_NPL.pdf	105789 e196301d5a061747cb20213250b1d9efac8702fa	no	5
Warnings:					
Information:					
35	Non Patent Literature	LAJOIE_2015_p65_NPL.pdf	1916046 ed3e51f71dde820bf195bd827035eaea55c171ae	no	28
Warnings:					
Information:					
36	Non Patent Literature	LAMBERT_2004_p914_NPL.pdf	730945 ad838318a2bba7725e0b65db938533e71f0f89ea	no	9
Warnings:					
Information:					

37	Non Patent Literature	LAMBERT-MESSERLIAN.pdf	303032 97ea46496d08028607b0deb79f24ef1030de44f3	no	2
Warnings:					
Information:					
38	Non Patent Literature	LANDEGREN_2003_p525_NPL.pdf	138810 3e174f70cbf185edaf84196fcd1c2e8c38cae75d	no	6
Warnings:					
Information:					
39	Non Patent Literature	Landegren-1998-Genome-Res_NPL.pdf	617202 5915b7366cda26a62b5c32cbb5cde1366348b67b	no	9
Warnings:					
Information:					
40	Non Patent Literature	LANDER_2001_860_NPL.pdf	1844955 b0dd9ac276df7b20637d0b74ed2621de9cf83fdb	no	62
Warnings:					
Information:					
41	Non Patent Literature	LANGMORE_2013_35pgs_NPL.pdf	25673168 d50d52b9fecddb108176ea8e7346eb87569d8c11	no	35
Warnings:					
Information:					
42	Non Patent Literature	LANMAN_2015_1-27_NPL.pdf	2190302 d065d46ca46b837b47bd4f821abd5fd2aced5c95	no	27
Warnings:					
Information:					
43	Non Patent Literature	LAPAIRE_2007_p616_NPL.pdf	3427236 0fefa3704748daf7d0fdaf2f57773c640c1591ea	no	6
Warnings:					
Information:					

44	Non Patent Literature	LAPIERRE_2000_p531_NPL.pdf	3921310 63896196878dbf4fb578e3217391eb6e30b71d02	no	10
Warnings:					
Information:					
45	Non Patent Literature	LARDEUX_2008_p485_NPL.pdf	1092763 00d1b31318b00c6cfd16856e5f68681a5281c0ed	no	8
Warnings:					
Information:					
46	Non Patent Literature	LARSEN_2005_p1119_NPL.pdf	2385561 36868e7b8bd35aede4b210337e7b8e8235d4399b	no	12
Warnings:					
Information:					
47	Non Patent Literature	LASKEN_2003_p531_NPL.pdf	6927006 8c0582e3238c7929369992b5040e7ef562d40464	no	5
Warnings:					
Information:					
48	Non Patent Literature	LATHI.pdf	407475 0d9cf0bc3d80b755b4d66ac431d2b42b01e7b148	no	5
Warnings:					
Information:					
49	Non Patent Literature	LAVEBRAT_2007_p2582_NPL.pdf	451078 8de9b1b3cb55933d0a2932fb201c7d7a2cc82f0e	no	10
Warnings:					
Information:					
50	Non Patent Literature	LAVEBRATT_2003_p97_NPL.pdf	155193 528d68c8c7fcdeddb727d3be791c43a3905414e2	no	6
Warnings:					
Information:					

51	Non Patent Literature	Lavrentieva_1999_p341_NPL.pdf	229681 fb7ccdff45813e36b2a960250cf3cb0deca526b4	no	7
Warnings:					
Information:					
52	Non Patent Literature	LEAMON_2003_p3777_NPL.pdf	342732 d666ff7c8e7dd06db3129698b0090f85824dc100	no	9
Warnings:					
Information:					
53	Non Patent Literature	LEARY.pdf	2733712 9b9f0cfa361b38fa956bcd3bbdc3180c65f014fc	no	14
Warnings:					
Information:					
54	Non Patent Literature	LEARY_2010_1_NPL.pdf	894208 56c4be76a1ddab81b5c5e892170c49eed4731d15	no	8
Warnings:					
Information:					
55	Non Patent Literature	LECOMTE_2002_p542_NPL.pdf	146831 d19bbe521f09d07e31d55411d18d3a7a25bdd90f2	no	7
Warnings:					
Information:					
56	Non Patent Literature	LEE_2001_p276_NPL.pdf	22979910 90b6dc6badd316d9b32be10037814defb96c568d	no	7
Warnings:					
Information:					
57	Non Patent Literature	LEE_2002_p1217_NPL.pdf	1610342 4c53c29961e4921b812835d6fe24e01e91bb62e9	no	5
Warnings:					
Information:					

58	Non Patent Literature	LEE_2006_89-94_NPL.pdf	394973 3a7c1dc8a89323d744cafda7ebe25a49b553c1d1	no	6
Warnings:					
Information:					
59	Non Patent Literature	Lee_2017_p47_NPL.pdf	56252 54fe5750131d4fec166099798ce1faeb3fbb60ed	no	1
Warnings:					
Information:					
60	Non Patent Literature	LEVSKY_2003_2833_NPL.pdf	109718 8a9d69067b55323e9964440a5e8235481b347987	no	6
Warnings:					
Information:					
		Total Files Size (in bytes):	117608576		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt	
EFS ID:	46902186
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:23:39
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	DONAGHUE_2005_65_NPL.pdf	634966 6c020059d07b3d89bb421bf5480a393d6c3836ce	no	8
Warnings:					

Information:					
2	Non Patent Literature	DONOHOE2000.pdf	1134358 cd0740967ace02812437f5947f32865e25466725	no	13
Warnings:					
Information:					
3	Non Patent Literature	DONOSO_2007.pdf	2623151 25b58a44b47b2eb9a6b61d095dd5ae80d7c1a03a	no	11
Warnings:					
Information:					
4	Non Patent Literature	DOOSTZADEH_2008_p4_NPL.pdf	154599 132334178cf3b36f72668107b4175117519 32dce	no	4
Warnings:					
Information:					
5	Non Patent Literature	DORIT_1992_p15_6_1_NPL.pdf	2472015 0a08452e6feb703dd70ba8ac603461e4aa897251	no	10
Warnings:					
Information:					
6	Non Patent Literature	DORIT_1993_p36_NPL.pdf	1438972 ce5eaa495ea2fca7c15680b960c3d00f3ee17fac	no	12
Warnings:					
Information:					
7	Non Patent Literature	DOWD_1995_p8171_NPL.pdf	5092692 a5bb650bb970156d0c208ab64426ebc0723d81ee	no	5
Warnings:					
Information:					
8	Non Patent Literature	DOWNWARD_2003_p11_NPL.pdf	2095442 83f13649a3b91314f77b41c49c3851db28ea4fd8	no	13
Warnings:					
Information:					

9	Non Patent Literature	DRESSMAN_2003_p8817_NPL.pdf	1080182 71bafbed4866170660444 1beee89158d423628c3	no	6
Warnings:					
Information:					
10	Non Patent Literature	DUESEN_Vol-128-5251_NPL.pdf	166554 e965387c3fd166e59631cb9d487aa05e063871b3	no	2
Warnings:					
Information:					
11	Non Patent Literature	Echeverri.pdf	1235882 1f28e1574d7a32faede49ea168adfd29654c85b3	no	11
Warnings:					
Information:					
12	Non Patent Literature	EDWARDS_1994_S65_NPL.pdf	850634 46f4f2e455c1aef1c7361679e0cf4a97b4c656f5	no	12
Warnings:					
Information:					
13	Non Patent Literature	EFRON_1986_p54_NPL.pdf	3694396 f79d873e007ee5c63469f4420b3d1a94a86669c7	no	22
Warnings:					
Information:					
14	Non Patent Literature	EHLAYEL_2021_p3077_NPL.pdf	1361181 8175f72588c6486c68704effad0663adf48c3d1a	no	11
Warnings:					
Information:					
15	Non Patent Literature	EHRICH_2011.pdf	2558891 c3b3ada5e06925e3d9952cff351654d911c1eeed	no	11
Warnings:					
Information:					

16	Non Patent Literature	EICHLER_1995.pdf	877780 1156267c1390d9ef5fad80b5fdad99fc643b10d6	no	5
Warnings:					
Information:					
17	Non Patent Literature	ELLISON.pdf	815269 0508b0d2e0d101ec5cb1375df06337612e9f16fa	no	13
Warnings:					
Information:					
18	Non Patent Literature	ELLONEN_2004.pdf	460105 e30ce5adc07120d2157ad4cceed24fc2834e8802	no	3
Warnings:					
Information:					
19	Non Patent Literature	ELNIFRO_2000_p559_NPL.pdf	4123314 bdddd170473e05c561d6de5d3a6fa0bcd6390e61	no	12
Warnings:					
Information:					
20	Non Patent Literature	ELTOUKHY_2006_p1032_NPL.pdf	371733 c607ef786f073d1a5598b7e5e3eb96f97b692b0e	no	4
Warnings:					
Information:					
21	Non Patent Literature	EP014198110_ISR.pdf	266493 4d32d0f4712f2ef9dcf87d841153b8e8b5508da7	no	3
Warnings:					
Information:					
22	Non Patent Literature	EP06838311_Communication.pdf	803701 a8ea4846e7bd74ae43eac966673df66ed81ca7dd	no	8
Warnings:					
Information:					

23	Non Patent Literature	EP08742125_COMMUNICATION.pdf	442907 721f80cb16720af2c142c781589f52faabae535b	no	5
Warnings:					
Information:					
24	Non Patent Literature	ERIJMAN_2011_p121_NPL.pdf	1081738 6ea1e7a174322dc5930b0afa8249576abe8dd211	no	7
Warnings:					
Information:					
25	Non Patent Literature	ERLICH_2011_13pgs_NPL.pdf	1639943 ee9d06e7c423e6a1d800e27270b422f09e8a1e2c	no	13
Warnings:					
Information:					
26	Non Patent Literature	ERONEN_2006_18pgs_NPL.pdf	9351313 0f2670f1e87ab84f709ba7abb84209ceafcefb7b	no	18
Warnings:					
Information:					
27	Non Patent Literature	EVERITT_2003_3pgs_NPL.pdf	1084049 44bc8c48e4c6cd0aadac575b61628d972720b7c8	no	3
Warnings:					
Information:					
28	Non Patent Literature	FACKENTHAL_2008_p37_NPL.pdf	749069 6fab727ef3f03f199158a1cdbb95f40d668c6666	no	6
Warnings:					
Information:					
29	Non Patent Literature	FAHAM_2012_p5173_NPL.pdf	648814 6199ccf946a7826b17dc50521c7bf5eee0be4c1c	no	8
Warnings:					
Information:					

30	Non Patent Literature	FALCON_2005_p151_NPL.pdf	1422394 0ca2af194b4d559849d873d5e6aeae65c1c2d3df	no	5
Warnings:					
Information:					
31	Non Patent Literature	FAN_2003_p69_NPL.pdf	1139069 5a4dff2d83e0c1eb17f77e77bf866064c5d7391e	no	11
Warnings:					
Information:					
32	Non Patent Literature	FAN_2006.pdf	1394294 867e00221fd1913df4e7cfc5ec25bccdd192509d	no	13
Warnings:					
Information:					
33	Non Patent Literature	Fan_2007_p7576_NPL.pdf	222560 de9b7e23abd6c3e08131d52d96b64fd9e02a8686	no	4
Warnings:					
Information:					
34	Non Patent Literature	FAN_2008.pdf	1528715 cd9b8e9eb2243b99db3ecfefd2f936300dd1de42	no	6
Warnings:					
Information:					
35	Non Patent Literature	FAN_2009_543e1_NPL.pdf	448725 686efb1931479537b6314ea5f915461c65e416b7	no	7
Warnings:					
Information:					
36	Non Patent Literature	FAN_2010.pdf	936115 3214c4e14eebeafd5fcadf7e52958dd18b944f04	no	7
Warnings:					
Information:					

37	Non Patent Literature	FAN_2010_16pgs_NPL.pdf	1167402 4ee9b2b2dcb49c187e7aa39f939a8d5d2fbf18ce	no	16
Warnings:					
Information:					
38	Non Patent Literature	FAN_2011.pdf	1111839 061d06fc1bf743a408b42e18fbdeeac157036223	no	9
Warnings:					
Information:					
39	Non Patent Literature	FAN_2012.pdf	7542932 31765bfa318613a09be27c4e8d3fe548bf07b607	no	26
Warnings:					
Information:					
40	Non Patent Literature	Fatsecret2014.pdf	151195 0f0efeef5131425d798d027d3b9a4e269ee0abdd	no	2
Warnings:					
Information:					
41	Non Patent Literature	Fazio_reference.pdf	1421748 28022afcdfbcbeae7a11236f8883ae010634c973	no	6
Warnings:					
Information:					
42	Non Patent Literature	Findlay-1995-Mol-Hum-Reproduction_NPL.pdf	1266912 cd8fea69c26711a36e0b2954ba767d663e102a28	no	7
Warnings:					
Information:					
43	Non Patent Literature	FinishingEuchromatic_10_21_04.pdf	3148288 f9acd5abdf195dcc2d072f22870f07c086291f9d	no	29
Warnings:					
Information:					

44	Non Patent Literature	FIORENTINO_2004.pdf	3102232 913ec06bc14323bc426868349effda505374e1cc	no	16
Warnings:					
Information:					
45	Non Patent Literature	FIORENTINO_2005.pdf	1046756 b70b25d668436f3f854b6bb49129aec192ff3a48	no	6
Warnings:					
Information:					
46	Non Patent Literature	FIORENTINO_2006.pdf	3330623 1f622e41e95b4afe940a89ec273a550e870f7683	no	15
Warnings:					
Information:					
47	Non Patent Literature	FITZGERALD_1992_p158_NPL.pdf	5095954 e61c72afb1c2f72281114 3db8c8080929605 49bc	no	5
Warnings:					
Information:					
48	Non Patent Literature	FixedMedium-Definition.pdf	36239 ceaa8b39ce35989010 4f6117ad8425a7b0b9dd9a	no	1
Warnings:					
Information:					
49	Non Patent Literature	FORD_2014_312_NPL.pdf	474609 b3a7c7bb8c4ee25b2e7a1c83ee45d717b0d89438	no	5
Warnings:					
Information:					
50	Non Patent Literature	Forejt2003.pdf	123955 9992fff48ede8cf16e155c8ce59e2d854484f961	no	6
Warnings:					
Information:					

51	Non Patent Literature	FORSHEW.pdf	1282571 a1c8bdb38b3c42510d383d78dbfd7b629df b69bf	no	12
Warnings:					
Information:					
52	Non Patent Literature	FORSHEW_2012_20pgs_NPL. pdf	1387811 7cdc6e14be86e8dd346272e679b5a5c3f14 4d621	no	20
Warnings:					
Information:					
53	Non Patent Literature	FORSHEW_33PGS_2012_NPL. pdf	2840441 f07ca60ab5f5ccc74247100ba28d45f3581d 1b20	no	33
Warnings:					
Information:					
54	Non Patent Literature	FORTINA_1992_p163_NPL.pdf	7784322 5c773aa1e7f02b5999150b9a5687f7f6bedb 3566	no	5
Warnings:					
Information:					
55	Non Patent Literature	FORTINA_2001_p211_NPL.pdf	462077 a81431d68b9b3256dc08ff2b0732c52b461 1739c	no	22
Warnings:					
Information:					
56	Non Patent Literature	FOUQUET_2004_p3479_NPL. pdf	1630434 27acbcfc463048a8d945994f95483de3f67b 9071	no	13
Warnings:					
Information:					
57	Non Patent Literature	FOURNIE_1995_p227_NPL.pdf	1007310 c33b30b45e5c16f6bf37b1a7b3fd2a9d1729 45e4	no	7
Warnings:					
Information:					

58	Non Patent Literature	FREDRIKSSON.pdf	440460 253b3181c80372df3aff4b7a2a677feb9e431703	no	6
Warnings:					
Information:					
59	Non Patent Literature	FREDRIKSSON_2003_p266_NPL.pdf	298457 8ee860ffa4fbe58f5b06661d3ba11467f08c226d	no	12
Warnings:					
Information:					
60	Non Patent Literature	FREEMAN.pdf	3312391 eafdf475c7eaf96820e30c6f04ce4e452f55a04c	no	13
Warnings:					
Information:					
		Total Files Size (in bytes):	105868973		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt	
EFS ID:	46902238
Application Number:	17738354
International Application Number:	
Confirmation Number:	8319
Title of Invention:	DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS
First Named Inventor/Applicant Name:	Joshua BABIARZ
Customer Number:	110711
Filer:	Nishita Alka Doshi/Jeremy Johnston
Filer Authorized By:	Nishita Alka Doshi
Attorney Docket Number:	N.012.US.44
Receipt Date:	27-OCT-2022
Filing Date:	06-MAY-2022
Time Stamp:	15:38:15
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	LEVSKY_2009_ps108_NPL.pdf	2353341 06b31c1ec0732ed1718e3b28d8095757f08c777b	no	10
Warnings:					

Information:					
2	Non Patent Literature	LI_2004_p658_NPL.pdf	133925 818374f73ccc53797b32e32373155b24528b6495	no	4
Warnings:					
Information:					
3	Non Patent Literature	LI_2005_p843_NPL.pdf	10990204 060c9b87b688cfb51a70c909572ab81d921f6e9f	no	8
Warnings:					
Information:					
4	Non Patent Literature	LI_2006_p147_NPL.pdf	130129 5d4216920bb1d26b0dd42b69fc135aef0cdf3c6e	no	4
Warnings:					
Information:					
5	Non Patent Literature	LI_2008_p1858_NPL.pdf	424828 7842b88e3eb950597f90fe04c83095e3d97f3c21	no	9
Warnings:					
Information:					
6	Non Patent Literature	LI_2009_p1124_NPL.pdf	1005897 d39f305210fdcdda6275a22c3de6507333c59d3b	no	10
Warnings:					
Information:					
7	Non Patent Literature	LI_2009_p1615_NPL.pdf	1057217 9a7cc5d7cd9c33b2c535346d6e163f7461cdce72	no	10
Warnings:					
Information:					
8	Non Patent Literature	LI_2009_p1967_NPL.pdf	90647 f19a44bd2485450560b6b7fbf4102eb363a6273c	no	2
Warnings:					
Information:					

9	Non Patent Literature	LI_Amplicon.pdf	86087 d817b10c83fea4708c8338335ec9c87ee15dec12	no	1
Warnings:					
Information:					
10	Non Patent Literature	LI_NonInvasive.pdf	1239558 9ab9fd7c07f8d7889771beaf5534ae9407b701bf	no	7
Warnings:					
Information:					
11	Non Patent Literature	LI_Separation.pdf	221855 be23e9238d7d9b9f05e2d0df42a84eb0b4b8fcb4	no	10
Warnings:					
Information:					
12	Non Patent Literature	LIAO.pdf	1581817 a27df7feaabbe7a3d7ec94ef65883be4cf74bd72	no	10
Warnings:					
Information:					
13	Non Patent Literature	LIAO_AN_ALTERNATIVE.pdf	531659 22fd6a7c546013275ad156a1b1c092adcb57159a	no	3
Warnings:					
Information:					
14	Non Patent Literature	LICHTENSTEIN_2001_p239_NPL.pdf	90620 f9d29576c75aaf16b6016801afd1a913fe1f587f	no	11
Warnings:					
Information:					
15	Non Patent Literature	LIEW2004.pdf	467932 28ea31c89b8ebee0019e9ea6ccaf57966b62cca3	no	9
Warnings:					
Information:					

16	Non Patent Literature	LIFE_TECHNOLOGIES_Ion_AmpliSeq_Designer_2012_4pgs_NPL.pdf	542245 7d816ffd2dbcb7622681c364e12cbc1396375798	no	4
Warnings:					
Information:					
17	Non Patent Literature	LILJEDAHL_2004_p10_2004.pdf	375760 83a50cc376eb53c8e8d1471907b56b80899fcd37	no	10
Warnings:					
Information:					
18	Non Patent Literature	LINDBERG_2013_347_NPL.pdf	778685 1ba3cbae38954e732d82e5bb836b9aa302e39b46	no	7
Warnings:					
Information:					
19	Non Patent Literature	LINDROOS.pdf	3375549 551d4441e30e4741850fed16e63df1d6395e62db	no	17
Warnings:					
Information:					
20	Non Patent Literature	LO_1989_1363.pdf	920249 7ba07b897f9ee0ef9026170f512e74d8e2c3d828	no	3
Warnings:					
Information:					
21	Non Patent Literature	LO_1990_1463.pdf	669889 82cca1a6bc3932b737f229e3df88e2436e8aadfd	no	2
Warnings:					
Information:					
22	Non Patent Literature	LO_1993_1147.pdf	598499 f784a87009adfb2b41b36a02d4485646b5a77bc1	no	2
Warnings:					
Information:					

23	Non Patent Literature	LO_1994_1060_NPL.pdf	598691 ca37b1b23bc53c0ea5f261e050c5fceb38759d2a	no	6
Warnings:					
Information:					
24	Non Patent Literature	LO_1994_204.pdf	2307677 376fbb7a56ae03bc6bca3501b4441f87073afb73	no	12
Warnings:					
Information:					
25	Non Patent Literature	LO_1994_229.pdf	430181 69350b3a7c1f5dd266e985a8e108da4060bba4a4	no	8
Warnings:					
Information:					
26	Non Patent Literature	LO_1994_658.pdf	584410 4dfb809af76c2bb5c50544323dc0a05f2439ddc5	no	3
Warnings:					
Information:					
27	Non Patent Literature	LO_1996_4390.pdf	2289540 b6cc467e886d1f6369876a144f2969b04c2f590d	no	7
Warnings:					
Information:					
28	Non Patent Literature	LO_1997_485.pdf	179593 e264deb75d0c6b3f5cb223d5f1c9c8db64675746	no	3
Warnings:					
Information:					
29	Non Patent Literature	LO_1998_768.pdf	600554 7ca8ff1df94108057969c22552b26ee815aa3054	no	8
Warnings:					
Information:					

30	Non Patent Literature	LO_1998_p1330_NPL.pdf	1372133 d8ef33338ee99569ea3a07fae95ab8543867ecbe	no	4
Warnings:					
Information:					
31	Non Patent Literature	LO_1998_p1734_NPL.pdf	599193 0859974c121cb582dfb0f4014b44d9e6cd5c80f7	no	5
Warnings:					
Information:					
32	Non Patent Literature	LO_1999_218.pdf	1462996 d24845f56122e8f1ef4fa439a8a036045e47b576	no	7
Warnings:					
Information:					
33	Non Patent Literature	LO_2001_p7_NPL.pdf	116721 0d20bb87a931c72684908ea9c557877ccc64a784	no	7
Warnings:					
Information:					
34	Non Patent Literature	LO_2004_2835.pdf	673432 6e295e3c05b4bb8a1fa26297bdd36a41dc12c353	no	3
Warnings:					
Information:					
35	Non Patent Literature	LO_2007_13116.pdf	1745867 b9a07345251f94280ca0b77895ee0c6d23d2c181	no	6
Warnings:					
Information:					
36	Non Patent Literature	LO_2007_218.pdf	1248363 bf1a75260f76261c769d6e407978309f195b819a	no	6
Warnings:					
Information:					

37	Non Patent Literature	LO_2007_p71_NPL.pdf	13482368 38ab59e0e9250f42dbdad049253ac0e3743c6537	no	7
Warnings:					
Information:					
38	Non Patent Literature	LO_2008_140.pdf	788676 a207d83d989d9b1938a6c7fd39a349041e3ce19d	no	4
Warnings:					
Information:					
39	Non Patent Literature	LO_2009_152_NPL.pdf	1419781 6f97602ac18725ad71b5e8b0f1f14b850958eea6	no	6
Warnings:					
Information:					
40	Non Patent Literature	LO_2009_p608_NPL.pdf	46024 adb64324240f88d91a3a0d19c7abdb6e8aa50bcf	no	2
Warnings:					
Information:					
41	Non Patent Literature	LO_2010_1.pdf	2668499 925f6f82caab9a7de99634b89607ff63fb8d1c27	no	13
Warnings:					
Information:					
42	Non Patent Literature	LO_2012_1.pdf	179957 ad85aa2ff72eff53efb765e3526cff0cabaef1cc	no	5
Warnings:					
Information:					
43	Non Patent Literature	LO_2012_995.pdf	81082 fa0df255a9f0ef97d693d8836d5622bf03339748	no	5
Warnings:					
Information:					

44	Non Patent Literature	LO_FetalDNAinMaternalPlasma_2000_p1903_NPL.pdf	5716079 c1075d6c514176dc26e4dd6647d461eaa7b1486b	no	4
Warnings:					
Information:					
45	Non Patent Literature	LOH_1991_p11_NPL.pdf	2306523 b3552c857eec1bc40543c8bfed9bf3a97cd3c435	no	9
Warnings:					
Information:					
46	Non Patent Literature	LOVMAR_2003_9pgs_NPL.pdf	11218365 3456c46dcbcdf6b6a342403d77a864e82d8c7a33	no	9
Warnings:					
Information:					
47	Non Patent Literature	LU_2009_2055_NPL.pdf	1983796 54860a72bc162cdcac4c08c8cb76e5aafaf9b663	no	10
Warnings:					
Information:					
48	Non Patent Literature	LU_2012_p1627_NPL.pdf	639398 467a0ae2d752013853d12e1bb38f3f869946aafe	no	5
Warnings:					
Information:					
49	Non Patent Literature	LUI_2002_421_NPL.pdf	784338 e75d093d6b64722d75ada96f65ffef81d9c49455	no	7
Warnings:					
Information:					
50	Non Patent Literature	LUI_2002_p968_NPL.pdf	71992 0e6b925fad8108ed2407d09c134446eee71f76c9	no	7
Warnings:					
Information:					

51	Non Patent Literature	LUI_2003_p496_NPL.pdf	117862 b690844916d91bd8a9359b376d5b00642923b9b3	no	2
Warnings:					
Information:					
52	Non Patent Literature	LUN.pdf	1514958 31ee593319bf530e12ae06513ae8c9648734ed63	no	6
Warnings:					
Information:					
53	Non Patent Literature	LUN_2008_p1672_NPL.pdf	341477 b76fd4c41c55f2268688b16008be2eb9eb61d363	no	9
Warnings:					
Information:					
54	Non Patent Literature	MA_2015_1_NPL.pdf	3006720 e157dccae658a2f86c475cb6628cf0852d69e48a	no	12
Warnings:					
Information:					
55	Non Patent Literature	MACKIEWICZ_2013_11pgs_NPL.pdf	912047 6b7f14d1efbaafc69d3f6ed50a0a51aa9741b8d3	no	11
Warnings:					
Information:					
56	Non Patent Literature	MAGBANUA_2018_NPL.pdf	150548 7fa02f3befc680fdd103495523f5917953b24289	no	4
Warnings:					
Information:					
57	Non Patent Literature	MAMON_2008_1582_NPL.pdf	491929 149c882d79313b5375fefa22e2543f0e848ede2a	no	3
Warnings:					
Information:					

58	Non Patent Literature	MANIATIS.pdf	574741 0af0a98df81cddc130039159725e44b1e65b245b	no	4
Warnings:					
Information:					
59	Non Patent Literature	MANSFIELD.pdf	2120843 15cd42cf9cf998304ff8ca57922709bd169346de	no	8
Warnings:					
Information:					
60	Non Patent Literature	MARDIS_2008_133_NPL.pdf	1197039 d2ee600934ef37938077f4d67a52be05d5d2afd9	no	9
Warnings:					
Information:					
		Total Files Size (in bytes):	93690985		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.